Safety	O
outcomes	O
were	O
assessed	O
throughout	O
the	O
36-week	O
treatment	O
and	O
48-week	O
follow-up	O
periods	O
.	O

Based	O
on	O
non-compartmental	O
analysis	O
,	O
the	O
mean	O
t1/2	O
values	O
of	O
quilizumab	O
across	O
the	O
dose	O
groups	O
ranged	O
from	O
16.4	O
to	O
18.7	O
days	O
,	O
which	O
suggests	O
that	O
steady-state	O
was	O
attained	O
by	O
the	O
time	O
the	O
final	O
doses	O
were	O
administered	O
for	O
both	O
monthly	O
and	O
quarterly	O
regimens	O
.	O

4	O
)	O
.	O

Asthma	O
exacerbations	O
were	O
defined	O
as	O
new	O
or	O
increased	O
asthma	O
symptoms	O
(	O
wheezing	O
,	O
cough	O
,	O
chest	O
tightness	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
nighttime	O
awakening	O
due	O
to	O
symptoms	O
)	O
that	O
led	O
to	O
treatment	O
with	O
systemic	O
corticosteroids	O
for	O
at	O
least	O
3	O
days	O
or	O
to	O
hospitalization	O
.	O

Peripheral	O
blood	O
eosinophil	O
counts	O
were	O
obtained	O
from	O
standard	O
complete	O
blood	O
counts	O
.	O

There	O
were	O
no	O
major	O
imbalances	O
between	O
treatment	O
groups	O
,	O
but	O
the	O
300	O
mg	O
monthly	O
quilizumab	O
group	O
had	O
a	O
lower	O
mean	O
age	O
(	O
45	O
versus	O
47–48	O
years	O
)	O
and	O
a	O
lower	O
median	O
IgE	O
level	O
(	O
190	O
versus	O
234–254	O
IU/mL	O
)	O
compared	O
to	O
the	O
other	O
treatment	O
arms	O
(	O
Table	O
1	O
)	O
.	O

Safety	O
Quilizumab	O
was	O
well	O
tolerated	O
,	O
and	O
the	O
number	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
adverse	O
event	O
(	O
AE	O
)	O
was	O
comparable	O
between	O
all	O
treatment	O
groups	O
(	O
Table	O
2	O
)	O
.	O

Allergen-specific	O
and	O
total	O
IgE	O
were	O
measured	O
in	O
serum	O
by	O
ImmunoCAP®	O
Specific	O
IgE	O
blood	O
tests	O
(	O
ViraCor-IBT	O
Laboratories	O
,	O
Lee	O
’	O
s	O
Summit	O
,	O
MO	O
)	O
.	O

Baseline	O
values	O
were	O
derived	O
from	O
a	O
minimum	O
of	O
10	O
days	O
of	O
patient	O
diary	O
entries	O
during	O
the	O
14	O
days	O
prior	O
to	O
the	O
first	O
treatment	O
.	O

Through	O
Week	O
36	O
,	O
the	O
most	O
frequent	O
AEs	O
across	O
all	O
quilizumab	O
dose	O
groups	O
were	O
worsening	O
of	O
asthma	O
(	O
27	O
%	O
)	O
,	O
nasopharyngitis	O
(	O
15	O
%	O
)	O
,	O
upper	O
respiratory	O
tract	O
infection	O
(	O
7	O
%	O
)	O
,	O
bronchitis	O
(	O
5	O
%	O
)	O
,	O
sinusitis	O
(	O
5	O
%	O
)	O
,	O
and	O
injection	O
site	O
pain	O
(	O
5	O
%	O
)	O
.	O

5	O
)	O
.	O

The	O
relative	O
change	O
in	O
pre-bronchodilator	O
FEV1	O
from	O
baseline	O
was	O
calculated	O
as	O
the	O
absolute	O
change	O
in	O
FEV1	O
(	O
volume	O
in	O
liters	O
)	O
from	O
baseline	O
divided	O
by	O
the	O
FEV1	O
at	O
baseline	O
.	O

Peripheral	O
blood	O
eosinophils	O
and	O
FeNO	O
levels	O
were	O
not	O
modified	O
following	O
quilizumab	O
treatment	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S3	O
)	O
.	O

The	O
rates	O
of	O
asthma	O
exacerbations	O
were	O
compared	O
between	O
study	O
groups	O
using	O
a	O
Poisson	O
regression	O
with	O
overdispersion	O
model	O
,	O
including	O
terms	O
for	O
periostin	O
status	O
(	O
<	O
50	O
,	O
≥50	O
ng/mL	O
)	O
,	O
number	O
of	O
prior	O
exacerbations	O
(	O
1	O
,	O
>	O
1	O
)	O
,	O
and	O
IgE	O
level	O
(	O
<	O
200	O
,	O
≥200	O
IU/mL	O
)	O
.	O

Exclusion	O
criteria	O
Patients	O
were	O
excluded	O
from	O
the	O
study	O
if	O
they	O
had	O
an	O
asthma	O
exacerbation	O
requiring	O
systemic	O
steroids	O
in	O
the	O
30	O
days	O
prior	O
to	O
screening	O
,	O
or	O
between	O
screening	O
and	O
randomization	O
,	O
a	O
>	O
20	O
%	O
relative	O
change	O
in	O
FEV1	O
between	O
screening	O
and	O
randomization	O
,	O
any	O
pre-existing	O
active	O
lung	O
disease	O
other	O
than	O
asthma	O
,	O
any	O
infections	O
,	O
elevated	O
IgE	O
levels	O
for	O
reasons	O
other	O
than	O
allergy	O
,	O
or	O
were	O
former	O
or	O
current	O
smokers	O
.	O

2	O
)	O
.	O

Biomarkers	O
Samples	O
for	O
biomarker	O
assessments	O
were	O
collected	O
throughout	O
the	O
study	O
.	O

Results	O
Patient	O
demographics	O
and	O
study	O
flow	O
1212	O
patients	O
were	O
screened	O
for	O
eligibility	O
and	O
578	B-Sample_Size_Actual_at_Enrollment
adult	O
asthma	O
patients	O
(	O
18–75	O
years	O
old	O
)	O
were	O
enrolled	O
(	O
Fig	O
.	O

For	O
the	O
analyses	O
of	O
symptom	O
scores	O
,	O
rescue	O
medication	O
use	O
,	O
and	O
nighttime	O
awakenings	O
,	O
daily	O
scores	O
were	O
averaged	O
over	O
the	O
previous	O
7	O
days	O
prior	O
to	O
the	O
time	O
point	O
of	O
interest	O
.	O

1	O
)	O
from	O
April	O
2012	O
to	O
September	O
2013	O
;	O
the	O
study	O
was	O
completed	O
in	O
November	O
2014	O
.	O

Secondary	O
efficacy	O
outcomes	O
included	O
assessments	O
of	O
lung	O
function	O
using	O
the	O
relative	O
change	O
in	O
pre-bronchodilator	O
FEV1	O
from	O
baseline	O
to	O
Weeks	O
12	O
and	O
36	O
and	O
the	O
change	O
in	O
asthma	O
symptoms	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
using	O
total	O
and	O
daytime	O
symptom	O
severity	O
scores	O
derived	O
from	O
a	O
daily	O
patient	O
diary	O
.	O

The	O
sponsor	O
terminated	O
the	O
trial	O
early	O
because	O
of	O
the	O
lack	O
of	O
efficacy	O
for	O
the	O
primary	O
end-point	O
(	O
asthma	O
exacerbations	O
)	O
at	O
Week	O
36	O
,	O
with	O
the	O
median	O
time	O
in	O
the	O
study	O
at	O
72	O
weeks	O
.	O

In	O
the	O
ITT	O
population	O
,	O
the	O
reduction	O
in	O
the	O
asthma	O
exacerbation	O
rate	O
relative	O
to	O
placebo	O
was	O
19.6	O
%	O
(	O
90	O
%	O
CI	O
:	O
−21	O
to	O
47	O
;	O
p	O
=	O
0.38	O
)	O
,	O
−11.2	O
%	O
(	O
90	O
%	O
CI	O
:	O
−63	O
to	O
24	O
;	O
p	O
=	O
0.65	O
)	O
,	O
and	O
−5.7	O
%	O
(	O
90	O
%	O
CI	O
:	O
−55	O
to	O
28	O
;	O
p	O
=	O
0.81	O
)	O
in	O
the	O
300	O
mg	O
M	O
,	O
450	O
mg	O
Q	O
,	O
and	O
150	O
mg	O
Q	O
quilizumab	O
treatment	O
arms	O
,	O
respectively	O
(	O
Fig	O
.	O

Patient-reported	O
outcomes	O
During	O
the	O
36-week	O
treatment	O
period	O
,	O
no	O
meaningful	O
differences	O
were	O
observed	O
between	O
the	O
quilizumab	O
dose	O
groups	O
compared	O
with	O
the	O
placebo	O
group	O
for	O
the	O
total	O
mTASS	O
,	O
daytime	O
mTASS	O
,	O
ACQ-5	O
,	O
AQLQ	O
(	O
S	O
)	O
,	O
or	O
RQLQ	O
(	O
S	O
)	O
scores	O
(	O
Table	O
3	O
)	O
.	O

The	O
pharmacokinetic	O
outcomes	O
included	O
:	O
serum	O
concentrations	O
prior	O
to	O
dosing	O
at	O
Weeks	O
0	O
,	O
4	O
,	O
12	O
,	O
24	O
,	O
and	O
32	O
;	O
serum	O
concentrations	O
at	O
Week	O
5	O
and	O
Week	O
25	O
;	O
maximum	O
observed	O
serum	O
concentrations	O
(	O
Cmax	O
,	O
obs	O
)	O
;	O
time	O
of	O
maximum	O
observed	O
serum	O
concentration	O
(	O
Tmax	O
,	O
obs	O
)	O
;	O
and	O
terminal	O
elimination	O
half-life	O
(	O
t1/2	O
)	O
.	O

Analysis	O
of	O
FEV1	O
in	O
the	O
biomarker	O
subgroups	O
demonstrated	O
no	O
consistent	O
or	O
meaningful	O
improvements	O
of	O
FEV1	O
in	O
the	O
quilizumab-treated	O
arms	O
over	O
placebo	O
(	O
see	O
Additional	O
file	O
2	O
:	O
Table	O
S1	O
and	O
Additional	O
file	O
3	O
:	O
Table	O
S2	O
)	O
.	O

Pharmacokinetics	O
and	O
immunogenicity	O
Serum	O
levels	O
of	O
quilizumab	O
for	O
pharmacokinetic	O
assessments	O
were	O
measured	O
using	O
a	O
validated	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
;	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

ATA	O
incidence	O
for	O
all	O
dosing	O
groups	O
was	O
1.6	O
%	O
(	O
7	O
of	O
427	O
quilizumab-dosed	O
patients	O
)	O
.	O

5	O
;	O
see	O
Additional	O
file	O
2	O
:	O
Table	O
S1	O
and	O
Additional	O
file	O
3	O
:	O
Table	O
S2	O
)	O
.	O

89	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
384/433	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
who	I-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
quilizumab	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
91	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
132/145	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
who	I-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
placebo	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
treatment	O
.	O

Participants	O
Inclusion	O
criteria	O
Adult	O
asthma	O
patients	O
,	O
aged	O
18–75	O
years	O
,	O
were	O
required	O
to	O
have	O
:	O
bronchodilator	O
reversibility	O
of	O
either	O
≥12	O
%	O
β-agonist	O
reversibility	O
using	O
4	O
puffs	O
of	O
a	O
short-acting	O
β	O
−	O
agonist	O
(	O
SABA	O
)	O
or	O
a	O
PC20	O
FEV1	O
methacholine	O
(	O
provocative	O
concentration	O
of	O
methacholine	O
producing	O
a	O
20	O
%	O
fall	O
in	O
FEV1	O
(	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
)	O
)	O
of	O
8	O
mg/mL	O
or	O
less	O
,	O
within	O
the	O
last	O
2	O
years	O
;	O
a	O
pre-bronchodilator	O
FEV1	O
at	O
screening	O
of	O
40–80	O
%	O
predicted	O
;	O
daily	O
use	O
of	O
ICS	O
(	O
≥400	O
μg/day	O
total	O
daily	O
dose	O
of	O
fluticasone	O
propionate	O
or	O
equivalent	O
)	O
and	O
a	O
second	O
controller	O
for	O
a	O
minimum	O
of	O
3	O
consecutive	O
months	O
;	O
inadequately-controlled	O
asthma	O
as	O
documented	O
by	O
a	O
5-item	O
Asthma	O
Control	O
Questionnaire	O
(	O
ACQ-5	O
)	O
score	O
≥1.50	O
at	O
screening	O
and	O
randomization	O
,	O
despite	O
compliance	O
with	O
asthma	O
controller	O
therapy	O
;	O
at	O
least	O
one	O
positive	O
aeroallergen-specific	O
IgE	O
(	O
≥0.35	O
kU	O
(	O
A	O
)	O
/L	O
)	O
,	O
or	O
a	O
total	O
serum	O
IgE	O
≥75	O
IU/mL	O
;	O
and	O
a	O
history	O
of	O
at	O
least	O
one	O
protocol-defined	O
asthma	O
exacerbation	O
in	O
the	O
18	O
months	O
prior	O
to	O
screening	O
.	O

Exploratory	O
outcome	O
measures	O
included	O
the	O
change	O
in	O
asthma	O
control	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
as	O
measured	O
by	O
the	O
ACQ-5	O
.	O

Assessments	O
The	O
patient	O
daily	O
diary	O
included	O
two	O
sections	O
in	O
addition	O
to	O
peak	O
flow	O
measurements	O
:	O
1	O
)	O
a	O
morning	O
section	O
capturing	O
awakenings	O
and	O
rescue	O
medication	O
use	O
at	O
night	O
,	O
and	O
symptoms	O
on	O
awakening	O
;	O
and	O
2	O
)	O
an	O
evening	O
section	O
capturing	O
daytime	O
symptom	O
severity	O
,	O
rescue	O
medication	O
use	O
,	O
preventive	O
inhaler	O
use	O
,	O
activity	O
impairment	O
during	O
the	O
day	O
,	O
and	O
nasal	O
symptoms	O
.	O

Corresponding	O
two-sided	O
p-values	O
and	O
90	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
reported	O
.	O

Patients	B-Blinding_Object_Patients
and	O
study	B-Blinding_Object_Care_Providers
site	I-Blinding_Object_Care_Providers
personnel	I-Blinding_Object_Care_Providers
were	O
blinded	O
to	O
treatment	O
assignments	O
until	O
all	O
follow-up	O
data	O
through	O
Week	O
84	O
were	O
collected	O
and	O
verified	O
.	O

Specific	O
IgE	O
was	O
measured	O
for	O
the	O
following	O
allergens	O
:	O
cat	O
,	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
Dermatophagoides	O
farinae	O
,	O
HDM	O
Dermatophagoides	O
pteronyssinus	O
,	O
ragweed	O
,	O
aspergillus	O
,	O
timothy	O
grass	O
,	O
bermuda	O
grass	O
,	O
oak	O
,	O
birch	O
,	O
plantain	O
,	O
and	O
orchard	O
grass	O
.	O

Only	O
observed	O
values	O
of	O
IgE	O
levels	O
were	O
analyzed	O
,	O
with	O
no	O
imputation	O
performed	O
for	O
missing	O
IgE	O
data	O
.	O

Missing	O
values	O
were	O
imputed	O
using	O
the	O
last-observation-carried-forward	O
(	O
LOCF	O
)	O
approach	O
,	O
as	O
prespecified	O
in	O
the	O
statistical	O
analysis	O
plan	O
.	O

3	O
)	O
.	O

Outcome	O
measures	O
The	O
primary	O
efficacy	O
outcome	O
was	O
the	O
annualized	O
rate	O
of	O
protocol-defined	O
asthma	O
exacerbations	O
from	O
baseline	O
to	O
Week	O
36	O
.	O

At	O
treatment	O
Weeks	O
4	O
,	O
12	O
,	O
and	O
24	O
,	O
the	O
mean	O
trough	O
serum	O
concentrations	O
of	O
quilizumab	O
were	O
:	O
(	O
150	O
mg	O
Q	O
)	O
5.7	O
±	O
2.3	O
μg/mL	O
,	O
2.6	O
±	O
2.0	O
μg/mL	O
,	O
and	O
1.3	O
±	O
4.6	O
μg/mL	O
,	O
respectively	O
;	O
(	O
450	O
mg	O
Q	O
)	O
17.1	O
±	O
7.0	O
μg/mL	O
,	O
7.2	O
±	O
3.8	O
μg/mL	O
,	O
and	O
2.3	O
±	O
2.2	O
μg/mL	O
,	O
respectively	O
;	O
and	O
(	O
300	O
mg	O
M	O
)	O
11.6	O
±	O
4.5	O
μg/mL	O
,	O
16.7	O
±	O
6.7	O
μg/mL	O
,	O
and	O
16.8	O
±	O
7.7	O
μg/mL	O
,	O
respectively	O
.	O

Relative	O
changes	O
from	O
baseline	O
in	O
FEV1	O
compared	O
to	O
placebo	O
were	O
3.8	O
%	O
(	O
90	O
%	O
CI	O
:	O
−1.2	O
to	O
8.9	O
,	O
p	O
=	O
0.21	O
)	O
at	O
Week	O
12	O
and	O
5.6	O
%	O
(	O
90	O
%	O
CI	O
:	O
0.6	O
to	O
10.6	O
,	O
p	O
=	O
0.07	O
)	O
at	O
Week	O
36	O
in	O
the	O
150	O
mg	O
Q	O
treatment	O
arm	O
;	O
2.2	O
%	O
(	O
90	O
%	O
CI	O
:	O
−2.8	O
to	O
7.2	O
,	O
p	O
=	O
0.48	O
)	O
at	O
Week	O
12	O
and	O
0.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−5.0	O
to	O
5.1	O
,	O
p	O
=	O
0.98	O
)	O
at	O
Week	O
36	O
in	O
the	O
450	O
mg	O
Q	O
arm	O
;	O
and	O
1.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−3.9	O
to	O
6.1	O
,	O
p	O
=	O
0.72	O
)	O
at	O
Week	O
12	O
and	O
0.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−4.9	O
to	O
5.2	O
,	O
p	O
=	O
0.96	O
)	O
at	O
Week	O
36	O
in	O
the	O
300	O
mg	O
M	O
arm	O
(	O
Fig	O
.	O

Demographic	O
and	O
baseline	O
characteristics	O
were	O
summarized	O
using	O
descriptive	O
statistics	O
.	O

To	O
assess	O
the	O
change	O
in	O
allergy-related	O
quality-of-life	O
measures	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
the	O
Standardized	O
Asthma	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
AQLQ	O
(	O
S	O
)	O
)	O
and	O
the	O
Standardized	O
Rhinoconjunctivitis	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
RQLQ	O
(	O
S	O
)	O
)	O
were	O
administered	O
at	O
patient	O
visits	O
throughout	O
the	O
treatment	O
and	O
follow-up	O
periods	O
.	O

Trial	O
design	O
The	O
COSTA	O
trial	O
of	O
quilizumab	O
was	O
a	O
Phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
study	O
(	O
including	O
recruiting	B-Settings_Multicenter
sites	I-Settings_Multicenter
from	I-Settings_Multicenter
14	I-Settings_Multicenter
countries	I-Settings_Multicenter
:	O
Argentina	B-Settings_Location
,	I-Settings_Location
Belgium	I-Settings_Location
,	I-Settings_Location
Bulgaria	I-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
,	I-Settings_Location
Germany	I-Settings_Location
,	I-Settings_Location
Hungary	I-Settings_Location
,	I-Settings_Location
Mexico	I-Settings_Location
,	I-Settings_Location
New	I-Settings_Location
Zealand	I-Settings_Location
,	I-Settings_Location
Peru	I-Settings_Location
,	I-Settings_Location
Poland	I-Settings_Location
,	I-Settings_Location
Romania	I-Settings_Location
,	I-Settings_Location
Russia	I-Settings_Location
,	I-Settings_Location
Ukraine	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
States	I-Settings_Location
)	O
that	O
enrolled	O
578	B-Sample_Size_Actual_at_Enrollment
adults	O
with	O
uncontrolled	O
allergic	O
asthma	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
based	O
on	O
serum	B-Randomization_Stratified_Criteria
periostin	I-Randomization_Stratified_Criteria
level	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
50	I-Randomization_Stratified_Criteria
ng/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
≥50	I-Randomization_Stratified_Criteria
ng/mL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
exacerbation	B-Randomization_Stratified_Criteria
history	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
number	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
exacerbations	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
1	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
1	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
requiring	I-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
systemic	I-Randomization_Stratified_Criteria
corticosteroids	I-Randomization_Stratified_Criteria
in	I-Randomization_Stratified_Criteria
the	I-Randomization_Stratified_Criteria
prior	I-Randomization_Stratified_Criteria
18	I-Randomization_Stratified_Criteria
months	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
IgE	B-Randomization_Stratified_Criteria
level	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
≤75	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
75–200	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
200	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
and	O
country	B-Randomization_Stratified_Criteria
.	O

Subgroup	O
analysis	O
by	O
baseline	O
serum	O
periostin	O
(	O
≥50	O
ng/ml	O
,	O
<	O
50	O
ng/ml	O
)	O
,	O
blood	O
eosinophils	O
(	O
≥300	O
cells/μl	O
,	O
<	O
300	O
cells/μl	O
)	O
,	O
FeNO	O
(	O
≥20	O
ppb	O
,	O
<	O
20	O
ppb	O
)	O
and	O
serum	O
total	O
IgE	O
(	O
≥200	O
IU/mL	O
,	O
<	O
200	O
IU/mL	O
)	O
demonstrated	O
no	O
consistent	O
effect	O
of	O
quilizumab	O
on	O
the	O
exacerbation	O
rate	O
across	O
all	O
doses	O
when	O
compared	O
to	O
the	O
ITT	O
population	O
(	O
Fig	O
.	O

The	O
maximum	O
specific	O
IgE	O
was	O
defined	O
as	O
the	O
specific	O
IgE	O
with	O
the	O
highest	O
titer	O
of	O
specific	O
IgEs	O
pre-dose	O
in	O
each	O
patient	O
.	O

Quilizumab	O
(	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
was	O
delivered	O
subcutaneously	O
at	O
nine	O
monthly	O
intervals	O
at	O
300	O
mg	O
per	O
dose	O
(	O
300	O
mg	O
M	O
)	O
,	O
or	O
at	O
three	O
quarterly	O
intervals	O
and	O
at	O
Week	O
4	O
at	O
150	O
or	O
450	O
mg	O
per	O
dose	O
(	O
150	O
or	O
450	O
mg	O
Q	O
)	O
.	O

Asthma	O
exacerbation	O
rates	O
Quilizumab	O
treatment	O
did	O
not	O
produce	O
a	O
clinically	O
meaningful	O
reduction	O
of	O
the	O
rate	O
of	O
asthma	O
exacerbations	O
over	O
the	O
36-week	O
treatment	O
period	O
.	O

Statistical	O
methods	O
All	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
(	O
intention-to-treat	O
,	O
ITT	O
population	O
)	O
and	O
were	O
included	O
in	O
all	O
safety	O
and	O
efficacy	O
analyses	O
.	O

For	O
the	O
150	O
mg	O
Q	O
,	O
450	O
mg	O
Q	O
,	O
and	O
300	O
mg	O
M	O
doses	O
,	O
the	O
mean	O
Cmax	O
,	O
obs	O
values	O
were	O
18	O
±	O
7.8	O
μg/mL	O
,	O
51.6	O
±	O
19.5	O
μg/mL	O
,	O
and	O
34	O
±	O
12.6	O
μg/mL	O
,	O
which	O
occurred	O
at	O
Tmax	O
,	O
obs	O
of	O
36.4	O
±	O
4.3	O
days	O
,	O
36.2	O
±	O
3.0	O
days	O
,	O
and	O
36.2	O
±	O
3.5	O
days	O
,	O
respectively	O
,	O
approximately	O
7	O
days	O
following	O
the	O
second	O
doses	O
.	O

We	O
also	O
evaluated	O
the	O
ability	O
of	O
biomarkers	O
(	O
serum	O
periostin	O
,	O
blood	O
eosinophils	O
,	O
exhaled	O
NO	O
,	O
and	O
serum	O
IgE	O
)	O
to	O
predict	O
benefit	O
from	O
quilizumab	O
.	O

The	O
highest	O
relative	O
improvement	O
compared	O
to	O
placebo	O
occurred	O
in	O
the	O
lowest	O
dose	O
arm	O
(	O
150	O
mg	O
Q	O
)	O
,	O
but	O
no	O
meaningful	O
improvements	O
were	O
observed	O
in	O
the	O
higher	O
dose	O
arms	O
(	O
450	O
mg	O
Q	O
and	O
300	O
mg	O
M	O
)	O
.	O

For	O
secondary	O
and	O
exploratory	O
end	O
points	O
,	O
the	O
means	O
and	O
standard	O
deviations	O
of	O
all	O
values	O
for	O
relative	O
change	O
were	O
calculated	O
according	O
to	O
study	O
group	O
at	O
Weeks	O
12	O
and	O
36	O
.	O

Pharmacokinetics	O
Quilizumab	O
displayed	O
linear	O
pharmacokinetics	O
with	O
a	O
dose-proportional	O
increase	O
in	O
exposure	O
as	O
shown	O
by	O
increases	O
in	O
Cmax	O
values	O
between	O
the	O
150	O
and	O
450	O
mg	O
Q	O
doses	O
at	O
Weeks	O
5	O
and	O
25	O
.	O

Serum	O
periostin	O
was	O
measured	O
by	O
immunoassay	O
using	O
the	O
Roche	O
Elecsys	O
platform	O
(	O
Roche	O
Diagnostics	O
Ltd.	O
,	O
Rotkreuz	O
,	O
Switzerland	O
)	O
.	O

The	O
mean	O
relative	O
changes	O
from	O
baseline	O
were	O
compared	O
between	O
the	O
study	O
groups	O
using	O
the	O
differences	O
between	O
the	O
means	O
for	O
each	O
group	O
,	O
with	O
the	O
associated	O
two-sided	O
90	O
%	O
CIs	O
.	O

Pharmacodynamic	O
biomarkers	O
Quilizumab	O
gradually	O
reduced	O
mean	O
serum	O
total	O
and	O
allergen-specific	O
IgE	O
,	O
reaching	O
a	O
30–40	O
%	O
reduction	O
at	O
Week	O
36	O
in	O
all	O
three	O
quilizumab	O
cohorts	O
(	O
p	O
<	O
0.01	O
compared	O
to	O
placebo	O
;	O
Fig	O
.	O

Lung	O
function	O
No	O
significant	O
evidence	O
of	O
improved	O
FEV1	O
at	O
Weeks	O
12	O
and	O
36	O
was	O
observed	O
in	O
quilizumab-treated	O
patients	O
compared	O
to	O
placebo	O
(	O
Fig	O
.	O

This	O
sample	O
size	O
provided	O
approximately	O
84	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
50	O
%	O
reduction	O
in	O
average	O
exacerbation	O
rates	O
due	O
to	O
quilizumab	O
,	O
assuming	O
0.63	O
exacerbations	O
per	O
patient	O
in	O
the	O
placebo	O
group	O
over	O
a	O
36-week	O
treatment	O
period	O
,	O
and	O
a	O
significance	O
level	O
of	O
α	O
=	O
0.10	B-Sample_Size_Calculation_Alpha_Value
.	O

The	O
primary	O
endpoint	O
,	O
the	O
annualized	O
exacerbation	O
rate	O
,	O
was	O
calculated	O
by	O
the	O
total	O
number	O
of	O
protocol-defined	O
exacerbations	O
observed	O
in	O
the	O
group	O
over	O
the	O
treatment	O
period	O
divided	O
by	O
total	O
patient-weeks	O
at	O
risk	O
(	O
number	O
of	O
weeks	O
from	O
first	O
study	O
drug	O
administration	O
to	O
the	O
earliest	O
of	O
Week	O
36	O
or	O
study	O
discontinuation	O
)	O
for	O
the	O
group	O
and	O
multiplied	O
by	O
52	O
.	O

Ethics	O
,	O
consent	O
,	O
and	O
permissions	O
Quorum	O
Review	O
based	O
in	O
Seattle	O
,	O
WA	O
was	O
the	O
primary	O
central	O
IRB	O
used	O
by	O
sites	O
in	O
North	O
America	O
,	O
however	O
multiple	O
other	O
site-specific	O
institutional	O
review	O
boards	O
at	O
other	O
global	O
sites	O
approved	O
the	O
protocol	O
and	O
patients	O
gave	O
written	O
,	O
informed	O
consent	O
.	O

The	O
trial	O
was	O
conducted	O
in	O
full	O
conformance	O
with	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
E6	O
guidelines	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
or	O
laws	O
and	O
regulations	O
of	O
the	O
country	O
where	O
the	O
research	O
was	O
conducted	O
,	O
whichever	O
afforded	O
greater	O
protection	O
to	O
the	O
individual	O
.	O

The	O
diary	O
was	O
also	O
used	O
to	O
determine	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
no	O
nighttime	O
awakenings	O
due	O
to	O
asthma	O
symptoms	O
and	O
the	O
proportion	O
of	O
patients	O
with	O
fewer	O
than	O
2	O
days	O
of	O
SABA	O
use	O
per	O
week	O
by	O
Week	O
36	O
.	O

For	O
biomarker	O
subgroup	O
analyses	O
,	O
unadjusted	O
asthma	O
exacerbation	O
rates	O
were	O
calculated	O
.	O

The	O
treatment	O
period	O
ended	O
36	O
weeks	O
after	O
randomization	O
and	O
was	O
followed	O
by	O
a	O
48-week	O
period	O
to	O
assess	O
the	O
sustained	O
efficacy	O
and	O
safety	O
of	O
quilizumab	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S1	O
)	O
.	O

Fractional	O
exhaled	O
nitric	O
oxide	O
(	O
FeNO	O
)	O
was	O
measured	O
using	O
a	O
hand-held	O
portable	O
device	O
,	O
NIOX	O
MINO®	O
(	O
Niox	O
;	O
Morrisville	O
,	O
NC	O
)	O
,	O
according	O
to	O
American	O
Thoracic	O
Society/European	O
Respiratory	O
Society	O
2009	O
guidelines	O
.	O

The	O
largest	O
decreases	O
in	O
total	O
and	O
allergen-specific	O
IgE	O
were	O
observed	O
at	O
Week	O
42	O
in	O
the	O
300	O
mg	O
M	O
treatment	O
cohort	O
.	O

The	O
modified	O
total	O
asthma	O
symptom	O
score	O
(	O
mTASS	O
)	O
was	O
generated	O
from	O
a	O
subset	O
of	O
diary	O
questions	O
adapted	O
from	O
a	O
previous	O
questionnaire	O
,	O
scoring	O
nighttime	O
awakenings	O
(	O
0–3	O
)	O
,	O
symptoms	O
on	O
awakening	O
(	O
0–1	O
)	O
,	O
and	O
daytime	O
symptom	O
severity	O
(	O
0–4	O
)	O
,	O
for	O
a	O
total	O
score	O
range	O
of	O
0–8	O
.	O

The	O
treatment-emergent	O
ATA	O
rate	O
was	O
1.4	O
%	O
in	O
both	O
the	O
150	O
mg	O
Q	O
and	O
300	O
mg	O
M	O
groups	O
,	O
and	O
2.1	O
%	O
in	O
the	O
450	O
mg	O
Q	O
group	O
.	O

This	O
sample	O
size	O
also	O
provided	O
approximately	O
70	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
50	O
%	O
reduction	O
in	O
average	O
exacerbation	O
rates	O
in	O
the	O
subgroup	O
of	O
periostin-high	O
patients	O
,	O
assuming	O
0.69	O
exacerbations	O
per	O
patient	O
in	O
the	O
placebo	O
group	O
over	O
the	O
36-week	O
period	O
,	O
a	O
significance	O
level	O
of	O
0.15	B-Sample_Size_Calculation_Alpha_Value
,	O
and	O
50	O
%	O
of	O
patients	O
in	O
each	O
treatment	O
arm	O
to	O
be	O
periostin	O
high	O
.	O

(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S2	O
)	O
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
1:1:1:1	B-Randomization_Ratio
)	O
to	O
one	B-Design_Parallel_Group
of	I-Design_Parallel_Group
three	I-Design_Parallel_Group
dosing	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
of	I-Design_Parallel_Group
quilizumab	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
using	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

Treatment	O
with	O
quilizumab	O
failed	O
to	O
increase	O
either	O
the	O
proportion	O
of	O
patients	O
who	O
used	O
a	O
SABA	O
for	O
fewer	O
than	O
2	O
days	O
in	O
the	O
prior	O
week	O
or	O
the	O
proportion	O
of	O
patients	O
who	O
did	O
not	O
awaken	O
at	O
night	O
due	O
to	O
asthma	O
symptoms	O
for	O
all	O
dosing	O
levels	O
relative	O
to	O
the	O
placebo	O
group	O
at	O
Week	O
36	O
(	O
Table	O
3	O
)	O
.	O

Sample	O
size	O
determination	O
We	O
planned	O
to	O
randomize	O
560	B-Sample_Size_Required
patients	O
to	O
one	O
of	O
three	O
dose	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
of	I-Design_Parallel_Group
quilizumab	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
in	O
a	O
1:1:1:1	B-Randomization_Ratio
ratio	O
(	O
140	O
patients	O
per	O
group	O
)	O
.	O

For	O
patients	O
who	O
discontinued	O
the	O
study	O
prematurely	O
,	O
there	O
was	O
no	O
imputation	O
of	O
additional	O
exacerbations	O
.	O

There	O
was	O
no	O
apparent	O
impact	O
of	O
positive	O
ATA	O
results	O
on	O
either	O
pharmacokinetic	O
profiles	O
or	O
safety	O
.	O

An	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
model	O
with	O
factors	O
for	O
baseline	O
level	O
,	O
periostin	O
status	O
(	O
<	O
50	O
ng/mL	O
,	O
≥50	O
ng/mL	O
)	O
,	O
number	O
of	O
prior	O
exacerbations	O
(	O
1	O
,	O
>	O
1	O
)	O
,	O
and	O
IgE	O
level	O
(	O
<	O
200	O
IU/mL	O
,	O
≥200	O
IU/mL	O
)	O
was	O
fit	O
to	O
assess	O
the	O
treatment	O
effect	O
.	O

Serum	O
total	O
and	O
allergen-specific	O
IgE	O
in	O
quilizumab-treated	O
patients	O
gradually	O
increased	O
throughout	O
the	O
safety	O
follow-up	O
period	O
,	O
but	O
did	O
not	O
return	O
to	O
pre-dose	O
levels	O
by	O
the	O
end	O
of	O
the	O
study	O
period	O
(	O
Week	O
84	O
)	O
.	O

Serum	O
anti-therapeutic	O
antibodies	O
(	O
ATAs	O
)	O
were	O
assessed	O
in	O
samples	O
at	O
Weeks	O
0	O
,	O
4	O
,	O
12	O
,	O
24	O
,	O
36	O
,	O
48	O
,	O
60	O
,	O
and	O
84	O
using	O
a	O
validated	O
bridging	O
ELISA	O
(	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

Safety	O
outcomes	O
were	O
assessed	O
throughout	O
the	O
36-week	O
treatment	O
and	O
48-week	O
follow-up	O
periods	O
.	O

Based	O
on	O
non-compartmental	O
analysis	O
,	O
the	O
mean	O
t1/2	O
values	O
of	O
quilizumab	O
across	O
the	O
dose	O
groups	O
ranged	O
from	O
16.4	O
to	O
18.7	O
days	O
,	O
which	O
suggests	O
that	O
steady-state	O
was	O
attained	O
by	O
the	O
time	O
the	O
final	O
doses	O
were	O
administered	O
for	O
both	O
monthly	O
and	O
quarterly	O
regimens	O
.	O

4	O
)	O
.	O

Asthma	O
exacerbations	O
were	O
defined	O
as	O
new	O
or	O
increased	O
asthma	O
symptoms	O
(	O
wheezing	O
,	O
cough	O
,	O
chest	O
tightness	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
nighttime	O
awakening	O
due	O
to	O
symptoms	O
)	O
that	O
led	O
to	O
treatment	O
with	O
systemic	O
corticosteroids	O
for	O
at	O
least	O
3	O
days	O
or	O
to	O
hospitalization	O
.	O

Peripheral	O
blood	O
eosinophil	O
counts	O
were	O
obtained	O
from	O
standard	O
complete	O
blood	O
counts	O
.	O

There	O
were	O
no	O
major	O
imbalances	O
between	O
treatment	O
groups	O
,	O
but	O
the	O
300	O
mg	O
monthly	O
quilizumab	O
group	O
had	O
a	O
lower	O
mean	O
age	O
(	O
45	O
versus	O
47–48	O
years	O
)	O
and	O
a	O
lower	O
median	O
IgE	O
level	O
(	O
190	O
versus	O
234–254	O
IU/mL	O
)	O
compared	O
to	O
the	O
other	O
treatment	O
arms	O
(	O
Table	O
1	O
)	O
.	O

Safety	O
Quilizumab	O
was	O
well	O
tolerated	O
,	O
and	O
the	O
number	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
adverse	O
event	O
(	O
AE	O
)	O
was	O
comparable	O
between	O
all	O
treatment	O
groups	O
(	O
Table	O
2	O
)	O
.	O

Allergen-specific	O
and	O
total	O
IgE	O
were	O
measured	O
in	O
serum	O
by	O
ImmunoCAP®	O
Specific	O
IgE	O
blood	O
tests	O
(	O
ViraCor-IBT	O
Laboratories	O
,	O
Lee	O
’	O
s	O
Summit	O
,	O
MO	O
)	O
.	O

Baseline	O
values	O
were	O
derived	O
from	O
a	O
minimum	O
of	O
10	O
days	O
of	O
patient	O
diary	O
entries	O
during	O
the	O
14	O
days	O
prior	O
to	O
the	O
first	O
treatment	O
.	O

Through	O
Week	O
36	O
,	O
the	O
most	O
frequent	O
AEs	O
across	O
all	O
quilizumab	O
dose	O
groups	O
were	O
worsening	O
of	O
asthma	O
(	O
27	O
%	O
)	O
,	O
nasopharyngitis	O
(	O
15	O
%	O
)	O
,	O
upper	O
respiratory	O
tract	O
infection	O
(	O
7	O
%	O
)	O
,	O
bronchitis	O
(	O
5	O
%	O
)	O
,	O
sinusitis	O
(	O
5	O
%	O
)	O
,	O
and	O
injection	O
site	O
pain	O
(	O
5	O
%	O
)	O
.	O

5	O
)	O
.	O

The	O
relative	O
change	O
in	O
pre-bronchodilator	O
FEV1	O
from	O
baseline	O
was	O
calculated	O
as	O
the	O
absolute	O
change	O
in	O
FEV1	O
(	O
volume	O
in	O
liters	O
)	O
from	O
baseline	O
divided	O
by	O
the	O
FEV1	O
at	O
baseline	O
.	O

Peripheral	O
blood	O
eosinophils	O
and	O
FeNO	O
levels	O
were	O
not	O
modified	O
following	O
quilizumab	O
treatment	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S3	O
)	O
.	O

The	O
rates	O
of	O
asthma	O
exacerbations	O
were	O
compared	O
between	O
study	O
groups	O
using	O
a	O
Poisson	O
regression	O
with	O
overdispersion	O
model	O
,	O
including	O
terms	O
for	O
periostin	O
status	O
(	O
<	O
50	O
,	O
≥50	O
ng/mL	O
)	O
,	O
number	O
of	O
prior	O
exacerbations	O
(	O
1	O
,	O
>	O
1	O
)	O
,	O
and	O
IgE	O
level	O
(	O
<	O
200	O
,	O
≥200	O
IU/mL	O
)	O
.	O

Exclusion	O
criteria	O
Patients	O
were	O
excluded	O
from	O
the	O
study	O
if	O
they	O
had	O
an	O
asthma	O
exacerbation	O
requiring	O
systemic	O
steroids	O
in	O
the	O
30	O
days	O
prior	O
to	O
screening	O
,	O
or	O
between	O
screening	O
and	O
randomization	O
,	O
a	O
>	O
20	O
%	O
relative	O
change	O
in	O
FEV1	O
between	O
screening	O
and	O
randomization	O
,	O
any	O
pre-existing	O
active	O
lung	O
disease	O
other	O
than	O
asthma	O
,	O
any	O
infections	O
,	O
elevated	O
IgE	O
levels	O
for	O
reasons	O
other	O
than	O
allergy	O
,	O
or	O
were	O
former	O
or	O
current	O
smokers	O
.	O

2	O
)	O
.	O

Biomarkers	O
Samples	O
for	O
biomarker	O
assessments	O
were	O
collected	O
throughout	O
the	O
study	O
.	O

Results	O
Patient	O
demographics	O
and	O
study	O
flow	O
1212	O
patients	O
were	O
screened	O
for	O
eligibility	O
and	O
578	B-Sample_Size_Actual_at_Enrollment
adult	O
asthma	O
patients	O
(	O
18–75	O
years	O
old	O
)	O
were	O
enrolled	O
(	O
Fig	O
.	O

For	O
the	O
analyses	O
of	O
symptom	O
scores	O
,	O
rescue	O
medication	O
use	O
,	O
and	O
nighttime	O
awakenings	O
,	O
daily	O
scores	O
were	O
averaged	O
over	O
the	O
previous	O
7	O
days	O
prior	O
to	O
the	O
time	O
point	O
of	O
interest	O
.	O

1	O
)	O
from	O
April	O
2012	O
to	O
September	O
2013	O
;	O
the	O
study	O
was	O
completed	O
in	O
November	O
2014	O
.	O

Secondary	O
efficacy	O
outcomes	O
included	O
assessments	O
of	O
lung	O
function	O
using	O
the	O
relative	O
change	O
in	O
pre-bronchodilator	O
FEV1	O
from	O
baseline	O
to	O
Weeks	O
12	O
and	O
36	O
and	O
the	O
change	O
in	O
asthma	O
symptoms	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
using	O
total	O
and	O
daytime	O
symptom	O
severity	O
scores	O
derived	O
from	O
a	O
daily	O
patient	O
diary	O
.	O

The	O
sponsor	O
terminated	O
the	O
trial	O
early	O
because	O
of	O
the	O
lack	O
of	O
efficacy	O
for	O
the	O
primary	O
end-point	O
(	O
asthma	O
exacerbations	O
)	O
at	O
Week	O
36	O
,	O
with	O
the	O
median	O
time	O
in	O
the	O
study	O
at	O
72	O
weeks	O
.	O

In	O
the	O
ITT	O
population	O
,	O
the	O
reduction	O
in	O
the	O
asthma	O
exacerbation	O
rate	O
relative	O
to	O
placebo	O
was	O
19.6	O
%	O
(	O
90	O
%	O
CI	O
:	O
−21	O
to	O
47	O
;	O
p	O
=	O
0.38	O
)	O
,	O
−11.2	O
%	O
(	O
90	O
%	O
CI	O
:	O
−63	O
to	O
24	O
;	O
p	O
=	O
0.65	O
)	O
,	O
and	O
−5.7	O
%	O
(	O
90	O
%	O
CI	O
:	O
−55	O
to	O
28	O
;	O
p	O
=	O
0.81	O
)	O
in	O
the	O
300	O
mg	O
M	O
,	O
450	O
mg	O
Q	O
,	O
and	O
150	O
mg	O
Q	O
quilizumab	O
treatment	O
arms	O
,	O
respectively	O
(	O
Fig	O
.	O

Patient-reported	O
outcomes	O
During	O
the	O
36-week	O
treatment	O
period	O
,	O
no	O
meaningful	O
differences	O
were	O
observed	O
between	O
the	O
quilizumab	O
dose	O
groups	O
compared	O
with	O
the	O
placebo	O
group	O
for	O
the	O
total	O
mTASS	O
,	O
daytime	O
mTASS	O
,	O
ACQ-5	O
,	O
AQLQ	O
(	O
S	O
)	O
,	O
or	O
RQLQ	O
(	O
S	O
)	O
scores	O
(	O
Table	O
3	O
)	O
.	O

The	O
pharmacokinetic	O
outcomes	O
included	O
:	O
serum	O
concentrations	O
prior	O
to	O
dosing	O
at	O
Weeks	O
0	O
,	O
4	O
,	O
12	O
,	O
24	O
,	O
and	O
32	O
;	O
serum	O
concentrations	O
at	O
Week	O
5	O
and	O
Week	O
25	O
;	O
maximum	O
observed	O
serum	O
concentrations	O
(	O
Cmax	O
,	O
obs	O
)	O
;	O
time	O
of	O
maximum	O
observed	O
serum	O
concentration	O
(	O
Tmax	O
,	O
obs	O
)	O
;	O
and	O
terminal	O
elimination	O
half-life	O
(	O
t1/2	O
)	O
.	O

Analysis	O
of	O
FEV1	O
in	O
the	O
biomarker	O
subgroups	O
demonstrated	O
no	O
consistent	O
or	O
meaningful	O
improvements	O
of	O
FEV1	O
in	O
the	O
quilizumab-treated	O
arms	O
over	O
placebo	O
(	O
see	O
Additional	O
file	O
2	O
:	O
Table	O
S1	O
and	O
Additional	O
file	O
3	O
:	O
Table	O
S2	O
)	O
.	O

Pharmacokinetics	O
and	O
immunogenicity	O
Serum	O
levels	O
of	O
quilizumab	O
for	O
pharmacokinetic	O
assessments	O
were	O
measured	O
using	O
a	O
validated	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
;	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

ATA	O
incidence	O
for	O
all	O
dosing	O
groups	O
was	O
1.6	O
%	O
(	O
7	O
of	O
427	O
quilizumab-dosed	O
patients	O
)	O
.	O

5	O
;	O
see	O
Additional	O
file	O
2	O
:	O
Table	O
S1	O
and	O
Additional	O
file	O
3	O
:	O
Table	O
S2	O
)	O
.	O

89	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
384/433	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
who	I-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
quilizumab	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
91	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
132/145	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
who	I-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
placebo	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
treatment	O
.	O

Participants	O
Inclusion	O
criteria	O
Adult	O
asthma	O
patients	O
,	O
aged	O
18–75	O
years	O
,	O
were	O
required	O
to	O
have	O
:	O
bronchodilator	O
reversibility	O
of	O
either	O
≥12	O
%	O
β-agonist	O
reversibility	O
using	O
4	O
puffs	O
of	O
a	O
short-acting	O
β	O
−	O
agonist	O
(	O
SABA	O
)	O
or	O
a	O
PC20	O
FEV1	O
methacholine	O
(	O
provocative	O
concentration	O
of	O
methacholine	O
producing	O
a	O
20	O
%	O
fall	O
in	O
FEV1	O
(	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
)	O
)	O
of	O
8	O
mg/mL	O
or	O
less	O
,	O
within	O
the	O
last	O
2	O
years	O
;	O
a	O
pre-bronchodilator	O
FEV1	O
at	O
screening	O
of	O
40–80	O
%	O
predicted	O
;	O
daily	O
use	O
of	O
ICS	O
(	O
≥400	O
μg/day	O
total	O
daily	O
dose	O
of	O
fluticasone	O
propionate	O
or	O
equivalent	O
)	O
and	O
a	O
second	O
controller	O
for	O
a	O
minimum	O
of	O
3	O
consecutive	O
months	O
;	O
inadequately-controlled	O
asthma	O
as	O
documented	O
by	O
a	O
5-item	O
Asthma	O
Control	O
Questionnaire	O
(	O
ACQ-5	O
)	O
score	O
≥1.50	O
at	O
screening	O
and	O
randomization	O
,	O
despite	O
compliance	O
with	O
asthma	O
controller	O
therapy	O
;	O
at	O
least	O
one	O
positive	O
aeroallergen-specific	O
IgE	O
(	O
≥0.35	O
kU	O
(	O
A	O
)	O
/L	O
)	O
,	O
or	O
a	O
total	O
serum	O
IgE	O
≥75	O
IU/mL	O
;	O
and	O
a	O
history	O
of	O
at	O
least	O
one	O
protocol-defined	O
asthma	O
exacerbation	O
in	O
the	O
18	O
months	O
prior	O
to	O
screening	O
.	O

Exploratory	O
outcome	O
measures	O
included	O
the	O
change	O
in	O
asthma	O
control	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
as	O
measured	O
by	O
the	O
ACQ-5	O
.	O

Assessments	O
The	O
patient	O
daily	O
diary	O
included	O
two	O
sections	O
in	O
addition	O
to	O
peak	O
flow	O
measurements	O
:	O
1	O
)	O
a	O
morning	O
section	O
capturing	O
awakenings	O
and	O
rescue	O
medication	O
use	O
at	O
night	O
,	O
and	O
symptoms	O
on	O
awakening	O
;	O
and	O
2	O
)	O
an	O
evening	O
section	O
capturing	O
daytime	O
symptom	O
severity	O
,	O
rescue	O
medication	O
use	O
,	O
preventive	O
inhaler	O
use	O
,	O
activity	O
impairment	O
during	O
the	O
day	O
,	O
and	O
nasal	O
symptoms	O
.	O

Corresponding	O
two-sided	O
p-values	O
and	O
90	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
reported	O
.	O

Patients	B-Blinding_Object_Patients
and	O
study	B-Blinding_Object_Care_Providers
site	I-Blinding_Object_Care_Providers
personnel	I-Blinding_Object_Care_Providers
were	O
blinded	O
to	O
treatment	O
assignments	O
until	O
all	O
follow-up	O
data	O
through	O
Week	O
84	O
were	O
collected	O
and	O
verified	O
.	O

Specific	O
IgE	O
was	O
measured	O
for	O
the	O
following	O
allergens	O
:	O
cat	O
,	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
Dermatophagoides	O
farinae	O
,	O
HDM	O
Dermatophagoides	O
pteronyssinus	O
,	O
ragweed	O
,	O
aspergillus	O
,	O
timothy	O
grass	O
,	O
bermuda	O
grass	O
,	O
oak	O
,	O
birch	O
,	O
plantain	O
,	O
and	O
orchard	O
grass	O
.	O

Only	O
observed	O
values	O
of	O
IgE	O
levels	O
were	O
analyzed	O
,	O
with	O
no	O
imputation	O
performed	O
for	O
missing	O
IgE	O
data	O
.	O

Missing	O
values	O
were	O
imputed	O
using	O
the	O
last-observation-carried-forward	O
(	O
LOCF	O
)	O
approach	O
,	O
as	O
prespecified	O
in	O
the	O
statistical	O
analysis	O
plan	O
.	O

3	O
)	O
.	O

Outcome	O
measures	O
The	O
primary	O
efficacy	O
outcome	O
was	O
the	O
annualized	O
rate	O
of	O
protocol-defined	O
asthma	O
exacerbations	O
from	O
baseline	O
to	O
Week	O
36	O
.	O

At	O
treatment	O
Weeks	O
4	O
,	O
12	O
,	O
and	O
24	O
,	O
the	O
mean	O
trough	O
serum	O
concentrations	O
of	O
quilizumab	O
were	O
:	O
(	O
150	O
mg	O
Q	O
)	O
5.7	O
±	O
2.3	O
μg/mL	O
,	O
2.6	O
±	O
2.0	O
μg/mL	O
,	O
and	O
1.3	O
±	O
4.6	O
μg/mL	O
,	O
respectively	O
;	O
(	O
450	O
mg	O
Q	O
)	O
17.1	O
±	O
7.0	O
μg/mL	O
,	O
7.2	O
±	O
3.8	O
μg/mL	O
,	O
and	O
2.3	O
±	O
2.2	O
μg/mL	O
,	O
respectively	O
;	O
and	O
(	O
300	O
mg	O
M	O
)	O
11.6	O
±	O
4.5	O
μg/mL	O
,	O
16.7	O
±	O
6.7	O
μg/mL	O
,	O
and	O
16.8	O
±	O
7.7	O
μg/mL	O
,	O
respectively	O
.	O

Relative	O
changes	O
from	O
baseline	O
in	O
FEV1	O
compared	O
to	O
placebo	O
were	O
3.8	O
%	O
(	O
90	O
%	O
CI	O
:	O
−1.2	O
to	O
8.9	O
,	O
p	O
=	O
0.21	O
)	O
at	O
Week	O
12	O
and	O
5.6	O
%	O
(	O
90	O
%	O
CI	O
:	O
0.6	O
to	O
10.6	O
,	O
p	O
=	O
0.07	O
)	O
at	O
Week	O
36	O
in	O
the	O
150	O
mg	O
Q	O
treatment	O
arm	O
;	O
2.2	O
%	O
(	O
90	O
%	O
CI	O
:	O
−2.8	O
to	O
7.2	O
,	O
p	O
=	O
0.48	O
)	O
at	O
Week	O
12	O
and	O
0.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−5.0	O
to	O
5.1	O
,	O
p	O
=	O
0.98	O
)	O
at	O
Week	O
36	O
in	O
the	O
450	O
mg	O
Q	O
arm	O
;	O
and	O
1.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−3.9	O
to	O
6.1	O
,	O
p	O
=	O
0.72	O
)	O
at	O
Week	O
12	O
and	O
0.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−4.9	O
to	O
5.2	O
,	O
p	O
=	O
0.96	O
)	O
at	O
Week	O
36	O
in	O
the	O
300	O
mg	O
M	O
arm	O
(	O
Fig	O
.	O

Demographic	O
and	O
baseline	O
characteristics	O
were	O
summarized	O
using	O
descriptive	O
statistics	O
.	O

To	O
assess	O
the	O
change	O
in	O
allergy-related	O
quality-of-life	O
measures	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
the	O
Standardized	O
Asthma	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
AQLQ	O
(	O
S	O
)	O
)	O
and	O
the	O
Standardized	O
Rhinoconjunctivitis	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
RQLQ	O
(	O
S	O
)	O
)	O
were	O
administered	O
at	O
patient	O
visits	O
throughout	O
the	O
treatment	O
and	O
follow-up	O
periods	O
.	O

Trial	O
design	O
The	O
COSTA	O
trial	O
of	O
quilizumab	O
was	O
a	O
Phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
study	O
(	O
including	O
recruiting	B-Settings_Multicenter
sites	I-Settings_Multicenter
from	I-Settings_Multicenter
14	I-Settings_Multicenter
countries	I-Settings_Multicenter
:	O
Argentina	B-Settings_Location
,	I-Settings_Location
Belgium	I-Settings_Location
,	I-Settings_Location
Bulgaria	I-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
,	I-Settings_Location
Germany	I-Settings_Location
,	I-Settings_Location
Hungary	I-Settings_Location
,	I-Settings_Location
Mexico	I-Settings_Location
,	I-Settings_Location
New	I-Settings_Location
Zealand	I-Settings_Location
,	I-Settings_Location
Peru	I-Settings_Location
,	I-Settings_Location
Poland	I-Settings_Location
,	I-Settings_Location
Romania	I-Settings_Location
,	I-Settings_Location
Russia	I-Settings_Location
,	I-Settings_Location
Ukraine	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
States	I-Settings_Location
)	O
that	O
enrolled	O
578	B-Sample_Size_Actual_at_Enrollment
adults	O
with	O
uncontrolled	O
allergic	O
asthma	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
based	O
on	O
serum	B-Randomization_Stratified_Criteria
periostin	I-Randomization_Stratified_Criteria
level	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
50	I-Randomization_Stratified_Criteria
ng/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
≥50	I-Randomization_Stratified_Criteria
ng/mL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
exacerbation	B-Randomization_Stratified_Criteria
history	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
number	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
exacerbations	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
1	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
1	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
requiring	I-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
systemic	I-Randomization_Stratified_Criteria
corticosteroids	I-Randomization_Stratified_Criteria
in	I-Randomization_Stratified_Criteria
the	I-Randomization_Stratified_Criteria
prior	I-Randomization_Stratified_Criteria
18	I-Randomization_Stratified_Criteria
months	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
IgE	B-Randomization_Stratified_Criteria
level	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
≤75	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
75–200	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
200	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
and	O
country	B-Randomization_Stratified_Criteria
.	O

Subgroup	O
analysis	O
by	O
baseline	O
serum	O
periostin	O
(	O
≥50	O
ng/ml	O
,	O
<	O
50	O
ng/ml	O
)	O
,	O
blood	O
eosinophils	O
(	O
≥300	O
cells/μl	O
,	O
<	O
300	O
cells/μl	O
)	O
,	O
FeNO	O
(	O
≥20	O
ppb	O
,	O
<	O
20	O
ppb	O
)	O
and	O
serum	O
total	O
IgE	O
(	O
≥200	O
IU/mL	O
,	O
<	O
200	O
IU/mL	O
)	O
demonstrated	O
no	O
consistent	O
effect	O
of	O
quilizumab	O
on	O
the	O
exacerbation	O
rate	O
across	O
all	O
doses	O
when	O
compared	O
to	O
the	O
ITT	O
population	O
(	O
Fig	O
.	O

The	O
maximum	O
specific	O
IgE	O
was	O
defined	O
as	O
the	O
specific	O
IgE	O
with	O
the	O
highest	O
titer	O
of	O
specific	O
IgEs	O
pre-dose	O
in	O
each	O
patient	O
.	O

Quilizumab	O
(	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
was	O
delivered	O
subcutaneously	O
at	O
nine	O
monthly	O
intervals	O
at	O
300	O
mg	O
per	O
dose	O
(	O
300	O
mg	O
M	O
)	O
,	O
or	O
at	O
three	O
quarterly	O
intervals	O
and	O
at	O
Week	O
4	O
at	O
150	O
or	O
450	O
mg	O
per	O
dose	O
(	O
150	O
or	O
450	O
mg	O
Q	O
)	O
.	O

Asthma	O
exacerbation	O
rates	O
Quilizumab	O
treatment	O
did	O
not	O
produce	O
a	O
clinically	O
meaningful	O
reduction	O
of	O
the	O
rate	O
of	O
asthma	O
exacerbations	O
over	O
the	O
36-week	O
treatment	O
period	O
.	O

Statistical	O
methods	O
All	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
(	O
intention-to-treat	O
,	O
ITT	O
population	O
)	O
and	O
were	O
included	O
in	O
all	O
safety	O
and	O
efficacy	O
analyses	O
.	O

For	O
the	O
150	O
mg	O
Q	O
,	O
450	O
mg	O
Q	O
,	O
and	O
300	O
mg	O
M	O
doses	O
,	O
the	O
mean	O
Cmax	O
,	O
obs	O
values	O
were	O
18	O
±	O
7.8	O
μg/mL	O
,	O
51.6	O
±	O
19.5	O
μg/mL	O
,	O
and	O
34	O
±	O
12.6	O
μg/mL	O
,	O
which	O
occurred	O
at	O
Tmax	O
,	O
obs	O
of	O
36.4	O
±	O
4.3	O
days	O
,	O
36.2	O
±	O
3.0	O
days	O
,	O
and	O
36.2	O
±	O
3.5	O
days	O
,	O
respectively	O
,	O
approximately	O
7	O
days	O
following	O
the	O
second	O
doses	O
.	O

We	O
also	O
evaluated	O
the	O
ability	O
of	O
biomarkers	O
(	O
serum	O
periostin	O
,	O
blood	O
eosinophils	O
,	O
exhaled	O
NO	O
,	O
and	O
serum	O
IgE	O
)	O
to	O
predict	O
benefit	O
from	O
quilizumab	O
.	O

The	O
highest	O
relative	O
improvement	O
compared	O
to	O
placebo	O
occurred	O
in	O
the	O
lowest	O
dose	O
arm	O
(	O
150	O
mg	O
Q	O
)	O
,	O
but	O
no	O
meaningful	O
improvements	O
were	O
observed	O
in	O
the	O
higher	O
dose	O
arms	O
(	O
450	O
mg	O
Q	O
and	O
300	O
mg	O
M	O
)	O
.	O

For	O
secondary	O
and	O
exploratory	O
end	O
points	O
,	O
the	O
means	O
and	O
standard	O
deviations	O
of	O
all	O
values	O
for	O
relative	O
change	O
were	O
calculated	O
according	O
to	O
study	O
group	O
at	O
Weeks	O
12	O
and	O
36	O
.	O

Pharmacokinetics	O
Quilizumab	O
displayed	O
linear	O
pharmacokinetics	O
with	O
a	O
dose-proportional	O
increase	O
in	O
exposure	O
as	O
shown	O
by	O
increases	O
in	O
Cmax	O
values	O
between	O
the	O
150	O
and	O
450	O
mg	O
Q	O
doses	O
at	O
Weeks	O
5	O
and	O
25	O
.	O

Serum	O
periostin	O
was	O
measured	O
by	O
immunoassay	O
using	O
the	O
Roche	O
Elecsys	O
platform	O
(	O
Roche	O
Diagnostics	O
Ltd.	O
,	O
Rotkreuz	O
,	O
Switzerland	O
)	O
.	O

The	O
mean	O
relative	O
changes	O
from	O
baseline	O
were	O
compared	O
between	O
the	O
study	O
groups	O
using	O
the	O
differences	O
between	O
the	O
means	O
for	O
each	O
group	O
,	O
with	O
the	O
associated	O
two-sided	O
90	O
%	O
CIs	O
.	O

Pharmacodynamic	O
biomarkers	O
Quilizumab	O
gradually	O
reduced	O
mean	O
serum	O
total	O
and	O
allergen-specific	O
IgE	O
,	O
reaching	O
a	O
30–40	O
%	O
reduction	O
at	O
Week	O
36	O
in	O
all	O
three	O
quilizumab	O
cohorts	O
(	O
p	O
<	O
0.01	O
compared	O
to	O
placebo	O
;	O
Fig	O
.	O

Lung	O
function	O
No	O
significant	O
evidence	O
of	O
improved	O
FEV1	O
at	O
Weeks	O
12	O
and	O
36	O
was	O
observed	O
in	O
quilizumab-treated	O
patients	O
compared	O
to	O
placebo	O
(	O
Fig	O
.	O

This	O
sample	O
size	O
provided	O
approximately	O
84	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
50	O
%	O
reduction	O
in	O
average	O
exacerbation	O
rates	O
due	O
to	O
quilizumab	O
,	O
assuming	O
0.63	O
exacerbations	O
per	O
patient	O
in	O
the	O
placebo	O
group	O
over	O
a	O
36-week	O
treatment	O
period	O
,	O
and	O
a	O
significance	O
level	O
of	O
α	O
=	O
0.10	B-Sample_Size_Calculation_Alpha_Value
.	O

The	O
primary	O
endpoint	O
,	O
the	O
annualized	O
exacerbation	O
rate	O
,	O
was	O
calculated	O
by	O
the	O
total	O
number	O
of	O
protocol-defined	O
exacerbations	O
observed	O
in	O
the	O
group	O
over	O
the	O
treatment	O
period	O
divided	O
by	O
total	O
patient-weeks	O
at	O
risk	O
(	O
number	O
of	O
weeks	O
from	O
first	O
study	O
drug	O
administration	O
to	O
the	O
earliest	O
of	O
Week	O
36	O
or	O
study	O
discontinuation	O
)	O
for	O
the	O
group	O
and	O
multiplied	O
by	O
52	O
.	O

Ethics	O
,	O
consent	O
,	O
and	O
permissions	O
Quorum	O
Review	O
based	O
in	O
Seattle	O
,	O
WA	O
was	O
the	O
primary	O
central	O
IRB	O
used	O
by	O
sites	O
in	O
North	O
America	O
,	O
however	O
multiple	O
other	O
site-specific	O
institutional	O
review	O
boards	O
at	O
other	O
global	O
sites	O
approved	O
the	O
protocol	O
and	O
patients	O
gave	O
written	O
,	O
informed	O
consent	O
.	O

The	O
trial	O
was	O
conducted	O
in	O
full	O
conformance	O
with	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
E6	O
guidelines	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
or	O
laws	O
and	O
regulations	O
of	O
the	O
country	O
where	O
the	O
research	O
was	O
conducted	O
,	O
whichever	O
afforded	O
greater	O
protection	O
to	O
the	O
individual	O
.	O

The	O
diary	O
was	O
also	O
used	O
to	O
determine	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
no	O
nighttime	O
awakenings	O
due	O
to	O
asthma	O
symptoms	O
and	O
the	O
proportion	O
of	O
patients	O
with	O
fewer	O
than	O
2	O
days	O
of	O
SABA	O
use	O
per	O
week	O
by	O
Week	O
36	O
.	O

For	O
biomarker	O
subgroup	O
analyses	O
,	O
unadjusted	O
asthma	O
exacerbation	O
rates	O
were	O
calculated	O
.	O

The	O
treatment	O
period	O
ended	O
36	O
weeks	O
after	O
randomization	O
and	O
was	O
followed	O
by	O
a	O
48-week	O
period	O
to	O
assess	O
the	O
sustained	O
efficacy	O
and	O
safety	O
of	O
quilizumab	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S1	O
)	O
.	O

Fractional	O
exhaled	O
nitric	O
oxide	O
(	O
FeNO	O
)	O
was	O
measured	O
using	O
a	O
hand-held	O
portable	O
device	O
,	O
NIOX	O
MINO®	O
(	O
Niox	O
;	O
Morrisville	O
,	O
NC	O
)	O
,	O
according	O
to	O
American	O
Thoracic	O
Society/European	O
Respiratory	O
Society	O
2009	O
guidelines	O
.	O

The	O
largest	O
decreases	O
in	O
total	O
and	O
allergen-specific	O
IgE	O
were	O
observed	O
at	O
Week	O
42	O
in	O
the	O
300	O
mg	O
M	O
treatment	O
cohort	O
.	O

The	O
modified	O
total	O
asthma	O
symptom	O
score	O
(	O
mTASS	O
)	O
was	O
generated	O
from	O
a	O
subset	O
of	O
diary	O
questions	O
adapted	O
from	O
a	O
previous	O
questionnaire	O
,	O
scoring	O
nighttime	O
awakenings	O
(	O
0–3	O
)	O
,	O
symptoms	O
on	O
awakening	O
(	O
0–1	O
)	O
,	O
and	O
daytime	O
symptom	O
severity	O
(	O
0–4	O
)	O
,	O
for	O
a	O
total	O
score	O
range	O
of	O
0–8	O
.	O

The	O
treatment-emergent	O
ATA	O
rate	O
was	O
1.4	O
%	O
in	O
both	O
the	O
150	O
mg	O
Q	O
and	O
300	O
mg	O
M	O
groups	O
,	O
and	O
2.1	O
%	O
in	O
the	O
450	O
mg	O
Q	O
group	O
.	O

This	O
sample	O
size	O
also	O
provided	O
approximately	O
70	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
50	O
%	O
reduction	O
in	O
average	O
exacerbation	O
rates	O
in	O
the	O
subgroup	O
of	O
periostin-high	O
patients	O
,	O
assuming	O
0.69	O
exacerbations	O
per	O
patient	O
in	O
the	O
placebo	O
group	O
over	O
the	O
36-week	O
period	O
,	O
a	O
significance	O
level	O
of	O
0.15	B-Sample_Size_Calculation_Alpha_Value
,	O
and	O
50	O
%	O
of	O
patients	O
in	O
each	O
treatment	O
arm	O
to	O
be	O
periostin	O
high	O
.	O

(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S2	O
)	O
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
1:1:1:1	B-Randomization_Ratio
)	O
to	O
one	B-Design_Parallel_Group
of	I-Design_Parallel_Group
three	I-Design_Parallel_Group
dosing	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
of	I-Design_Parallel_Group
quilizumab	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
using	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

Treatment	O
with	O
quilizumab	O
failed	O
to	O
increase	O
either	O
the	O
proportion	O
of	O
patients	O
who	O
used	O
a	O
SABA	O
for	O
fewer	O
than	O
2	O
days	O
in	O
the	O
prior	O
week	O
or	O
the	O
proportion	O
of	O
patients	O
who	O
did	O
not	O
awaken	O
at	O
night	O
due	O
to	O
asthma	O
symptoms	O
for	O
all	O
dosing	O
levels	O
relative	O
to	O
the	O
placebo	O
group	O
at	O
Week	O
36	O
(	O
Table	O
3	O
)	O
.	O

Sample	O
size	O
determination	O
We	O
planned	O
to	O
randomize	O
560	B-Sample_Size_Required
patients	O
to	O
one	O
of	O
three	O
dose	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
of	I-Design_Parallel_Group
quilizumab	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
in	O
a	O
1:1:1:1	B-Randomization_Ratio
ratio	O
(	O
140	O
patients	O
per	O
group	O
)	O
.	O

For	O
patients	O
who	O
discontinued	O
the	O
study	O
prematurely	O
,	O
there	O
was	O
no	O
imputation	O
of	O
additional	O
exacerbations	O
.	O

There	O
was	O
no	O
apparent	O
impact	O
of	O
positive	O
ATA	O
results	O
on	O
either	O
pharmacokinetic	O
profiles	O
or	O
safety	O
.	O

An	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
model	O
with	O
factors	O
for	O
baseline	O
level	O
,	O
periostin	O
status	O
(	O
<	O
50	O
ng/mL	O
,	O
≥50	O
ng/mL	O
)	O
,	O
number	O
of	O
prior	O
exacerbations	O
(	O
1	O
,	O
>	O
1	O
)	O
,	O
and	O
IgE	O
level	O
(	O
<	O
200	O
IU/mL	O
,	O
≥200	O
IU/mL	O
)	O
was	O
fit	O
to	O
assess	O
the	O
treatment	O
effect	O
.	O

Serum	O
total	O
and	O
allergen-specific	O
IgE	O
in	O
quilizumab-treated	O
patients	O
gradually	O
increased	O
throughout	O
the	O
safety	O
follow-up	O
period	O
,	O
but	O
did	O
not	O
return	O
to	O
pre-dose	O
levels	O
by	O
the	O
end	O
of	O
the	O
study	O
period	O
(	O
Week	O
84	O
)	O
.	O

Serum	O
anti-therapeutic	O
antibodies	O
(	O
ATAs	O
)	O
were	O
assessed	O
in	O
samples	O
at	O
Weeks	O
0	O
,	O
4	O
,	O
12	O
,	O
24	O
,	O
36	O
,	O
48	O
,	O
60	O
,	O
and	O
84	O
using	O
a	O
validated	O
bridging	O
ELISA	O
(	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

Results	O
In	O
total	O
,	O
149	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomised	O
and	O
141	B-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
.	O

The	O
corresponding	O
author	O
had	O
full	O
access	O
to	O
all	O
the	O
data	O
in	O
the	O
study	O
and	O
had	O
final	O
responsibility	O
for	O
the	O
decision	O
to	O
submit	O
for	O
publication	O
.	O

Duration	O
of	O
illness	O
before	O
enrolment	O
and	O
antiviral	O
treatment	O
before	O
enrolment	O
were	O
not	O
significant	O
predictors	O
in	O
the	O
multivariate	O
model	O
:	O
odds	O
ratio	O
1.48	O
(	O
95	O
%	O
confidence	O
interval	O
0.79	O
to	O
2.80	O
;	O
P=0.22	O
)	O
for	O
duration	O
of	O
illness	O
over	O
two	O
days	O
and	O
1.53	O
(	O
0.51	O
to	O
4.55	O
;	O
P=0.45	O
)	O
for	O
antiviral	O
treatment	O
.	O

Vasomotor	O
response	O
Of	O
the	O
26	B-Sample_Size_Actual_at_Enrollment
patients	O
enrolled	O
,	O
15	B-Sample_Size_Actual_at_Outcome_Analysis
underwent	O
vascular	O
assessment	O
(	O
eight	O
randomised	O
to	O
receive	O
etanercept	O
)	O
.	O

They	O
independently	O
assessed	O
the	O
photographs	O
for	O
each	O
participant	O
to	O
determine	O
whether	O
the	O
plantar	O
wart	O
had	O
cleared	O
.	O

RESULTS	O
:	O
In	O
REDUCE-1	O
,	O
the	O
primary	O
end	O
point	O
analysis	O
of	O
gastric	O
ulcers	O
at	O
24	O
weeks	O
with	O
HZT-501	O
vs.	O
ibuprofen	O
was	O
12.7	O
%	O
vs.	O
22.9	O
%	O
(	O
P=0.0044	O
)	O
in	O
the	O
post-adjudication	O
analysis	O
.	O

The	O
largest	O
difference	O
from	O
placebo	O
was	O
with	O
tiotropium	O
Respimat®	O
5	O
μg	O
(	O
188	O
mL	O
)	O
.	O

Evidence	O
for	O
the	O
efficacy	O
of	O
colchicine	O
as	O
prophylaxis	O
against	O
flares	O
comes	O
from	O
two	O
small	O
studies	O
and	O
a	O
larger	O
study	O
performed	O
50	O
years	O
ago	O
.	O

During	O
the	O
post-trial	O
period	O
,	O
the	O
incidence	O
rates	O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
(	O
RR	O
0·96	O
[	O
95	O
%	O
CI	O
0·88–1·04	O
]	O
;	O
p=0·31	O
)	O
,	O
although	O
a	O
further	O
reduction	O
was	O
recorded	O
in	O
first	O
non-fatal	O
myocardial	O
infarction	O
(	O
413	O
[	O
4·8	O
%	O
]	O
vs	O
465	O
[	O
5·7	O
%	O
]	O
;	O
p=0·01	O
)	O
.	O

There	O
was	O
a	O
64	O
%	O
to	O
72	O
%	O
reduction	O
in	O
the	O
risk	O
of	O
experiencing	O
≥1	O
flare	O
for	O
canakinumab	O
doses	O
≥50	O
mg	O
versus	O
colchicine	O
at	O
16	O
weeks	O
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
:	O
0.28–0.36	O
,	O
p≤0.05	O
)	O
.	O

This	O
was	O
because	O
the	O
randomisation	O
analyses	O
compared	O
intervention	O
and	O
control	O
groups	O
in	O
which	O
half	O
of	O
each	O
control	O
group	O
had	O
received	O
an	O
effective	O
intervention	O
from	O
the	O
other	O
randomisation	O
,	O
thus	O
reducing	O
the	O
apparent	O
effect	O
size	O
.	O

Among	O
45	O
WHO	O
stage	O
3	O
or	O
4	O
events	O
reported	O
on	O
clinically	O
driven	O
monitoring	O
and	O
21	O
on	O
routine	O
laboratory	O
monitoring	O
from	O
the	O
second	O
year	O
onwards	O
,	O
14	O
versus	O
one	O
were	O
failure-to-thrive	O
and	O
15	O
versus	O
15	O
were	O
extrapulmonary	O
or	O
pulmonary	O
tuberculosis	O
,	O
highlighting	O
the	O
potential	O
of	O
weight	O
monitoring	O
to	O
identify	O
first-line	O
CD4	O
failure	O
clinically	O
.	O

Randomisation	O
used	O
computer-generated	B-Randomization_Sequence_Generation_Method
sequentially	I-Randomization_Sequence_Generation_Method
numbered	I-Randomization_Sequence_Generation_Method
tables	I-Randomization_Sequence_Generation_Method
incorporated	O
securely	O
within	O
the	O
database	O
.	O

Quilizumab	O
is	O
a	O
humanized	O
,	O
monoclonal	O
IgG1	O
that	O
binds	O
to	O
the	O
M1-prime	O
segment	O
present	O
only	O
on	O
membrane	O
IgE	O
,	O
but	O
not	O
on	O
soluble	O
IgE	O
in	O
serum	O
.	O

Evaluation	O
of	O
safety	O
and	O
tolerability	O
was	O
performed	O
on	O
the	O
treated	O
set	O
,	O
defined	O
as	O
all	O
randomised	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
medication	O
.	O

Introduction	O
Each	O
year	O
,	O
about	O
22	O
million	O
people	O
have	O
a	O
stroke	O
world-wide	O
,	O
of	O
whom	O
4	O
million	O
reside	O
in	O
high-income	O
countries	O
,	O
where	O
thrombolytic	O
therapy	O
is	O
affordable	O
and	O
feasible	O
.	O

In	O
addition	O
,	O
antacids	O
could	O
not	O
be	O
taken	O
for	O
>	O
3	O
days	O
in	O
any	O
2-week	O
period	O
;	O
patients	O
requiring	O
further	O
antacid	O
therapy	O
were	O
to	O
be	O
discontinued	O
from	O
the	O
trial	O
.	O

The	O
statistical	O
analysis	O
plan	O
was	O
published	O
before	O
unmasking	O
of	O
the	O
authors	O
to	O
the	O
data	O
.	O

Secondary	O
endpoints	O
Day	O
five	O
clinical	O
failure	O
The	O
criteria	O
for	O
clinical	O
failure	O
on	O
day	O
five	O
were	O
met	O
in	O
16/161	O
(	O
9.9	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
6.2	O
%	O
to	O
15.5	O
%	O
)	O
patients	O
in	O
the	O
double	O
dose	O
and	O
20/158	O
(	O
13	O
%	O
,	O
8.3	O
%	O
to	O
18.7	O
%	O
)	O
in	O
the	O
standard	O
dose	O
arm	O
(	O
P=0.44	O
)	O
;	O
all	O
received	O
five	O
additional	O
days	O
of	O
oseltamivir	O
.	O

Heart	O
rate	O
and	O
systemic	O
blood	O
pressure	O
were	O
similar	O
in	O
both	O
groups	O
and	O
were	O
unaffected	O
by	O
either	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

Statistical	O
analyses	O
Data	O
were	O
analysed	O
with	O
Stata	O
v10	O
(	O
Stata	O
Corporation	O
,	O
Washington	O
DC	O
)	O
.	O

Conclusions	O
Salicylic	O
acid	O
and	O
the	O
cryotherapy	O
were	O
equally	O
effective	O
for	O
clearance	O
of	O
plantar	O
warts	O
.	O

Safety	O
Quilizumab	O
was	O
well	O
tolerated	O
,	O
and	O
the	O
number	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
adverse	O
event	O
(	O
AE	O
)	O
was	O
comparable	O
between	O
all	O
treatment	O
groups	O
(	O
Table	O
2	O
)	O
.	O

Participants	O
121	B-Sample_Size_Actual_at_Enrollment
patients	O
(	O
73	O
women	O
,	O
mean	O
age	O
54	O
years	O
)	O
with	O
clinician	O
diagnosed	O
pyoderma	O
gangrenosum	O
.	O

The	O
primary	O
outcome	O
specified	O
in	O
version	O
1·93	O
of	O
the	O
protocol	O
and	O
in	O
the	O
published	O
statistical	O
analysis	O
plan	O
was	O
the	O
proportion	O
of	O
patients	O
alive	O
and	O
independent	O
as	O
measured	O
by	O
the	O
Oxford	O
Handicap	O
Score	O
(	O
OHS	O
)	O
,	O
a	O
commonly	O
used	O
variant	O
of	O
the	O
modified	O
Rankin	O
score	O
.	O

There	O
was	O
no	O
evidence	O
of	O
interaction	O
between	O
monitoring	O
and	O
induction-maintenance	O
ART	O
strategies	O
in	O
primary	O
or	O
secondary	O
outcomes	O
(	O
heterogeneity	O
p	O
>	O
0·1	O
)	O
except	O
for	O
WHO	O
stage	O
4	O
events	O
or	O
death	O
in	O
the	O
first	O
year	O
on	O
ART	O
,	O
for	O
which	O
the	O
relative	O
difference	O
between	O
clinically	O
driven	O
and	O
routine	O
laboratory	O
monitoring	O
varied	O
by	O
first-line	O
ART	O
strategy	O
(	O
appendix	O
)	O
.	O

The	O
results	O
for	O
the	O
primary	O
end	O
point	O
in	O
REDUCE-2	O
showed	O
the	O
proportions	O
of	O
patients	O
with	O
upper	O
GI	O
ulcers	O
of	O
13.0	O
%	O
for	O
HZT-501	O
and	O
20.5	O
%	O
for	O
ibuprofen	O
(	O
P=0.0587	O
)	O
.	O

In	O
view	O
of	O
the	O
high	O
confirmation	O
rate	O
(	O
>	O
95	O
%	O
)	O
in	O
central	O
adjudication	O
of	O
cancers	O
reported	O
during	O
the	O
in-trial	O
period	O
,	O
further	O
information	O
was	O
not	O
routinely	O
sought	O
about	O
non-fatal	O
cancers	O
reported	O
during	O
the	O
post-trial	O
period	O
.	O

Among	O
151	O
first-line	O
drug	O
changes	O
,	O
equal	O
numbers	O
were	O
due	O
to	O
adverse	O
events	O
and	O
antituberculosis	O
therapy	O
(	O
both	O
59	O
changes	O
[	O
39	O
%	O
]	O
;	O
table	O
2	O
)	O
.	O

In	O
an	O
analysis	O
of	O
alkaline	O
phosphatase	O
values	O
,	O
adjusted	O
for	O
baseline	O
values	O
,	O
mean	O
values	O
were	O
marginally	O
lower	O
in	O
the	O
Ca+D	O
group	O
than	O
the	O
Ca	O
group	O
at	O
12	O
weeks	O
(	O
p=0.06	O
)	O
but	O
not	O
at	O
24	O
weeks	O
(	O
p=0.40	O
)	O
.	O

The	O
main	O
factor	O
that	O
limits	O
NSAID	O
use	O
is	O
the	O
development	O
of	O
upper	O
gastrointestinal	O
(	O
GI	O
)	O
adverse	O
effects	O
including	O
ulcers	O
,	O
complications	O
such	O
as	O
bleeding	O
,	O
and	O
dyspepsia	O
.	O

The	O
absolute	O
difference	O
of	O
0·32	O
per	O
100	O
child-years	O
(	O
95	O
%	O
CI	O
−0·47	O
to	O
1·12	O
)	O
translated	O
into	O
a	O
relative	O
HR	O
of	O
1·13	O
(	O
95	O
%	O
CI	O
0·73–1·73	O
,	O
p=0·59	O
;	O
figure	O
3	O
)	O
.	O

Assessment	O
of	O
secondary	O
end	O
points	O
in	O
REDUCE-2	O
showed	O
that	O
the	O
6.7	O
%	O
reduction	O
in	O
life	O
table	O
estimate	O
of	O
gastric	O
ulcers	O
was	O
not	O
significant	O
in	O
the	O
initial	O
comparison	O
(	O
P=0.0795	O
)	O
and	O
the	O
5.3	O
%	O
reduction	O
in	O
the	O
post-adjudication	O
analysis	O
was	O
not	O
formally	O
tested	O
based	O
on	O
the	O
predefined	O
hierarchical	O
testing	O
sequence	O
for	O
the	O
analysis	O
.	O

We	O
chose	O
speed	O
of	O
healing	O
for	O
the	O
primary	O
outcome	O
as	O
previous	O
studies	O
have	O
shown	O
it	O
to	O
be	O
a	O
good	O
predictor	O
of	O
healing	O
in	O
patients	O
with	O
leg	O
ulcers	O
,	O
and	O
because	O
blinded	O
outcome	O
assessment	O
was	O
possible	O
using	O
digital	O
images	O
and	O
independent	O
assessors	O
.	O

The	O
other	O
patient	O
was	O
reported	O
with	O
inguinal	O
hernia	O
,	O
which	O
led	O
to	O
hospitalisation	O
.	O

1617	O
(	O
53	O
%	O
)	O
patients	O
were	O
older	O
than	O
80	O
years	O
of	O
age	O
.	O

Concomitant	O
use	O
of	O
systemic	O
antibiotics	O
,	O
analgaesics	O
and	O
topical	O
treatments	O
for	O
wound	O
care	O
were	O
allowed	O
,	O
and	O
randomised	O
treatment	O
was	O
administered	O
in	O
addition	O
to	O
the	O
usual	O
,	O
stable	O
(	O
over	O
the	O
previous	O
month	O
)	O
treatment	O
for	O
Raynaud	O
's	O
phenomenon	O
.	O

In	O
patients	O
with	O
mild	O
asthma	O
,	O
quilizumab	O
reduced	O
serum	O
IgE	O
and	O
attenuated	O
the	O
early	O
and	O
late	O
asthmatic	O
reaction	O
following	O
whole	O
lung	O
allergen	O
challenge	O
.	O

As	O
a	O
result	O
,	O
the	O
absolute	O
reduction	O
in	O
all-cause	O
mortality	O
that	O
emerged	O
with	O
simvastatin	O
allocation	O
during	O
the	O
in-trial	O
period	O
persisted	O
roughly	O
unchanged	O
after	O
11	O
years	O
of	O
follow-up	O
.	O

Unlike	O
classical	O
vitamin	O
D-deficiency	O
rickets	O
,	O
all	O
children	O
were	O
over	O
the	O
age	O
of	O
1	O
year	O
at	O
presentation	O
and	O
most	O
had	O
regular	O
sun	O
exposure	O
.	O

With	O
a	O
power	O
of	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
and	O
a	B-Sample_Size_Calculation_Alpha_Value
type	I-Sample_Size_Calculation_Alpha_Value
I	I-Sample_Size_Calculation_Alpha_Value
error	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
5	I-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
,	O
the	O
total	O
sample	O
size	O
was	O
found	O
to	O
be	O
17	B-Sample_Size_Required
patients	I-Sample_Size_Required
per	I-Sample_Size_Required
group	I-Sample_Size_Required
.	O

Results	O
Of	O
499	O
patients	O
screened	O
from	O
June	O
2009	O
to	O
November	O
2012	O
,	O
121	B-Sample_Size_Actual_at_Enrollment
were	O
eligible	O
and	O
gave	O
written	O
informed	O
consent	O
(	O
86	O
%	O
of	O
target	O
of	O
140	B-Sample_Size_Required
participants	O
)	O
(	O
fig	O
1	O
)	O
.	O

Role	O
of	O
the	O
funding	O
source	O
The	O
trial	O
was	O
designed	O
,	O
conducted	O
,	O
analysed	O
,	O
and	O
interpreted	O
by	O
the	O
investigators	O
,	O
independently	O
of	O
all	O
funding	O
sources	O
.	O

Co-primary	O
endpoints	O
for	O
the	O
ART-strategy	O
randomisation	O
were	O
change	O
in	O
CD4	O
percentage	O
from	O
randomisation	O
to	O
72	O
and	O
144	O
weeks	O
(	O
efficacy	O
)	O
and	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
(	O
safety	O
)	O
.	O

The	O
effects	O
of	O
statin	O
allocation	O
on	O
vascular	O
mortality	O
in	O
both	O
the	O
in-trial	O
and	O
post-trial	O
periods	O
were	O
unaffected	O
by	O
age	O
or	O
pretreatment	O
lipid	O
profiles	O
(	O
webappendix	O
,	O
p	O
5	O
)	O
.	O

The	O
subgroup	O
analyses	O
for	O
a	O
specific	O
factor	O
provide	O
estimated	O
effects	O
within	O
sub-categories	O
that	O
adjust	O
for	O
such	O
imbalances	O
.	O

Dietary	O
calcium	O
intake	O
was	O
uniformly	O
low	O
,	O
reflecting	O
minimal	O
dairy	O
product	O
intake	O
.	O

Contraceptive	O
measures	O
and	O
monthly	O
pregnancy	O
testing	O
were	O
required	O
during	O
and	O
for	O
3	O
months	O
after	O
the	O
end	O
of	O
study	O
treatment	O
.	O

There	O
were	O
15	O
versus	O
41	O
versus	O
31	O
definitely	O
,	O
probably	O
,	O
or	O
uncertainly	O
ART-related	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
,	O
respectively	O
.	O

Briefly	O
,	O
between	O
July	O
,	O
1994	O
,	O
and	O
May	O
,	O
1997	O
,	O
20	O
536	B-Sample_Size_Actual_at_Enrollment
men	O
and	O
women	O
aged	O
about	O
40–80	O
years	O
,	O
who	O
were	O
at	O
increased	O
risk	O
of	O
vascular	O
events	O
,	O
were	O
randomly	O
allocated	O
to	O
receive	O
40	B-Design_Parallel_Group
mg	I-Design_Parallel_Group
simvastatin	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
or	I-Design_Parallel_Group
matching	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

All	O
children	O
were	O
examined	O
for	O
clinical	O
signs	O
of	O
rickets	O
.	O

Oversight	O
of	O
the	O
trial	O
included	O
a	O
trial	O
management	O
group	O
and	O
independent	O
trial	O
steering	O
and	O
data	O
monitoring	O
committees	O
.	O

It	O
has	O
been	O
suggested	O
,	O
therefore	O
,	O
that	O
lowering	O
LDL	O
cholesterol	O
(	O
particularly	O
to	O
low	O
levels	O
)	O
might	O
produce	O
increases	O
in	O
the	O
rates	O
of	O
cancers	O
and	O
other	O
types	O
of	O
adverse	O
events	O
that	O
take	O
longer	O
than	O
5	O
years	O
to	O
emerge	O
.	O

Total	O
lymphocytes	O
and	O
CD4	O
tests	O
were	O
never	O
returned	O
for	O
participants	O
on	O
clinically	O
driven	O
monitoring	O
,	O
but	O
for	O
all	O
children	O
other	O
investigations	O
could	O
be	O
requested	O
and	O
concomitant	O
drugs	O
prescribed	O
,	O
as	O
clinically	O
indicated	O
.	O

The	O
oxandrolone	O
effect	O
of	O
+4.3	O
cm	O
(	O
P=0.002	O
)	O
was	O
similar	O
to	O
that	O
for	O
final	O
height	O
(	O
+4.6	O
cm	O
)	O
,	O
and	O
the	O
late	O
induction	O
effect	O
of	O
+2.4	O
cm	O
(	O
P=0.2	O
)	O
was	O
appreciably	O
smaller	O
than	O
the	O
+3.8	O
cm	O
for	O
final	O
height	O
.	O

All	O
drug	O
treatments	O
were	O
supervised	O
by	O
the	O
research	O
team	O
.	O

In	O
the	O
primary	O
population	O
,	O
five	O
patients	O
in	O
REDUCE-1	O
(	O
one	O
HZT-501	O
(	O
no	O
ulcer	O
)	O
,	O
four	O
ibuprofen	O
(	O
four	O
esophageal	O
ulcers	O
)	O
)	O
and	O
seven	O
patients	O
in	O
REDUCE-2	O
(	O
three	O
HZT-501	O
(	O
two	O
no	O
ulcer	O
,	O
one	O
esophageal	O
ulcer	O
)	O
,	O
four	O
ibuprofen	O
(	O
one	O
no	O
ulcer	O
,	O
three	O
esophageal	O
ulcers	O
)	O
)	O
had	O
esophageal	O
ulcers	O
misclassified	O
as	O
gastric	O
ulcers	O
or	O
had	O
no	O
gastric	O
ulcer	O
present	O
;	O
duodenal	O
ulcers	O
were	O
not	O
affected	O
.	O

At	O
the	O
end	O
of	O
24	O
weeks	O
,	O
mean	O
serum	O
calcium	O
values	O
increased	O
similarly	O
in	O
the	O
two	O
treatment	O
groups	O
,	O
and	O
mean	O
25	O
(	O
OH	O
)	O
D	O
values	O
had	O
increased	O
to	O
55.4±17.0	O
nmol/L	O
and	O
37.9±20.0	O
nmol/L	O
in	O
the	O
Ca+D	O
and	O
the	O
Ca	O
groups	O
,	O
respectively	O
,	O
(	O
p	O
<	O
0.001	O
;	O
figure	O
4	O
)	O
.	O

In	O
REDUCE-2	O
,	O
the	O
primary	O
end	O
point	O
analysis	O
of	O
upper	O
gastrointestinal	O
(	O
GI	O
)	O
ulcers	O
was	O
13.0	O
%	O
vs.	O
20.5	O
%	O
(	O
P=0.0587	O
)	O
in	O
the	O
post-adjudication	O
analysis	O
.	O

Summary	O
Background	O
Findings	O
of	O
large	O
randomised	O
trials	O
have	O
shown	O
that	O
lowering	O
LDL	O
cholesterol	O
with	O
statins	O
reduces	O
vascular	O
morbidity	O
and	O
mortality	O
rapidly	O
,	O
but	O
limited	O
evidence	O
exists	O
about	O
the	O
long-term	O
efficacy	O
and	O
safety	O
of	O
statin	O
treatment	O
.	O

Randomisation	O
and	O
masking	O
To	O
avoid	O
predictable	O
alternation	O
of	O
treatment	O
allocation	O
,	O
and	O
thus	O
potential	O
loss	O
of	O
allocation	O
concealment	O
,	O
patients	O
were	O
allocated	O
with	O
a	O
probability	O
of	O
0·80	O
to	O
the	O
treatment	O
group	O
that	O
would	O
minimise	B-Randomization_Type_Minimization
the	O
difference	O
between	O
the	O
groups	O
on	O
the	O
key	O
prognostic	O
factors	O
.	O

Results	O
A	O
dose-response	O
for	O
canakinumab	O
was	O
not	O
apparent	O
with	O
any	O
of	O
the	O
four	O
predefined	O
dose-response	O
models	O
.	O

We	O
chose	O
the	O
proportion	O
of	O
patients	O
with	O
viral	O
RNA	O
shedding	O
at	O
day	O
five	O
after	O
the	O
start	O
of	O
treatment	O
as	O
the	O
primary	O
endpoint	O
as	O
this	O
represents	O
the	O
duration	O
of	O
one	O
standard	O
course	O
of	O
oseltamivir	O
and	O
clinical	O
failure	O
is	O
generally	O
evaluated	O
after	O
five	O
days	O
of	O
treatment	O
.	O

Among	O
patients	O
allocated	O
to	O
the	O
rt-PA	O
group	O
,	O
the	O
mean	O
time	O
from	O
randomisation	O
to	O
injection	O
of	O
the	O
bolus	O
was	O
18	O
min	O
,	O
the	O
mean	O
time	O
from	O
onset	O
to	O
treatment	O
was	O
4·2	O
h	O
(	O
SD	O
1·2	O
)	O
,	O
median	O
4·2	O
h	O
(	O
IQR	O
3·2–5·2	O
)	O
.	O

However	O
,	O
in	O
the	O
memantine	O
group	O
,	O
we	O
observed	O
significantly	O
better	O
results	O
(	O
vs	O
placebo	O
)	O
for	O
the	O
overall	O
UPDRS	O
score	O
(	O
F	O
(	O
1,21	O
)	O
=4.9	O
;	O
p=0.039	O
(	O
−1	O
)	O
)	O
and	O
its	O
axial	O
subscore	O
(	O
F	O
(	O
1,21	O
)	O
=7.2	O
;	O
p=0.014	O
(	O
−1.1	O
)	O
)	O
,	O
axial	O
hypertonia	O
,	O
the	O
axial	O
and	O
overall	O
DRS	O
and	O
axial	O
strength	O
.	O

Patients	B-Blinding_Object_Patients
,	O
care	B-Blinding_Object_Care_Providers
providers	I-Blinding_Object_Care_Providers
,	O
and	O
all	B-Blinding_Object_Others
study	I-Blinding_Object_Others
personnel	I-Blinding_Object_Others
were	O
blinded	O
to	O
the	O
treatment	O
.	O

For	O
the	O
virological	O
endpoints	O
,	O
we	O
included	O
only	O
patients	O
with	O
RT-PCR	O
proved	O
influenza	O
virus	O
infection	O
on	O
screening	O
(	O
day	O
0	O
)	O
.	O

Population	O
Nigerian	O
children	O
with	O
active	O
rickets	O
treated	O
with	O
calcium	O
carbonate	O
as	O
limestone	O
(	O
approximately	O
938	O
mg	O
elemental	O
calcium	O
twice	O
daily	O
)	O
were	O
,	O
in	O
addition	O
,	O
randomised	O
to	O
receive	O
either	B-Design_Parallel_Group
oral	I-Design_Parallel_Group
vitamin	I-Design_Parallel_Group
D2	I-Design_Parallel_Group
50	I-Design_Parallel_Group
000	I-Design_Parallel_Group
IU	I-Design_Parallel_Group
(	I-Design_Parallel_Group
Ca+D	I-Design_Parallel_Group
,	I-Design_Parallel_Group
n=44	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	I-Design_Parallel_Group
Ca	I-Design_Parallel_Group
,	I-Design_Parallel_Group
n=28	I-Design_Parallel_Group
)	I-Design_Parallel_Group
monthly	I-Design_Parallel_Group
for	I-Design_Parallel_Group
24	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
.	O

Subcutaneous	O
etanercept	O
has	O
23	O
%	O
bioavailability	O
and	O
achieves	O
peak	O
plasma	O
concentrations	O
of	O
0.43	O
µg/ml	O
at	O
66	O
h.	O
In	O
contrast	O
,	O
a	O
single	O
intravenous	O
dose	O
of	O
10	O
mg	O
etanercept	O
achieves	O
a	O
maximum	O
concentration	O
of	O
2.32	O
µg/ml	O
at	O
50	O
min	O
.	O

Trials	O
in	O
adults	O
have	O
compared	O
routine	O
laboratory	O
with	O
clinical	O
monitoring	O
on	O
ART	O
.	O

There	O
was	O
also	O
no	O
evidence	O
of	O
a	O
difference	O
in	O
the	O
number	O
of	O
plantar	O
warts	O
at	O
12	O
weeks	O
(	O
incident	O
rate	O
ratio	O
1.08	O
(	O
0.81	O
to	O
1.43	O
)	O
,	O
P=0.62	O
)	O
.	O

Vasomotor	O
assessment	O
Assessment	O
of	O
vasomotor	O
function	O
in	O
response	O
to	O
intra-arterial	O
vasodilators	O
was	O
performed	O
as	O
described	O
previously	O
.	O

In	O
children	O
,	O
the	O
corresponding	O
rates	O
were	O
71	O
%	O
(	O
85/120	O
;	O
62.2	O
%	O
to	O
78.2	O
%	O
)	O
in	O
the	O
double	O
dose	O
arm	O
versus	O
67	O
%	O
(	O
79/118	O
;	O
58.0	O
%	O
to	O
74.8	O
%	O
)	O
in	O
the	O
standard	O
dose	O
arm	O
(	O
P=0.52	O
)	O
,	O
and	O
in	O
adults	O
77	O
%	O
(	O
30/39	O
;	O
61.7	O
%	O
to	O
87.4	O
%	O
)	O
versus	O
72	O
%	O
(	O
26/36	O
;	O
56.0	O
%	O
to	O
84.2	O
%	O
)	O
,	O
respectively	O
(	O
P=0.64	O
)	O
.	O

Bosentan	O
treatment	O
of	O
digital	O
ulcers	O
related	O
to	O
systemic	O
sclerosis	O
:	O
results	O
from	O
the	O
RAPIDS-2	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
trial	O

Randomisation	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
target	B-Randomization_Stratified_Criteria
lesion	I-Randomization_Stratified_Criteria
size	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
20	I-Randomization_Stratified_Criteria
cm2	I-Randomization_Stratified_Criteria
;	I-Randomization_Stratified_Criteria
≥20	I-Randomization_Stratified_Criteria
cm2	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and	O
presence	B-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
absence	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
underlying	I-Randomization_Stratified_Criteria
systemic	I-Randomization_Stratified_Criteria
disease	I-Randomization_Stratified_Criteria
.	O

All	O
IST-3	O
monitoring	O
procedures	O
were	O
compliant	O
with	O
requirements	O
of	O
all	O
study	O
sponsors	O
,	O
the	O
national	O
ethics	O
committees	O
and	O
regulatory	O
agencies	O
in	O
the	O
12	O
participating	O
countries	O
,	O
and	O
they	O
met	O
all	O
appropriate	O
regulatory	O
and	O
Good	O
Clinical	O
Practice	O
requirements	O
.	O

The	O
present	O
study	O
(	O
RAPIDS-2	O
,	O
for	O
‘	O
RAndomized	O
,	O
double-blind	O
,	O
Placebo-controlled	O
study	O
with	O
bosentan	O
on	O
healing	O
and	O
prevention	O
of	O
Ischemic	O
Digital	O
ulcers	O
in	O
patients	O
with	O
systemic	O
Sclerosis	O
’	O
)	O
was	O
designed	O
to	O
further	O
investigate	O
the	O
effects	O
of	O
bosentan	O
as	O
a	O
treatment	O
for	O
DUs	O
secondary	O
to	O
SSc	O
over	O
a	O
24-week	O
treatment	O
period	O
in	O
a	O
larger	O
population	O
of	O
patients	O
,	O
all	O
of	O
whom	O
had	O
active	O
DUs	O
at	O
study	O
entry	O
.	O

We	O
chose	O
a	O
difference	O
of	O
0.5	O
standard	O
deviations	O
as	O
being	O
a	O
clinically	O
meaningful	O
between	O
group	O
difference	O
,	O
as	O
observational	O
data	O
suggested	O
that	O
ciclosporin	O
was	O
potentially	O
more	O
effective	O
,	O
but	O
at	O
higher	O
cost	O
,	O
than	O
prednisolone	O
.	O

Blood	O
anticoagulated	O
with	O
PPACK	O
was	O
labelled	O
with	O
the	O
appropriate	O
antibodies	O
exactly	O
5	O
min	O
from	O
collection	O
and	O
incubated	O
in	O
the	O
dark	O
for	O
20	O
min	O
at	O
room	O
temperature	O
.	O

During	O
the	O
post-trial	O
period	O
,	O
self-reported	O
statin	O
use	O
was	O
similar	O
in	O
both	O
groups	O
,	O
rising	O
from	O
about	O
59	O
%	O
at	O
the	O
end	O
of	O
the	O
first	O
year	O
to	O
84	O
%	O
by	O
the	O
end	O
of	O
the	O
fifth	O
year	O
(	O
table	O
2	O
)	O
.	O

30	O
children	O
in	O
group	O
A	O
,	O
20	O
in	O
group	O
B	O
,	O
and	O
nine	O
in	O
group	O
C	O
stopped	O
nevirapine	O
because	O
of	O
starting	O
antituberculosis	O
treatment	O
.	O

Trial	O
registration	O
ClinicalTrials.gov	O
identifier	O
NCT01233284	O
.	O

Randomisation	O
and	O
masking	O
The	O
British	O
Society	O
for	O
Paediatric	O
Endocrinology	O
and	O
Diabetes	O
Clinical	O
Trials	O
Unit	O
(	O
Cambridge	O
,	O
UK	O
)	O
used	O
minimisation	B-Randomization_Type_Minimization
by	O
weighted	B-Randomization_Minimization_Criteria
randomisation	I-Randomization_Minimization_Criteria
for	O
the	O
study	O
’	O
s	O
two	O
randomisations	O
.	O

No	O
serious	O
infections	O
were	O
reported	O
in	O
patients	O
receiving	O
colchicine	O
.	O

Allergen-specific	O
and	O
total	O
IgE	O
were	O
measured	O
in	O
serum	O
by	O
ImmunoCAP®	O
Specific	O
IgE	O
blood	O
tests	O
(	O
ViraCor-IBT	O
Laboratories	O
,	O
Lee	O
’	O
s	O
Summit	O
,	O
MO	O
)	O
.	O

Patients	O
and	O
methods	O
The	O
present	O
randomised	B-Randomization_Type_Simple
trial	O
complied	O
with	O
the	O
CONSORT	O
2010	O
guidelines	O
and	O
was	O
registered	O
at	O
ClinicalTrials.gov	O
(	O
identifier	O
:	O
NCT01108029	O
)	O
.	O

Children	O
's	O
heights	O
were	O
significantly	O
stunted	O
,	O
in	O
part	O
reflecting	O
their	O
leg	O
deformities	O
,	O
but	O
their	O
relatively	O
normal	O
weight	O
for	O
height	O
and	O
serum	O
albumin	O
did	O
not	O
indicate	O
acute	O
malnutrition	O
.	O

Secondary	O
analyses	O
Trough	O
FEV1	O
,	O
FEV1	O
AUC	O
(	O
0-3h	O
)	O
,	O
peak	O
FVC	O
(	O
0-3h	O
)	O
,	O
trough	O
FVC	O
and	O
FVC	O
AUC	O
(	O
0-3h	O
)	O
responses	O
with	O
all	O
doses	O
of	O
tiotropium	O
Respimat®	O
were	O
larger	O
than	O
the	O
responses	O
observed	O
with	O
placebo	O
Respimat®	O
,	O
and	O
all	O
were	O
statistically	O
significant	O
except	O
for	O
trough	O
FVC	O
in	O
the	O
1.25	O
μg	O
group	O
(	O
Figure	O
3	O
,	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

The	O
study	O
was	O
approved	O
by	O
local	O
ethics	O
committees	O
and	O
conducted	O
in	O
accordance	O
with	O
the	O
amended	O
Declaration	O
of	O
Helsinki	O
.	O

CRP	O
levels	O
An	O
initial	O
decrease	O
in	O
median	O
CRP	O
levels	O
was	O
seen	O
in	O
all	O
treatment	O
groups	O
(	O
figure	O
3	O
)	O
.	O

Qualitative	O
RT-PCR	O
for	O
detection	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
and	O
for	O
subtyping	O
of	O
influenza	O
A	O
viruses	O
was	O
done	O
according	O
to	O
WHO/US	O
CDC	O
protocols	O
.	O

Means±SEs	O
are	O
presented	O
for	O
numerical	O
variables	O
and	O
Kaplan–Meier	O
estimates	O
for	O
time-to-event	O
variables	O
.	O

Biomarkers	O
Samples	O
for	O
biomarker	O
assessments	O
were	O
collected	O
throughout	O
the	O
study	O
.	O

Gastric	O
erosions	O
were	O
noted	O
at	O
endoscopy	O
in	O
all	O
three	O
patients	O
.	O

Platelet	O
activation	O
PMA	O
and	O
platelet	O
P-selectin	O
expression	O
were	O
similar	O
between	O
the	O
groups	O
at	O
baseline	O
.	O

Further	O
,	O
in	O
patients	O
who	O
fail	O
to	O
gain	O
control	O
with	O
an	O
ICS	O
+	O
LABA	O
fixed-dose	O
combination	O
,	O
the	O
remaining	O
options	O
,	O
such	O
as	O
further	O
upwards	O
titration	O
of	O
ICS	O
,	O
systemic	O
glucocorticosteroids	O
and	O
anti-immunoglobulin	O
E	O
therapy	O
,	O
may	O
have	O
several	O
limitations	O
with	O
respect	O
to	O
side	O
effects	O
,	O
risk	O
:	O
benefit	O
ratio	O
,	O
convenience	O
and	O
efficacy	O
.	O

During	O
four-drug	O
induction	O
,	O
a	O
drug	O
could	O
be	O
dropped	O
because	O
of	O
toxicity	O
or	O
drug	O
interactions	O
with	O
antituberculosis	O
treatment	O
.	O

Clinical	O
diagnosis	O
was	O
revised	O
in	O
nine	O
participants	O
after	O
randomisation	O
,	O
leaving	O
112	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
in	O
the	O
analysis	O
set	O
(	O
59	O
ciclosporin	O
;	O
53	O
prednisolone	O
)	O
.	O

Data	O
on	O
potential	O
reports	O
of	O
any	O
of	O
these	O
events	O
were	O
extracted	O
from	O
the	O
trial	O
database	O
and	O
presented	O
to	O
the	O
adjudication	O
committee	O
who	O
were	O
masked	O
to	O
treatment	O
allocation	O
.	O

Study	O
endoscopies	O
were	O
done	O
at	O
8	O
,	O
16	O
,	O
and	O
24	O
weeks	O
.	O

Pre-dose	O
lung	O
function	O
tests	O
were	O
scheduled	O
between	O
18:00	O
and	O
20:00	O
.	O

For	O
example	O
,	O
van	O
Soest	O
et	O
al	O
.	O

This	O
suggests	O
that	O
selective	O
blockade	O
of	O
IL-1β	O
signalling	O
may	O
provide	O
effective	O
prophylaxis	O
against	O
flares	O
in	O
patients	O
with	O
gouty	O
arthritis	O
and	O
is	O
supported	O
by	O
results	O
showing	O
that	O
IL-1β	O
blockade	O
with	O
canakinumab	O
,	O
a	O
fully	O
human	O
monoclonal	O
antibody	O
to	O
IL-1β	O
with	O
a	O
half-life	O
of	O
3–4	O
weeks	O
,	O
can	O
effectively	O
reduce	O
pain	O
,	O
inflammation	O
and	O
the	O
risk	O
of	O
recurrent	O
flares	O
in	O
patients	O
with	O
acute	O
gouty	O
arthritis	O
.	O

No	O
significant	O
difference	O
was	O
seen	O
in	O
suppression	O
less	O
than	O
80	O
copies	O
per	O
mL	O
at	O
week	O
24	O
(	O
p=0·41	O
)	O
;	O
however	O
,	O
suppression	O
less	O
than	O
80	O
copies	O
per	O
mL	O
was	O
significantly	O
greater	O
in	O
groups	O
A	O
and	O
B	O
at	O
week	O
144	O
and	O
latest	O
test	O
(	O
466	O
[	O
79	O
%	O
]	O
in	O
groups	O
A	O
and	O
B	O
vs	O
176	O
[	O
57	O
%	O
]	O
in	O
group	O
C	O
;	O
p	O
<	O
0·0001	O
)	O
.	O

Similar	O
patterns	O
were	O
seen	O
for	O
each	O
component	O
of	O
major	O
vascular	O
events	O
(	O
figure	O
1	O
)	O
.	O

Analyses	O
were	O
conducted	O
in	O
SAS	O
version	O
9.2	O
(	O
SAS	O
Institute	O
,	O
NC	O
,	O
USA	O
)	O
and	O
SPSS	O
version	O
17.0.2	O
(	O
SPSS	O
)	O
using	O
two	O
sided	O
significance	O
tests	O
at	O
the	O
5	O
%	O
significance	O
level	O
for	O
the	O
primary	O
outcome	O
measure	O
and	O
1	O
%	O
significance	O
level	O
for	O
secondary	O
outcome	O
measures	O
.	O

It	O
was	O
not	O
possible	O
to	O
blind	O
clinicians	O
and	O
participants	O
to	O
treatment	O
allocation	O
owing	O
to	O
resource	O
limitations	O
and	O
the	O
complexities	O
of	O
different	O
dosing	O
regimens	O
and	O
safety	O
testing	O
of	O
the	O
two	O
drugs	O
.	O

Responses	O
for	O
each	O
of	O
these	O
end	O
points	O
were	O
all	O
largest	O
in	O
the	O
5	O
μg	O
group	O
(	O
Figure	O
3	O
,	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

This	O
effect	O
is	O
seen	O
in	O
figure	O
3	O
(	O
top	O
panel	O
)	O
,	O
which	O
shows	O
SITAR	O
summary	O
curves	O
calculated	O
separately	O
for	O
oxandrolone	O
and	O
placebo	O
.	O

Baseline	O
values	O
were	O
derived	O
from	O
a	O
minimum	O
of	O
10	O
days	O
of	O
patient	O
diary	O
entries	O
during	O
the	O
14	O
days	O
prior	O
to	O
the	O
first	O
treatment	O
.	O

Trial	O
design	O
and	O
oversight	O
We	O
carried	O
out	O
a	O
multicentre	B-Settings_Multicenter
,	O
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
,	O
observer	B-Blinding_Object_Outcome_Assessors
blind	I-Blinding_Single_Blind
randomised	O
controlled	O
trial	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
ciclosporin	O
with	O
that	O
of	O
prednisolone	O
.	O

As	O
a	O
result	O
of	O
the	O
current	O
European	O
Union	O
(	O
EU	O
)	O
approval	O
criteria	O
,	O
treatment	O
is	O
only	O
applicable	O
to	O
a	O
small	O
proportion	O
of	O
patients	O
with	O
acute	O
stroke	O
.	O

The	O
increase	O
in	O
height	O
over	O
the	O
course	O
of	O
treatment	O
was	O
significantly	O
related	O
to	O
the	O
final	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
r=0.28	O
;	O
p=0.02	O
)	O
.	O

Safety	O
and	O
baseline	O
data	O
were	O
summarised	O
descriptively	O
,	O
with	O
no	O
statistical	O
testing	O
planned	O
or	O
given	O
.	O

After	O
acute	O
administration	O
of	O
L-dopa	O
at	O
9:00	O
,	O
the	O
‘	O
best	O
on	O
’	O
condition	O
was	O
assessed	O
at	O
between	O
9:30	O
and	O
10:00	O
on	O
the	O
same	O
morning	O
.	O

Objective	O
To	O
compare	O
the	O
clinical	O
effectiveness	O
of	O
cryotherapy	O
versus	O
salicylic	O
acid	O
for	O
the	O
treatment	O
of	O
plantar	O
warts	O
.	O

The	O
Wilcoxon	O
test	O
was	O
used	O
to	O
compare	O
non-normally	O
distributed	O
variables	O
.	O

Kerstjens	O
and	O
colleagues	O
subsequently	O
reported	O
results	O
from	O
two	O
long-term	O
,	O
replicate	O
,	O
1-year	O
Phase	O
III	O
trials	O
of	O
tiotropium	O
Respimat®	O
5	O
μg	O
,	O
also	O
in	O
patients	O
with	O
symptomatic	O
severe	O
asthma	O
despite	O
using	O
ICS	O
+	O
LABA	O
.	O

The	O
trial	O
was	O
registered	O
with	O
http	O
:	O
//www.clinicaltrials.gov	O
(	O
registration	O
number	O
:	O
NCT00819585	O
)	O
.	O

Of	O
17	O
patients	O
infected	O
with	O
avian	O
H5N1	O
virus	O
,	O
only	O
three	O
survived	O
to	O
the	O
day	O
five	O
evaluation	O
,	O
all	O
of	O
whom	O
met	O
the	O
criteria	O
for	O
clinical	O
failure	O
.	O

In	O
addition	O
,	O
no	O
comparisons	O
showed	O
less	O
frequent	O
virus	O
RNA	O
detection	O
in	O
the	O
double	O
dose	O
group	O
on	O
treatment	O
day	O
one	O
or	O
three	O
in	O
any	O
subgroup	O
of	O
interest	O
(	O
data	O
not	O
shown	O
)	O
.	O

All	O
randomly	O
assigned	O
patients	O
were	O
included	O
in	O
the	O
analysis	O
.	O

The	O
latter	O
were	O
confirmed	O
as	O
false	O
positive	O
tests	O
as	O
there	O
was	O
no	O
rise	O
in	O
haemagglutination	O
inhibition	O
titers	O
during	O
convalescence	O
.	O

Overall	O
,	O
28	O
(	O
5	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
35	O
(	O
6	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
switched	O
to	O
second-line	O
treatment	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0·78	O
,	O
95	O
%	O
CI	O
0·48–1·29	O
,	O
p=0·22	O
;	O
table	O
2	O
;	O
figure	O
2	O
)	O
,	O
after	O
median	O
2·8	O
(	O
IQR	O
1·8–3·3	O
)	O
years	O
versus	O
2·2	O
(	O
1·5–3·0	O
)	O
years	O
,	O
respectively	O
.	O

There	O
is	O
therefore	O
a	O
need	O
for	O
more	O
rigorous	O
assessment	O
of	O
the	O
efficacy	O
of	O
colchicine	O
as	O
prophylaxis	O
against	O
flares	O
following	O
ULT	O
initiation	O
and	O
the	O
introduction	O
of	O
alternative	O
therapies	O
.	O

The	O
maximum	O
specific	O
IgE	O
was	O
defined	O
as	O
the	O
specific	O
IgE	O
with	O
the	O
highest	O
titer	O
of	O
specific	O
IgEs	O
pre-dose	O
in	O
each	O
patient	O
.	O

However	O
,	O
the	O
positive	O
effects	O
of	O
oxandrolone	O
and	O
late	O
induction	O
were	O
not	O
additive	O
.	O

At	O
Week	O
36	O
,	O
the	O
300	O
mg	O
monthly	O
quilizumab	O
group	O
showed	O
a	O
19.6	O
%	O
reduction	O
(	O
p	O
=	O
0.38	O
)	O
in	O
the	O
asthma	O
exacerbation	O
rate	O
relative	O
to	O
placebo	O
,	O
but	O
this	O
was	O
neither	O
statistically	O
nor	O
clinically	O
significant	O
.	O

The	O
eligibility	O
criteria	O
can	O
be	O
summarised	O
in	O
terms	O
of	O
the	O
uncertainty	O
principle	O
.	O

We	O
also	O
evaluated	O
the	O
ability	O
of	O
biomarkers	O
(	O
serum	O
periostin	O
,	O
blood	O
eosinophils	O
,	O
exhaled	O
NO	O
,	O
and	O
serum	O
IgE	O
)	O
to	O
predict	O
benefit	O
from	O
quilizumab	O
.	O

Haematocrit	O
and	O
white	O
cell	O
count	O
were	O
determined	O
using	O
an	O
automated	O
Coulter	O
counter	O
(	O
Beckman-Coulter	O
)	O
.	O

Patients	O
were	O
excluded	O
for	O
any	O
of	O
the	O
following	O
reasons	O
:	O
a	O
diagnosis	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
or	O
any	O
respiratory	O
disease	O
other	O
than	O
asthma	O
;	O
myocardial	O
infarction	O
within	O
the	O
last	O
6	O
months	O
;	O
hospitalisation	O
due	O
to	O
cardiac	O
failure	O
or	O
unstable	O
cardiac	O
arrhythmia	O
within	O
the	O
past	O
year	O
;	O
treatment	O
with	O
anti-immunoglobulin	O
E	O
antibodies	O
within	O
6	O
months	O
prior	O
to	O
Visit	O
1	O
.	O

Patients	O
recruited	O
within	O
1–2	O
h	O
of	O
onset	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
a	O
more	O
severe	O
neurological	O
deficit	O
did	O
than	O
those	O
recruited	O
at	O
later	O
timepoints	O
after	O
onset	O
(	O
test	O
for	O
linear	O
trend	O
p	O
<	O
0·0001	O
)	O
.	O

Of	O
these	O
,	O
260	O
(	O
79.8	O
%	O
)	O
were	O
infected	O
with	O
influenza	O
virus	O
A	O
(	O
133	O
(	O
40.8	O
%	O
)	O
with	O
A/H3N2	O
,	O
72	O
(	O
22.1	O
%	O
)	O
with	O
A/H1N1-pdm09	O
,	O
38	O
(	O
11.7	O
%	O
)	O
with	O
seasonal	O
A/H1N1	O
,	O
17	O
(	O
5.2	O
%	O
)	O
with	O
A/H5N1	O
)	O
and	O
53	O
(	O
16.2	O
%	O
)	O
with	O
influenza	O
virus	O
B	O
.	O

No	O
GI	O
complications	O
were	O
reported	O
in	O
REDUCE-2	O
.	O

FACS-Lyse	O
was	O
obtained	O
from	O
Becton-Dickinson	O
(	O
Cowley	O
,	O
UK	O
)	O
.	O

ET	O
receptor	O
antagonists	O
including	O
bosentan	O
are	O
now	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
PAH	O
in	O
SSc	O
.	O

Given	O
a	O
plasma	O
half-life	O
of	O
approximately	O
70	O
h	O
,	O
we	O
judged	O
that	O
24	O
h	O
would	O
be	O
an	O
appropriate	O
time	O
point	O
to	O
capture	O
any	O
potential	O
beneficial	O
cardiovascular	O
effects	O
of	O
intravenous	O
etanercept	O
.	O

Th2	O
cells	O
produce	O
interleukin	O
(	O
IL	O
)	O
-4	O
,	O
IL-5	O
,	O
IL-13	O
,	O
and	O
other	O
cytokines	O
that	O
promote	O
immunoglobulin	O
E	O
(	O
IgE	O
)	O
class	O
switching	O
of	O
B	O
cells	O
,	O
increased	O
IgE	O
synthesis	O
by	O
plasma	O
B	O
cells	O
,	O
and	O
recruitment	O
and	O
activation	O
of	O
eosinophils	O
and	O
other	O
inflammatory	O
cells	O
.	O

Randomisation	O
and	O
masking	O
Both	O
factorial	B-Design_Factorial
randomisations	O
were	O
stratified	B-Randomization_Type_Stratified
by	O
centre	B-Randomization_Stratified_Criteria
and	O
age	B-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
7	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
7–12	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
≥13	I-Randomization_Stratified_Criteria
years	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
.	O

Median	O
follow-up	O
to	O
planned	O
trial	O
closure	O
(	O
March	O
16	O
,	O
2012	O
)	O
was	O
4·0	O
(	O
IQR	O
3·7–4·4	O
)	O
years	O
in	O
each	O
monitoring	O
and	O
ART-strategy	O
group	O
(	O
maximum	O
5·0	O
years	O
;	O
total	O
4685	O
child-years	O
)	O
.	O

All	O
patients	O
gave	O
written	O
informed	O
consent	O
.	O

Secondary	O
efficacy	O
outcomes	O
included	O
:	O
mean	O
number	O
of	O
flares	O
per	O
patient	O
,	O
proportion	O
of	O
patients	O
with	O
at	O
least	O
one	O
flare	O
,	O
time	O
to	O
first	O
flare	O
,	O
average	O
duration	O
of	O
flares	O
and	O
CRP	O
levels	O
(	O
see	O
supplementary	O
material	O
for	O
further	O
details	O
)	O
.	O

However	O
,	O
dose–response	O
curves	O
were	O
similar	O
at	O
24	O
h	O
and	O
were	O
unaffected	O
by	O
either	O
treatment	O
(	O
p	O
>	O
0.1	O
for	O
all	O
;	O
table	O
2	O
;	O
figure	O
2	O
)	O
.	O

Whereas	O
in	O
group	O
A	O
nevirapine	O
was	O
mainly	O
substituted	O
with	O
zidovudine	O
(	O
<	O
3	O
years	O
)	O
or	O
efavirenz	O
(	O
>	O
3	O
years	O
)	O
,	O
in	O
the	O
four-drug	O
groups	O
,	O
about	O
a	O
third	O
(	O
five	O
children	O
in	O
group	O
B	O
and	O
six	O
in	O
C	O
)	O
simply	O
dropped	O
nevirapine	O
during	O
four-drug	O
induction	O
to	O
continue	O
on	O
three	O
NRTIs	O
.	O

There	O
were	O
small	O
but	O
significant	O
differences	O
by	O
ART	O
strategy	O
,	O
with	O
fewer	O
reporting	O
missing	O
doses	O
in	O
the	O
past	O
28	O
days	O
in	O
group	O
A	O
through	O
week	O
36	O
(	O
induction	O
period	O
;	O
7·9	O
%	O
[	O
253/2966	O
]	O
in	O
group	O
A	O
,	O
9·8	O
%	O
[	O
326/3014	O
]	O
in	O
group	O
B	O
,	O
9·0	O
%	O
[	O
295/2999	O
]	O
in	O
group	O
C	O
;	O
p=0·02	O
)	O
and	O
overall	O
(	O
6·1	O
%	O
[	O
1059/16345	O
]	O
,	O
7·3	O
%	O
[	O
1302/16640	O
]	O
,	O
6·5	O
%	O
[	O
1135/16371	O
]	O
,	O
respectively	O
;	O
p	O
<	O
0·0001	O
)	O
.	O

Although	O
not	O
mandated	O
when	O
public	O
health	O
ART	O
rollout	O
started	O
,	O
the	O
extent	O
to	O
which	O
HIV	O
treatment	O
programmes	O
in	O
resource-limited	O
settings	O
should	O
provide	O
routine	O
laboratory	O
monitoring	O
versus	O
focus	O
resources	O
on	O
expanding	O
ART	O
access	O
for	O
the	O
many	O
in	O
need	O
,	O
remains	O
an	O
ongoing	O
debate	O
,	O
particularly	O
relevant	O
with	O
slowing	O
growth	O
in	O
health	O
assistance	O
for	O
resource-limited	O
countries	O
in	O
the	O
current	O
economic	O
crisis	O
.	O

The	O
figure	O
shows	O
the	O
flow	O
of	O
patients	O
through	O
the	O
trial	O
.	O

reported	O
that	O
the	O
risk	O
of	O
an	O
upper	O
GI	O
clinical	O
event	O
(	O
bleeding	O
,	O
perforation	O
,	O
or	O
symptomatic	O
ulcer	O
)	O
in	O
NSAID	O
users	O
at	O
increased	O
GI	O
risk	O
rose	O
16	O
%	O
for	O
every	O
10	O
%	O
decrease	O
in	O
the	O
proportion	O
of	O
time	O
a	O
proton-pump	O
inhibitor	O
or	O
H2RA	O
was	O
prescribed	O
.	O

Inflammatory	O
response	O
and	O
cytokine	O
analyses	O
Consistent	O
with	O
effective	O
conjugation	O
of	O
circulating	O
TNF-α	O
,	O
plasma	O
TNF-α	O
concentrations	O
increased	O
in	O
all	O
patients	O
following	O
etanercept	O
infusion	O
(	O
254±15	O
vs	O
0.12±0.02	O
pg/ml	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Safety	O
outcomes	O
were	O
assessed	O
throughout	O
the	O
36-week	O
treatment	O
and	O
48-week	O
follow-up	O
periods	O
.	O

Briefly	O
,	O
studies	O
were	O
performed	O
in	O
a	O
quiet	O
,	O
temperature-controlled	O
environment	O
with	O
the	O
patient	O
in	O
the	O
supine	O
position	O
throughout	O
.	O

Healing	O
of	O
all	O
DUs	O
(	O
baseline	O
and	O
new	O
combined	O
)	O
at	O
week	O
24	O
was	O
observed	O
in	O
35/95	O
(	O
36.8	O
%	O
)	O
and	O
35/89	O
(	O
39.3	O
%	O
)	O
of	O
patients	O
on	O
bosentan	O
and	O
placebo	O
,	O
respectively	O
(	O
RR	O
0.94	O
(	O
95	O
%	O
CI	O
0.65	O
to	O
1.35	O
)	O
,	O
p=0.76	O
)	O
.	O

Co-primary	O
endpoints	O
for	O
the	O
monitoring	O
randomisation	O
were	O
progression	O
to	O
new	O
WHO	O
stage	O
4	O
event	O
or	O
death	O
(	O
efficacy	O
)	O
,	O
and	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
not	O
solely	O
related	O
to	O
HIV	O
(	O
safety	O
)	O
.	O

89	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
384/433	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
who	I-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
quilizumab	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
91	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
132/145	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
of	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
who	I-Sample_Size_Actual_at_Outcome_Analysis
received	I-Sample_Size_Actual_at_Outcome_Analysis
placebo	I-Sample_Size_Actual_at_Outcome_Analysis
completed	O
the	O
study	O
treatment	O
.	O

In	O
addition	O
to	O
the	O
screening	O
upper	O
endoscopy	O
at	O
baseline	O
,	O
patients	O
had	O
endoscopy	O
at	O
weeks	O
8	O
,	O
16	O
,	O
and	O
24	O
(	O
or	O
earlier	O
if	O
premature	O
study	O
termination	O
)	O
of	O
study	O
therapy	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
PMA	O
.	O

Blood	O
pressure	O
was	O
managed	O
in	O
the	O
same	O
way	O
in	O
both	O
treatment	O
groups	O
,	O
according	O
to	O
local	O
protocol	O
.	O

The	O
study	O
was	O
conducted	O
in	O
19	B-Settings_Multicenter
sites	I-Settings_Multicenter
in	O
three	O
European	O
countries	O
(	O
Germany	B-Settings_Location
,	I-Settings_Location
Austria	I-Settings_Location
and	I-Settings_Location
Ukraine	I-Settings_Location
;	O
ClinicalTrials.gov	O
identifier	O
NCT01233284	O
)	O
,	O
and	O
was	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
principles	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
Good	O
Clinical	O
Practice	O
Guidelines	O
.	O

Conclusions	O
There	O
were	O
no	O
virological	O
or	O
clinical	O
advantages	O
with	O
double	B-Design_Parallel_Group
dose	I-Design_Parallel_Group
oseltamivir	I-Design_Parallel_Group
compared	I-Design_Parallel_Group
with	I-Design_Parallel_Group
standard	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
in	O
patients	O
with	O
severe	O
influenza	O
admitted	O
to	O
hospital	O
.	O

Masked	O
analysis	O
of	O
the	O
patients	O
'	O
baseline	O
characteristics	O
showed	O
clear	O
differences	O
in	O
key	O
prognostic	O
factors	O
(	O
age	O
,	O
stroke	O
severity	O
,	O
degree	O
of	O
ischaemic	O
change	O
on	O
baseline	O
CT	O
or	O
MRI	O
)	O
in	O
patients	O
randomly	O
assigned	O
at	O
different	O
times	O
after	O
stroke	O
onset	O
,	O
which	O
might	O
complicate	O
the	O
estimation	O
of	O
the	O
effect	O
of	O
treatment	O
overall	O
and	O
in	O
subgroups	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
at	O
24	O
h	O
compared	O
with	O
baseline	O
in	O
those	O
patients	O
randomised	O
to	O
placebo	O
(	O
p	O
>	O
0.05	O
for	O
all	O
;	O
table	O
2	O
)	O
.	O

The	O
results	O
of	O
these	O
in-trial	O
analyses	O
differ	O
slightly	O
from	O
previously	O
published	O
findings	O
because	O
of	O
the	O
inclusion	O
of	O
events	O
taking	O
place	O
between	O
the	O
participants	O
'	O
final	O
follow-up	O
visit	O
and	O
Nov	O
11	O
,	O
2001	O
(	O
mean	O
extra	O
follow-up	O
of	O
3·5	O
months	O
[	O
SD	O
1·4	O
]	O
)	O
.	O

Adverse	O
events	O
Data	O
on	O
adverse	O
events	O
were	O
collected	O
by	O
the	O
treating	O
healthcare	O
professional	O
,	O
by	O
review	O
of	O
patients	O
’	O
medical	O
notes	O
by	O
the	O
trial	O
coordinator	O
at	O
site	O
monitoring	O
visits	O
,	O
or	O
by	O
review	O
of	O
participant	O
follow-up	O
questionnaires	O
.	O

Methods	O
This	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
trial	O
conducted	O
at	O
41	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
Europe	B-Settings_Location
and	I-Settings_Location
North	I-Settings_Location
America	I-Settings_Location
randomised	O
188	B-Sample_Size_Actual_at_Enrollment
patients	O
with	O
SSc	O
with	O
at	O
least	O
1	O
active	O
DU	O
(	O
‘	O
cardinal	O
ulcer	O
’	O
)	O
to	O
bosentan	B-Design_Parallel_Group
62.5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
for	I-Design_Parallel_Group
4	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
and	I-Design_Parallel_Group
125	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
thereafter	I-Design_Parallel_Group
for	I-Design_Parallel_Group
20	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	I-Design_Parallel_Group
n=98	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
matching	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	O
n=90	O
;	O
total	O
24	O
weeks	O
)	O
.	O

The	O
statistical-analysis-plan	O
writing	O
committee	O
,	O
which	O
did	O
not	O
have	O
access	O
to	O
the	O
accumulating	O
data	O
,	O
was	O
therefore	O
expanded	O
to	O
include	O
an	O
independent	O
statistician	O
(	O
Gordon	O
Murray	O
,	O
University	O
of	O
Edinburgh	O
,	O
Edinburgh	O
,	O
UK	O
)	O
to	O
advise	O
on	O
the	O
correct	O
approach	O
.	O

All	O
comparisons	O
were	O
as	O
randomised	O
(	O
intention-to-treat	O
)	O
.	O

One	O
patient	O
on	O
placebo	O
died	O
from	O
acute	O
respiratory	O
distress	O
syndrome	O
during	O
the	O
post-treatment	O
follow-up	O
.	O

The	O
following	O
secondary	O
efficacy	O
end	O
points	O
were	O
investigated	O
:	O
trough	O
FEV1	O
;	O
peak	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
within	O
the	O
first	O
3	O
hours	O
after	O
dosing	O
(	O
FVC	O
)	O
(	O
0-3h	O
)	O
;	O
trough	O
FVC	O
;	O
FEV1	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
within	O
the	O
first	O
3	O
hours	O
after	O
dosing	O
(	O
FEV1	O
AUC	O
(	O
0-3h	O
)	O
)	O
;	O
FVC	O
AUC	O
(	O
0-3h	O
)	O
;	O
pre-dose	O
PEFam	O
and	O
PEFpm	O
using	O
the	O
Asthma	O
Monitor2+	O
device	O
(	O
AM2+®	O
;	O
ERT	O
,	O
Philadelphia	O
,	O
Pennsylvania	O
,	O
USA	O
)	O
based	O
on	O
the	O
mean	O
of	O
the	O
final	O
week	O
of	O
each	O
treatment	O
period	O
.	O

Statistical	O
methods	O
Efficacy	O
analyses	O
were	O
performed	O
on	O
all	O
treated	O
patients	O
using	O
SAS	O
software	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
North	O
Carolina	O
,	O
USA	O
)	O
.	O

Intervention	O
Cryotherapy	O
Participants	O
randomised	B-Randomization_Type_Simple
to	O
cryotherapy	O
with	O
liquid	O
nitrogen	O
received	O
a	O
maximum	O
of	O
four	O
treatments	O
given	O
two	O
to	O
three	O
weeks	O
apart	O
by	O
a	O
healthcare	O
professional	O
.	O

Urinalysis	O
was	O
done	O
at	O
baseline	O
and	O
final	O
visit	O
.	O

There	O
was	O
no	O
difference	O
between	O
adults	O
and	O
children	O
in	O
reported	O
adverse	O
events	O
.	O

All	O
statistical	O
tests	O
were	O
two-tailed	O
and	O
performed	O
with	O
SAS	O
software	O
(	O
V.9.2	O
,	O
SAS	O
Institute	O
Inc.	O
,	O
Cary	O
,	O
North	O
Carolina	O
,	O
USA	O
)	O
.	O

The	O
study	O
is	O
registered	O
,	O
ISRCTN25765518	O
.	O

On	O
the	O
basis	O
of	O
previous	O
work	O
examining	O
the	O
effect	O
of	O
clopidogrel	O
on	O
PMA	O
we	O
estimated	O
that	O
a	O
5	O
%	O
absolute	O
change	O
in	O
PMA	O
would	O
be	O
of	O
clinical	O
significance	O
and	O
that	O
at	O
least	O
12	B-Sample_Size_Required
paired	I-Sample_Size_Required
samples	I-Sample_Size_Required
would	O
provide	O
an	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
10	O
%	O
absolute	O
difference	O
in	O
PMA	O
from	O
baseline	O
at	O
a	O
significance	O
level	O
of	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
.	O

During	O
the	O
post-trial	O
period	O
,	O
non-vascular	O
mortality	O
rates	O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
(	O
943	O
[	O
10·6	O
%	O
]	O
vs	O
942	O
[	O
10·9	O
%	O
]	O
;	O
RR	O
0·97	O
[	O
95	O
%	O
CI	O
0·89–1·06	O
]	O
;	O
p=0·55	O
)	O
,	O
with	O
no	O
differences	O
reported	O
in	O
deaths	O
from	O
cancer	O
,	O
respiratory	O
disease	O
,	O
or	O
non-medical	O
causes	O
.	O

90	O
%	O
of	O
children	O
with	O
HIV	O
live	O
in	O
sub-Saharan	O
Africa	O
;	O
in	O
2011	O
,	O
only	O
about	O
28	O
%	O
of	O
those	O
needing	O
ART	O
were	O
receiving	O
it	O
.	O

A	O
second	O
proof-of-concept	O
study	O
(	O
three-way	O
crossover	O
,	O
8	O
weeks	O
per	O
treatment	O
)	O
in	O
patients	O
with	O
more	O
severe	O
disease	O
–	O
severe	O
persistent	O
asthma	O
,	O
and	O
receiving	O
ICS	O
+	O
LABA	O
–	O
demonstrated	O
that	O
lung	O
function	O
improved	O
significantly	O
with	O
tiotropium	O
Respimat®	O
10	O
μg	O
or	O
5	O
μg	O
.	O

Seven	O
clinic	O
visits	O
were	O
scheduled	O
:	O
at	O
screening	O
(	O
Visit	O
0	O
)	O
;	O
prior	O
to	O
the	O
4-week	O
run-in	O
(	O
Visit	O
1	O
)	O
;	O
at	O
randomisation	O
(	O
after	O
the	O
4-week	O
run-in	O
[	O
Visit	O
2	O
]	O
)	O
;	O
every	O
4	O
weeks	O
at	O
the	O
end	O
of	O
each	O
treatment	O
period	O
(	O
Visits	O
3–6	O
)	O
;	O
and	O
21	O
days	O
following	O
the	O
end	O
of	O
the	O
final	O
treatment	O
period	O
(	O
Visit	O
7	O
)	O
.	O

The	O
mean	O
relative	O
changes	O
from	O
baseline	O
were	O
compared	O
between	O
the	O
study	O
groups	O
using	O
the	O
differences	O
between	O
the	O
means	O
for	O
each	O
group	O
,	O
with	O
the	O
associated	O
two-sided	O
90	O
%	O
CIs	O
.	O

Lung	O
function	O
No	O
significant	O
evidence	O
of	O
improved	O
FEV1	O
at	O
Weeks	O
12	O
and	O
36	O
was	O
observed	O
in	O
quilizumab-treated	O
patients	O
compared	O
to	O
placebo	O
(	O
Fig	O
.	O

Overall	O
,	O
2581	O
(	O
95	O
%	O
)	O
of	O
2714	O
patients	O
with	O
data	O
(	O
data	O
for	O
some	O
relevant	O
variables	O
were	O
not	O
collected	O
in	O
the	O
initial	O
phase	O
)	O
did	O
not	O
meet	O
the	O
prevailing	O
EU-licence-approval	O
criteria	O
.	O

The	O
estimated	O
canakinumab	O
dose	O
with	O
equivalent	O
efficacy	O
to	O
colchicine	O
was	O
below	O
the	O
range	O
of	O
canakinumab	O
doses	O
tested	O
.	O

Mean	O
(	O
±SD	O
)	O
25-hydroxyvitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
was	O
30.2±13.2	O
nmol/L	O
at	O
baseline	O
,	O
and	O
29	O
(	O
43	O
%	O
)	O
had	O
values	O
<	O
30	O
nmol/L	O
.	O

Efficacy	O
criteria	O
The	O
primary	O
efficacy	O
criterion	O
was	O
the	O
change	O
in	O
stride	O
length	O
(	O
m	O
)	O
under	O
‘	O
on-L-dopa	O
’	O
conditions	O
.	O

1	O
)	O
from	O
April	O
2012	O
to	O
September	O
2013	O
;	O
the	O
study	O
was	O
completed	O
in	O
November	O
2014	O
.	O

All	O
measurements	O
were	O
recorded	O
in	O
a	O
double-blind	O
manner	O
in	O
our	O
hospital	O
's	O
gait	O
laboratory	O
by	O
CM	O
,	O
AD	O
and	O
VT.	O
Standardised	O
assessment	O
Efficacy	O
criteria	O
were	O
assessed	O
at	O
8:30	O
in	O
the	O
morning	O
under	O
‘	O
off-L-dopa	O
’	O
conditions	O
,	O
that	O
is	O
,	O
at	O
least	O
8	O
h	O
after	O
the	O
withdrawal	O
of	O
dopaminergic	O
medications	O
.	O

The	O
proportion	O
of	O
patients	O
developing	O
ulcers	O
was	O
also	O
prespecified	O
to	O
be	O
assessed	O
in	O
the	O
following	O
subgroups	O
:	O
use	O
of	O
low-dose	O
aspirin	O
and/or	O
anticoagulants	O
,	O
prior	O
ulcer	O
history	O
,	O
age	O
(	O
≥65	O
vs.	O
<	O
65	O
years	O
)	O
,	O
gender	O
,	O
and	O
race	O
.	O

Secondary	O
outcomes	O
were	O
:	O
major	O
vascular	O
events	O
during	O
each	O
year	O
of	O
follow-up	O
and	O
in	O
various	O
subcategories	O
of	O
patients	O
;	O
major	O
coronary	O
events	O
(	O
ie	O
,	O
non-fatal	O
myocardial	O
infarction	O
or	O
coronary	O
death	O
)	O
,	O
strokes	O
,	O
and	O
revascularisations	O
separately	O
;	O
deaths	O
from	O
vascular	O
and	O
non-vascular	O
causes	O
separately	O
;	O
and	O
cancers	O
at	O
all	O
sites	O
(	O
excluding	O
non-melanoma	O
skin	O
cancer	O
)	O
.	O

At	O
the	O
end	O
of	O
each	O
4-week	O
treatment	O
period	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
improvement	O
in	O
ACQ-7	O
score	O
with	O
all	O
three	O
tiotropium	O
Respimat®	O
doses	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
respiratory	O
failure	O
(	O
n=14	O
)	O
,	O
diarrhoea	O
(	O
n=11	O
)	O
,	O
and	O
multi-organ	O
failure	O
(	O
n=6	O
)	O
.	O

Of	O
the	O
10	O
subjects	O
with	O
25	O
(	O
OH	O
)	O
D	O
<	O
30	O
nmol/L	O
at	O
24	O
weeks	O
,	O
two	O
(	O
20	O
%	O
)	O
attained	O
the	O
primary	O
outcome	O
compared	O
with	O
66	O
%	O
of	O
those	O
with	O
25	O
(	O
OH	O
)	O
D	O
≥30	O
nmol/L	O
(	O
p=0.006	O
)	O
.	O

The	O
REDUCE-1	O
trial	O
took	O
place	O
from	O
March	O
2007	O
through	O
August	O
2008	O
at	O
68	O
centers	O
in	O
the	O
United	O
States	O
and	O
REDUCE-2	O
took	O
place	O
from	O
March	O
2007	O
through	O
September	O
2008	O
at	O
68	B-Settings_Multicenter
centers	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
States	I-Settings_Location
.	O

Approximately	O
6	O
%	O
of	O
patients	O
had	O
reduced	O
renal	O
function	O
,	O
defined	O
as	O
having	O
an	O
estimated	O
creatinine	O
clearance	O
rate	O
(	O
CrCl	O
)	O
below	O
the	O
normal	O
range	O
for	O
age	O
and	O
sex	O
(	O
table	O
1	O
)	O
.	O

Participants	O
whose	O
plantar	O
warts	O
had	O
not	O
cleared	O
were	O
treated	O
as	O
censored	O
,	O
and	O
we	O
calculated	O
their	O
duration	O
in	O
the	O
trial	O
from	O
their	O
date	O
of	O
trial	O
exit	O
,	O
date	O
of	O
last	O
available	O
assessment	O
,	O
or	O
the	O
183	O
days	O
to	O
trial	O
cessation	O
,	O
as	O
appropriate	O
.	O

In	O
animal	O
studies	O
,	O
anti-M1	O
prime	O
bound	O
membrane	O
IgE	O
on	O
IgE-switched	O
B	O
cells	O
and	O
plasmablasts	O
and	O
depleted	O
them	O
through	O
apoptosis	O
and	O
antibody-dependent	O
cell-mediated	O
cytotoxicity	O
,	O
leading	O
to	O
fewer	O
IgE	O
plasma	O
cells	O
and	O
less	O
production	O
of	O
soluble	O
IgE	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
the	O
proinflammatory	O
cytokine	O
,	O
interleukin	O
1β	O
(	O
IL-1β	O
)	O
,	O
plays	O
a	O
key	O
role	O
in	O
mediating	O
the	O
initiation	O
of	O
inflammation	O
in	O
gouty	O
arthritis	O
in	O
a	O
similar	O
manner	O
to	O
that	O
occurring	O
in	O
the	O
hereditary	O
autoinflammatory	O
syndrome	O
,	O
cryopyrin-associated	O
periodic	O
syndrome	O
(	O
CAPS	O
)	O
,	O
and	O
may	O
also	O
contribute	O
to	O
joint	O
destruction	O
in	O
gouty	O
arthritis	O
.	O

Figure	O
1	O
shows	O
the	O
flow	O
chart	O
of	O
the	O
design	O
and	O
participants	O
.	O

25	O
(	O
4	O
%	O
)	O
children	O
died	O
in	O
the	O
clinically	O
driven	O
monitoring	O
group	O
versus	O
29	O
(	O
5	O
%	O
)	O
in	O
the	O
routine	O
laboratory	O
monitoring	O
group	O
(	O
1·1	O
vs	O
1·3	O
per	O
100	O
child-years	O
,	O
respectively	O
;	O
difference	O
−0·2	O
per	O
100	O
child-years	O
,	O
95	O
%	O
CI	O
−0·82	O
to	O
0·41	O
;	O
HR	O
0·84	O
,	O
95	O
%	O
CI	O
0·49–1·44	O
;	O
p=0·45	O
;	O
appendix	O
)	O
.	O

Subjects	O
returned	O
every	O
4	O
weeks	O
for	O
their	O
supplements	O
and	O
assessment	O
of	O
adverse	O
events	O
.	O

For	O
comparison	O
of	O
subgroups	O
with	O
<	O
100	O
patients	O
across	O
the	O
combined	O
treatment	O
arms	O
,	O
a	O
Fisher	O
's	O
exact	O
test	O
was	O
used	O
.	O

Safety	O
was	O
continually	O
monitored	O
.	O

Nine	O
were	O
excluded	O
after	O
randomisation	O
because	O
histological	O
findings	O
failed	O
to	O
support	O
a	O
diagnosis	O
of	O
pyoderma	O
gangrenosum	O
.	O

The	O
present	O
study	O
(	O
RAPIDS-2	O
,	O
for	O
‘	O
RAndomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
Placebo-controlled	O
study	O
with	O
bosentan	O
on	O
healing	O
and	O
prevention	O
of	O
Ischemic	O
Digital	O
ulcers	O
in	O
patients	O
with	O
systemic	O
Sclerosis	O
’	O
)	O
was	O
conducted	O
to	O
more	O
fully	O
evaluate	O
the	O
effects	O
of	O
bosentan	O
treatment	O
on	O
DUs	O
associated	O
with	O
SSc	O
.	O

At	O
Visits	O
2–6	O
,	O
lung	O
function	O
tests	O
were	O
performed	O
10	O
minutes	O
prior	O
to	O
and	O
up	O
to	O
3	O
hours	O
after	O
dosing	O
of	O
study	O
treatment	O
.	O

Adverse	O
events	O
and	O
concomitant	O
medications	O
were	O
recorded	O
on	O
the	O
electronic	O
case	O
report	O
form	O
at	O
each	O
visit	O
.	O

Of	O
those	O
assigned	O
to	O
the	O
rt-PA	O
group	O
,	O
26	O
(	O
2	O
%	O
)	O
did	O
not	O
receive	O
any	O
rt-PA	O
treatment	O
,	O
and	O
of	O
those	O
assigned	O
to	O
the	O
control	O
group	O
,	O
seven	O
(	O
<	O
1	O
%	O
)	O
received	O
at	O
least	O
some	O
rt-PA	O
.	O

Analysis	O
of	O
FEV1	O
in	O
the	O
biomarker	O
subgroups	O
demonstrated	O
no	O
consistent	O
or	O
meaningful	O
improvements	O
of	O
FEV1	O
in	O
the	O
quilizumab-treated	O
arms	O
over	O
placebo	O
(	O
see	O
Additional	O
file	O
2	O
:	O
Table	O
S1	O
and	O
Additional	O
file	O
3	O
:	O
Table	O
S2	O
)	O
.	O

This	O
indicated	O
that	O
the	O
developmental	O
age	O
scale	O
in	O
the	O
oxandrolone	O
arm	O
was	O
foreshortened	O
by	O
23	O
%	O
,	O
increasing	O
the	O
velocity	O
and	O
making	O
the	O
oxandrolone	O
curve	O
correspondingly	O
steeper	O
than	O
the	O
placebo	O
curve	O
,	O
although	O
the	O
age	O
of	O
final	O
height	O
was	O
no	O
earlier	O
.	O

Adverse	O
reactions	O
differed	O
between	O
the	O
treatments	O
in	O
line	O
with	O
known	O
side	O
effects	O
of	O
each	O
drug	O
.	O

Similar	O
proportions	O
of	O
patients	O
were	O
negative	O
for	O
RT-PCR	O
on	O
day	O
five	O
of	O
treatment	O
:	O
115/159	O
(	O
72.3	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
64.9	O
%	O
to	O
78.7	O
%	O
)	O
double	O
dose	O
recipients	O
versus	O
105/154	O
(	O
68.2	O
%	O
,	O
60.5	O
%	O
to	O
75.0	O
%	O
)	O
standard	O
dose	O
recipients	O
;	O
difference	O
4.2	O
%	O
(	O
−5.9	O
to	O
14.2	O
)	O
;	O
P=0.42	O
.	O

Effect	O
of	O
double	O
dose	O
oseltamivir	O
on	O
clinical	O
and	O
virological	O
outcomes	O
in	O
children	O
and	O
adults	O
admitted	O
to	O
hospital	O
with	O
severe	O
influenza	O
:	O
double	B-Blinding_Double_Blind
blind	I-Blinding_Double_Blind
randomised	O
controlled	O
trial	O

For	O
exploratory	O
purposes	O
,	O
statistical	O
tests	O
of	O
treatment	O
difference	O
were	O
provided	O
for	O
planned	O
secondary/exploratory	O
and	O
unplanned	O
post	O
hoc	O
efficacy	O
analyses	O
and	O
included	O
the	O
Pitman	O
permutation	O
(	O
for	O
changes	O
from	O
baseline	O
)	O
,	O
the	O
Fisher	O
exact	O
test	O
(	O
for	O
proportions	O
)	O
and	O
the	O
log-rank	O
test	O
(	O
for	O
times	O
to	O
event	O
)	O
,	O
each	O
performed	O
without	O
correction	O
for	O
multiple	O
testing	O
.	O

The	O
largest	O
decreases	O
in	O
total	O
and	O
allergen-specific	O
IgE	O
were	O
observed	O
at	O
Week	O
42	O
in	O
the	O
300	O
mg	O
M	O
treatment	O
cohort	O
.	O

In	O
Portugal	O
,	O
patients	O
were	O
followed	O
up	O
in	O
clinic	O
by	O
clinicians	B-Blinding_Object_Others
not	O
involved	O
in	O
the	O
patients	O
'	O
initial	O
treatment	O
,	O
again	O
,	O
masked	O
to	O
treatment	O
allocation	O
as	O
far	O
as	O
possible	O
.	O

Among	O
38	O
patients	O
infected	O
with	O
seasonal	O
H1N1	O
viruses	O
,	O
32	O
(	O
11	O
in	O
double	O
dose	O
arm	O
,	O
21	O
in	O
standard	O
dose	O
arm	O
)	O
could	O
be	O
sequenced	O
and	O
18	O
(	O
56	O
%	O
;	O
six	O
double	O
dose	O
,	O
12	O
standard	O
dose	O
)	O
of	O
these	O
had	O
the	O
H275Y	O
mutation	O
at	O
baseline	O
.	O

5	O
)	O
.	O

The	O
proportional	O
hazard	O
assumption	O
was	O
tested	O
and	O
not	O
violated	O
,	O
either	O
separately	O
for	O
each	O
covariate	O
(	O
cryotherapy	O
v	O
salicylic	O
acid	O
(	O
P=0.3107	O
)	O
,	O
age	O
(	O
P=0.9508	O
)	O
,	O
type	O
of	O
plantar	O
wart	O
(	O
P=0.7024	O
)	O
,	O
previous	O
treatment	O
(	O
P=0.4456	O
)	O
)	O
or	O
globally	O
(	O
P=0.8208	O
)	O
.	O

Oseltamivir	O
capsules	O
,	O
paediatric	O
oseltamivir	O
suspensions	O
,	O
and	O
placebo	O
suspensions	O
were	O
provided	O
by	O
Roche	O
(	O
Basel	O
,	O
Switzerland	O
)	O
.	O

Figure	O
2	O
shows	O
individual	O
height	O
curves	O
unadjusted	O
(	O
top	O
panel	O
)	O
and	O
SITAR	O
adjusted	O
with	O
the	O
summary	O
curve	O
(	O
bottom	O
panel	O
)	O
.	O

Table	O
3	O
also	O
includes	O
the	O
results	O
for	O
maximum	O
height	O
,	O
based	O
on	O
the	O
92	O
girls	O
still	O
in	O
the	O
trial	O
.	O

This	O
difference	O
of	O
17	O
%	O
was	O
not	O
statistically	O
significant	O
.	O

Findings	O
During	O
the	O
in-trial	O
period	O
,	O
allocation	O
to	O
simvastatin	O
yielded	O
an	O
average	O
reduction	O
in	O
LDL	O
cholesterol	O
of	O
1·0	O
mmol/L	O
and	O
a	O
proportional	O
decrease	O
in	O
major	O
vascular	O
events	O
of	O
23	O
%	O
(	O
95	O
%	O
CI	O
19–28	O
;	O
p	O
<	O
0·0001	O
)	O
,	O
with	O
significant	O
divergence	O
each	O
year	O
after	O
the	O
first	O
.	O

Findings	O
1206	B-Sample_Size_Actual_at_Enrollment
children	I-Sample_Size_Actual_at_Enrollment
were	O
randomly	O
assigned	O
to	O
clinically	O
driven	O
(	O
n=606	O
)	O
versus	O
routine	O
laboratory	O
monitoring	O
(	O
n=600	O
)	O
,	O
and	O
groups	O
A	O
(	O
n=397	O
)	O
,	O
B	O
(	O
n=404	O
)	O
,	O
and	O
C	O
(	O
n=405	O
)	O
.	O

Normally	O
distributed	O
continuous	O
data	O
were	O
compared	O
between	O
the	O
two	O
arms	O
with	O
the	O
unpaired	O
t	O
test	O
;	O
the	O
Mann-Whitney	O
U	O
or	O
Kruskal-Wallis	O
tests	O
were	O
used	O
for	O
skewed	O
data	O
.	O

Pharmacokinetics	O
and	O
immunogenicity	O
Serum	O
levels	O
of	O
quilizumab	O
for	O
pharmacokinetic	O
assessments	O
were	O
measured	O
using	O
a	O
validated	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
;	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

Of	O
1170	O
adverse	O
events	O
(	O
621	O
clinically	O
driven	O
monitoring	O
,	O
549	O
routine	O
laboratory	O
monitoring	O
)	O
,	O
810	O
(	O
69	O
%	O
)	O
were	O
asymptomatic	O
laboratory	O
results	O
,	O
most	O
commonly	O
grade	O
3	O
neutropenia	O
(	O
171	O
clinically	O
driven	O
monitoring	O
,	O
167	O
routine	O
laboratory	O
monitoring	O
;	O
appendix	O
)	O
;	O
only	O
87	O
(	O
7	O
%	O
)	O
were	O
definitely	O
,	O
probably	O
,	O
or	O
uncertainly	O
ART-related	O
(	O
41	O
clinically	O
driven	O
monitoring	O
,	O
46	O
routine	O
laboratory	O
monitoring	O
)	O
.	O

Infrastructure	O
,	O
personnel	O
,	O
and	O
supply	O
chain	O
constraints	O
all	O
affect	O
the	O
ability	O
to	O
monitor	O
,	O
and	O
tests	O
for	O
detecting	O
toxicity	O
and	O
measuring	O
efficacy	O
are	O
generally	O
unavailable	O
,	O
particularly	O
at	O
low-level	O
facilities	O
.	O

Objective	O
This	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
canakinumab	O
,	O
a	O
fully	O
human	O
anti-interleukin	O
1β	O
monoclonal	O
antibody	O
,	O
for	O
prophylaxis	O
against	O
acute	O
gouty	O
arthritis	O
flares	O
in	O
patients	O
initiating	O
urate-lowering	O
treatment	O
.	O

Results	O
A	O
total	O
of	O
254	O
children	O
presented	O
with	O
leg	O
deformities	O
,	O
and	O
72	B-Sample_Size_Actual_at_Enrollment
subjects	O
with	O
radiographically	O
active	O
rickets	O
were	O
enrolled	O
between	O
February	O
2004	O
and	O
November	O
2006	O
(	O
figure	O
1	O
)	O
.	O

If	O
the	O
previous	O
step	O
was	O
not	O
successful	O
,	O
analysis	O
of	O
the	O
current	O
step	O
was	O
to	O
be	O
considered	O
descriptive	O
.	O

In	O
a	O
logistic	O
regression	O
analysis	O
that	O
controlled	O
for	O
baseline	O
values	O
of	O
alkaline	O
phosphatase	O
,	O
radiographic	O
score	O
,	O
serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
height	O
for	O
age	O
,	O
treatment	O
with	O
calcium	O
plus	O
vitamin	O
D	O
was	O
significantly	O
superior	O
to	O
treatment	O
with	O
calcium	O
alone	O
(	O
table	O
2	O
)	O
.	O

By	O
six	O
months	O
,	O
ulcers	O
had	O
healed	O
in	O
28/59	O
(	O
47	O
%	O
)	O
participants	O
in	O
the	O
ciclosporin	O
group	O
compared	O
with	O
25/53	O
(	O
47	O
%	O
)	O
in	O
the	O
prednisolone	O
group	O
.	O

According	O
to	O
this	O
analysis	O
,	O
there	O
was	O
a	O
62	O
%	O
to	O
72	O
%	O
reduction	O
in	O
the	O
mean	O
number	O
of	O
flares	O
per	O
patient	O
for	O
canakinumab	O
doses	O
≥50	O
mg	O
versus	O
colchicine	O
(	O
rate	O
ratio	O
:	O
0.28–0.38	O
,	O
p≤0.0083	O
)	O
(	O
table	O
2	O
)	O
.	O

We	O
analysed	O
adverse	O
reactions	O
that	O
occurred	O
during	O
the	O
trial	O
according	O
to	O
the	O
original	O
randomised	O
allocation	O
,	O
regardless	O
of	O
whether	O
other	O
drugs	O
had	O
been	O
introduced	O
before	O
the	O
adverse	O
reaction	O
.	O

Children	O
with	O
HIV	O
start	O
ART	O
early	O
and	O
will	O
need	O
to	O
take	O
treatment	O
for	O
longer	O
than	O
adults	O
.	O

Participants	O
applied	O
salicylic	O
acid	O
on	O
a	O
mean	O
of	O
6.3	O
days	O
in	O
week	O
1	O
and	O
5.4	O
days	O
in	O
week	O
3	O
.	O

Permitted	O
medication	O
for	O
the	O
treatment	O
of	O
acute	O
asthma	O
exacerbations	O
included	O
salbutamol	O
hydrofluoroalkane	O
metered-dose	O
inhaler	O
,	O
systemic	O
corticosteroids	O
and	O
short-acting	O
theophylline	O
preparations	O
.	O

Introduction	O
Gouty	O
arthritis	O
is	O
a	O
painful	O
inflammatory	O
arthritis	O
that	O
becomes	O
increasingly	O
prevalent	O
with	O
age	O
,	O
affecting	O
around	O
10	O
%	O
of	O
men	O
and	O
6	O
%	O
of	O
women	O
over	O
70	O
years	O
old	O
.	O

Oral	O
ethinylestradiol	O
(	O
UCB	O
Pharma	O
,	O
Slough	O
,	O
UK	O
)	O
was	O
given	O
daily	O
as	O
follows	O
,	O
regardless	O
of	O
the	O
age	O
at	O
starting	O
:	O
year	O
1	O
,	O
2	O
μg	O
;	O
year	O
2	O
,	O
4	O
μg	O
;	O
year	O
3	O
,	O
four	O
months	O
each	O
of	O
6	O
,	O
8	O
,	O
and	O
10	O
μg	O
.	O

The	O
primary	O
endpoint	O
,	O
the	O
annualized	O
exacerbation	O
rate	O
,	O
was	O
calculated	O
by	O
the	O
total	O
number	O
of	O
protocol-defined	O
exacerbations	O
observed	O
in	O
the	O
group	O
over	O
the	O
treatment	O
period	O
divided	O
by	O
total	O
patient-weeks	O
at	O
risk	O
(	O
number	O
of	O
weeks	O
from	O
first	O
study	O
drug	O
administration	O
to	O
the	O
earliest	O
of	O
Week	O
36	O
or	O
study	O
discontinuation	O
)	O
for	O
the	O
group	O
and	O
multiplied	O
by	O
52	O
.	O

Allopurinol	O
treatment	O
(	O
100–300	O
mg	O
)	O
was	O
initiated	O
at	O
baseline	O
or	O
within	O
1	O
month	O
before	O
baseline	O
and	O
was	O
administered	O
to	O
all	O
randomised	O
patients	O
once	O
daily	O
for	O
24	O
weeks	O
(	O
see	O
supplementary	O
material	O
for	O
details	O
)	O
.	O

157	O
(	O
40	O
%	O
)	O
children	O
in	O
group	O
A	O
,	O
190	O
(	O
47	O
%	O
)	O
in	O
group	O
B	O
,	O
and	O
218	O
(	O
54	O
%	O
)	O
in	O
group	O
C	O
had	O
one	O
or	O
more	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
(	O
co-primary	O
endpoint	O
;	O
HR	O
[	O
B	O
:	O
A	O
]	O
1·32	O
,	O
95	O
%	O
CI	O
1·07–1·63	O
;	O
HR	O
[	O
C	O
:	O
A	O
]	O
1·58	O
,	O
1·29–1·94	O
;	O
global	O
p=0·0001	O
;	O
figure	O
4	O
)	O
.	O

The	O
treatment	O
period	O
ended	O
36	O
weeks	O
after	O
randomization	O
and	O
was	O
followed	O
by	O
a	O
48-week	O
period	O
to	O
assess	O
the	O
sustained	O
efficacy	O
and	O
safety	O
of	O
quilizumab	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S1	O
)	O
.	O

All	O
of	O
these	O
patients	O
were	O
included	O
in	O
the	O
analyses	O
(	O
1515	O
in	O
the	O
rt-PA	O
group	O
vs	O
1520	O
in	O
the	O
control	O
group	O
)	O
,	O
of	O
whom	O
1617	O
(	O
53	O
%	O
)	O
were	O
older	O
than	O
80	O
years	O
of	O
age	O
.	O

Recruited	O
patients	O
were	O
≥18	O
years	O
old	O
,	O
with	O
SSc	O
as	O
defined	O
by	O
the	O
preliminary	O
classification	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
and	O
at	O
least	O
one	O
active	O
DU	O
(	O
onset	O
between	O
1	O
week	O
and	O
3	O
months	O
prior	O
to	O
randomisation	O
)	O
that	O
was	O
selected	O
by	O
the	O
investigator	O
and	O
termed	O
the	O
‘	O
cardinal	O
ulcer	O
’	O
(	O
painful	O
area	O
,	O
≥2	O
mm	O
in	O
diameter	O
with	O
visible	O
depth	O
and	O
loss	O
of	O
dermis	O
,	O
amenable	O
to	O
healing	O
and	O
in	O
a	O
location	O
judged	O
compatible	O
with	O
a	O
vascular	O
aetiology	O
,	O
specified	O
by	O
protocol	O
as	O
volar	O
surface	O
of	O
the	O
digit	O
distal	O
to	O
the	O
proximal	O
interphalangeal	O
digital	O
crease	O
)	O
.	O

The	O
study	O
was	O
performed	O
in	O
accordance	O
with	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
of	O
Technical	O
Requirements	O
for	O
Registration	O
of	O
Pharmaceuticals	O
for	O
Human	O
Use	O
(	O
ICH	O
)	O
Harmonised	O
Tripartite	O
Guidelines	O
for	O
Good	O
Clinical	O
Practice	O
and	O
the	O
ethical	O
principles	O
laid	O
down	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
all	O
patients	O
provided	O
written	O
informed	O
consent	O
.	O

The	O
proportions	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
adverse	O
event	O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
(	O
table	O
4	O
)	O
.	O

A	O
steering	O
committee	O
(	O
British	O
Society	O
for	O
Paediatric	O
Endocrinology	O
and	O
Diabetes	O
Clinical	O
Trials/Audit	O
Group	O
)	O
supervised	O
the	O
study	O
,	O
and	O
an	O
independent	O
data	O
and	O
safety	O
monitoring	O
group	O
was	O
established	O
.	O

An	O
analysis	O
of	O
the	O
treatment	O
effect	O
in	O
each	O
of	O
three	O
equal-sized	O
cohorts	O
of	O
patients	O
(	O
ie	O
,	O
those	O
recruited	O
in	O
2000–06	O
,	O
2007–08	O
,	O
2009–11	O
)	O
did	O
not	O
provide	O
any	O
evidence	O
of	O
period	O
effects	O
(	O
data	O
not	O
shown	O
)	O
.	O

Because	O
we	O
found	O
no	O
heterogeneity	O
,	O
we	O
used	O
conditional	O
multiple	O
logistic	O
regression	O
to	O
investigate	O
independent	O
predictors	O
of	O
viral	O
RNA	O
clearance	O
on	O
day	O
five	O
,	O
stratified	O
by	O
study	O
sites	O
.	O

However	O
,	O
there	O
were	O
no	O
differences	O
in	O
the	O
dose–response	O
curves	O
between	O
etanercept	O
and	O
placebo	O
(	O
p	O
>	O
0.1	O
for	O
all	O
;	O
figure	O
1	O
)	O
.	O

In	O
nasal	O
samples	O
by	O
day	O
10	O
,	O
4/138	O
(	O
2.9	O
%	O
)	O
and	O
4/132	O
(	O
3.0	O
%	O
)	O
patients	O
remained	O
positive	O
for	O
viral	O
RNA	O
in	O
double	O
and	O
standard	O
dose	O
arms	O
.	O

Similar	O
results	O
were	O
observed	O
for	O
sensitivity	O
analyses	O
in	O
which	O
missing	O
data	O
were	O
imputed	O
(	O
0.001	O
cm2/day	O
,	O
−0.20	O
to	O
0.21	O
;	O
P=0.99	O
)	O
,	O
and	O
separately	O
,	O
after	O
adjusting	O
for	O
additional	O
baseline	O
covariates	O
(	O
−0.10	O
cm2/day	O
,	O
−0.33	O
to	O
0.13	O
;	O
P=0.38	O
)	O
.	O

At	O
16	O
weeks	O
38.9	O
%	O
to	O
53.7	O
%	O
of	O
patients	O
treated	O
with	O
canakinumab	O
and	O
46.3	O
%	O
of	O
patients	O
treated	O
with	O
colchicine	O
achieved	O
SU	O
levels	O
<	O
6	O
mg/dl	O
and	O
similar	O
results	O
were	O
reported	O
for	O
week	O
24	O
(	O
canakinumab	O
,	O
37.0	O
%	O
to	O
50.9	O
%	O
;	O
colchicine	O
,	O
41.7	O
%	O
)	O
.	O

Whether	O
addition	O
of	O
one	O
drug	O
for	O
a	O
short	O
period	O
in	O
an	O
induction-maintenance	O
approach	O
might	O
have	O
benefits	O
across	O
childhood	O
is	O
unknown	O
.	O

No	O
serious	O
adverse	O
events	O
occurred	O
during	O
the	O
study	O
.	O

Peak	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
(	O
0-3h	O
)	O
,	O
trough	O
FVC	O
and	O
FVC	O
AUC	O
(	O
0-3h	O
)	O
responses	O
,	O
versus	O
placebo	O
,	O
were	O
greatest	O
with	O
tiotropium	O
Respimat®	O
5	O
μg	O
(	O
P	O
<	O
0.0001	O
,	O
P	O
=	O
0.0012	O
and	O
P	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

The	O
two	O
treatments	O
together	O
were	O
thus	O
no	O
more	O
effective	O
than	O
either	O
one	O
alone	O
,	O
as	O
shown	O
by	O
the	O
substantial	O
and	O
close	O
to	O
significant	O
negative	O
interaction	O
.	O

An	O
analysis	O
of	O
subgroups	O
based	O
on	O
randomisation	O
month	O
(	O
October–February	O
,	O
March–September	O
)	O
confined	O
to	O
the	O
first	O
12	O
weeks	O
of	O
treatment	O
(	O
to	O
avoid	O
overlapping	O
time	O
periods	O
)	O
found	O
no	O
effect	O
of	O
season	O
on	O
the	O
treatment	O
effect	O
(	O
table	O
2	O
)	O
.	O

Oseltamivir	O
resistance	O
No	O
patients	O
with	O
H1N1-pdm09	O
or	O
H5N1	O
had	O
the	O
oseltamivir	O
resistance	O
associated	O
mutation	O
H275Y	O
at	O
baseline	O
or	O
after	O
treatment	O
.	O

Here	O
,	O
we	O
report	O
the	O
results	O
of	O
a	O
dose-ranging	O
,	O
active-controlled	O
phase	O
II	O
trial	O
to	O
assess	O
the	O
efficacy	O
,	O
safety	O
and	O
tolerability	O
of	O
canakinumab	O
as	O
prophylaxis	O
against	O
flares	O
in	O
patients	O
initiating	O
allopurinol	O
treatment	O
.	O

Strategies	O
recommended	O
to	O
decrease	O
GI	O
injury	O
in	O
NSAID	O
users	O
include	O
co-therapy	O
with	O
misoprostol	O
or	O
proton-pump	O
inhibitors	O
and/or	O
use	O
of	O
COX-2	O
selective	O
inhibitors	O
.	O

The	O
study	O
's	O
Data	O
and	O
Safety	O
Monitoring	O
Board	O
examined	O
adverse	O
event	O
reports	O
periodically	O
but	O
the	O
blinding	O
code	O
was	O
not	O
broken	O
.	O

Adverse	O
events	O
Oseltamivir	O
was	O
generally	O
well	O
tolerated	O
;	O
55	O
(	O
16.9	O
%	O
)	O
patients	O
had	O
75	O
treatment	O
emergent	O
adverse	O
events	O
with	O
similar	O
rates	O
between	O
the	O
two	O
arms	O
(	O
table	O
7	O
)	O
.	O

Study	O
evaluations	O
Patients	O
with	O
severe	O
influenza-like	O
illness	O
were	O
screened	O
with	O
the	O
Quickvue	O
rapid	O
test	O
(	O
Quidel	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
US	O
)	O
and/or	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
of	O
throat	O
and	O
nose	O
swabs	O
.	O

Outcome	O
measures	O
The	O
primary	O
efficacy	O
outcome	O
was	O
the	O
annualized	O
rate	O
of	O
protocol-defined	O
asthma	O
exacerbations	O
from	O
baseline	O
to	O
Week	O
36	O
.	O

In	O
accordance	O
with	O
the	O
Global	O
Initiative	O
for	O
Asthma	O
guidelines	O
,	O
for	O
patients	O
with	O
moderate	O
asthma	O
who	O
remain	O
symptomatic	O
despite	O
using	O
ICS	O
,	O
therapy	O
is	O
typically	O
‘	O
stepped	O
up	O
’	O
by	O
increasing	O
the	O
ICS	O
dose	O
and/or	O
adding	O
a	O
long-acting	O
β2-agonist	O
(	O
LABA	O
)	O
to	O
the	O
maintenance	O
treatment	O
regimen	O
.	O

Plasma	O
ET	O
concentrations	O
are	O
increased	O
in	O
patients	O
with	O
SSc	O
,	O
and	O
there	O
is	O
evidence	O
for	O
increased	O
ETB	O
receptor	O
expression	O
in	O
lung	O
,	O
skin	O
and	O
blood	O
vessels	O
in	O
this	O
disease	O
.	O

End	O
points	O
and	O
analysis	O
The	O
primary	O
end	O
point	O
for	O
REDUCE-1	O
was	O
gastric	O
ulcers	O
identified	O
at	O
endoscopy	O
during	O
the	O
24-week	O
study	O
period	O
,	O
with	O
three	O
secondary	O
end	O
points	O
:	O
upper	O
GI	O
ulcers	O
(	O
gastric	O
and	O
duodenal	O
)	O
,	O
duodenal	O
ulcers	O
,	O
and	O
GI	O
complications	O
(	O
bleeding	O
,	O
ulcer	O
perforation	O
,	O
and	O
gastric	O
outlet	O
obstruction	O
due	O
to	O
ulcer	O
)	O
.	O

Primary	O
end	O
points	O
New	O
DUs	O
After	O
24	O
weeks	O
of	O
bosentan	O
treatment	O
there	O
was	O
a	O
30	O
%	O
reduction	O
in	O
the	O
occurrence	O
of	O
new	O
DUs	O
compared	O
with	O
placebo	O
in	O
the	O
study	O
population	O
(	O
1.9	O
(	O
95	O
%	O
CI	O
1.4	O
to	O
2.3	O
)	O
vs	O
2.7	O
(	O
2.0	O
to	O
3.4	O
)	O
new	O
DUs	O
,	O
p=0.0351	O
,	O
figure	O
2	O
)	O
.	O

The	O
independent	O
variables	O
prior	O
ulcer	O
history	O
,	O
gender	O
,	O
age	O
,	O
low-dose	O
aspirin	O
use	O
,	O
baseline	O
erosions	O
,	O
and	O
therapy	O
also	O
were	O
included	O
in	O
a	O
proportional	O
hazards	O
model	O
to	O
determine	O
the	O
effect	O
on	O
the	O
dependent	O
variable	O
of	O
development	O
of	O
upper	O
GI	O
ulcer	O
.	O

Treatment	O
failure	O
was	O
documented	O
in	O
29/59	O
(	O
49	O
%	O
)	O
participants	O
in	O
the	O
ciclosporin	O
group	O
and	O
26/53	O
(	O
49	O
%	O
)	O
in	O
the	O
prednisolone	O
group	O
(	O
P=0.88	O
)	O
.	O

We	O
compared	O
the	O
time	O
to	O
clearance	O
of	O
the	O
plantar	O
warts	O
between	O
the	O
two	O
groups	O
adjusting	O
for	O
the	O
same	O
covariates	O
as	O
above	O
(	O
age	O
,	O
previous	O
treatment	O
,	O
and	O
type	O
of	O
wart	O
)	O
.	O

Of	O
the	O
13	O
non-serious	O
adverse	O
events	O
in	O
the	O
salicylic	O
acid	O
group	O
,	O
nine	O
were	O
unrelated	O
to	O
the	O
trial	O
treatment	O
and	O
four	O
were	O
unlikely	O
to	O
be	O
related	O
to	O
the	O
treatment	O
.	O

Three	O
patients	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
enrolment	O
across	O
both	O
arms	O
(	O
two	O
double	O
dose	O
,	O
one	O
standard	O
dose	O
)	O
.	O

CD4	O
percentage	O
increased	O
throughout	O
the	O
first	O
3	O
years	O
on	O
ART	O
before	O
plateauing	O
in	O
both	O
groups	O
(	O
figure	O
3	O
;	O
p=0·23	O
)	O
.	O

Immunostaining	O
and	O
flow	O
cytometry	O
All	O
reagents	O
were	O
obtained	O
from	O
AbD	O
Serotec	O
(	O
Oxford	O
,	O
UK	O
)	O
unless	O
otherwise	O
stated	O
.	O

After	O
year	O
1	O
,	O
23	O
(	O
4	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
six	O
(	O
1	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
a	O
first	O
WHO	O
stage	O
4	O
event	O
or	O
died	O
(	O
difference	O
0·99	O
per	O
100	O
child-years	O
,	O
95	O
%	O
CI	O
0·37–1·60	O
,	O
p=0·002	O
)	O
.	O

ACQ-7	O
was	O
self-administered	O
at	O
Visits	O
1–6	O
prior	O
to	O
lung	O
function	O
tests	O
.	O

No	O
cases	O
of	O
virilisation	O
were	O
reported	O
.	O

Furthermore	O
,	O
the	O
covariance	O
model	O
's	O
validity	O
was	O
checked	O
by	O
analysing	O
the	O
residuals	O
and	O
the	O
Cook	O
distances	O
.	O

Antiretroviral	O
drugs	O
could	O
be	O
substituted	O
,	O
preferably	O
within	O
class	O
,	O
after	O
adverse	O
events	O
.	O

Primary	O
efficacy	O
endpoints	O
were	O
new	O
WHO	O
stage	O
4	O
events	O
or	O
death	O
for	O
monitoring	O
and	O
change	O
in	O
CD4	O
percentage	O
at	O
72	O
and	O
144	O
weeks	O
for	O
ART-strategy	O
randomisations	O
;	O
the	O
co-primary	O
toxicity	O
endpoint	O
was	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
.	O

Approval	O
for	O
the	O
study	O
was	O
obtained	O
from	O
the	O
Ethical	O
Committee	O
of	O
the	O
Jos	O
University	O
Teaching	O
Hospital	O
and	O
the	O
Institutional	O
Review	O
Board	O
of	O
Mayo	O
Clinic	O
,	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
a	O
parent	O
of	O
each	O
enrolled	O
child	O
.	O

The	O
treatment	O
period	O
was	O
completed	O
by	O
75/98	B-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
76.5	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
and	I-Sample_Size_Actual_at_Outcome_Analysis
73/90	I-Sample_Size_Actual_at_Outcome_Analysis
(	I-Sample_Size_Actual_at_Outcome_Analysis
81.1	I-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
)	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
,	O
respectively	O
(	O
figure	O
1	O
)	O
,	O
with	O
9.2	O
%	O
and	O
7.8	O
%	O
,	O
respectively	O
,	O
discontinued	O
due	O
to	O
an	O
adverse	O
event	O
.	O

Patients	O
were	O
directed	O
to	O
fix	O
the	O
adhesive	O
ring	O
with	O
the	O
hole	O
over	O
the	O
verruca	O
and	O
to	O
squeeze	O
a	O
little	O
ointment	O
into	O
the	O
hole	O
and	O
directly	O
on	O
to	O
the	O
verruca	O
.	O

In	O
an	O
earlier	O
trial	O
,	O
treatment	O
with	O
bosentan	O
,	O
an	O
oral	O
endothelin	O
receptor	O
antagonist	O
,	O
reduced	O
the	O
occurrence	O
of	O
new	O
DUs	O
by	O
48	O
%	O
.	O

Key	O
exclusion	O
criteria	O
were	O
:	O
having	O
a	O
gouty	O
arthritis	O
flare	O
within	O
2	O
weeks	O
of	O
screening	O
,	O
present	O
at	O
screening	O
,	O
or	O
having	O
pain	O
associated	O
with	O
a	O
flare	O
at	O
screening	O
;	O
history	O
of	O
allergy	O
,	O
contraindication	O
,	O
or	O
intolerance	O
to	O
allopurinol	O
or	O
colchicine	O
(	O
see	O
supplementary	O
material	O
for	O
further	O
details	O
)	O
.	O

Powdered	O
limestone	O
was	O
locally	O
available	O
at	O
a	O
much	O
lower	O
cost	O
than	O
calcium	O
tablets	O
.	O

Benefit	O
did	O
not	O
seem	O
to	O
be	O
diminished	O
in	O
elderly	O
patients	O
.	O

Tiotropium	B-Design_Parallel_Group
Respimat®	I-Design_Parallel_Group
(	I-Design_Parallel_Group
two	I-Design_Parallel_Group
puffs	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
Respimat®	I-Design_Parallel_Group
(	I-Design_Parallel_Group
two	I-Design_Parallel_Group
puffs	I-Design_Parallel_Group
)	I-Design_Parallel_Group
was	O
administered	O
once	O
daily	O
in	O
the	O
evening	O
between	O
18:00	O
and	O
20:00	O
.	O

Serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
measured	O
by	O
isotope-dilution	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(	O
LC-MS/MS	O
)	O
.	O

Plasma	O
TNF-α	O
and	O
IL-6	O
concentrations	O
were	O
determined	O
as	O
described	O
previously	O
using	O
ELISA	O
(	O
Quantikine	O
human	O
TNF	O
and	O
IL-6	O
immunoassays	O
,	O
R	O
&	O
D	O
Systems	O
;	O
and	O
Dako	O
A/S	O
,	O
respectively	O
)	O
and	O
fibrinolytic	O
activities	O
using	O
a	O
photometric	O
method	O
(	O
Coatest	O
t-PA	O
and	O
PAI-1	O
,	O
Chomogenix	O
AB	O
)	O
.	O

This	O
analysis	O
was	O
repeated	O
by	O
giving	O
these	O
samples	O
the	O
value	O
of	O
0	O
.	O

Treatment	O
with	O
growth	O
hormone	O
and	O
oxandrolone	O
continued	O
until	O
final	O
height	O
was	O
reached	O
.	O

The	O
median	O
plasma	O
concentration	O
of	O
memantine	O
was	O
83	O
ng/ml	O
(	O
76.5–98.3	O
)	O
.	O

As	O
a	O
result	O
,	O
no	O
single	O
pharmacological	O
treatment	O
is	O
entirely	O
effective	O
.	O

Funding	O
UK	O
Medical	O
Research	O
Council	O
,	O
Health	O
Foundation	O
UK	O
,	O
Stroke	O
Association	O
UK	O
,	O
Research	O
Council	O
of	O
Norway	O
,	O
Arbetsmarknadens	O
Partners	O
Forsakringsbolag	O
(	O
AFA	O
)	O
Insurances	O
Sweden	O
,	O
Swedish	O
Heart	O
Lung	O
Fund	O
,	O
The	O
Foundation	O
of	O
Marianne	O
and	O
Marcus	O
Wallenberg	O
,	O
Polish	O
Ministry	O
of	O
Science	O
and	O
Education	O
,	O
the	O
Australian	O
Heart	O
Foundation	O
,	O
Australian	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
)	O
,	O
Swiss	O
National	O
Research	O
Foundation	O
,	O
Swiss	O
Heart	O
Foundation	O
,	O
Assessorato	O
alla	O
Sanita	O
,	O
Regione	O
dell'Umbria	O
,	O
Italy	O
,	O
and	O
Danube	O
University	O
.	O

The	O
baseline	O
characteristics	O
at	O
enrolment	O
are	O
shown	O
in	O
table	O
1	O
.	O

Secondary	O
and	O
exploratory	O
end	O
points	O
New	O
DUs	O
The	O
proportion	O
of	O
patients	O
with	O
no	O
new	O
DUs	O
up	O
to	O
week	O
24	O
was	O
similar	O
with	O
bosentan	O
and	O
placebo	O
(	O
observed	O
in	O
32/95	O
(	O
33.7	O
%	O
)	O
and	O
26/89	O
(	O
29.2	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
RR	O
1.15	O
(	O
95	O
%	O
CI	O
0.75	O
to	O
1.77	O
)	O
;	O
p=0.53	O
)	O
.	O

These	O
showed	O
no	O
benefit	O
from	O
routine	O
toxicity	O
monitoring	O
,	O
small	O
but	O
significant	O
benefits	O
from	O
CD4	O
monitoring	O
,	O
and	O
no	O
significant	O
additional	O
benefit	O
of	O
viral	O
load	O
over	O
CD4	O
monitoring	O
.	O

Similarly	O
,	O
patients	O
recruited	O
at	O
earlier	O
time	O
points	O
were	O
significantly	O
older	O
than	O
those	O
recruited	O
later	O
(	O
test	O
for	O
linear	O
trend	O
p	O
<	O
0·0001	O
)	O
.	O

Patients	O
with	O
H5N1	O
influenza	O
were	O
stratified	O
separately	O
.	O

Their	O
calcium	O
intakes	O
were	O
well	O
below	O
the	O
Institute	O
of	O
Medicine	O
's	O
estimated	O
average	O
daily	O
requirements	O
of	O
500	O
mg	O
and	O
800	O
mg	O
for	O
children	O
1–3	O
years	O
of	O
age	O
and	O
4–8	O
years	O
of	O
age	O
,	O
respectively	O
.	O

We	O
monitored	O
the	O
quality	O
and	O
integrity	O
of	O
the	O
accumulating	O
clinical	O
data	O
according	O
to	O
a	O
protocol	O
agreed	O
with	O
the	O
study	O
sponsors	O
,	O
which	O
involved	O
central	O
statistical	O
monitoring	O
according	O
to	O
the	O
principles	O
described	O
by	O
Buyse	O
and	O
colleagues	O
,	O
supplemented	O
by	O
onsite	O
monitoring	O
and	O
detailed	O
source	O
data	O
verification	O
in	O
a	O
random	O
sample	O
of	O
10	O
%	O
of	O
records	O
in	O
centres	O
that	O
had	O
recruited	O
more	O
than	O
30	O
patients	O
,	O
or	O
when	O
patterns	O
in	O
the	O
data	O
at	O
a	O
centre	O
seemed	O
anomalous	O
.	O

The	O
research	O
protocol	O
was	O
approved	O
by	O
the	O
local	O
independent	O
ethics	O
committee	O
(	O
Protocol	O
ID	O
:	O
2008-008210-38	O
)	O
.	O

Use	O
of	O
antibiotics	O
and	O
steroids	O
For	O
patients	O
not	O
taking	O
antibiotics	O
at	O
enrolment	O
,	O
antibiotic	O
prescribing	O
was	O
similar	O
(	O
P=0.27	O
)	O
for	O
both	O
arms	O
after	O
enrolment	O
:	O
31/50	O
(	O
62	O
%	O
)	O
in	O
the	O
double	O
dose	O
and	O
33/45	O
(	O
73	O
%	O
)	O
in	O
the	O
standard	O
dose	O
arm	O
.	O

The	O
assessors	O
disagreed	O
in	O
51	O
cases	O
:	O
in	O
three	O
cases	O
the	O
disagreement	O
was	O
between	O
whether	O
the	O
plantar	O
wart	O
was	O
“	O
cleared	O
”	O
or	O
“	O
not	O
cleared	O
,	O
”	O
in	O
five	O
cases	O
it	O
was	O
between	O
“	O
cleared	O
”	O
and	O
“	O
unable	O
to	O
assess	O
,	O
”	O
and	O
in	O
the	O
remaining	O
43	O
cases	O
it	O
was	O
between	O
“	O
not	O
cleared	O
”	O
and	O
“	O
unable	O
to	O
assess.	O
”	O
This	O
might	O
lead	O
to	O
an	O
underestimation	O
of	O
the	O
clearance	O
rate	O
,	O
but	O
as	O
the	O
assessment	O
was	O
blind	O
to	O
treatment	O
allocation	O
it	O
is	O
unlikely	O
to	O
lead	O
to	O
a	O
difference	O
between	O
the	O
two	O
treatments	O
groups	O
.	O

During	O
the	O
post-trial	O
period	O
(	O
when	O
statin	O
use	O
and	O
lipid	O
concentrations	O
were	O
similar	O
in	O
both	O
groups	O
)	O
,	O
no	O
further	O
significant	O
reductions	O
were	O
noted	O
in	O
either	O
major	O
vascular	O
events	O
(	O
risk	O
ratio	O
[	O
RR	O
]	O
0·95	O
[	O
0·89–1·02	O
]	O
)	O
or	O
vascular	O
mortality	O
(	O
0·98	O
[	O
0·90–1·07	O
]	O
)	O
.	O

We	O
conclude	O
that	O
TNF-α	O
antagonism	O
is	O
unlikely	O
to	O
be	O
a	O
beneficial	O
therapeutic	O
strategy	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

Primary	O
outcome	O
Of	O
the	O
108	O
participants	O
with	O
data	O
at	O
baseline	O
and	O
six	O
weeks	O
,	O
86	O
(	O
80	O
%	O
)	O
had	O
blinded	O
outcome	O
data	O
based	O
on	O
digital	O
images	O
.	O

At	O
week	O
1	O
,	O
more	O
patients	O
were	O
happy	O
with	O
salicylic	O
acid	O
than	O
cryotherapy	O
but	O
also	O
more	O
patients	O
were	O
very	O
happy	O
with	O
cryotherapy	O
than	O
salicylic	O
acid	O
.	O

Number	O
of	O
treatment	O
failures—defined	O
as	O
those	O
who	O
withdrew	O
from	O
their	O
randomised	O
treatment	O
because	O
of	O
treatment	O
intolerance	O
,	O
whose	O
pyoderma	O
gangrenosum	O
worsened	O
,	O
or	O
whose	O
target	O
lesion	O
remained	O
unhealed	O
after	O
six	O
months	O
of	O
follow-up	O
.	O

Methods	O
Trial	O
design	O
The	O
COSTA	O
trial	O
of	O
quilizumab	O
was	O
a	O
Phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
randomized	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
study	O
(	O
including	O
recruiting	B-Settings_Multicenter
sites	I-Settings_Multicenter
from	I-Settings_Multicenter
14	I-Settings_Multicenter
countries	I-Settings_Multicenter
:	O
Argentina	B-Settings_Location
,	I-Settings_Location
Belgium	I-Settings_Location
,	I-Settings_Location
Bulgaria	I-Settings_Location
,	I-Settings_Location
Canada	I-Settings_Location
,	I-Settings_Location
Germany	I-Settings_Location
,	I-Settings_Location
Hungary	I-Settings_Location
,	I-Settings_Location
Mexico	I-Settings_Location
,	I-Settings_Location
New	I-Settings_Location
Zealand	I-Settings_Location
,	I-Settings_Location
Peru	I-Settings_Location
,	I-Settings_Location
Poland	I-Settings_Location
,	I-Settings_Location
Romania	I-Settings_Location
,	I-Settings_Location
Russia	I-Settings_Location
,	I-Settings_Location
Ukraine	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
the	I-Settings_Location
United	I-Settings_Location
States	I-Settings_Location
)	O
that	O
enrolled	O
578	B-Sample_Size_Actual_at_Enrollment
adults	O
with	O
uncontrolled	O
allergic	O
asthma	O
.	O

The	O
treated	O
set	O
comprised	O
all	O
149	O
patients	O
and	O
the	O
full	O
analysis	O
set	O
comprised	O
148	O
patients	O
(	O
one	O
patient	O
had	O
missing	O
efficacy	O
data	O
and	O
was	O
lost	O
to	O
follow-up	O
after	O
Visit	O
2	O
)	O
(	O
Figure	O
2	O
)	O
.	O

Neither	O
was	O
considered	O
to	O
be	O
drug-related	O
.	O

We	O
wished	O
to	O
determine	O
the	O
effects	O
of	O
TNF-α	O
antagonism	O
on	O
endothelial	O
function	O
and	O
platelet	O
activation	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
.	O

The	O
study	O
was	O
not	O
formally	O
powered	O
to	O
detect	O
a	O
significant	O
interaction	O
between	O
the	O
two	O
randomisations	O
.	O

In	O
both	O
subgroups	O
,	O
the	O
estimated	O
proportion	O
of	O
patients	O
without	O
each	O
subsequent	O
new	O
DU	O
was	O
larger	O
in	O
the	O
bosentan	O
than	O
placebo	O
group	O
except	O
the	O
first	O
new	O
DU	O
(	O
table	O
3	O
)	O
,	O
and	O
the	O
difference	O
between	O
treatment	O
groups	O
was	O
larger	O
among	O
patients	O
with	O
at	O
least	O
four	O
new	O
DUs	O
than	O
in	O
those	O
with	O
fewer	O
than	O
four	O
new	O
DUs	O
.	O

Use	O
of	O
glibenclamide	O
,	O
fluconazole	O
,	O
calcineurin	O
inhibitors	O
or	O
ciclosporin	O
A	O
was	O
not	O
allowed	O
due	O
to	O
potential	O
drug	O
interactions	O
.	O

Participants	O
were	O
excluded	O
from	O
the	O
study	O
if	O
they	O
had	O
impaired	O
healing	O
(	O
such	O
as	O
from	O
diabetes	O
or	O
peripheral	O
vascular	O
disease	O
)	O
;	O
were	O
immunosuppressed	O
(	O
such	O
as	O
agammaglobulinaemia	O
)	O
or	O
were	O
taking	O
immunosuppressant	O
drugs	O
(	O
such	O
as	O
oral	O
corticosteroids	O
)	O
;	O
had	O
neuropathy	O
;	O
were	O
receiving	O
renal	O
dialysis	O
;	O
had	O
cold	O
intolerance	O
(	O
such	O
as	O
Raynaud	O
’	O
s	O
syndrome	O
or	O
cold	O
urticaria	O
)	O
;	O
had	O
any	O
of	O
the	O
following	O
conditions	O
(	O
blood	O
dyscrasias	O
of	O
unknown	O
origin	O
,	O
cryoglobulinaemia	O
,	O
cryofibrinogenaemia	O
,	O
collagen	O
or	O
autoimmune	O
disease	O
)	O
;	O
were	O
unable	O
to	O
give	O
informed	O
consent	O
;	O
or	O
were	O
currently	O
in	O
a	O
trial	O
evaluating	O
other	O
treatments	O
for	O
their	O
plantar	O
wart	O
.	O

Acute-care	O
protocols	O
were	O
not	O
specified	O
by	O
the	O
trial	O
,	O
but	O
had	O
to	O
include	O
the	O
components	O
of	O
effective	O
stroke-unit	O
care	O
,	O
including	O
,	O
soon	O
after	O
admission	O
,	O
intravenous	O
access	O
,	O
monitoring	O
of	O
physiological	O
variables	O
,	O
correction	O
of	O
any	O
abnormalities	O
,	O
and	O
where	O
clinically	O
appropriate	O
,	O
intravenous-fluid	O
therapy	O
.	O

Both	O
participants	O
developed	O
a	O
blister	O
that	O
was	O
larger	O
than	O
expected	O
in	O
routine	O
practice	O
.	O

Of	O
the	O
68	B-Sample_Size_Actual_at_Outcome_Analysis
children	I-Sample_Size_Actual_at_Outcome_Analysis
(	O
94	O
%	O
of	O
original	O
cohort	O
)	O
who	O
completed	O
24	O
weeks	O
of	O
treatment	O
,	O
29	O
(	O
67	O
%	O
)	O
in	O
the	O
Ca+D	O
group	O
and	O
11	O
(	O
44	O
%	O
)	O
in	O
the	O
Ca	O
group	O
achieved	O
the	O
primary	O
outcome	O
(	O
p=0.06	O
)	O
.	O

Height	O
,	O
weight	O
,	O
venous	O
blood	O
,	O
wrist	O
and	O
knee	O
radiographs	O
,	O
and	O
forearm	O
bone	O
density	O
measurements	O
were	O
obtained	O
at	O
baseline	O
and	O
at	O
12	O
and	O
24	O
weeks	O
after	O
enrolment	O
.	O

Collectively	O
,	O
findings	O
of	O
HPS	O
and	O
other	O
major	O
trials	O
of	O
statins	O
provide	O
compelling	O
evidence	O
that	O
lowering	O
LDL	O
cholesterol	O
by	O
about	O
1	O
mmol/L	O
reduces	O
vascular	O
mortality	O
and	O
morbidity	O
by	O
about	O
a	O
quarter	O
in	O
a	O
wide	O
range	O
of	O
patients	O
(	O
including	O
elderly	O
people	O
and	O
those	O
with	O
low	O
cholesterol	O
concentrations	O
)	O
,	O
without	O
increasing	O
the	O
risk	O
of	O
non-vascular	O
mortality	O
or	O
morbidity	O
(	O
apart	O
from	O
a	O
small	O
myopathy	O
excess	O
)	O
during	O
about	O
5	O
years	O
of	O
treatment	O
.	O

Randomization	O
was	O
stratified	B-Randomization_Type_Stratified
based	O
on	O
serum	B-Randomization_Stratified_Criteria
periostin	I-Randomization_Stratified_Criteria
level	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
<	I-Randomization_Stratified_Criteria
50	I-Randomization_Stratified_Criteria
ng/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
≥50	I-Randomization_Stratified_Criteria
ng/mL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
exacerbation	B-Randomization_Stratified_Criteria
history	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
number	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
exacerbations	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
1	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
1	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
requiring	I-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
systemic	I-Randomization_Stratified_Criteria
corticosteroids	I-Randomization_Stratified_Criteria
in	I-Randomization_Stratified_Criteria
the	I-Randomization_Stratified_Criteria
prior	I-Randomization_Stratified_Criteria
18	I-Randomization_Stratified_Criteria
months	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
IgE	B-Randomization_Stratified_Criteria
level	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
≤75	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
75–200	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
,	I-Randomization_Stratified_Criteria
>	I-Randomization_Stratified_Criteria
200	I-Randomization_Stratified_Criteria
IU/mL	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
,	O
and	O
country	B-Randomization_Stratified_Criteria
.	O

Of	O
the	O
46	O
girls	O
not	O
randomised	O
at	O
12	O
years	O
,	O
21	O
enrolled	O
after	O
12	O
years	O
(	O
the	O
late	O
group	O
)	O
,	O
18	O
had	O
spontaneous	O
puberty	O
,	O
and	O
seven	O
had	O
withdrawn	O
before	O
the	O
age	O
of	O
12	O
years	O
.	O

Safety	O
and	O
tolerability	O
Safety	O
results	O
for	O
the	O
individual	O
dose	O
groups	O
are	O
summarised	O
in	O
table	O
3	O
.	O

Secondary	O
end	O
points	O
included	O
pain	O
,	O
disability	O
and	O
safety	O
.	O

The	O
period	O
of	O
follow-up	O
available	O
varied	O
depending	O
on	O
the	O
time	O
at	O
which	O
participants	O
were	O
randomised	O
into	O
the	O
trial	O
.	O

All	O
assessments	O
were	O
made	O
masked	O
to	O
all	O
patient	O
details	O
and	O
treatment	O
allocation	O
.	O

Outcomes	O
were	O
assessed	O
at	O
baseline	O
and	O
six	O
weeks	O
and	O
when	O
the	O
ulcer	O
had	O
healed	O
(	O
to	O
a	O
maximum	O
of	O
six	O
months	O
)	O
.	O

Proportional	O
hazards	O
analysis	O
of	O
multiple	O
potential	O
risk	O
factors	O
showed	O
the	O
risk	O
ratio	O
of	O
upper	O
GI	O
ulcers	O
with	O
HZT-501	B-Design_Parallel_Group
vs.	I-Design_Parallel_Group
ibuprofen	I-Design_Parallel_Group
was	O
0.46	O
,	O
95	O
%	O
confidence	O
interval	O
was	O
0.34–0.61	O
.	O

Healing	O
of	O
the	O
cardinal	O
ulcer	O
No	O
difference	O
between	O
bosentan	O
and	O
placebo	O
treatments	O
was	O
observed	O
in	O
the	O
time	O
to	O
healing	O
of	O
the	O
cardinal	O
ulcer	O
(	O
HR	O
0.91	O
(	O
95	O
%	O
CI	O
0.61	O
to	O
1.35	O
)	O
,	O
p=0.63	O
,	O
figure	O
3	O
)	O
.	O

Funding	O
UK	O
Medical	O
Research	O
Council	O
,	O
British	O
Heart	O
Foundation	O
,	O
Merck	O
&	O
Co	O
,	O
Roche	O
Vitamins	O
.	O

Other	O
actions	O
of	O
ET	O
relevant	O
to	O
SSc	O
include	O
proinflammatory	O
and	O
proliferative	O
effects	O
as	O
well	O
as	O
mediation	O
of	O
vasoconstriction	O
.	O

We	O
therefore	O
specified	O
in	O
the	O
statistical	O
analysis	O
plan	O
an	O
ordinal	O
logistic	O
regression	O
analysis	O
,	O
as	O
a	O
secondary	O
outcome	O
,	O
in	O
which	O
the	O
OHS	O
as	O
a	O
dependent	O
variable	O
had	O
5	O
levels	O
:	O
levels	O
4	O
,	O
5	O
,	O
and	O
6	O
were	O
combined	O
into	O
a	O
single	O
level	O
and	O
levels	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
were	O
retained	O
as	O
distinct	O
.	O

Similarly	O
,	O
a	O
trial	O
in	O
patients	O
with	O
severe	O
PAH	O
associated	O
with	O
SSc	O
indicated	O
there	O
may	O
be	O
a	O
beneficial	O
effect	O
of	O
epoprostenol	O
on	O
the	O
number	O
of	O
DUs	O
.	O

ART-modifying	O
adverse	O
events	O
occurred	O
in	O
31	O
(	O
5	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
32	O
(	O
5	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
(	O
HR	O
0·95	O
,	O
0·58–1·56	O
,	O
p=0·84	O
)	O
.	O

At	O
24	O
h	O
,	O
treatment	O
with	O
etanercept	O
was	O
associated	O
with	O
a	O
reduced	O
neutrophil	O
count	O
(	O
8.8±0.6	O
vs	O
7.4±0.5	O
cells	O
109/l	O
;	O
p=0.02	O
)	O
,	O
and	O
a	O
rise	O
in	O
the	O
lymphocyte	O
count	O
(	O
2.3±0.2	O
vs	O
2.7±0.26	O
;	O
p=0.001	O
)	O
,	O
with	O
a	O
reduction	O
in	O
the	O
neutrophil	O
to	O
lymphocyte	O
ratio	O
following	O
etanercept	O
compared	O
with	O
placebo	O
(	O
−1.3±0.4	O
vs	O
0.17±0.2	O
;	O
p=0.001	O
)	O
.	O

In	O
the	O
cryotherapy	O
group	O
,	O
there	O
were	O
two	O
treatment	O
related	O
,	O
non-serious	O
adverse	O
events	O
in	O
two	O
participants	O
.	O

Any	O
discrepancies	O
were	O
referred	O
to	O
a	O
third	O
assessor	O
.	O

Setting	O
39	B-Settings_Multicenter
UK	B-Settings_Location
hospitals	I-Settings_Multicenter
,	O
recruiting	O
from	O
June	O
2009	O
to	O
November	O
2012	O
.	O

Change	O
in	O
CD4	O
percentage	O
was	O
compared	O
with	O
normal	O
linear	O
regression	O
adjusted	O
for	O
randomisation	O
stratification	O
factors	O
.	O

Statistical	O
analysis	O
We	O
prespecified	O
all	O
analyses	O
in	O
a	O
statistical	O
analysis	O
plan	O
.	O

Girls	O
with	O
a	O
follicle	O
stimulating	O
hormone	O
concentration	O
below	O
10U/L	O
and	O
a	O
karyotype	O
associated	O
with	O
preservation	O
of	O
ovarian	O
function	O
(	O
45	O
,	O
X/46	O
,	O
XX	O
and	O
45	O
,	O
X/47	O
,	O
XXX	O
)	O
(	O
the	O
spontaneous	O
puberty	O
group	O
)	O
were	O
not	O
randomised	O
at	O
randomisation	O
2	O
.	O

For	O
children	O
assigned	O
to	O
clinically	O
driven	O
monitoring	O
,	O
clinicians	O
could	O
request	O
individual	O
laboratory	O
toxicity	O
results	O
from	O
routine	O
haematology	O
or	O
biochemistry	O
panels	O
for	O
clinical	O
reasons	O
.	O

However	O
,	O
these	O
effects	O
were	O
not	O
additive	O
,	O
so	O
using	O
both	O
had	O
no	O
advantage	O
.	O

Numbers-needed-to-treat	O
(	O
NNTs	O
)	O
and	O
absolute	O
risk	O
reductions	O
were	O
calculated	O
using	O
crude	O
proportions	O
.	O

Treatment	O
with	O
quilizumab	O
failed	O
to	O
increase	O
either	O
the	O
proportion	O
of	O
patients	O
who	O
used	O
a	O
SABA	O
for	O
fewer	O
than	O
2	O
days	O
in	O
the	O
prior	O
week	O
or	O
the	O
proportion	O
of	O
patients	O
who	O
did	O
not	O
awaken	O
at	O
night	O
due	O
to	O
asthma	O
symptoms	O
for	O
all	O
dosing	O
levels	O
relative	O
to	O
the	O
placebo	O
group	O
at	O
Week	O
36	O
(	O
Table	O
3	O
)	O
.	O

Table	O
1	O
summarises	O
the	O
baseline	O
characteristics	O
of	O
the	O
participants	O
.	O

The	O
remainder	O
of	O
the	O
study	O
population	O
had	O
never	O
smoked	O
(	O
80.5	O
%	O
;	O
n	O
=	O
120	O
)	O
(	O
Table	O
1	O
)	O
.	O

As	O
a	O
result	O
,	O
we	O
felt	O
that	O
a	O
substantial	O
treatment	O
effect	O
was	O
necessary	O
to	O
justify	O
a	O
change	O
in	O
clinical	O
practice	O
.	O

Only	O
11	O
(	O
2	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
two	O
(	O
<	O
1	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
CD4	O
less	O
than	O
5	O
%	O
at	O
their	O
last	O
visit	O
(	O
exact	O
p=0·01	O
;	O
appendix	O
)	O
.	O

Although	O
there	O
was	O
no	O
difference	O
in	O
grade	O
4	O
adverse	O
events	O
,	O
147	O
(	O
24	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
117	O
(	O
20	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
one	O
or	O
more	O
serious	O
adverse	O
events	O
(	O
any	O
grade	O
;	O
HR	O
1·30	O
,	O
1·02–1·66	O
,	O
p=0·04	O
)	O
.	O

Long-standing	O
elevated	O
body	O
uric	O
acid	O
pools	O
can	O
lead	O
to	O
increased	O
serum	O
urate	O
(	O
SU	O
)	O
levels	O
and	O
formation	O
of	O
MSU	O
crystals	O
.	O

Patients	O
with	O
positive	O
results	O
for	O
influenza	O
virus	O
who	O
met	O
the	O
inclusion	O
criteria	O
were	O
randomised	O
.	O

Baseline	O
alkaline	O
phosphatase	O
and	O
radiographic	O
scores	O
were	O
unrelated	O
to	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
.	O

Fractional	O
exhaled	O
nitric	O
oxide	O
(	O
FeNO	O
)	O
was	O
measured	O
using	O
a	O
hand-held	O
portable	O
device	O
,	O
NIOX	O
MINO®	O
(	O
Niox	O
;	O
Morrisville	O
,	O
NC	O
)	O
,	O
according	O
to	O
American	O
Thoracic	O
Society/European	O
Respiratory	O
Society	O
2009	O
guidelines	O
.	O

Other	O
than	O
a	O
slight	O
worsening	O
of	O
pre-existing	O
alopecia	O
in	O
one	O
female	O
patient	O
,	O
no	O
adverse	O
events	O
were	O
reported	O
.	O

Results	O
1210	B-Sample_Size_Actual_at_Enrollment
children	I-Sample_Size_Actual_at_Enrollment
were	O
enrolled	O
(	O
March	O
15	O
,	O
2007–Nov	O
18	O
,	O
2008	O
)	O
.	O

This	O
trial	O
was	O
a	O
superiority	O
study	O
of	O
cryotherapy	O
compared	O
with	O
salicylic	O
acid	O
and	O
was	O
powered	O
to	O
show	O
a	O
15	O
%	O
difference	O
in	O
effectiveness	O
.	O

Fatal	O
or	O
non-fatal	O
symptomatic	O
intracranial	O
haemorrhage	O
within	O
7	O
days	O
occurred	O
in	O
104	O
(	O
7	O
%	O
)	O
patients	O
in	O
the	O
rt-PA	O
group	O
versus	O
16	O
(	O
1	O
%	O
)	O
in	O
the	O
control	O
group	O
(	O
adjusted	O
OR	O
6·94	O
,	O
95	O
%	O
CI	O
4·07–11·8	O
;	O
absolute	O
excess	O
58/1000	O
,	O
95	O
%	O
CI	O
44–72	O
)	O
.	O

Table	O
3	O
summarises	O
the	O
results	O
of	O
the	O
randomised	O
comparisons	O
.	O

Samples	O
were	O
then	O
fixed	O
and	O
run	O
through	O
a	O
FACSCalibur	O
(	O
Becton-Dickinson	O
)	O
flow	O
cytometer	O
within	O
2	O
h	O
of	O
fixing	O
using	O
an	O
established	O
flow	O
protocol	O
.	O

The	O
combined	O
trial	O
cumulative	O
incidence	O
for	O
crude	O
rate	O
of	O
ulcers	O
by	O
visit	O
is	O
shown	O
in	O
Figure	O
2	O
.	O

Overall	O
,	O
96	O
784	O
person-years	O
of	O
follow-up	O
were	O
available	O
for	O
those	O
originally	O
allocated	O
simvastatin	O
and	O
95	O
084	O
for	O
those	O
allocated	O
placebo	O
(	O
ratio	O
1·02	O
)	O
.	O

An	O
endoscopic	O
diagnosis	O
of	O
ulcer	O
required	O
unequivocal	O
depth	O
and	O
diameter	O
of	O
≥3	O
mm	O
.	O

Further	O
details	O
were	O
sought	O
from	O
the	O
participants	O
'	O
family	O
doctors	O
(	O
plus	O
,	O
if	O
necessary	O
,	O
hospital	O
records	O
)	O
about	O
all	O
reports	O
that	O
might	O
relate	O
to	O
major	O
vascular	O
events	O
or	O
deaths	O
.	O

No	O
virilisation	O
was	O
reported	O
;	O
in	O
particular	O
,	O
no	O
voice	O
deepening	O
or	O
clitoromegaly	O
was	O
noted	O
.	O

By	O
contrast	O
,	O
similarly	O
to	O
week	O
144	O
,	O
at	O
the	O
latest	O
test	O
suppression	O
was	O
significantly	O
greater	O
in	O
children	O
receiving	O
two	O
NRTIs	O
plus	O
an	O
NNRTI	O
(	O
496	O
[	O
84	O
%	O
]	O
of	O
591	O
in	O
groups	O
A	O
and	O
B	O
vs	O
200	O
[	O
65	O
%	O
]	O
of	O
310	O
in	O
group	O
C	O
)	O
.	O

Sample	O
size	O
determination	O
and	O
statistical	O
analysis	O
A	O
sample	O
size	O
of	O
350	B-Sample_Size_Required
patients	O
(	O
50	O
patients	O
in	O
each	O
of	O
the	O
5	O
canakinumab	O
single-dose	O
groups	O
and	O
100	O
patients	O
in	O
the	O
colchicine	O
group	O
)	O
was	O
considered	O
sufficient	O
to	O
give	O
a	O
95	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
confidence	I-Sample_Size_Calculation_Alpha_Value
interval	I-Sample_Size_Calculation_Alpha_Value
(	O
CI	O
)	O
of	O
the	O
target	O
dose	O
with	O
reasonable	O
precision	O
.	O

One	O
death	O
occurred	O
in	O
the	O
colchicine	O
group	O
,	O
a	O
possible	O
myocardial	O
infarction	O
,	O
but	O
was	O
not	O
regarded	O
by	O
the	O
investigator	O
as	O
being	O
related	O
to	O
study	O
medication	O
.	O

The	O
mean	O
effect	O
on	O
final	O
height	O
of	O
oxandrolone	O
,	O
late	O
induction	O
of	O
puberty	O
,	O
or	O
both	O
compared	O
with	O
placebo	O
and	O
early	O
induction	O
was	O
+7.1	O
cm	O
(	O
that	O
is	O
,	O
the	O
mean	O
final	O
height	O
in	O
the	O
combined	O
oxandrolone/early	O
,	O
oxandrolone/late	O
,	O
and	O
placebo/late	O
groups	O
compared	O
with	O
the	O
placebo/early	O
group	O
)	O
,	O
which	O
is	O
appreciably	O
larger	O
than	O
the	O
effects	O
for	O
either	O
randomisation	O
alone	O
(	O
table	O
3	O
,	O
combination	O
)	O
.	O

Statistical	O
analysis	O
1200	B-Sample_Size_Required
children	I-Sample_Size_Required
followed	O
up	O
for	O
3·5–5·0	O
years	O
with	O
less	O
than	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
loss	I-Sample_Size_Calculation_Dropout_Rate_Value
to	I-Sample_Size_Calculation_Dropout_Rate_Value
follow-up	I-Sample_Size_Calculation_Dropout_Rate_Value
provided	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
establish	O
that	O
clinically	O
driven	O
monitoring	O
was	O
not	B-Design_Comparative_Intent_NonInferiority
inferior	I-Design_Comparative_Intent_NonInferiority
to	O
routine	O
laboratory	O
monitoring	O
on	O
the	O
primary	O
efficacy	O
outcome	O
,	O
defined	O
as	O
the	O
upper	O
95	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
confidence	I-Sample_Size_Calculation_Alpha_Value
limit	O
for	O
the	O
difference	O
(	O
clinically	O
driven	O
minus	O
routine	O
laboratory	O
monitoring	O
)	O
in	O
rate	O
of	O
first	O
new	O
WHO	O
stage	O
4	O
event	O
or	O
deaths	O
per	O
100	O
child-years	O
being	O
no	O
greater	O
than	O
1·6	O
per	O
100	O
child-years	O
(	O
assumed	O
rate	O
for	O
routine	O
laboratory	O
monitoring	O
of	O
2·5	O
per	O
100	O
child-years	O
)	O
.	O

Of	O
all	O
patients	O
with	O
SSc	O
,	O
32	O
%	O
(	O
666	O
patients	O
)	O
had	O
persistent	O
or	O
recurrent	O
DUs	O
for	O
≥6	O
months	O
;	O
of	O
these	O
,	O
30	O
%	O
(	O
197	O
patients	O
)	O
had	O
severe	O
DUs	O
(	O
complicated	O
by	O
gangrene	O
,	O
or	O
requiring	O
digital	O
sympathectomy	O
or	O
amputation	O
)	O
.	O

Such	O
participants	O
were	O
randomised	O
before	O
confirmation	O
of	O
biopsy	O
results	O
as	O
it	O
was	O
considered	O
unethical	O
to	O
delay	O
treatment	O
for	O
those	O
with	O
painful	O
and	O
rapidly	O
spreading	O
ulcers	O
.	O

The	O
overall	O
cure	O
rates	O
from	O
this	O
study	O
are	O
smaller	O
than	O
those	O
observed	O
in	O
two	O
placebo	O
controlled	O
trials	O
of	O
salicylic	O
acid	O
,	O
both	O
of	O
which	O
reported	O
cure	O
rates	O
of	O
85	O
%	O
for	O
active	O
treatment	O
,	O
possibly	O
because	O
more	O
resistant	O
verrucae	O
were	O
included	O
in	O
the	O
study	O
comparing	O
cryotherapy	O
with	O
salicylic	O
acid	O
.	O

Procedures	O
and	O
follow-up	O
During	O
the	O
in-trial	O
treatment	O
period	O
,	O
routine	O
follow-up	O
in	O
study	O
clinics	O
was	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
months	O
and	O
then	O
every	O
6	O
months	O
.	O

The	O
statistical	O
model	O
included	O
‘	O
treatment	O
’	O
and	O
‘	O
period	O
’	O
as	O
fixed	O
effects	O
and	O
‘	O
patient	O
’	O
as	O
a	O
random	O
effect	O
.	O

During	O
the	O
trial	O
,	O
16/112	O
(	O
14	O
%	O
)	O
participants	O
switched	O
to	O
the	O
alternative	O
trial	O
drug	O
and	O
a	O
further	O
eight	O
(	O
7	O
%	O
)	O
received	O
the	O
two	O
drugs	O
together	O
.	O

No	O
trials	O
have	O
evaluated	O
monitoring	O
strategies	O
in	O
children	O
on	O
ART	O
;	O
results	O
in	O
adults	O
might	O
not	O
be	O
generalisable	O
because	O
of	O
differences	O
in	O
frequency	O
of	O
ART	O
toxicity	O
,	O
predictive	O
value	O
of	O
CD4s	O
,	O
and	O
the	O
clinical	O
spectrum	O
of	O
paediatric	O
HIV	O
and	O
its	O
comorbidities	O
,	O
particularly	O
in	O
Africa	O
.	O

The	O
worst	O
of	O
either	O
the	O
calculated	O
number	O
or	O
observed	O
values	O
at	O
week	O
24	O
was	O
used	O
for	O
patients	O
who	O
prematurely	O
discontinued	O
study	O
treatment	O
.	O

Methods	O
Five	B-Sample_Size_Actual_at_Enrollment
hundred	I-Sample_Size_Actual_at_Enrollment
seventy-eight	I-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomized	O
to	O
monthly	B-Design_Parallel_Group
or	I-Design_Parallel_Group
quarterly	I-Design_Parallel_Group
dosing	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
of	I-Design_Parallel_Group
subcutaneous	I-Design_Parallel_Group
quilizumab	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
for	O
36	O
weeks	O
,	O
with	O
a	O
48-week	O
safety	O
follow-up	O
.	O

CONCLUSIONS	O
:	O
Combined	O
results	O
of	O
the	O
REDUCE	O
studies	O
indicate	O
that	O
double-dose	O
famotidine	O
plus	O
ibuprofen	O
,	O
given	O
as	O
a	O
combination	O
tablet	O
,	O
decreases	O
endoscopic	O
upper	O
GI	O
ulcers	O
as	O
compared	O
with	O
ibuprofen	O
alone	O
.	O

Trial	O
registration	O
Current	O
Controlled	O
Trials	O
ISRCTN18994246	O
,	O
National	O
Research	O
Register	O
N0484189151	O
.	O

The	O
memantine	O
and	O
placebo	O
group	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
stride	O
length	O
.	O

The	O
average	O
duration	O
(	O
LS	O
mean	O
)	O
for	O
all	O
flares	O
over	O
the	O
16-week	O
period	O
was	O
shorter	O
in	O
all	O
canakinumab	O
groups	O
compared	O
with	O
colchicine	O
0.5	O
mg	O
:	O
2.8–4.6	O
days	O
versus	O
5.1	O
days	O
(	O
table	O
2	O
)	O
.	O

Data	O
and	O
statistical	O
analysis	O
Cytometric	O
data	O
analysis	O
was	O
performed	O
with	O
FlowJo	O
V.7.2.5	O
(	O
Flow	O
Cytometry	O
Analysis	O
Software	O
)	O
.	O

Cardiovascular	O
effects	O
of	O
tumour	O
necrosis	O
factor	O
α	O
antagonism	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
:	O
a	O
first	O
in	O
human	O
study	O

Data	O
on	O
adherence	O
to	O
study	O
drugs	O
from	O
daily	O
diaries	O
were	O
available	O
for	O
68/112	O
(	O
61	O
%	O
)	O
participants	O
.	O

In	O
the	O
ITT	O
population	O
,	O
the	O
reduction	O
in	O
the	O
asthma	O
exacerbation	O
rate	O
relative	O
to	O
placebo	O
was	O
19.6	O
%	O
(	O
90	O
%	O
CI	O
:	O
−21	O
to	O
47	O
;	O
p	O
=	O
0.38	O
)	O
,	O
−11.2	O
%	O
(	O
90	O
%	O
CI	O
:	O
−63	O
to	O
24	O
;	O
p	O
=	O
0.65	O
)	O
,	O
and	O
−5.7	O
%	O
(	O
90	O
%	O
CI	O
:	O
−55	O
to	O
28	O
;	O
p	O
=	O
0.81	O
)	O
in	O
the	O
300	O
mg	O
M	O
,	O
450	O
mg	O
Q	O
,	O
and	O
150	O
mg	O
Q	O
quilizumab	O
treatment	O
arms	O
,	O
respectively	O
(	O
Fig	O
.	O

Histamine2-receptor	O
antagonists	O
(	O
H2RAs	O
)	O
have	O
not	O
been	O
recommended	O
for	O
preventive	O
therapy	O
in	O
NSAID	O
users	O
because	O
,	O
when	O
given	O
in	O
standard	O
doses	O
,	O
they	O
significantly	O
decrease	O
duodenal	O
but	O
not	O
gastric	O
ulcers	O
.	O

However	O
,	O
it	O
was	O
clear	O
by	O
2007	O
that	O
obtaining	O
a	O
sample	O
of	O
6000	O
was	O
no	O
longer	O
feasible	O
,	O
and	O
the	O
Steering	O
Committee	O
agreed	O
a	O
revised	O
recruitment	O
target	O
.	O

26	B-Sample_Size_Actual_at_Enrollment
patients	O
presenting	O
with	O
acute	O
myocardial	O
infarction	O
randomised	O
to	O
receive	O
an	B-Design_Parallel_Group
intravenous	I-Design_Parallel_Group
infusion	I-Design_Parallel_Group
of	I-Design_Parallel_Group
etanercept	I-Design_Parallel_Group
(	I-Design_Parallel_Group
10	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
saline	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

As	O
a	O
result	O
we	O
implemented	O
ceiling	O
doses	O
of	O
75	O
mg/day	O
for	O
prednisolone	O
and	O
400	O
mg/day	O
for	O
ciclosporin	O
.	O

Objectives	O
Ischaemic	O
digital	O
ulcers	O
(	O
DUs	O
)	O
are	O
common	O
in	O
patients	O
with	O
systemic	O
sclerosis	O
(	O
SSc	O
)	O
and	O
are	O
a	O
cause	O
of	O
disease-related	O
morbidity	O
.	O

Objective	O
To	O
determine	O
whether	O
ciclosporin	O
is	O
superior	O
to	O
prednisolone	O
for	O
the	O
treatment	O
of	O
pyoderma	O
gangrenosum	O
,	O
a	O
painful	O
,	O
ulcerating	O
skin	O
disease	O
with	O
a	O
poor	O
evidence	O
base	O
for	O
management	O
.	O

At	O
baseline	O
,	O
many	O
patients	O
had	O
very	O
high	O
SU	O
levels	O
(	O
≥9	O
mg/dl	O
;	O
35	O
%	O
to	O
55	O
%	O
)	O
.	O

As	O
a	O
result	O
,	O
many	O
people	O
are	O
now	O
prescribed	O
long-term	O
statin	O
treatment	O
to	O
reduce	O
their	O
vascular	O
risk	O
.	O

This	O
sample	O
size	O
also	O
provided	O
approximately	O
70	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
50	O
%	O
reduction	O
in	O
average	O
exacerbation	O
rates	O
in	O
the	O
subgroup	O
of	O
periostin-high	O
patients	O
,	O
assuming	O
0.69	O
exacerbations	O
per	O
patient	O
in	O
the	O
placebo	O
group	O
over	O
the	O
36-week	O
period	O
,	O
a	O
significance	O
level	O
of	O
0.15	B-Sample_Size_Calculation_Alpha_Value
,	O
and	O
50	O
%	O
of	O
patients	O
in	O
each	O
treatment	O
arm	O
to	O
be	O
periostin	O
high	O
.	O

At	O
6	O
months	O
,	O
554	O
(	O
37	O
%	O
)	O
patients	O
in	O
the	O
rt-PA	O
group	O
versus	O
534	O
(	O
35	O
%	O
)	O
in	O
the	O
control	O
group	O
were	O
alive	O
and	O
independent	O
(	O
OHS	O
0–2	O
;	O
adjusted	O
odds	O
ratio	O
[	O
OR	O
]	O
1·13	O
,	O
95	O
%	O
CI	O
0·95–1·35	O
,	O
p=0·181	O
;	O
a	O
non-significant	O
absolute	O
increase	O
of	O
14/1000	O
,	O
95	O
%	O
CI	O
−20	O
to	O
48	O
)	O
.	O

The	O
appearance	O
of	O
axial	O
signs	O
immediately	O
after	O
the	O
initiation	O
of	O
STN	O
stimulation	O
was	O
also	O
an	O
exclusion	O
criterion	O
.	O

Low-dose	O
colchicine	O
is	O
the	O
most	O
commonly	O
prescribed	O
drug	O
for	O
prophylaxis	O
in	O
patients	O
initiating	O
ULT	O
,	O
but	O
it	O
has	O
significant	O
shortcomings	O
.	O

Main	O
outcome	O
measures	O
The	O
primary	O
outcome	O
was	O
speed	O
of	O
healing	O
over	O
six	O
weeks	O
,	O
captured	O
using	O
digital	O
images	O
and	O
assessed	O
by	O
blinded	O
investigators	O
.	O

Most	O
of	O
these	O
interventions	O
occurred	O
before	O
or	O
at	O
the	O
time	O
of	O
enrolment	O
.	O

Other	O
notable	O
exclusion	O
criteria	O
included	O
(	O
i	O
)	O
inability	O
to	O
walk	O
unaided	O
while	O
on	O
dopaminergic	O
treatment	O
,	O
(	O
ii	O
)	O
dementia	O
(	O
diagnosed	O
according	O
to	O
the	O
DSM-IV-R	O
criteria	O
and	O
with	O
a	O
Mattis	O
Dementia	O
Rating	O
Scale	O
score	O
<	O
130	O
)	O
and	O
(	O
iii	O
)	O
the	O
ongoing	O
administration	O
of	O
an	O
NMDA	O
antagonist	O
other	O
than	O
memantine	O
.	O

The	O
intention	O
to	O
treat	O
population	O
included	O
all	O
patients	O
randomised	O
,	O
whether	O
or	O
not	O
they	O
received	O
study	O
drug	O
.	O

Participants	O
enrolled	O
after	O
the	O
age	O
of	O
12.25	O
years	O
and	O
without	O
spontaneous	O
puberty	O
(	O
the	O
late	O
group	O
)	O
started	O
ethinylestradiol	O
at	O
14	O
years	O
.	O

Sample	O
size	O
The	O
Cochrane	O
systematic	O
review	O
found	O
only	O
one	O
small	O
trial	O
directly	O
comparing	O
the	O
effectiveness	O
of	O
a	O
chemical	O
treatment	O
,	O
salicylic	O
acid	O
,	O
with	O
cryotherapy	O
in	O
patients	O
with	O
warts	O
on	O
their	O
feet	O
alone	O
.	O

Table	O
2	O
shows	O
details	O
of	O
final	O
height	O
and	O
maximum	O
height	O
according	O
to	O
the	O
study	O
’	O
s	O
two	O
randomisations	O
.	O

Other	O
fatal	O
and	O
non-fatal	O
non-cerebral	O
events	O
were	O
also	O
recorded	O
and	O
coded	O
.	O

Overall	O
,	O
improvements	O
were	O
largest	O
with	O
tiotropium	O
Respimat®	O
5	O
μg	O
.	O

The	O
effects	O
of	O
the	O
randomisations	O
can	O
be	O
explored	O
by	O
comparing	O
the	O
values	O
of	O
the	O
random	O
effects	O
by	O
trial	O
arm	O
.	O

Exclusion	O
criteria	O
Patients	O
were	O
excluded	O
from	O
the	O
study	O
if	O
they	O
had	O
an	O
asthma	O
exacerbation	O
requiring	O
systemic	O
steroids	O
in	O
the	O
30	O
days	O
prior	O
to	O
screening	O
,	O
or	O
between	O
screening	O
and	O
randomization	O
,	O
a	O
>	O
20	O
%	O
relative	O
change	O
in	O
FEV1	O
between	O
screening	O
and	O
randomization	O
,	O
any	O
pre-existing	O
active	O
lung	O
disease	O
other	O
than	O
asthma	O
,	O
any	O
infections	O
,	O
elevated	O
IgE	O
levels	O
for	O
reasons	O
other	O
than	O
allergy	O
,	O
or	O
were	O
former	O
or	O
current	O
smokers	O
.	O

Since	O
most	O
variation	O
was	O
between	O
groups	O
B	O
and	O
C	O
,	O
who	O
received	O
identical	O
ART	O
for	O
the	O
first	O
36	O
weeks	O
,	O
this	O
year	O
1	O
interaction	O
appeared	O
attributable	O
to	O
chance	O
in	O
children	O
initiating	O
ART	O
with	O
severe	O
immunodeficiency	O
.	O

At	O
switch	O
,	O
median	O
CD4	O
percentage	O
was	O
8·5	O
%	O
(	O
IQR	O
1·5–22·5	O
)	O
in	O
the	O
clinically	O
driven	O
monitoring	O
group	O
and	O
7	O
%	O
(	O
3–13	O
)	O
in	O
the	O
routine	O
laboratory	O
monitoring	O
group	O
;	O
11	O
children	O
(	O
39	O
%	O
)	O
versus	O
14	O
(	O
40	O
%	O
)	O
had	O
CD4	O
percentage	O
less	O
than	O
5	O
%	O
and	O
six	O
children	O
(	O
21	O
%	O
)	O
versus	O
none	O
had	O
CD4	O
percentage	O
greater	O
than	O
25	O
%	O
,	O
respectively	O
.	O

The	O
highest	O
relative	O
improvement	O
compared	O
to	O
placebo	O
occurred	O
in	O
the	O
lowest	O
dose	O
arm	O
(	O
150	O
mg	O
Q	O
)	O
,	O
but	O
no	O
meaningful	O
improvements	O
were	O
observed	O
in	O
the	O
higher	O
dose	O
arms	O
(	O
450	O
mg	O
Q	O
and	O
300	O
mg	O
M	O
)	O
.	O

All	O
baseline	O
data	O
,	O
7-day	O
,	O
and	O
6-month	O
outcome	O
data	O
were	O
subject	O
to	O
verification	O
checks	O
built	O
into	O
the	O
randomisation	O
and	O
data	O
management	O
system	O
.	O

More	O
patients	O
died	O
within	O
7	O
days	O
in	O
the	O
rt-PA	O
group	O
than	O
in	O
the	O
control	O
group	O
,	O
but	O
between	O
7	O
days	O
and	O
6	O
months	O
there	O
were	O
correspondingly	O
fewer	O
deaths	O
in	O
the	O
rt-PA	O
group	O
.	O

In	O
order	O
to	O
increase	O
the	O
precision	O
of	O
the	O
analysis	O
the	O
planned	O
total	O
sample	O
size	O
of	O
400	O
was	O
increased	O
to	O
approximately	O
440	B-Sample_Size_Target
patients	O
(	O
see	O
supplementary	O
material	O
for	O
more	O
details	O
)	O
.	O

The	O
percentage	O
of	O
unclothed	O
skin	O
at	O
enrolment	O
was	O
estimated	O
with	O
a	O
Lund	O
and	O
Browder	O
age-related	O
burn	O
chart	O
.	O

The	O
backing	O
paper	O
from	O
the	O
plaster	O
was	O
then	O
removed	O
and	O
the	O
plaster	O
applied	O
to	O
cover	O
the	O
ring	O
completely	O
.	O

However	O
,	O
the	O
increase	O
in	O
proximal	O
1/3	O
forearm	O
bone	O
mineral	O
in	O
the	O
Ca	O
group	O
(	O
least	O
squares	O
mean	O
increase	O
0.130	O
g	O
)	O
was	O
similar	O
to	O
that	O
of	O
the	O
Ca+D	O
group	O
(	O
least	O
squares	O
mean	O
increase	O
0.109	O
g	O
;	O
p=0.22	O
)	O
.	O

The	O
effects	O
of	O
statin	O
allocation	O
on	O
major	O
vascular	O
events	O
during	O
the	O
in-trial	O
and	O
post-trial	O
periods	O
were	O
unaffected	O
by	O
age	O
or	O
pretreatment	O
lipid	O
profiles	O
(	O
webappendix	O
p	O
3	O
)	O
.	O

We	O
used	O
conditional	O
univariate	O
logistic	O
regression	O
to	O
calculate	O
and	O
compare	O
the	O
odds	O
ratios	O
of	O
viral	O
clearance	O
for	O
categorical	O
data	O
between	O
the	O
treatment	O
arms	O
stratified	O
by	O
study	O
site	O
and	O
the	O
Mantel-Haenszel	O
method	O
when	O
the	O
numbers	O
of	O
patients	O
were	O
small	O
.	O

A	O
secondary	O
ordinal	O
analysis	O
provided	O
evidence	O
of	O
a	O
favourable	O
shift	O
in	O
the	O
distribution	O
of	O
OHS	O
scores	O
at	O
6	O
months	O
with	O
treatment	O
(	O
p	O
<	O
0·001	O
;	O
figure	O
2	O
)	O
.	O

The	O
findings	O
from	O
the	O
adjusted	O
analysis	O
were	O
similar	O
to	O
those	O
of	O
the	O
unadjusted	O
analysis	O
(	O
odds	O
ratio	O
1.17	O
(	O
0.62	O
to	O
2.21	O
)	O
,	O
P=0.62	O
)	O
.	O

The	O
following	O
antibodies	O
were	O
used	O
:	O
IgG1-FITC	O
,	O
CD14-PE	O
,	O
CD42a-FITC	O
,	O
IgG2a-PE	O
,	O
CD62P-PE	O
,	O
IgG1-PE	O
(	O
eBioscience	O
Ltd.	O
UK	O
)	O
and	O
CD14-RPE	O
and	O
IgG1-RPE	O
(	O
DakoCytomation	O
,	O
Denmark	O
)	O
.	O

Concomitant	O
use	O
of	O
the	O
following	O
was	O
not	O
permitted	O
for	O
maintenance	O
treatment	O
:	O
systemic	O
oral	O
or	O
depot	O
corticosteroids	O
;	O
anticholinergics	O
other	O
than	O
tiotropium	O
;	O
LABAs	O
;	O
ICS	O
plus	O
short-acting	O
β2-agonist	O
or	O
ICS	O
+	O
LABA	O
fixed-dose	O
combinations	O
;	O
leukotriene	O
modifiers	O
;	O
anti-immunoglobulin	O
E	O
treatment	O
;	O
chromone	O
;	O
methylxanthines	O
;	O
and	O
phosphodiesterase-4	O
inhibitors	O
.	O

Salicylic	O
acid	O
Participants	O
randomised	B-Randomization_Type_Simple
to	O
self	O
treatment	O
with	O
50	O
%	O
salicylic	O
acid	O
(	O
Verrugon	O
,	O
William	O
Ransom	O
and	O
Son	O
)	O
were	O
instructed	O
how	O
to	O
apply	O
the	O
treatment	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
by	O
the	O
treating	O
healthcare	O
professional	O
.	O

During	O
vasomotor	O
assessments	O
,	O
venous	O
blood	O
was	O
withdrawn	O
simultaneously	O
from	O
each	O
arm	O
and	O
collected	O
into	O
tubes	O
containing	O
acidified	O
buffered	O
citrate	O
(	O
for	O
t-PA	O
assays	O
)	O
,	O
trisodium	O
citrate	O
(	O
for	O
plasminogen	O
activator	O
inhibitor	O
type	O
1	O
(	O
PAI-1	O
)	O
assays	O
)	O
and	O
potassium	O
EDTA	O
(	O
for	O
cytokine	O
assays	O
)	O
.	O

Patients	B-Blinding_Object_Patients
and	O
study	B-Blinding_Object_Care_Providers
site	I-Blinding_Object_Care_Providers
personnel	I-Blinding_Object_Care_Providers
were	O
blinded	O
to	O
treatment	O
assignments	O
until	O
all	O
follow-up	O
data	O
through	O
Week	O
84	O
were	O
collected	O
and	O
verified	O
.	O

In	O
the	O
event	O
,	O
more	O
than	O
100	O
patients	O
were	O
recruited	O
,	O
but	O
fewer	O
than	O
100	O
were	O
followed	O
up	O
to	O
final	O
height	O
.	O

The	O
curves	O
are	O
labelled	O
according	O
to	O
randomisation	O
1	O
,	O
and	O
the	O
oxandrolone	O
curves	O
tend	O
to	O
be	O
above	O
and	O
to	O
the	O
left	O
of	O
the	O
placebo	O
curves	O
.	O

Results	O
Patients	O
’	O
characteristics	O
Between	O
April	O
2007	O
and	O
February	O
2010	O
,	O
699	O
patients	O
were	O
screened	O
and	O
326	B-Sample_Size_Actual_at_Enrollment
were	O
enrolled	O
and	O
randomised	O
:	O
165	O
received	O
double	O
dose	O
and	O
161	O
standard	O
dose	O
oseltamivir	O
.	O

At	O
trial	O
end	O
,	O
578	O
(	O
95	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
565	O
(	O
94	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
were	O
still	O
on	O
first-line	O
ART	O
(	O
table	O
2	O
)	O
;	O
330	O
(	O
83	O
%	O
)	O
children	O
in	O
group	O
A	O
,	O
356	O
(	O
88	O
%	O
)	O
in	O
group	O
B	O
,	O
and	O
367	O
(	O
91	O
%	O
)	O
in	O
group	O
C	O
were	O
still	O
on	O
their	O
original	O
randomised	O
regimen	O
.	O

Adverse	O
reactions	O
Overall	O
,	O
40	O
(	O
68	O
%	O
)	O
participants	O
in	O
the	O
ciclosporin	O
group	O
and	O
35	O
(	O
66	O
%	O
)	O
in	O
the	O
prednisolone	O
group	O
experienced	O
at	O
least	O
one	O
adverse	O
reaction	O
.	O

Among	O
a	O
cohort	O
of	O
2080	O
patients	O
with	O
SSc	O
identified	O
between	O
1972	O
and	O
1995	O
and	O
prospectively	O
followed-up	O
for	O
a	O
mean	O
of	O
10	O
years	O
,	O
58	O
%	O
of	O
patients	O
had	O
a	O
history	O
of	O
DUs	O
.	O

Dual	O
energy	O
X-ray	O
absorptiometry	O
of	O
the	O
left	O
distal	O
and	O
proximal	O
1/3	O
forearm	O
was	O
performed	O
by	O
a	O
single	O
investigator	O
(	O
TDT	O
)	O
with	O
a	O
portable	O
densitometer	O
(	O
Norland	O
pDEXA	O
,	O
Model	O
476A110	O
)	O
.	O

For	O
33	O
participants	O
(	O
14	O
in	O
the	O
prednisolone	O
group	O
;	O
19	O
in	O
the	O
ciclosporin	O
group	O
)	O
the	O
pyoderma	O
gangrenosum	O
worsened	O
(	O
increased	O
in	O
size	O
)	O
between	O
baseline	O
and	O
week	O
2	O
.	O

These	O
were	O
GI	O
bleeding	O
episodes	O
in	O
which	O
hemoglobin	O
dropped	O
1.6	O
,	O
2.1	O
,	O
and	O
3.1	O
g/dl	O
without	O
clinical	O
evidence	O
of	O
overt	O
GI	O
bleeding	O
,	O
transfusions	O
,	O
or	O
hospitalizations	O
.	O

All	O
106	O
participants	O
were	O
randomised	O
at	O
or	O
after	O
9	O
years	O
of	O
age	O
to	O
oxandrolone	O
or	O
placebo	O
(	O
randomisation	O
1	O
)	O
,	O
and	O
60	O
were	O
also	O
randomised	O
at	O
12	O
years	O
to	O
early	O
or	O
late	O
induction	O
of	O
puberty	O
(	O
randomisation	O
2	O
)	O
.	O

Secondary	O
outcome	O
The	O
primary	O
analysis	O
was	O
repeated	O
after	O
controlling	O
for	O
age	O
,	O
whether	O
the	O
plantar	O
warts	O
had	O
been	O
previously	O
treated	O
(	O
yes	O
or	O
no	O
)	O
,	O
and	O
the	O
type	O
of	O
plantar	O
wart	O
(	O
mosaic	O
or	O
non-mosaic	O
,	O
where	O
a	O
mosaic	O
was	O
defined	O
as	O
a	O
group	O
of	O
numerous	O
,	O
closely	O
aggregated	O
plantar	O
warts	O
on	O
the	O
sole	O
of	O
the	O
foot	O
)	O
.	O

Biomarkers	O
in	O
sputum	O
,	O
bronchoalveolar	O
lavage	O
,	O
blood	O
,	O
and	O
bronchial	O
biopsies	O
may	O
indicate	O
a	O
particular	O
endotype	O
and	O
potentially	O
identify	O
patients	O
with	O
increased	O
responsiveness	O
to	O
endotype-specific	O
treatments	O
.	O

Safety	O
criteria	O
Adverse	O
events	O
,	O
arterial	O
blood	O
pressure	O
values	O
,	O
an	O
electrocardiogram	O
and	O
a	O
standard	O
blood	O
biochemistry	O
profile	O
were	O
recorded	O
monthly	O
.	O

The	O
study	O
took	O
place	O
between	O
April	O
2007	O
and	O
February	O
2010	O
in	O
13	B-Settings_Multicenter
hospitals	I-Settings_Multicenter
in	O
Indonesia	B-Settings_Location
,	I-Settings_Location
Singapore	I-Settings_Location
,	I-Settings_Location
Thailand	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
Vietnam	I-Settings_Location
.	O

The	O
most	O
common	O
WHO	O
stage	O
4	O
events	O
were	O
oesophageal	O
candidiasis	O
(	O
eight	O
on	O
clinically	O
driven	O
and	O
five	O
on	O
routine	O
laboratory	O
monitoring	O
)	O
and	O
severe	O
unexplained	O
failure-to-thrive	O
(	O
nine	O
on	O
clinically	O
driven	O
and	O
three	O
on	O
routine	O
laboratory	O
monitoring	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
differences	O
in	O
weight	O
for	O
age	O
(	O
p=0·58	O
)	O
or	O
height	O
for	O
age	O
(	O
p=0·90	O
)	O
across	O
ART	O
strategies	O
(	O
appendix	O
)	O
.	O

In	O
addition	O
,	O
we	O
applied	O
SITAR	O
(	O
superimposition	O
by	O
translation	O
and	O
rotation	O
)	O
,	O
a	O
novel	O
method	O
of	O
growth	O
curve	O
analysis	O
,	O
to	O
the	O
data	O
.	O

We	O
also	O
undertook	O
a	O
sensitivity	O
analysis	O
restricted	O
to	O
the	O
2939	O
(	O
96	O
%	O
)	O
patients	O
with	O
known	O
6-month	O
vital	O
and	O
disability	O
status	O
(	O
appendix	O
pp	O
4–5	O
)	O
,	O
and	O
the	O
results	O
were	O
not	O
qualitatively	O
different	O
from	O
those	O
in	O
table	O
2	O
.	O

The	O
treatment	O
was	O
delivered	O
according	O
to	O
the	O
site	O
’	O
s	O
usual	O
practice	O
(	O
such	O
as	O
debridement	O
before	O
treatment	O
,	O
masking	O
of	O
the	O
surrounding	O
area	O
,	O
and	O
padding	O
after	O
treatment	O
)	O
.	O

Study	O
design	O
and	O
sites	O
This	O
was	O
a	O
prospective	O
,	O
multicentre	B-Settings_Multicenter
,	O
double	B-Blinding_Double_Blind
blinded	I-Blinding_Double_Blind
,	O
randomised	O
trial	O
of	O
standard	B-Design_Parallel_Group
dose	I-Design_Parallel_Group
oseltamivir	I-Design_Parallel_Group
(	I-Design_Parallel_Group
75	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
a	I-Design_Parallel_Group
day	I-Design_Parallel_Group
or	I-Design_Parallel_Group
paediatric	I-Design_Parallel_Group
equivalent	I-Design_Parallel_Group
)	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
double	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
(	I-Design_Parallel_Group
150	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
a	I-Design_Parallel_Group
day	I-Design_Parallel_Group
or	I-Design_Parallel_Group
paediatric	I-Design_Parallel_Group
equivalent	I-Design_Parallel_Group
)	I-Design_Parallel_Group
for	O
treating	O
severe	O
influenza	O
.	O

Equally	O
,	O
separate	O
summary	O
curves	O
can	O
be	O
constructed	O
for	O
each	O
trial	O
arm	O
.	O

Safety	O
and	O
tolerability	O
Serious	O
adverse	O
events	O
occurred	O
in	O
9.4	O
%	O
and	O
16.7	O
%	O
of	O
patients	O
on	O
bosentan	O
and	O
placebo	O
,	O
respectively	O
(	O
table	O
4	O
)	O
,	O
with	O
only	O
one	O
serious	O
event	O
(	O
pneumonia	O
)	O
reported	O
for	O
more	O
than	O
one	O
patient	O
on	O
bosentan	O
.	O

All	O
but	O
74	O
participants	O
(	O
42	O
simvastatin	O
and	O
32	O
placebo	O
)	O
could	O
be	O
followed	O
up	O
for	O
cancer	O
reports	O
and	O
death	O
certification	O
through	O
national	O
registries	O
.	O

Appendix	O
pp	O
2–3	O
documents	O
deviations	O
from	O
the	O
protocol	O
and	O
the	O
background	O
treatments	O
that	O
were	O
given	O
during	O
the	O
first	O
7	O
days	O
.	O

The	O
aim	O
of	O
the	O
extended	O
follow-up	O
of	O
the	O
Heart	O
Protection	O
Study	O
(	O
HPS	O
)	O
is	O
to	O
assess	O
long-term	O
efficacy	O
and	O
safety	O
of	O
lowering	O
LDL	O
cholesterol	O
with	O
statins	O
,	O
and	O
here	O
we	O
report	O
cause-specific	O
mortality	O
and	O
major	O
morbidity	O
in	O
the	O
in-trial	O
and	O
post-trial	O
periods	O
.	O

2	O
%	O
of	O
follow-up	O
(	O
40/2373	O
child-years	O
)	O
was	O
spent	O
on	O
second-line	O
treatment	O
in	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
3	O
%	O
(	O
67/2311	O
child-years	O
)	O
in	O
those	O
on	O
routine	O
laboratory	O
monitoring	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ISRCTN	O
,	O
number	O
48489393	O
.	O

Post-trial	O
follow-up	O
of	O
serious	O
adverse	O
events	O
was	O
conducted	O
by	O
mailing	O
questionnaires	O
to	O
all	O
surviving	O
participants	O
in	O
late	O
November	O
,	O
2001	O
,	O
and	O
then	O
annually	O
until	O
November	O
,	O
2006	O
,	O
with	O
a	O
reminder	O
mailed	O
about	O
2	O
months	O
later	O
.	O

Images	O
were	O
assessed	O
with	O
all	O
original	O
identifiers	O
stripped	O
from	O
the	O
record	O
,	O
and	O
then	O
viewed	O
via	O
a	O
secure	O
web-based	O
image	O
viewing	O
system	O
by	O
an	O
international	O
panel	O
of	O
expert	O
radiologists	O
.	O

Randomisation	O
2	O
took	O
place	O
at	O
age	O
12	O
years	O
in	O
girls	O
with	O
ovarian	O
failure	O
(	O
basal	O
serum	O
follicle	O
stimulating	O
hormone	O
concentration	O
>	O
10	O
U/L	O
)	O
,	O
with	O
additional	O
minimisation	B-Randomization_Type_Minimization
for	O
randomisation	O
1	O
,	O
to	O
begin	O
oral	O
ethinylestradiol	O
or	O
placebo	O
at	O
12	O
years	O
;	O
the	O
placebo	O
group	O
subsequently	O
started	O
ethinylestradiol	O
at	O
14	O
years	O
.	O

Memantine	O
's	O
effects	O
in	O
the	O
‘	O
on-L-dopa	O
’	O
condition	O
are	O
presented	O
in	O
the	O
table	O
2	O
.	O

Similar	O
variation	O
over	O
time	O
(	O
heterogeneity	O
p=0·03	O
;	O
appendix	O
)	O
was	O
observed	O
for	O
deaths	O
alone	O
as	O
for	O
the	O
combined	O
endpoint	O
of	O
WHO	O
stage	O
4	O
or	O
death	O
(	O
13	O
deaths	O
on	O
clinically	O
driven	O
and	O
27	O
on	O
routine	O
laboratory	O
monitoring	O
in	O
first	O
year	O
,	O
12	O
vs	O
two	O
subsequently	O
;	O
difference	O
0·56	O
per	O
100	O
child-years	O
,	O
95	O
%	O
CI	O
0·15–0·97	O
,	O
with	O
12	O
of	O
the	O
14	O
deaths	O
after	O
1	O
year	O
in	O
children	O
aged	O
>	O
8	O
years	O
)	O
.	O

Numerical	O
safety	O
data	O
for	O
all	O
randomised	O
patients	O
were	O
assessed	O
in	O
an	O
analysis	O
of	O
variance	O
.	O

A	O
linear	O
regression	O
model	O
was	O
used	O
to	O
analyse	O
differences	O
between	O
treatment	O
groups	O
for	O
the	O
primary	O
outcome	O
at	O
six	O
weeks	O
,	O
adjusting	O
for	O
the	O
stratification	O
variables	O
.	O

.	O

For	O
participants	O
whose	O
pyoderma	O
gangrenosum	O
had	O
healed	O
,	O
we	O
assessed	O
recurrence	O
and	O
time	O
to	O
recurrence	O
from	O
medical	O
notes	O
.	O

4	O
)	O
.	O

Table	O
4	O
summarises	O
the	O
treatment	O
details	O
for	O
the	O
salicylic	O
acid	O
group	O
.	O

Both	O
oxandrolone	O
and	O
late	O
pubertal	O
induction	O
increased	O
final	O
height	O
:	O
by	O
4.6	O
(	O
95	O
%	O
confidence	O
interval	O
1.9	O
to	O
7.2	O
)	O
cm	O
(	O
P=0.001	O
,	O
n=82	O
)	O
for	O
oxandrolone	O
and	O
3.8	O
(	O
0.0	O
to	O
7.5	O
)	O
cm	O
(	O
P=0.05	O
,	O
n=48	O
)	O
for	O
late	O
pubertal	O
induction	O
with	O
ethinylestradiol	O
.	O

The	O
writing	O
committee	O
had	O
full	O
access	O
to	O
the	O
study	O
data	O
and	O
had	O
final	O
responsibility	O
for	O
the	O
decision	O
to	O
submit	O
for	O
publication	O
.	O

Study	O
design	O
In	O
a	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
design	O
,	O
patients	O
were	O
evaluated	O
on	O
two	O
occasions	O
:	O
before	O
and	O
24	O
h	O
after	O
intravenous	O
administration	B-Design_Parallel_Group
of	I-Design_Parallel_Group
the	I-Design_Parallel_Group
TNF-α	I-Design_Parallel_Group
antagonist	I-Design_Parallel_Group
,	I-Design_Parallel_Group
etanercept	I-Design_Parallel_Group
(	I-Design_Parallel_Group
10	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
saline	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Mortality	O
rates	O
for	O
H5N1	O
by	O
country	O
were	O
similar	O
,	O
with	O
10/11	O
(	O
90	O
%	O
)	O
in	O
Indonesia	O
and	O
5/6	O
(	O
83	O
%	O
)	O
in	O
Vietnam	O
.	O

By	O
twice	O
randomised	O
group	O
,	O
the	O
mean	O
final	O
heights	O
were	O
placebo/early	O
induction	O
147.0	O
cm	O
,	O
placebo/late	O
induction	O
153.1	O
cm	O
,	O
oxandrolone/early	O
induction	O
154.4	O
cm	O
,	O
and	O
oxandrolone/late	O
induction	O
155.1	O
cm	O
(	O
table	O
1	O
)	O
.	O

The	O
review	O
also	O
suggested	O
that	O
treatment	O
might	O
be	O
beneficial	O
up	O
to	O
6	O
h.	O
An	O
individual	O
patient	O
data	O
meta-analysis	O
of	O
a	O
subset	O
of	O
intravenous	O
rt-PA	O
trials	O
further	O
showed	O
that	O
the	O
earlier	O
treatment	O
was	O
given	O
,	O
the	O
greater	O
the	O
chance	O
of	O
a	O
favourable	O
outcome	O
.	O

Randomisation	O
and	O
interventions	O
After	O
screening	O
,	O
patients	O
were	O
randomised	O
to	O
bosentan	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	O
1:1	B-Randomization_Ratio
ratio	O
)	O
by	O
sequential	B-Randomization_Sequence_Generation_Method
allocation	I-Randomization_Sequence_Generation_Method
of	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
numbers	I-Randomization_Sequence_Generation_Method
distributed	O
to	O
each	O
centre	O
in	O
blocks	B-Randomization_Type_Block
of	O
four	B-Randomization_Block_Size
.	O

An	O
ordinal	O
analysis	O
showed	O
a	O
significant	O
shift	O
in	O
OHS	O
scores	O
;	O
common	O
OR	O
1·27	O
(	O
95	O
%	O
CI	O
1·10–1·47	O
,	O
p=0·001	O
)	O
.	O

Secondary	O
endpoints	O
for	O
both	O
randomisations	O
(	O
if	O
not	O
co-primary	O
)	O
were	O
:	O
mortality	O
;	O
new	O
(	O
or	O
new	O
or	O
recurrent	O
)	O
WHO	O
stage	O
4	O
event	O
or	O
death	O
;	O
new	O
(	O
or	O
new	O
or	O
recurrent	O
)	O
WHO	O
stage	O
3	O
or	O
4	O
event	O
or	O
death	O
;	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
definitely	O
,	O
probably	O
,	O
or	O
uncertainly	O
ART-related	O
;	O
serious	O
adverse	O
events	O
not	O
solely	O
HIV-related	O
;	O
ART-modifying	O
adverse	O
events	O
;	O
admissions	O
to	O
hospital	O
;	O
height	O
,	O
weight	O
,	O
and	O
body-mass	O
index	O
for	O
age	O
;	O
CD4	O
;	O
number	O
and	O
class	O
of	O
antiretrovirals	O
received	O
;	O
switch	O
to	O
second-line	O
regimen	O
;	O
adherence	O
;	O
viral	O
load	O
and	O
resistance	O
(	O
done	O
retrospectively	O
;	O
see	O
appendix	O
)	O
.	O

An	B-Blinding_Object_Outcome_Assessors
expert	I-Blinding_Object_Outcome_Assessors
radiologist	I-Blinding_Object_Outcome_Assessors
checked	O
all	O
scans	O
,	O
masked	O
to	O
clinical	O
details	O
and	O
treatment	O
allocation	O
,	O
immediately	O
on	O
receipt	O
at	O
the	O
trial	O
office	O
,	O
for	O
evidence	O
of	O
adverse	O
events	O
and	O
protocol	O
deviations	O
.	O

In	O
cases	O
where	O
digital	O
images	O
were	O
unavailable	O
,	O
or	O
of	O
poor	O
quality	O
,	O
we	O
used	O
physical	O
measurements	O
of	O
the	O
ulcer	O
taken	O
by	O
non-blinded	O
clinicians	O
at	O
baseline	O
and	O
six	O
weeks	O
.	O

Patients	O
≥65	O
years	O
had	O
a	O
significantly	O
higher	O
risk	O
ratio	O
of	O
upper	O
GI	O
ulcer	O
formation	O
(	O
initial	O
:	O
1.47	O
,	O
1.06–2.05	O
;	O
post-adjudication	O
:	O
1.54	O
,	O
1.10–2.17	O
)	O
than	O
those	O
<	O
65	O
years	O
.	O

At	O
the	O
intermediate	O
time	O
point	O
of	O
12	O
weeks	O
,	O
11	O
(	O
26	O
%	O
)	O
in	O
the	O
Ca+D	O
group	O
and	O
1	O
(	O
4.2	O
%	O
)	O
in	O
the	O
Ca	O
group	O
had	O
achieved	O
the	O
combined	O
outcome	O
(	O
p=0.03	O
)	O
.	O

The	O
median	O
number	O
of	O
plantar	O
warts	O
at	O
12	O
weeks	O
in	O
the	O
salicylic	O
acid	O
group	O
was	O
two	O
(	O
range	O
0–20	O
)	O
and	O
in	O
the	O
cryotherapy	O
group	O
was	O
one	O
(	O
0–40	O
)	O
,	O
and	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
incident	O
rate	O
ratio	O
1.08	O
(	O
0.81	O
to	O
1.43	O
)	O
,	O
P=0.62	O
)	O
.	O

Children	O
with	O
acute	O
infections	O
,	O
on	O
drugs	O
contraindicated	O
with	O
ART	O
,	O
unlikely	O
to	O
adhere	O
or	O
to	O
attend	O
regularly	O
,	O
with	O
laboratory	O
abnormalities	O
contraindicating	O
ART	O
,	O
pregnant	O
or	O
breastfeeding	O
,	O
or	O
perinatally	O
exposed	O
to	O
ART	O
(	O
if	O
<	O
6	O
months	O
old	O
)	O
were	O
excluded	O
.	O

Of	O
these	O
,	O
36/37	O
(	O
97	O
%	O
)	O
in	O
the	O
ciclosporin	O
group	O
and	O
29/31	O
(	O
94	O
%	O
)	O
in	O
the	O
prednisolone	O
group	O
took	O
their	O
treatment	O
every	O
day	O
throughout	O
the	O
first	O
six	O
weeks	O
of	O
the	O
trial	O
.	O

Sample	O
size	O
calculations	O
Based	O
on	O
previous	O
studies	O
,	O
we	O
assumed	O
that	O
children	O
and	O
adults	O
admitted	O
to	O
hospital	O
with	O
influenza	O
would	O
have	O
detectable	O
virus	O
for	O
an	O
average	O
of	O
6.3	O
days	O
(	O
plus	O
or	O
minus	O
1.5	O
days	O
)	O
and	O
4	O
days	O
after	O
onset	O
of	O
treatment	O
,	O
respectively	O
.	O

OBJECTIVES	O
:	O
We	O
performed	O
two	O
24-week	O
double-blind	B-Blinding_Double_Blind
trials	O
(	O
REDUCE-1	O
and	O
-2	O
(	O
Registration	O
Endoscopic	O
Studies	O
to	O
Determine	O
Ulcer	O
Formation	O
of	O
HZT-501	O
Compared	O
with	O
Ibuprofen	O
:	O
Efficacy	O
and	O
Safety	O
Studies	O
)	O
)	O
to	O
assess	O
whether	O
double-dose	O
famotidine	O
given	O
in	O
a	O
single-tablet	O
combination	O
with	O
ibuprofen	O
(	O
HZT-501	O
)	O
significantly	O
reduces	O
gastric	O
and	O
duodenal	O
ulcers	O
as	O
compared	O
with	O
ibuprofen	O
.	O

Randomisation	O
was	O
undertaken	O
by	O
clinicians	B-Randomization_Personnel
phoning	O
the	O
local	O
trials	O
centre	O
.	O

Patients	O
could	O
receive	O
rescue	O
medication	O
as	O
needed	O
(	O
see	O
supplementary	O
material	O
for	O
details	O
)	O
.	O

The	O
content	O
of	O
elemental	O
calcium	O
in	O
1.0	O
g	O
of	O
limestone	O
was	O
268	O
mg	O
(	O
courtesy	O
of	O
Michael	O
Gruzak	O
,	O
USDA/ARS	O
Children	O
's	O
Nutrition	O
Research	O
Center	O
,	O
Houston	O
,	O
Texas	O
,	O
USA	O
)	O
.	O

The	O
study	O
’	O
s	O
central	O
pharmacy	O
(	O
Royal	O
Hospital	O
for	O
Sick	O
Children	O
,	O
Glasgow	O
,	O
UK	O
)	O
supplied	O
all	O
tablets	O
in	O
a	O
double	O
blind	O
,	O
placebo	O
controlled	O
fashion	O
;	O
only	O
staff	O
at	O
the	O
British	O
Society	O
for	O
Paediatric	O
Endocrinology	O
and	O
Diabetes	O
Clinical	O
Trials	O
Unit	O
and	O
the	O
central	O
distributing	O
pharmacy	O
were	O
not	O
blinded	O
to	O
treatment	O
allocations	O
.	O

There	O
were	O
also	O
no	O
differences	O
in	O
clinical	O
failure	O
in	O
the	O
subgroup	O
of	O
patients	O
with	O
seasonal	O
influenza	O
viruses	O
(	O
see	O
above	O
)	O
:	O
3/114	O
(	O
2.6	O
%	O
,	O
0.9	O
%	O
to	O
7.5	O
%	O
)	O
patients	O
in	O
the	O
double	O
dose	O
and	O
5/110	O
(	O
4.5	O
%	O
,	O
2.0	O
%	O
to	O
10.2	O
%	O
)	O
in	O
the	O
standard	O
dose	O
arm	O
(	O
P=0.50	O
)	O
.	O

Asthma	O
exacerbation	O
rates	O
Quilizumab	O
treatment	O
did	O
not	O
produce	O
a	O
clinically	O
meaningful	O
reduction	O
of	O
the	O
rate	O
of	O
asthma	O
exacerbations	O
over	O
the	O
36-week	O
treatment	O
period	O
.	O

Sensitivity	O
analysis	O
of	O
the	O
primary	O
outcome	O
and	O
time	O
to	O
healing	O
were	O
further	O
adjusted	O
for	O
additional	O
baseline	O
variables	O
including	O
age	O
,	O
sex	O
,	O
weight	O
,	O
size	O
of	O
recruiting	O
centre	O
and	O
geographical	O
region	O
;	O
missing	O
data	O
;	O
and	O
participants	O
who	O
switched	O
randomised	O
treatments	O
or	O
received	O
the	O
trial	O
drugs	O
in	O
combination	O
during	O
the	O
period	O
of	O
the	O
trial	O
.	O

This	O
sample	O
size	O
provided	O
approximately	O
84	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
50	O
%	O
reduction	O
in	O
average	O
exacerbation	O
rates	O
due	O
to	O
quilizumab	O
,	O
assuming	O
0.63	O
exacerbations	O
per	O
patient	O
in	O
the	O
placebo	O
group	O
over	O
a	O
36-week	O
treatment	O
period	O
,	O
and	O
a	O
significance	O
level	O
of	O
α	O
=	O
0.10	B-Sample_Size_Calculation_Alpha_Value
.	O

The	O
plaster	O
was	O
then	O
sealed	O
into	O
position	O
.	O

A	O
triple	O
NRTI	O
regimen	O
after	O
four-drug	O
NRTI	O
plus	O
NNRTI	O
induction	O
also	O
avoids	O
challenges	O
of	O
managing	O
interactions	O
with	O
antituberculosis	O
drugs	O
,	O
particularly	O
for	O
young	O
children	O
unable	O
to	O
take	O
efavirenz	O
.	O

Therefore	O
a	O
post	O
hoc	O
analysis	O
using	O
a	O
negative	O
binomial	O
model	O
with	O
treatment	O
group	O
,	O
allopurinol	O
dose	O
at	O
baseline	O
and	O
BMI	O
at	O
baseline	O
as	O
covariates	O
and	O
log	O
(	O
time	O
on	O
study	O
)	O
as	O
an	O
offset	O
was	O
performed	O
with	O
an	O
adjustment	O
made	O
for	O
multiplicity	O
(	O
see	O
supplementary	O
material	O
for	O
further	O
details	O
of	O
analyses	O
for	O
secondary	O
outcomes	O
)	O
.	O

At	O
screening	O
,	O
patients	O
indicated	O
which	O
of	O
their	O
joints	O
was	O
most	O
affected	O
by	O
previous	O
gouty	O
arthritis	O
flares	O
.	O

Comparison	O
of	O
the	O
two	O
most	O
commonly	O
used	O
treatments	O
for	O
pyoderma	O
gangrenosum	O
:	O
results	O
of	O
the	O
STOP	O
GAP	O
randomised	O
controlled	O
trial	O

Patients	O
receiving	O
STN	O
stimulation	O
had	O
to	O
have	O
shown	O
an	O
improvement	O
of	O
at	O
least	O
50	O
%	O
in	O
motor	O
symptoms	O
during	O
the	O
first	O
year	O
of	O
this	O
treatment	O
(	O
without	O
a	O
worsening	O
in	O
gait	O
and	O
posture	O
)	O
.	O

All	O
P	O
values	O
are	O
two	O
tailed	O
.	O

ART-modifying	O
adverse	O
events	O
occurred	O
in	O
eight	O
(	O
2	O
%	O
)	O
children	O
in	O
group	O
A	O
versus	O
30	O
(	O
7	O
%	O
)	O
in	O
group	O
B	O
and	O
25	O
(	O
6	O
%	O
)	O
in	O
group	O
C	O
(	O
HR	O
[	O
B	O
:	O
A	O
]	O
3·80	O
,	O
95	O
%	O
CI	O
1·74–8·29	O
;	O
HR	O
(	O
C	O
:	O
A	O
)	O
3·09	O
,	O
1·39–6·85	O
;	O
global	O
p=0·002	O
;	O
figure	O
4	O
)	O
.	O

The	O
14	O
%	O
(	O
SE	O
3	O
)	O
proportional	O
reduction	O
in	O
all-cause	O
mortality	O
(	O
p=0·0001	O
)	O
seen	O
during	O
the	O
in-trial	O
period	O
reflects	O
the	O
combination	O
of	O
an	O
18	O
%	O
(	O
SE	O
4	O
)	O
proportional	O
reduction	O
in	O
vascular	O
mortality	O
and	O
little	O
effect	O
on	O
non-vascular	O
mortality	O
(	O
webappendix	O
p	O
4	O
)	O
.	O

This	O
multicentre	B-Settings_Multicenter
,	O
two	O
arm	O
,	O
randomised	B-Randomization_Type_Simple
,	O
controlled	O
,	O
open	B-Blinding_Open_Label
trial	O
was	O
carried	O
out	O
in	O
13	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
Kingdom	I-Settings_Location
and	O
one	O
in	O
the	B-Settings_Location
Republic	I-Settings_Location
of	I-Settings_Location
Ireland	I-Settings_Location
.	O

Twenty	O
children	O
(	O
10	O
in	O
each	O
arm	O
)	O
and	O
10	O
adults	O
(	O
five	O
in	O
each	O
arm	O
)	O
were	O
given	O
inhaled	O
steroids	O
for	O
bronchospasm	O
.	O

Long-acting	O
β2-agonists	O
were	O
not	O
permitted	O
during	O
the	O
treatment	O
phase	O
.	O

Main	O
outcome	O
measure	O
Viral	O
status	O
according	O
to	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
for	O
influenza	O
RNA	O
in	O
nasal	O
and	O
throat	O
swabs	O
on	O
day	O
five	O
.	O

Introduction	O
In	O
high-income	O
countries	O
,	O
routine	O
laboratory	O
tests	O
are	O
done	O
(	O
typically	O
every	O
3–4	O
months	O
)	O
to	O
monitor	O
efficacy	O
(	O
HIV	O
viral	O
load	O
,	O
CD4	O
counts	O
)	O
and	O
toxicity	O
(	O
haematology	O
or	O
biochemistry	O
panels	O
)	O
in	O
patients	O
with	O
HIV	O
on	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
.	O

Among	O
event-free	O
survivors	O
at	O
the	O
start	O
of	O
the	O
post-trial	O
period	O
,	O
1636	O
(	O
21·7	O
%	O
)	O
first	O
events	O
arose	O
in	O
patients	O
previously	O
allocated	O
simvastatin	O
versus	O
1566	O
(	O
22·5	O
%	O
)	O
in	O
those	O
previously	O
allocated	O
placebo	O
(	O
risk	O
ratio	O
[	O
RR	O
]	O
0·95	O
[	O
95	O
%	O
CI	O
0·89–1·02	O
]	O
;	O
p=0·17	O
)	O
.	O

In	O
order	O
to	O
achieve	O
blinding	O
for	O
patients	B-Blinding_Object_Patients
and	O
investigators	B-Blinding_Object_Investigators
,	O
all	O
patients	O
received	O
subcutaneous	O
injections	O
of	O
canakinumab	O
or	O
canakinumab	O
placebo	O
on	O
day	O
1	O
,	O
and	O
at	O
weeks	O
4	O
,	O
8	O
and	O
12	O
,	O
and	O
took	O
capsules	O
of	O
colchicine	O
or	O
colchicine	O
placebo	O
daily	O
for	O
16	O
weeks	O
(	O
see	O
supplementary	O
material	O
for	O
details	O
)	O
.	O

Platelet	O
P-selectin	O
expression	O
was	O
not	O
affected	O
by	O
either	O
treatment	O
(	O
p	O
>	O
0.05	O
for	O
both	O
;	O
table	O
2	O
)	O
.	O

Children	O
switched	O
to	O
second-line	O
ART	O
for	O
WHO	O
stage	O
3	O
or	O
4	O
events	O
or	O
(	O
routine	O
laboratory	O
monitoring	O
only	O
)	O
age-dependent	O
WHO	O
CD4	O
criteria	O
.	O

(	O
95	O
%	O
CI	O
−2.3	O
to	O
−1.0	O
)	O
and	O
−1.5	O
(	O
−2.3	O
to	O
−0.7	O
)	O
DUs	O
,	O
respectively	O
;	O
p=0.76	O
)	O
.	O

Patients	O
were	O
also	O
excluded	O
if	O
they	O
received	O
systemic	O
antibiotics	O
to	O
treat	O
infected	O
DUs	O
within	O
2	O
weeks	O
prior	O
to	O
randomisation	O
.	O

Participants	O
Recruitment	O
took	O
place	O
at	O
39	B-Settings_Multicenter
hospitals	I-Settings_Multicenter
in	O
the	O
United	B-Settings_Location
Kingdom	I-Settings_Location
.	O

Vascular	O
mortality	O
during	O
the	O
in-trial	O
period	O
accounted	O
for	O
826	O
(	O
8·0	O
%	O
)	O
deaths	O
in	O
participants	O
allocated	O
simvastatin	O
versus	O
998	O
(	O
9·7	O
%	O
)	O
in	O
those	O
allocated	O
placebo	O
,	O
corresponding	O
to	O
an	O
18	O
%	O
(	O
SE	O
4	O
)	O
proportional	O
reduction	O
(	O
p	O
<	O
0·0001	O
,	O
figure	O
4	O
;	O
webappendix	O
,	O
p	O
4	O
)	O
.	O

Challenges	O
in	O
treatment	O
of	O
young	O
children	O
,	O
in	O
whom	O
viral	O
loads	O
are	O
higher	O
,	O
pharmacokinetics	O
more	O
variable	O
,	O
and	O
adherence	O
more	O
challenging	O
,	O
might	O
account	O
for	O
the	O
lower	O
virological	O
suppression	O
rates	O
in	O
children	O
compared	O
with	O
adults	O
in	O
similar	O
calendar	O
periods	O
.	O

6	O
months	O
after	O
randomisation	O
,	O
general	O
practitioners	O
(	O
or	O
hospital	O
coordinators	O
)	O
were	O
contacted	O
by	O
the	O
IST-3	O
trial	O
office	O
staff	O
to	O
check	O
that	O
the	O
patient	O
was	O
alive	O
and	O
inform	O
them	O
that	O
they	O
might	O
be	O
approached	O
for	O
follow-up	O
.	O

Outcome	O
measurements	O
Primary	O
outcome	O
The	O
primary	O
outcome	O
was	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
after	O
randomisation	O
.	O

Slightly	O
higher	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
responses	O
were	O
observed	O
in	O
the	O
10	O
μg	O
arm	O
,	O
and	O
there	O
were	O
statistically	O
significant	O
improvements	O
in	O
pre-dose	O
morning	O
and	O
evening	O
peak	O
expiratory	O
flow	O
(	O
PEFam	O
and	O
PEFpm	O
)	O
with	O
10	O
μg	O
versus	O
5	O
μg	O
.	O

Trial	O
registration	O
Current	O
Controlled	O
Trials	O
ISRCTN50343149	O
.	O

Screening	O
results	O
were	O
used	O
to	O
assess	O
eligibility	O
.	O

PMA	O
was	O
however	O
unaffected	O
by	O
saline	O
placebo	O
infusion	O
(	O
28±5	O
vs	O
33±6	O
%	O
;	O
p=0.23	O
)	O
.	O

Patients	O
received	O
bosentan	B-Design_Parallel_Group
62.5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
for	I-Design_Parallel_Group
4	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
and	I-Design_Parallel_Group
then	I-Design_Parallel_Group
125	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
for	I-Design_Parallel_Group
the	I-Design_Parallel_Group
remainder	I-Design_Parallel_Group
of	I-Design_Parallel_Group
the	I-Design_Parallel_Group
treatment	I-Design_Parallel_Group
period	I-Design_Parallel_Group
or	I-Design_Parallel_Group
matching	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Conclusions	O
Following	O
acute	O
myocardial	O
infarction	O
,	O
etanercept	O
reduces	O
systemic	O
inflammation	O
but	O
increases	O
platelet	O
activation	O
without	O
affecting	O
peripheral	O
vasomotor	O
or	O
fibrinolytic	O
function	O
.	O

If	O
neither	O
of	O
these	O
were	O
available	O
for	O
a	O
participant	O
,	O
the	O
patient	O
’	O
s	O
self	O
reported	O
outcome	O
recorded	O
in	O
the	O
week	O
12	O
patient	O
questionnaire	O
or	O
on	O
the	O
“	O
Verrucae	O
gone	O
form	O
”	O
was	O
used	O
.	O

Subjects	O
Children	O
with	O
active	O
rickets	O
were	O
identified	O
using	O
radiographs	O
of	O
the	O
wrists	O
and	O
the	O
knees	O
from	O
among	O
children	O
who	O
presented	O
with	O
leg	O
deformities	O
to	O
the	O
primary	O
care	O
setting	O
of	O
the	O
Family	O
Medicine	O
Department	O
of	O
the	O
Jos	B-Settings_Single_Center
University	I-Settings_Single_Center
Teaching	I-Settings_Single_Center
Hospital	I-Settings_Single_Center
in	O
the	O
geographic	O
centre	O
of	O
Nigeria	B-Settings_Location
(	O
10°	O
north	O
latitude	O
)	O
.	O

However	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
one	O
or	O
more	O
predefined	O
symptoms	O
consistent	O
with	O
dyspepsia	O
was	O
not	O
significantly	O
different	O
between	O
HZT-501	O
and	O
ibuprofen	O
(	O
12.3	O
%	O
vs.	O
14.9	O
%	O
)	O
.	O

Some	O
patients	O
have	O
contraindications	O
to	O
colchicine	O
whereas	O
others	O
do	O
not	O
tolerate	O
colchicine	O
or	O
still	O
experience	O
flares	O
.	O

Through	O
Week	O
36	O
,	O
the	O
most	O
frequent	O
AEs	O
across	O
all	O
quilizumab	O
dose	O
groups	O
were	O
worsening	O
of	O
asthma	O
(	O
27	O
%	O
)	O
,	O
nasopharyngitis	O
(	O
15	O
%	O
)	O
,	O
upper	O
respiratory	O
tract	O
infection	O
(	O
7	O
%	O
)	O
,	O
bronchitis	O
(	O
5	O
%	O
)	O
,	O
sinusitis	O
(	O
5	O
%	O
)	O
,	O
and	O
injection	O
site	O
pain	O
(	O
5	O
%	O
)	O
.	O

The	O
mean	O
(	O
SD	O
)	O
speed	O
of	O
healing	O
at	O
six	O
weeks	O
was	O
−0.21	O
(	O
1.00	O
)	O
cm2/day	O
in	O
the	O
ciclosporin	O
group	O
compared	O
with	O
−0.14	O
(	O
0.42	O
)	O
cm2/day	O
in	O
the	O
prednisolone	O
group	O
.	O

INTRODUCTION	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
widely	O
used	O
as	O
analgesics	O
.	O

The	O
excess	O
malaria	O
serious	O
adverse	O
events	O
in	O
the	O
clinically	O
driven	O
monitoring	O
group	O
were	O
mostly	O
in	O
children	O
with	O
parasite	O
counts	O
less	O
than	O
500	O
per	O
200	O
white	O
blood	O
cells	O
,	O
or	O
were	O
not	O
diagnostically	O
confirmed	O
(	O
figure	O
3	O
)	O
.	O

Two	O
trained	O
assessors	O
mapped	O
the	O
circumference	O
of	O
the	O
lesion	O
using	O
VERG	O
Videometry	O
VEV	O
MD	O
software	O
(	O
Vista	O
Medical	O
,	O
Winnipeg	O
,	O
Canada	O
)	O
.	O

At	O
the	O
time	O
of	O
writing	O
,	O
82	O
participants	O
had	O
attained	O
a	O
mean	O
final	O
height	O
of	O
151.8	O
(	O
SD	O
6.4	O
)	O
cm	O
,	O
and	O
10	O
others	O
continued	O
growing	O
.	O

Concentrations	O
of	O
25	O
(	O
OH	O
)	O
D	O
below	O
the	O
limit	O
of	O
detection	O
(	O
5	O
nmol/L	O
for	O
25	O
(	O
OH	O
)	O
D3	O
and	O
10	O
nmol/L	O
for	O
25	O
(	O
OH	O
)	O
D2	O
)	O
were	O
designated	O
as	O
zero	O
for	O
the	O
data	O
analysis	O
.	O

The	O
statistical	O
analysis	O
plan	O
specified	O
an	O
ordinal	O
analysis	O
of	O
the	O
OHS	O
score	O
at	O
6	O
months	O
.	O

Summary	O
Background	O
No	O
trials	O
have	O
investigated	O
routine	O
laboratory	O
monitoring	O
for	O
children	O
with	O
HIV	O
,	O
nor	O
four-drug	O
induction	O
strategies	O
to	O
increase	O
durability	O
of	O
first-line	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
.	O

At	O
week	O
3	O
,	O
more	O
patients	O
were	O
unhappy	O
with	O
salicylic	O
acid	O
than	O
with	O
cryotherapy	O
(	O
none	O
)	O
,	O
and	O
more	O
patients	O
were	O
very	O
happy	O
with	O
cryotherapy	O
than	O
salicylic	O
acid	O
.	O

Participants	O
unable	O
or	O
unwilling	O
to	O
attend	O
were	O
contacted	O
by	O
telephone	O
,	O
or	O
follow-up	O
was	O
sought	O
from	O
their	O
family	O
doctors	O
.	O

Patients	O
allocated	O
to	O
the	O
control	O
group	O
were	O
to	O
avoid	O
treatment	O
with	O
rt-PA	O
and	O
received	O
stroke	O
care	O
in	O
the	O
same	O
clinical	O
environment	O
as	O
those	O
allocated	O
to	O
the	O
rt-PA	O
group	O
.	O

Final	O
and	O
maximum	O
height	O
Table	O
1	O
shows	O
participants	O
’	O
characteristics	O
at	O
enrolment	O
,	O
at	O
maximum	O
height	O
,	O
and	O
at	O
final	O
height	O
by	O
treatment	O
group	O
.	O

In	O
order	O
to	O
estimate	O
the	O
final	O
plasma	O
concentration	O
of	O
memantine	O
,	O
a	O
blood	O
sample	O
was	O
taken	O
from	O
all	O
patients	O
(	O
ie	O
,	O
both	O
groups	O
,	O
to	O
maintain	O
blinding	O
)	O
before	O
the	O
morning	O
administration	O
of	O
study	O
medication	O
at	O
7:00	O
on	O
the	O
last	O
day	O
of	O
treatment	O
.	O

We	O
estimated	O
the	O
effects	O
of	O
the	O
two	O
randomisations	O
separately	O
by	O
using	O
multiple	O
regression	O
.	O

By	O
six	O
months	O
,	O
ulcers	O
had	O
healed	O
in	O
28/59	O
(	O
47	O
%	O
)	O
participants	O
in	O
the	O
ciclosporin	O
group	O
and	O
25/53	O
(	O
47	O
%	O
)	O
in	O
the	O
prednisolone	O
group	O
.	O

Randomisation	O
was	O
to	O
either	O
clinically	O
driven	O
monitoring	O
or	O
routine	O
laboratory	O
and	O
clinical	O
monitoring	O
for	O
toxicity	O
(	O
haematology	O
and	O
biochemistry	O
)	O
and	O
efficacy	O
(	O
CD4	O
cell	O
counts	O
;	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
monitoring	O
randomisation	O
)	O
;	O
and	O
simultaneously	O
to	O
standard	O
three-drug	O
or	O
to	O
four-drug	O
induction	O
first-line	O
ART	O
,	O
in	O
three	O
groups	O
:	O
three-drug	O
treatment	O
(	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
[	O
NNRTI	O
]	O
,	O
lamivudine	O
,	O
abacavir	O
;	O
group	O
A	O
)	O
versus	O
four-drug	O
induction	O
(	O
NNRTI	O
,	O
lamivudine	O
,	O
abacavir	O
,	O
zidovudine	O
;	O
groups	O
B	O
and	O
C	O
)	O
,	O
decreasing	O
after	O
week	O
36	O
to	O
three-drug	O
NNRTI	O
,	O
lamivudine	O
,	O
plus	O
abacavir	O
(	O
group	O
B	O
)	O
or	O
lamivudine	O
,	O
abacavir	O
,	O
plus	O
zidovudine	O
(	O
group	O
C	O
;	O
superiority	O
ART-strategy	O
randomisation	O
)	O
.	O

Therefore	O
,	O
when	O
initiating	O
a	O
patient	O
on	O
ULT	O
,	O
prophylactic	O
low-dose	O
anti-inflammatory	O
treatment	O
is	O
recommended	O
to	O
prevent	O
flares	O
and	O
foster	O
compliance	O
with	O
ULT	O
.	O

Background	O
Given	O
that	O
memantine	O
is	O
thought	O
to	O
decrease	O
N-methyl-D-aspartic-acid-related	O
(	O
NMDA	O
)	O
glutamatergic	O
hyperactivity	O
and	O
improve	O
locomotion	O
in	O
rats	O
,	O
we	O
sought	O
to	O
assess	O
the	O
drug	O
's	O
impact	O
on	O
axial	O
symptoms	O
in	O
advanced	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

Patients	O
and	O
methods	O
Study	O
design	O
This	O
double-blind	B-Blinding_Double_Blind
,	O
randomised	O
,	O
parallel-group	B-Design_Parallel_Group
,	O
placebo-controlled	O
study	O
consisted	O
of	O
a	O
≤2-week	O
screening	O
period	O
,	O
a	O
24-week	O
treatment	O
period	O
and	O
an	O
8-week	O
post-treatment	O
follow-up	O
period	O
.	O

Design	O
Multicentre	B-Settings_Multicenter
,	O
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
,	O
observer	B-Blinding_Object_Outcome_Assessors
blind	I-Blinding_Single_Blind
,	O
randomised	O
controlled	O
trial	O
.	O

In	O
particular	O
,	O
there	O
was	O
no	O
evidence	O
that	O
greater	O
initial	O
CD4	O
increases	O
in	O
groups	O
B	O
or	O
C	O
significantly	O
reduced	O
disease	O
progression	O
risks	O
in	O
the	O
first	O
year	O
(	O
13	O
deaths	O
in	O
group	O
A	O
vs	O
nine	O
in	O
group	O
B	O
vs	O
18	O
in	O
group	O
C	O
;	O
22	O
vs	O
19	O
vs	O
24	O
WHO	O
stage	O
4	O
events	O
or	O
deaths	O
;	O
36	O
vs	O
35	O
vs	O
37	O
WHO	O
stage	O
3	O
or	O
4	O
events	O
or	O
deaths	O
)	O
.	O

Assuming	O
a	O
standard	O
deviation	O
of	O
5	O
cm	O
,	O
we	O
needed	O
50	B-Sample_Size_Required
girls	I-Sample_Size_Required
in	I-Sample_Size_Required
each	I-Sample_Size_Required
group	I-Sample_Size_Required
to	O
detect	O
a	O
difference	O
between	O
groups	O
in	O
mean	O
final	O
height	O
of	O
2.8	O
cm	O
with	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
at	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
significance—a	O
total	O
of	O
100	B-Sample_Size_Required
patients	O
.	O

Resolution	O
of	O
inflammation—this	O
was	O
recorded	O
by	O
clinicians	O
and	O
participants	O
using	O
a	O
scale	O
reported	O
by	O
Foss	O
.	O

For	O
strokes	O
,	O
a	O
24	O
%	O
(	O
SE	O
5	O
)	O
reduction	O
was	O
seen	O
during	O
the	O
in-trial	O
period	O
(	O
p	O
<	O
0·0001	O
)	O
,	O
reflecting	O
a	O
29	O
%	O
(	O
SE	O
6	O
)	O
reduction	O
in	O
definite	O
ischaemic	O
stroke	O
and	O
no	O
difference	O
in	O
haemorrhagic	O
stroke	O
(	O
51	O
[	O
0·5	O
%	O
]	O
vs	O
56	O
[	O
0·5	O
%	O
]	O
;	O
p=0·59	O
)	O
.	O

Therefore	O
a	O
post	O
hoc	O
analysis	O
using	O
a	O
negative	O
binomial	O
model	O
(	O
the	O
model	O
used	O
for	O
the	O
primary	O
outcome	O
)	O
was	O
performed	O
after	O
unblinding	O
at	O
16	O
weeks	O
.	O

During	O
the	O
in-trial	O
period	O
,	O
compliance	O
with	O
study	O
treatment	O
was	O
assessed	O
at	O
each	O
follow-up	O
by	O
questioning	O
the	O
participant	O
and	O
reviewing	O
their	O
remaining	O
calendar-packed	O
tablets	O
.	O

The	O
rates	O
for	O
HZT-501	O
vs.	O
ibuprofen	O
in	O
the	O
pooled	O
results	O
were	O
4.7	O
%	O
vs.	O
8.0	O
%	O
for	O
dyspepsia	O
and	O
5.8	O
%	O
vs.	O
4.7	O
%	O
for	O
nausea	O
.	O

No	O
significant	O
differences	O
in	O
PEFam	O
or	O
PEFpm	O
responses	O
were	O
observed	O
between	O
the	O
different	O
tiotropium	O
Respimat®	O
doses	O
.	O

The	O
predefined	O
primary	O
population	O
for	O
analysis	O
included	O
all	O
patients	O
who	O
were	O
randomized	O
,	O
received	O
a	O
dose	O
of	O
study	O
medication	O
,	O
and	O
had	O
at	O
least	O
one	O
study-mandated	O
follow-up	O
endoscopy	O
.	O

Results	O
26	B-Sample_Size_Actual_at_Enrollment
patients	O
hospitalised	O
with	O
type	O
1	O
acute	O
non-ST	O
elevation	O
myocardial	O
infarction	O
were	O
recruited	O
into	O
the	O
study	O
.	O

Study	O
procedures	O
At	O
clinic	O
visits	O
every	O
four	O
to	O
six	O
months	O
,	O
height	O
was	O
measured	O
with	O
a	O
Harpenden	O
stadiometer	O
to	O
the	O
last	O
completed	O
1	O
mm	O
and	O
converted	O
to	O
an	O
SD	O
score	O
by	O
using	O
the	O
British	O
1990	O
reference	O
.	O

Non-responders	O
were	O
contacted	O
by	O
telephone	O
,	O
and	O
follow-up	O
data	O
was	O
obtained	O
by	O
telephone	O
interview	O
.	O

Categorical	O
variables	O
were	O
compared	O
with	O
χ2	O
or	O
exact	O
(	O
if	O
indicated	O
)	O
tests	O
.	O

Patients	O
were	O
excluded	O
in	O
the	O
event	O
of	O
significant	O
comorbidity	O
,	O
including	O
active	O
systemic	O
inflammatory	O
disorders	O
,	O
insulin-dependent	O
diabetes	O
mellitus	O
and	O
the	O
use	O
of	O
anti-inflammatory	O
drugs	O
other	O
than	O
aspirin	O
.	O

The	O
diary	O
was	O
also	O
used	O
to	O
determine	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
no	O
nighttime	O
awakenings	O
due	O
to	O
asthma	O
symptoms	O
and	O
the	O
proportion	O
of	O
patients	O
with	O
fewer	O
than	O
2	O
days	O
of	O
SABA	O
use	O
per	O
week	O
by	O
Week	O
36	O
.	O

Secondary	O
outcomes	O
were	O
maximum	O
height	O
(	O
that	O
is	O
,	O
the	O
most	O
recently	O
available	O
height	O
)	O
,	O
age	O
of	O
attaining	O
final	O
height	O
,	O
and	O
the	O
three	O
summary	O
growth	O
parameters	O
from	O
the	O
SITAR	O
analysis	O
described	O
below	O
.	O

Participants	O
Inclusion	O
criteria	O
Adult	O
asthma	O
patients	O
,	O
aged	O
18–75	O
years	O
,	O
were	O
required	O
to	O
have	O
:	O
bronchodilator	O
reversibility	O
of	O
either	O
≥12	O
%	O
β-agonist	O
reversibility	O
using	O
4	O
puffs	O
of	O
a	O
short-acting	O
β	O
−	O
agonist	O
(	O
SABA	O
)	O
or	O
a	O
PC20	O
FEV1	O
methacholine	O
(	O
provocative	O
concentration	O
of	O
methacholine	O
producing	O
a	O
20	O
%	O
fall	O
in	O
FEV1	O
(	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
)	O
)	O
of	O
8	O
mg/mL	O
or	O
less	O
,	O
within	O
the	O
last	O
2	O
years	O
;	O
a	O
pre-bronchodilator	O
FEV1	O
at	O
screening	O
of	O
40–80	O
%	O
predicted	O
;	O
daily	O
use	O
of	O
ICS	O
(	O
≥400	O
μg/day	O
total	O
daily	O
dose	O
of	O
fluticasone	O
propionate	O
or	O
equivalent	O
)	O
and	O
a	O
second	O
controller	O
for	O
a	O
minimum	O
of	O
3	O
consecutive	O
months	O
;	O
inadequately-controlled	O
asthma	O
as	O
documented	O
by	O
a	O
5-item	O
Asthma	O
Control	O
Questionnaire	O
(	O
ACQ-5	O
)	O
score	O
≥1.50	O
at	O
screening	O
and	O
randomization	O
,	O
despite	O
compliance	O
with	O
asthma	O
controller	O
therapy	O
;	O
at	O
least	O
one	O
positive	O
aeroallergen-specific	O
IgE	O
(	O
≥0.35	O
kU	O
(	O
A	O
)	O
/L	O
)	O
,	O
or	O
a	O
total	O
serum	O
IgE	O
≥75	O
IU/mL	O
;	O
and	O
a	O
history	O
of	O
at	O
least	O
one	O
protocol-defined	O
asthma	O
exacerbation	O
in	O
the	O
18	O
months	O
prior	O
to	O
screening	O
.	O

The	O
figure	O
shows	O
the	O
flow	O
of	O
participants	O
through	O
the	O
trial	O
,	O
and	O
table	O
1	O
summarises	O
their	O
baseline	O
characteristics	O
.	O

During	O
the	O
combined	O
in-trial	O
and	O
post-trial	O
periods	O
,	O
no	O
significant	O
differences	O
were	O
recorded	O
in	O
cancer	O
incidence	O
at	O
all	O
sites	O
(	O
0·98	O
[	O
0·92–1·05	O
]	O
)	O
or	O
any	O
particular	O
site	O
,	O
or	O
in	O
mortality	O
attributed	O
to	O
cancer	O
(	O
1·01	O
[	O
0·92–1·11	O
]	O
)	O
or	O
to	O
non-vascular	O
causes	O
(	O
0·96	O
[	O
0·89–1·03	O
]	O
)	O
.	O

Following	O
etanercept	O
infusion	O
,	O
there	O
was	O
a	O
50	O
%	O
relative	O
increase	O
in	O
PMA	O
(	O
30±5	O
vs	O
20±3	O
%	O
;	O
p=0.02	O
)	O
compared	O
with	O
baseline	O
.	O

To	O
detect	O
a	O
treatment	O
difference	O
of	O
80	O
mL	O
for	O
peak	O
FEV1	O
(	O
0-3h	O
)	O
with	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
,	O
and	O
assuming	O
a	O
standard	O
deviation	O
of	O
228	O
mL	O
,	O
it	O
was	O
calculated	O
that	O
88	B-Sample_Size_Required
completed	O
patients	O
were	O
required	O
.	O

Baseline	O
erosions	O
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
upper	O
GI	O
ulcer	O
formation	O
(	O
initial	O
:	O
1.20	O
,	O
0.86–1.67	O
;	O
post-adjudication	O
:	O
1.15	O
,	O
0.82–1.62	O
)	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

We	O
also	O
adjusted	O
randomisation	O
2	O
(	O
timing	O
of	O
pubertal	O
induction	O
)	O
for	O
randomisation	O
1	O
(	O
oxandrolone	O
)	O
and	O
tested	O
for	O
an	O
interaction	O
.	O

DU	O
healing	O
No	O
treatment	O
effects	O
were	O
observed	O
in	O
the	O
times	O
to	O
healing	O
up	O
to	O
week	O
24	O
for	O
all	O
baseline	O
DUs	O
(	O
HR	O
0.94	O
(	O
95	O
%	O
CI	O
0.65	O
to	O
1.37	O
)	O
,	O
p=0.74	O
)	O
or	O
of	O
all	O
new	O
DUs	O
(	O
HR	O
1.40	O
(	O
0.78	O
to	O
2.51	O
)	O
,	O
p=0.26	O
)	O
.	O

Peripheral	O
blood	O
eosinophils	O
and	O
FeNO	O
levels	O
were	O
not	O
modified	O
following	O
quilizumab	O
treatment	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S3	O
)	O
.	O

No	O
child	O
switched	O
to	O
second-line	O
treatment	O
during	O
their	O
first	O
year	O
on	O
ART	O
.	O

Hence	O
all	O
hazard	O
ratios	O
were	O
assumed	O
constant	O
during	O
the	O
follow-up	O
period	O
.	O

Secondary	O
outcomes	O
Time	O
to	O
healing	O
At	O
six	O
weeks	O
,	O
ulcers	O
had	O
healed	O
in	O
nine	O
(	O
15	O
%	O
)	O
participants	O
in	O
the	O
ciclosporin	O
group	O
and	O
11	O
(	O
21	O
%	O
)	O
in	O
the	O
prednisolone	O
group	O
.	O

Eligible	O
patients	O
were	O
subsequently	O
randomised	B-Randomization_Type_Simple
1:1:1:1:1:1:2	B-Randomization_Ratio
to	O
receive	O
a	B-Design_Parallel_Group
single	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
canakinumab	I-Design_Parallel_Group
,	I-Design_Parallel_Group
25	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
50	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
100	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
200	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
300	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
on	I-Design_Parallel_Group
day	I-Design_Parallel_Group
1	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
four	I-Design_Parallel_Group
canakinumab	I-Design_Parallel_Group
doses	I-Design_Parallel_Group
administered	I-Design_Parallel_Group
at	I-Design_Parallel_Group
4-weekly	I-Design_Parallel_Group
intervals	I-Design_Parallel_Group
(	I-Design_Parallel_Group
50	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
on	I-Design_Parallel_Group
day	I-Design_Parallel_Group
1	I-Design_Parallel_Group
and	I-Design_Parallel_Group
at	I-Design_Parallel_Group
week	I-Design_Parallel_Group
4	I-Design_Parallel_Group
,	I-Design_Parallel_Group
and	I-Design_Parallel_Group
25	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
at	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
8	I-Design_Parallel_Group
and	I-Design_Parallel_Group
12	I-Design_Parallel_Group
)	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
oral	I-Design_Parallel_Group
doses	I-Design_Parallel_Group
of	I-Design_Parallel_Group
colchicine	I-Design_Parallel_Group
0.5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
given	I-Design_Parallel_Group
for	I-Design_Parallel_Group
16	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
.	O

These	O
findings	O
provide	O
further	O
support	O
for	O
the	O
prompt	O
initiation	O
and	O
long-term	O
continuation	O
of	O
statin	O
treatment	O
.	O

Digital	O
image	O
assessments	O
A	O
template	O
was	O
photographed	O
alongside	O
the	O
target	O
ulcer	O
to	O
calibrate	O
the	O
image	O
in	O
the	O
image	O
analysis	O
software	O
(	O
see	O
supplementary	O
figure	O
)	O
.	O

Girls	O
with	O
other	O
karyotypes	O
were	O
tested	O
for	O
concentrations	O
of	O
gonadotrophin	O
releasing	O
hormone	O
and	O
were	O
randomised	O
at	O
randomisation	O
2	O
if	O
the	O
peak	O
follicle	O
stimulating	O
hormone	O
concentration	O
was	O
above	O
30	O
U/L	O
.	O

We	O
have	O
published	O
reports	O
of	O
the	O
rationale	O
for	O
the	O
trial	O
,	O
the	O
protocol	O
,	O
an	O
update	O
on	O
recruitment	O
,	O
amendments	O
to	O
the	O
protocol	O
and	O
the	O
baseline	O
characteristics	O
of	O
the	O
patients	O
recruited	O
,	O
and	O
the	O
statistical	O
analysis	O
plan	O
.	O

Satisfaction	O
with	O
treatment	O
Patients	O
were	O
asked	O
to	O
rate	O
their	O
satisfaction	O
with	O
their	O
treatment	O
on	O
a	O
five	O
point	O
scale	O
from	O
“	O
very	O
happy	O
”	O
to	O
“	O
very	O
unhappy	O
”	O
on	O
a	O
postal	O
or	O
web	O
based	O
questionnaire	O
at	O
one	O
,	O
three	O
,	O
and	O
12	O
weeks	O
(	O
see	O
table	O
5	O
)	O
.	O

Serum	O
periostin	O
was	O
measured	O
by	O
immunoassay	O
using	O
the	O
Roche	O
Elecsys	O
platform	O
(	O
Roche	O
Diagnostics	O
Ltd.	O
,	O
Rotkreuz	O
,	O
Switzerland	O
)	O
.	O

p	O
Values	O
less	O
than	O
0.05	O
were	O
considered	O
significant	O
.	O

The	O
remaining	O
27	O
were	O
assessed	O
as	O
non-serious	O
,	O
13	O
of	O
which	O
were	O
in	O
the	O
salicylic	O
acid	O
group	O
and	O
14	O
in	O
the	O
cryotherapy	O
group	O
.	O

Interventions	O
Cryotherapy	O
with	O
liquid	O
nitrogen	O
delivered	O
by	O
a	O
healthcare	O
professional	O
,	O
up	O
to	O
four	O
treatments	O
two	O
to	O
three	O
weeks	O
apart	O
.	O

Additionally	O
,	O
all	O
centres	O
were	O
asked	O
for	O
their	O
pretrial	O
experience	O
of	O
thrombolysis	O
for	O
treatment	O
of	O
stroke	O
,	O
and	O
if	O
the	O
centre	O
had	O
,	O
before	O
joining	O
the	O
trial	O
,	O
a	O
protocol	O
for	O
open-label	O
use	O
of	O
rt-PA	O
and	O
had	O
treated	O
at	O
least	O
three	O
people	O
in	O
the	O
12	O
months	O
before	O
joining	O
the	O
trial	O
,	O
the	O
centre	O
was	O
classed	O
as	O
experienced	O
.	O

All	O
follow-up	O
done	O
by	O
patient	O
contact	O
for	O
these	O
analyses	O
ceased	O
on	O
March	O
31	O
,	O
2012	O
,	O
but	O
recording	O
of	O
deaths	O
from	O
national	O
registries	O
of	O
deaths	O
continues	O
in	O
UK	O
,	O
Norway	O
,	O
and	O
Sweden	O
.	O

The	O
maximum	O
number	O
of	O
new	O
DUs	O
per	O
patient	O
was	O
10	O
on	O
bosentan	O
and	O
16	O
on	O
placebo	O
.	O

The	O
study	O
medication	O
was	O
dispensed	O
in	O
an	O
8-week	O
supply	O
at	O
0	O
,	O
8	O
,	O
and	O
16	O
weeks	O
.	O

Study	O
end	O
points	O
All	O
end	O
points	O
were	O
determined	O
at	O
the	O
end	O
of	O
each	O
4-week	O
treatment	O
period	O
(	O
Visits	O
3–6	O
)	O
and	O
analysed	O
as	O
a	O
response	O
defined	O
as	O
change	O
from	O
study	O
baseline	O
(	O
pre-treatment	O
value	O
measured	O
at	O
Visit	O
2	O
in	O
the	O
evening	O
)	O
.	O

The	O
main	O
exclusion	O
criterion	O
was	O
the	O
presence	O
of	O
axial	O
disorders	O
related	O
to	O
insufficient	O
doses	O
of	O
L-dopa	O
or	O
off-periods	O
of	O
motor	O
fluctuation	O
or	O
those	O
induced	O
by	O
STN	O
stimulation	O
.	O

For	O
biomarker	O
subgroup	O
analyses	O
,	O
unadjusted	O
asthma	O
exacerbation	O
rates	O
were	O
calculated	O
.	O

49	O
(	O
9	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
29	O
(	O
5	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
weight-for-age	O
Z	O
score	O
less	O
than	O
−3	O
(	O
approximate	O
one	O
thousandth	O
percentile	O
of	O
normal	O
UK	O
weight	O
)	O
at	O
last	O
visit	O
(	O
global	O
p=0·12	O
)	O
.	O

The	O
initial	O
pilot	O
phase	O
was	O
double-blinded	B-Blinding_Double_Blind
and	O
placebo-controlled	O
.	O

The	O
incremental	O
increase	O
in	O
the	O
distal	O
forearm	O
bone	O
mineral	O
content	O
in	O
the	O
Ca	O
group	O
(	O
least	O
squares	O
mean	O
increase	O
0.093	O
g	O
)	O
was	O
nearly	O
twice	O
that	O
of	O
the	O
Ca+D	O
group	O
(	O
least	O
squares	O
mean	O
increase	O
0.053	O
g	O
;	O
p=0.02	O
)	O
in	O
a	O
model	O
adjusting	O
for	O
baseline	O
bone	O
mineral	O
content	O
and	O
height	O
.	O

However	O
,	O
the	O
FDA	O
generally	O
has	O
approved	O
antisecretory	O
medications	O
for	O
prevention	O
of	O
gastric	O
ulcers	O
(	O
e.g.	O
,	O
lansoprazole	O
and	O
esomeprazole	O
)	O
.	O

Primary	O
virological	O
efficacy	O
endpoint	O
Day	O
five	O
negative	O
viral	O
RNA	O
by	O
RT-PCR	O
At	O
day	O
five	O
,	O
the	O
proportions	O
of	O
all	O
patients	O
negative	O
for	O
viral	O
RNA	O
in	O
the	O
nasal	O
and	O
throat	O
swabs	O
were	O
similar	O
between	O
the	O
double	O
(	O
115/159	O
;	O
72.3	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
64.9	O
%	O
to	O
78.7	O
%	O
)	O
and	O
standard	O
dose	O
arms	O
(	O
105/154	O
;	O
68.2	O
%	O
,	O
60.5	O
%	O
to	O
75.0	O
%	O
)	O
,	O
with	O
a	O
difference	O
of	O
4.2	O
%	O
(	O
−5.9	O
%	O
to	O
14.2	O
%	O
;	O
P=0.42	O
)	O
.	O

Control	O
of	O
asthma	O
,	O
as	O
assessed	O
by	O
ACQ-7	O
self-administered	O
at	O
the	O
end	O
of	O
each	O
4-week	O
treatment	O
period	O
,	O
was	O
an	O
additional	O
exploratory	O
end	O
point	O
.	O

Safety	O
assessments	O
were	O
performed	O
at	O
scheduled	O
visits	O
(	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
20	O
and	O
24	O
weeks	O
)	O
and	O
included	O
collection	O
of	O
blood	O
samples	O
for	O
assessment	O
of	O
the	O
inflammatory	O
marker	O
,	O
C	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
haematology	O
and	O
immunogenicity	O
(	O
at	O
baseline	O
and	O
weeks	O
8	O
,	O
16	O
and	O
24	O
)	O
and	O
doctor	O
's	O
assessments	O
of	O
local	O
tolerability	O
at	O
sites	O
of	O
subcutaneous	O
injections	O
.	O

During	O
the	O
trial	O
,	O
a	O
patient	O
joined	O
the	O
independent	O
trial	O
steering	O
committee	O
.	O

Statistical	O
analysis	O
The	O
primary	O
outcome	O
was	O
the	O
combined	O
attainment	O
of	O
a	O
radiographic	O
score	O
of	O
1.5	O
or	O
less	O
and	O
a	O
serum	O
alkaline	O
phosphatase	O
concentration	O
of	O
350	O
U/L	O
or	O
less	O
.	O

Cryotherapy	O
versus	O
salicylic	O
acid	O
for	O
the	O
treatment	O
of	O
plantar	O
warts	O
(	O
verrucae	O
)	O
:	O
a	O
randomised	B-Randomization_Type_Simple
controlled	O
trial	O

Results	O
Quilizumab	O
was	O
well	O
tolerated	O
and	O
reduced	O
serum	O
total	O
and	O
allergen-specific	O
IgE	O
by	O
30–40	O
%	O
,	O
but	O
had	O
no	O
impact	O
on	O
asthma	O
exacerbations	O
,	O
lung	O
function	O
,	O
or	O
patient-reported	O
symptom	O
measures	O
.	O

Adverse	O
events	O
(	O
AEs	O
)	O
were	O
reported	O
throughout	O
the	O
study	O
.	O

Outcomes	O
Primary	O
outcome	O
The	O
main	O
outcome	O
measure	O
was	O
speed	O
of	O
healing	O
over	O
six	O
weeks	O
,	O
captured	O
for	O
a	O
single	O
target	O
lesion	O
for	O
each	O
patient	O
.	O

During	O
the	O
feasibility	O
stage	O
,	O
priority	O
of	O
the	O
research	O
question	O
,	O
choice	O
of	O
outcome	O
measures	O
,	O
and	O
methods	O
of	O
recruitment	O
were	O
informed	O
by	O
discussions	O
with	O
patients	O
through	O
a	O
focus	O
group	O
session	O
and	O
two	O
structured	O
interviews	O
.	O

There	O
was	O
no	O
apparent	O
impact	O
of	O
positive	O
ATA	O
results	O
on	O
either	O
pharmacokinetic	O
profiles	O
or	O
safety	O
.	O

For	O
all	O
comparative	O
analyses	O
,	O
P	O
<	O
0.05	O
was	O
considered	O
significant	O
.	O

Some	O
patients	O
have	O
persistent	O
symptoms	O
despite	O
the	O
use	O
of	O
steroids	O
and	O
other	O
therapies	O
.	O

Vasodilatation	O
in	O
response	O
to	O
substance	O
P	O
,	O
acetylcholine	O
and	O
sodium	O
nitroprusside	O
,	O
and	O
acute	O
tissue	O
plasminogen	O
activator	O
release	O
were	O
unaffected	O
by	O
either	O
treatment	O
(	O
p	O
>	O
0.1	O
for	O
all	O
)	O
.	O

Serious	O
adverse	O
events	O
were	O
reported	O
for	O
two	O
patients	O
(	O
in	O
the	O
tiotropium	O
Respimat®	O
5	O
μg	O
group	O
)	O
.	O

The	O
incidence	O
of	O
genitourinary	O
,	O
gastrointestinal	O
,	O
respiratory	O
,	O
haematological	O
,	O
or	O
any	O
other	O
malignant	O
disease	O
did	O
not	O
differ	O
significantly	O
(	O
figure	O
6	O
)	O
,	O
even	O
in	O
patients	O
aged	O
70	O
years	O
or	O
older	O
at	O
baseline	O
or	O
with	O
below-average	O
pretreatment	O
cholesterol	O
concentrations	O
(	O
webappendix	O
,	O
p	O
7	O
)	O
.	O

A	O
key	O
advantage	O
might	O
be	O
more	O
rapid	O
reduction	O
of	O
high	O
viral	O
loads	O
in	O
ART-naive	O
children	O
,	O
which	O
could	O
have	O
long-term	O
benefits	O
.	O

Ibuprofen	O
is	O
the	O
most	O
commonly	O
used	O
non-aspirin	O
NSAID	O
,	O
with	O
about	O
one	O
quarter	O
of	O
the	O
US	O
population	O
aged	O
17	O
years	O
or	O
older	O
reporting	O
ibuprofen	O
intake	O
in	O
the	O
past	O
month	O
.	O

These	O
adverse	O
events	O
resulted	O
in	O
premature	O
discontinuation	O
of	O
bosentan	O
treatment	O
in	O
2.1	O
%	O
and	O
5.2	O
%	O
of	O
patients	O
,	O
respectively	O
(	O
vs	O
none	O
on	O
placebo	O
)	O
.	O

All	O
radiographs	O
were	O
scored	O
independently	O
by	O
two	O
of	O
the	O
authors	O
(	O
TDT	O
and	O
PRF	O
)	O
and	O
the	O
mean	O
score	O
was	O
used	O
for	O
analysis	O
.	O

Setting	O
36	B-Settings_Multicenter
paediatric	I-Settings_Multicenter
endocrinology	I-Settings_Multicenter
departments	I-Settings_Multicenter
in	O
UK	B-Settings_Location
hospitals	O
.	O

A	O
post	O
hoc	O
fixed	O
effect	O
meta-analysis	O
of	O
the	O
results	O
of	O
the	O
two	O
studies	O
for	O
end	O
points	O
of	O
upper	O
GI	O
,	O
gastric	O
,	O
and	O
duodenal	O
ulcers	O
was	O
also	O
performed	O
(	O
Review	O
Manager	O
5.1	O
,	O
Cochrane	O
Collaboration	O
,	O
Copenhagen	O
,	O
Denmark	O
)	O
.	O

Given	O
the	O
immunosuppressive	O
effects	O
of	O
etanercept	O
,	O
exclusion	O
criteria	O
also	O
included	O
any	O
history	O
of	O
recent	O
or	O
recurrent	O
infection	O
,	O
tuberculosis	O
or	O
any	O
opportunistic	O
infection	O
within	O
the	O
previous	O
6	O
months	O
.	O

White	O
,	O
uncoated	O
,	O
flat	O
bevelled	O
edge	O
placebo	O
tablets	O
(	O
7	O
and	O
5	O
mm	O
in	O
diameter	O
)	O
(	O
Essential	O
Nutrition	O
,	O
Brough	O
,	O
UK	O
)	O
were	O
specially	O
manufactured	O
to	O
match	O
the	O
size	O
,	O
weight	O
,	O
and	O
appearance	O
of	O
oxandrolone	O
2.5	O
mg	O
and	O
ethinylestradiol	O
2	O
µg	O
tablets	O
respectively	O
.	O

One	O
was	O
randomly	O
assigned	O
twice	O
at	O
different	O
centres	O
(	O
second	O
randomisation	O
was	O
excluded	O
)	O
,	O
and	O
three	O
had	O
major	O
eligibility	O
violations	O
,	O
leaving	O
600	O
children	O
assigned	O
to	O
routine	O
laboratory	O
and	O
606	O
to	O
clinically	O
driven	O
monitoring	O
,	O
and	O
397	O
to	O
group	O
A	O
,	O
404	O
to	O
group	O
B	O
,	O
and	O
405	O
to	O
group	O
C	O
(	O
figure	O
1	O
)	O
.	O

Effects	O
on	O
11-year	O
mortality	O
and	O
morbidity	O
of	O
lowering	O
LDL	O
cholesterol	O
with	O
simvastatin	O
for	O
about	O
5	O
years	O
in	O
20	O
536	O
high-risk	O
individuals	O
:	O
a	O
randomised	O
controlled	O
trial	O

All	O
participants	O
’	O
parents	O
gave	O
written	O
informed	O
consent	O
.	O

Methods	O
Study	O
design	O
This	O
was	O
a	O
24-week	O
,	O
dose-ranging	O
,	O
multicentre	B-Settings_Multicenter
,	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
,	O
active-controlled	O
study	O
and	O
was	O
approved	O
by	O
all	O
responsible	O
independent	O
ethics	O
committees	O
.	O

Oxandrolone	O
could	O
,	O
therefore	O
,	O
be	O
offered	O
as	O
an	O
alternative	O
to	O
late	O
pubertal	O
induction	O
for	O
increasing	O
final	O
height	O
in	O
Turner	O
’	O
s	O
syndrome	O
.	O

Continuous	O
variables	O
are	O
reported	O
as	O
means±SEM	O
.	O

Sample	O
size	O
determination	O
We	O
planned	O
to	O
randomize	O
560	B-Sample_Size_Required
patients	O
to	O
one	O
of	O
three	O
dose	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
of	I-Design_Parallel_Group
quilizumab	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
in	O
a	O
1:1:1:1	B-Randomization_Ratio
ratio	O
(	O
140	O
patients	O
per	O
group	O
)	O
.	O

Treatment	O
effects	O
for	O
the	O
primary	O
end	O
points	O
were	O
evaluated	O
using	O
the	O
Pitman	O
permutation	O
(	O
new	O
DUs	O
)	O
and	O
log-rank	O
test	O
with	O
asymptotic	O
approximation	O
(	O
time	O
to	O
healing	O
of	O
the	O
cardinal	O
ulcer	O
)	O
.	O

Recruitment	O
and	O
randomisation	O
of	O
participants	O
Participants	O
were	O
recruited	O
between	O
November	O
2006	O
and	O
January	O
2010	O
(	O
end	O
of	O
extended	O
recruitment	O
period	O
)	O
from	O
university	B-Settings_Multicenter
podiatry	I-Settings_Multicenter
school	I-Settings_Multicenter
clinics	I-Settings_Multicenter
,	I-Settings_Multicenter
NHS	I-Settings_Multicenter
podiatry	I-Settings_Multicenter
clinics	I-Settings_Multicenter
,	I-Settings_Multicenter
and	I-Settings_Multicenter
primary	I-Settings_Multicenter
care	I-Settings_Multicenter
.	O

The	O
most	O
common	O
modification	O
(	O
14	O
clinically	O
driven	O
,	O
13	O
routine	O
laboratory	O
monitoring	O
)	O
was	O
to	O
stop	O
(	O
on	O
four-drug	O
regimen	O
)	O
or	O
substitute	O
zidovudine	O
.	O

This	O
study	O
is	O
registered	O
,	O
ISRCTN25765518	O
.	O

Pyoderma	O
gangrenosum	O
specific	O
global	O
treatment	O
response—to	O
assess	O
treatment	O
response	O
we	O
used	O
a	O
seven	O
point	O
Likert	O
scale	O
ranging	O
from	O
completely	O
clear	O
through	O
to	O
worse	O
(	O
assessed	O
by	O
clinicians	O
and	O
participants	O
and	O
from	O
digital	O
images	O
for	O
blinded	O
assessment	O
)	O
.	O

Specific	O
IgE	O
was	O
measured	O
for	O
the	O
following	O
allergens	O
:	O
cat	O
,	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
Dermatophagoides	O
farinae	O
,	O
HDM	O
Dermatophagoides	O
pteronyssinus	O
,	O
ragweed	O
,	O
aspergillus	O
,	O
timothy	O
grass	O
,	O
bermuda	O
grass	O
,	O
oak	O
,	O
birch	O
,	O
plantain	O
,	O
and	O
orchard	O
grass	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
difference	O
between	O
the	O
salicylic	O
acid	O
and	O
cryotherapy	O
groups	O
in	O
self	O
reported	O
clearance	O
of	O
plantar	O
warts	O
at	O
six	O
months	O
(	O
29/95	O
(	O
31	O
%	O
)	O
v	O
33/98	O
(	O
34	O
%	O
)	O
,	O
difference	O
–3.15	O
%	O
(	O
–16.31	O
to	O
10.02	O
)	O
,	O
P=0.64	O
)	O
or	O
in	O
time	O
to	O
clearance	O
(	O
hazard	O
ratio	O
0.80	O
(	O
95	O
%	O
CI	O
0.51	O
to	O
1.25	O
)	O
,	O
P=0.33	O
)	O
.	O

The	O
liquid	O
nitrogen	O
was	O
applied	O
with	O
a	O
spray	O
(	O
method	O
of	O
choice	O
if	O
available	O
)	O
or	O
a	O
probe	O
.	O

As	O
a	O
result	O
,	O
the	O
cumulative	O
proportions	O
of	O
participants	O
who	O
had	O
major	O
vascular	O
events	O
diverged	O
throughout	O
the	O
in-trial	O
period	O
,	O
and	O
this	O
separation	O
then	O
persisted	O
roughly	O
unchanged	O
throughout	O
the	O
post-trial	O
period	O
(	O
figure	O
3	O
)	O
.	O

At	O
week	O
24	O
,	O
more	O
than	O
50	O
%	O
of	O
patients	O
in	O
both	O
groups	O
had	O
healing	O
of	O
the	O
cardinal	O
ulcer	O
maintained	O
for	O
at	O
least	O
12	O
weeks	O
.	O

When	O
a	O
fixed	O
effect	O
meta-analysis	O
of	O
the	O
two	O
studies	O
was	O
performed	O
,	O
the	O
differences	O
and	O
95	O
%	O
confidence	O
intervals	O
were	O
identical	O
to	O
those	O
shown	O
in	O
Table	O
2	O
for	O
the	O
pooled	O
analyses	O
of	O
upper	O
GI	O
,	O
gastric	O
,	O
and	O
duodenal	O
ulcers	O
without	O
evidence	O
of	O
heterogeneity	O
(	O
I2=0	O
for	O
upper	O
GI	O
,	O
gastric	O
,	O
and	O
duodenal	O
ulcer	O
analyses	O
)	O
.	O

Most	O
patients	O
were	O
children	O
(	O
246/326	O
,	O
75.5	O
%	O
)	O
aged	O
1-13.5	O
,	O
median	O
2	O
years	O
(	O
table	O
1	O
)	O
.	O

In	O
the	O
Ca+D	O
and	O
Ca	O
groups	O
,	O
the	O
response	O
to	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
.	O

Health	O
related	O
quality	O
of	O
life—assessed	O
using	O
the	O
dermatology	O
life	O
quality	O
index	O
and	O
European	O
quality	O
of	O
life-5	O
dimensions	O
,	O
three	O
levels	O
(	O
EQ-5D-3L	O
and	O
EQ	O
VAS	O
)	O
.	O

Participants	O
Patients	O
aged	O
≥1	O
year	O
admitted	O
to	O
hospital	O
with	O
confirmed	O
severe	O
influenza	O
.	O

ATA	O
incidence	O
for	O
all	O
dosing	O
groups	O
was	O
1.6	O
%	O
(	O
7	O
of	O
427	O
quilizumab-dosed	O
patients	O
)	O
.	O

Plethysmographic	O
data	O
and	O
net	O
t-PA	O
release	O
were	O
determined	O
as	O
described	O
previously	O
,	O
as	O
the	O
product	O
of	O
the	O
infused	O
forearm	O
plasma	O
ﬂow	O
(	O
based	O
on	O
the	O
mean	O
haematocrit	O
and	O
the	O
infused	O
FBF	O
)	O
and	O
the	O
concentration	O
difference	O
between	O
the	O
infused	O
(	O
[	O
t-PA	O
]	O
inf	O
)	O
and	O
non-infused	O
(	O
[	O
t-PA	O
]	O
non-inf	O
)	O
arms	O
:	O
estimated	O
net	O
t-PA	O
release=FBF×	O
(	O
1−Hct	O
)	O
×	O
(	O
[	O
tPA	O
]	O
inf−	O
[	O
tPA	O
]	O
non-inf	O
)	O
.	O

The	O
primary	O
objectives	O
were	O
to	O
evaluate	O
the	O
effect	O
of	O
bosentan	O
on	O
the	O
reduction	O
of	O
new	O
DUs	O
and	O
healing	O
of	O
DUs	O
in	O
patients	O
with	O
SSc	O
.	O

Results	O
106	B-Sample_Size_Actual_at_Enrollment
participants	O
were	O
recruited	O
,	O
of	O
whom	O
14	B-Sample_Size_Calculation_Dropout_Rate_Value
withdrew	I-Sample_Size_Calculation_Dropout_Rate_Value
and	O
82/92	O
reached	O
final	O
height	O
.	O

For	O
patients	O
known	O
to	O
be	O
alive	O
at	O
6	O
months	O
,	O
but	O
with	O
an	O
unknown	O
OHS	O
,	O
we	O
used	O
the	O
level	O
of	O
function	O
recorded	O
on	O
the	O
7-day	O
form	O
(	O
ie	O
,	O
measured	O
at	O
7	O
days	O
or	O
before	O
discharge	O
from	O
hospital	O
)	O
to	O
impute	O
6-month	O
functional	O
status	O
.	O

Secondary	O
efficacy	O
criteria	O
included	O
(	O
i	O
)	O
gait	O
velocity	O
(	O
m/s	O
)	O
and	O
cadence	O
(	O
steps/min	O
)	O
;	O
(	O
ii	O
)	O
motor	O
handicap	O
,	O
assessed	O
as	O
the	O
overall	O
UPDRS	O
motor	O
score	O
and	O
its	O
axial	O
subscore	O
(	O
the	O
sum	O
of	O
items	O
18	O
(	O
speech	O
)	O
,	O
19	O
(	O
facial	O
expression	O
)	O
,	O
22	O
(	O
neck	O
rigidity	O
)	O
,	O
27	O
(	O
arising	O
from	O
a	O
chair	O
)	O
,	O
28	O
(	O
posture	O
)	O
,	O
29	O
(	O
gait	O
)	O
and	O
30	O
(	O
postural	O
stability	O
)	O
)	O
;	O
(	O
iii	O
)	O
LID	O
,	O
assessed	O
as	O
the	O
overall	O
Dyskinesia	O
Rating	O
Scale	O
score	O
and	O
its	O
axial	O
subscore	O
;	O
(	O
iv	O
)	O
hypertonia	O
of	O
axial	O
flexors	O
and	O
extensors	O
,	O
assessed	O
as	O
the	O
mean	O
work	O
(	O
in	O
joules	O
)	O
performed	O
during	O
10	O
passive	O
trunk	O
movements	O
at	O
30°/s	O
on	O
a	O
CON-TREX	O
isokinetic	O
dynamometer	O
(	O
CMV	O
AG	O
,	O
Dübendorf	O
,	O
Switzerland	O
)	O
;	O
(	O
v	O
)	O
trunk	O
flexor	O
and	O
extensor	O
strength	O
,	O
measured	O
as	O
the	O
mean	O
work	O
(	O
in	O
joules	O
)	O
performed	O
over	O
three	O
repetitions	O
at	O
30°/s	O
in	O
active	O
flexion	O
and	O
extension	O
mode	O
on	O
the	O
isokinetic	O
dynamometer	O
.	O

Design	O
Randomised	B-Randomization_Type_Simple
controlled	O
trial	O
.	O

Data	O
analysis	O
Endpoints	O
The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
proportion	O
of	O
all	O
patients	O
with	O
no	O
detectable	O
viral	O
RNA	O
by	O
RT-PCR	O
in	O
a	O
combined	O
nasal	O
and	O
throat	O
swab	O
sample	O
on	O
day	O
five	O
.	O

Statistical	O
analysis	O
Descriptive	O
analyses	O
and	O
the	O
Shapiro-Wilk	O
test	O
were	O
used	O
to	O
check	O
whether	O
data	O
were	O
normally	O
distributed	O
.	O

The	O
benefits	O
and	O
harms	O
of	O
intravenous	O
thrombolysis	O
with	O
recombinant	O
tissue	O
plasminogen	O
activator	O
within	O
6	O
h	O
of	O
acute	O
ischaemic	O
stroke	O
(	O
the	O
third	O
international	O
stroke	O
trial	O
[	O
IST-3	O
]	O
)	O
:	O
a	O
randomised	O
controlled	O
trial	O

In	O
a	O
recent	O
small	O
placebo-controlled	O
study	O
,	O
atorvastatin	O
reduced	O
the	O
number	O
of	O
new	O
DUs	O
in	O
association	O
with	O
improvement	O
in	O
markers	O
of	O
endothelial	O
function	O
.	O

By	O
decreasing	O
NMDA-dependant	O
glutamatergic	O
hyperactivity	O
,	O
memantine	O
reduces	O
akinesia	O
and	O
rigidity	O
in	O
the	O
MPTP	O
(	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	O
)	O
rat	O
model	O
and	O
improves	O
locomotion	O
in	O
rats	O
treated	O
with	O
reserpine	O
and	O
α-methyl-p-tyrosine	O
.	O

Quilizumab	O
may	O
reset	O
the	O
IgE	O
repertoire	O
by	O
targeting	O
IgE	O
production	O
and	O
provide	O
a	O
more	O
sustained	O
effect	O
with	O
a	O
lower	O
dose	O
frequency	O
then	O
omalizumab	O
.	O

The	O
1	B-Randomization_Ratio
:	I-Randomization_Ratio
1	I-Randomization_Ratio
assignment	O
sequence	O
(	O
based	O
on	O
a	B-Randomization_Sequence_Generation_Method
computer	I-Randomization_Sequence_Generation_Method
random-number	I-Randomization_Sequence_Generation_Method
generator	I-Randomization_Sequence_Generation_Method
)	O
was	O
produced	O
by	O
our	O
Department	B-Randomization_Personnel
of	I-Randomization_Personnel
Biostatistics	I-Randomization_Personnel
.	O

Missing	O
values	O
were	O
imputed	O
using	O
the	O
last-observation-carried-forward	O
(	O
LOCF	O
)	O
approach	O
,	O
as	O
prespecified	O
in	O
the	O
statistical	O
analysis	O
plan	O
.	O

Treatment	O
Patients	O
were	O
randomised	O
to	O
receive	O
double	B-Design_Parallel_Group
or	I-Design_Parallel_Group
standard	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
oseltamivir	I-Design_Parallel_Group
based	O
on	O
a	B-Randomization_Sequence_Generation_Method
computer	I-Randomization_Sequence_Generation_Method
generated	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
that	O
was	O
stratified	B-Randomization_Type_Stratified
by	O
site	B-Randomization_Stratified_Criteria
and	O
age	B-Randomization_Stratified_Criteria
group	I-Randomization_Stratified_Criteria
.	O

The	O
apparent	O
reduction	O
in	O
deaths	O
attributed	O
to	O
other	O
medical	O
causes	O
in	O
participants	O
originally	O
allocated	O
simvastatin	O
(	O
200	O
[	O
2·3	O
%	O
]	O
vs	O
239	O
[	O
2·8	O
%	O
]	O
)	O
was	O
only	O
marginally	O
significant	O
(	O
p=0·03	O
)	O
and	O
involved	O
no	O
material	O
differences	O
in	O
deaths	O
due	O
to	O
renal	O
or	O
hepatic	O
disease	O
and	O
only	O
a	O
non-significant	O
difference	O
in	O
a	O
miscellaneous	O
group	O
of	O
other	O
non-vascular	O
causes	O
.	O

A	O
trial	O
of	O
that	O
size	O
could	O
detect	O
a	O
clinically	O
worthwhile	O
net	O
benefit	O
of	O
as	O
little	O
as	O
3	O
%	O
absolute	O
difference	O
in	O
the	O
primary	O
outcome	O
(	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
,	O
α=0·05	O
)	O
.	O

Results	O
of	O
the	O
pooled	O
analysis	O
of	O
the	O
two	O
studies	O
are	O
also	O
shown	O
in	O
Table	O
2	O
.	O

In	O
view	O
of	O
a	O
possible	O
antagonistic	O
effect	O
of	O
memantine	O
on	O
nicotinic	O
acetylcholine	O
receptors	O
,	O
drowsiness	O
was	O
assessed	O
on	O
the	O
Epworth	O
Sleepiness	O
Scale	O
.	O

Oral	O
oxandrolone	O
(	O
SPA	O
,	O
Milan	O
,	O
Italy	O
)	O
was	O
given	O
at	O
0.05	O
mg/kg/day	O
,	O
with	O
a	O
maximum	O
daily	O
dose	O
of	O
2.5	O
mg	O
.	O

No	O
clinically	O
relevant	O
change	O
in	O
mean	O
vital	O
sign	O
values	O
was	O
associated	O
with	O
tiotropium	O
Respimat®	O
.	O

Results	O
Patient	O
demographics	O
and	O
study	O
flow	O
1212	O
patients	O
were	O
screened	O
for	O
eligibility	O
and	O
578	B-Sample_Size_Actual_at_Enrollment
adult	O
asthma	O
patients	O
(	O
18–75	O
years	O
old	O
)	O
were	O
enrolled	O
(	O
Fig	O
.	O

Fewer	O
new	O
DUs	O
were	O
observed	O
with	O
bosentan	O
than	O
placebo	O
in	O
all	O
subgroups	O
except	O
among	O
current	O
smokers	O
(	O
table	O
2	O
,	O
subgroup	O
analyses	O
)	O
.	O

Placebo-corrected	O
changes	O
from	O
baseline	O
,	O
RR	O
and	O
HRs	O
from	O
Cox	O
modelling	O
were	O
each	O
reported	O
with	O
95	O
%	O
CIs	O
where	O
appropriate	O
.	O

Of	O
20	B-Sample_Size_Actual_at_Enrollment
536	I-Sample_Size_Actual_at_Enrollment
participants	O
,	O
17	B-Sample_Size_Actual_at_Outcome_Analysis
519	I-Sample_Size_Actual_at_Outcome_Analysis
were	O
still	O
alive	O
at	O
the	O
start	O
of	O
the	O
post-trial	O
follow-up	O
period	O
:	O
8863	O
allocated	O
simvastatin	O
versus	O
8656	O
placebo	O
(	O
ratio	O
1·02	O
;	O
because	O
simvastatin	O
reduced	O
mortality	O
)	O
.	O

To	O
assess	O
the	O
effect	O
of	O
treatment	O
on	O
the	O
primary	O
outcome	O
,	O
the	O
statistical	O
analysis	O
plan	O
predefined	O
a	O
small	O
subset	O
of	O
key	O
prognostic	O
subgroups	O
(	O
figure	O
3	O
)	O
.	O

In	O
addition	O
,	O
time	O
to	O
first	O
new	O
gouty	O
arthritis	O
flare	O
was	O
longer	O
with	O
all	O
canakinumab	O
groups	O
compared	O
with	O
colchicine	O
0.5	O
mg	O
(	O
figure	O
2	O
)	O
and	O
there	O
was	O
a	O
64	O
%	O
to	O
72	O
%	O
reduction	O
in	O
the	O
risk	O
of	O
experiencing	O
at	O
least	O
one	O
flare	O
for	O
canakinumab	O
doses	O
≥50	O
mg	O
versus	O
colchicine	O
at	O
16	O
weeks	O
(	O
HR	O
:	O
0.28–0.36	O
,	O
p≤0.05	O
)	O
(	O
table	O
2	O
)	O
.	O

Oxandrolone	O
supplies	O
In	O
2004	O
and	O
2008	O
,	O
the	O
sole	O
European	O
manufacturer	O
of	O
oxandrolone	O
2.5	O
mg	O
ceased	O
production	O
,	O
resulting	O
in	O
34	O
participants	O
in	O
2004	O
and	O
11	O
in	O
2008	O
temporarily	O
suspending	O
active	O
oxandrolone	O
treatment	O
(	O
mean	O
duration	O
:	O
2004	O
,	O
52	O
days	O
;	O
2008	O
,	O
163	O
days	O
)	O
.	O

The	O
independent	O
data	O
monitoring	O
committee	O
met	O
at	O
least	O
annually	O
to	O
review	O
the	O
unmasked	O
data	O
on	O
major	O
outcome	O
events	O
in	O
the	O
trial	O
,	O
on	O
the	O
background	O
stroke-unit	O
care	O
received	O
by	O
trial	O
patients	O
(	O
to	O
ensure	O
it	O
was	O
equal	O
in	O
both	O
treatment	O
groups	O
)	O
,	O
relevant	O
external	O
data	O
(	O
including	O
updates	O
of	O
the	O
Cochrane	O
systematic	O
review	O
and	O
reports	O
from	O
large-scale	O
registries	O
of	O
rt-PA	O
use	O
)	O
in	O
strict	O
confidence	O
throughout	O
the	O
course	O
of	O
the	O
trial	O
.	O

Patients	O
who	O
required	O
parenteral	O
,	O
oral	O
or	O
inhaled	O
prostanoid	O
treatment	O
during	O
the	O
study	O
were	O
first	O
discontinued	O
from	O
study	O
treatment	O
.	O

Most	O
deaths	O
(	O
15/21	O
,	O
71	O
%	O
)	O
were	O
in	O
patients	O
with	O
avian	O
H5N1	O
virus	O
.	O

Hospital	O
staff	O
completed	O
an	O
early	O
outcome	O
form	O
at	O
7	O
days	O
,	O
death	O
,	O
or	O
hospital	O
discharge	O
,	O
whichever	O
occured	O
first	O
,	O
recording	O
details	O
of	O
events	O
occurring	O
in	O
hospital	O
within	O
7	O
days	O
,	O
details	O
of	O
background	O
treatments	O
given	O
and	O
functional	O
status	O
.	O

Adverse	O
events	O
resulted	O
in	O
a	O
drug	O
being	O
substituted	O
or	O
dropped	O
in	O
five	O
children	O
in	O
group	O
A	O
,	O
28	O
in	O
group	O
B	O
,	O
and	O
26	O
in	O
group	O
C	O
;	O
most	O
changes	O
were	O
zidovudine-related	O
(	O
16	O
in	O
B	O
,	O
20	O
in	O
C	O
;	O
table	O
2	O
)	O
.	O

Only	O
the	O
case	O
of	O
erysipelas	O
was	O
considered	O
to	O
be	O
possibly	O
related	O
to	O
study	O
medication	O
.	O

As	O
such	O
,	O
the	O
intention	O
to	O
treat	O
population	O
was	O
112	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
(	O
59	O
ciclosporin	O
;	O
53	O
prednisolone	O
)	O
.	O

The	O
dose	O
could	O
remain	O
at	O
or	O
be	O
decreased	O
to	O
the	O
starting	O
dose	O
due	O
to	O
intolerance	O
,	O
with	O
possible	O
subsequent	O
increase	O
to	O
the	O
target	O
dose	O
.	O

For	O
patients	O
with	O
missing	O
results	O
on	O
day	O
five	O
,	O
we	O
carried	O
forward	O
the	O
last	O
available	O
results	O
.	O

There	O
was	O
no	O
difference	O
between	O
treatments	O
in	O
healing	O
rate	O
of	O
the	O
cardinal	O
ulcer	O
or	O
secondary	O
end	O
points	O
of	O
pain	O
and	O
disability	O
.	O

Secondary	O
and	O
exploratory	O
end	O
points	O
included	O
:	O
(	O
1	O
)	O
reduction	O
of	O
new	O
DUs	O
and	O
overall	O
DU	O
number	O
(	O
proportions	O
of	O
patients	O
with	O
no	O
new	O
DUs	O
and	O
with	O
each	O
number	O
of	O
new	O
DUs	O
up	O
to	O
week	O
24	O
,	O
time	O
to	O
onset	O
of	O
each	O
number	O
of	O
new	O
DUs	O
up	O
to	O
week	O
24	O
and	O
change	O
from	O
baseline	O
to	O
week	O
24	O
in	O
total	O
number	O
of	O
all	O
DUs	O
)	O
,	O
(	O
2	O
)	O
healing	O
(	O
time	O
to	O
healing	O
of	O
all	O
baseline	O
DUs	O
and	O
of	O
all	O
new	O
DUs	O
through	O
week	O
24	O
,	O
and	O
proportions	O
of	O
patients	O
with	O
healing	O
of	O
all	O
DUs	O
by	O
the	O
end	O
of	O
week	O
24	O
)	O
and	O
(	O
3	O
)	O
pain	O
and	O
disability	O
parameters	O
(	O
changes	O
from	O
baseline	O
to	O
week	O
24	O
:	O
in	O
pain	O
of	O
the	O
cardinal	O
ulcer	O
and	O
overall	O
hand	O
pain	O
assessed	O
on	O
visual	O
analogue	O
scales	O
;	O
hand	O
disability	O
index	O
(	O
an	O
averaged	O
score	O
from	O
the	O
three	O
Health	O
Assessment	O
Questionnaire	O
(	O
HAQ	O
)	O
domains	O
of	O
dressing/grooming	O
,	O
grip	O
and	O
hygiene	O
)	O
;	O
and	O
HAQ	O
disability	O
index	O
)	O
.	O

All	O
p	O
values	O
are	O
two-sided	O
.	O

Randomisation	O
was	O
simple	B-Randomization_Type_Simple
(	O
that	O
is	O
,	O
it	O
was	O
not	O
restricted	O
in	O
any	O
way	O
such	O
as	O
by	O
stratification	O
or	O
blocked	O
allocation	O
with	O
the	O
allocation	O
sequence	O
being	O
computer	O
generated	O
)	O
.	O

Results	O
Mean	O
follow-up	O
during	O
the	O
in-trial	O
period	O
for	O
all	O
randomised	O
participants	O
was	O
5·3	O
years	O
(	O
SD	O
1·2	O
)	O
,	O
and	O
the	O
mean	O
total	O
follow-up	O
for	O
participants	O
who	O
survived	O
to	O
the	O
end	O
of	O
the	O
post-trial	O
period	O
was	O
11·0	O
years	O
(	O
SD	O
0·6	O
)	O
.	O

The	O
relative	O
change	O
in	O
pre-bronchodilator	O
FEV1	O
from	O
baseline	O
was	O
calculated	O
as	O
the	O
absolute	O
change	O
in	O
FEV1	O
(	O
volume	O
in	O
liters	O
)	O
from	O
baseline	O
divided	O
by	O
the	O
FEV1	O
at	O
baseline	O
.	O

Forearm	O
blood	O
flow	O
was	O
measured	O
in	O
both	O
arms	O
by	O
venous	O
occlusion	O
plethysmography	O
with	O
the	O
use	O
of	O
mercury-in-silastic	O
strain	O
gauges	O
.	O

Completeness	O
of	O
nurse	O
visits	O
every	O
4–6	O
weeks	O
and	O
doctor	O
visits	O
every	O
12	O
weeks	O
was	O
more	O
than	O
95	O
%	O
(	O
46	O
531/48	O
461	O
nurse	O
,	O
19	O
088/19	O
765	O
doctor	O
visits	O
)	O
and	O
was	O
similar	O
in	O
all	O
groups	O
.	O

Interpretation	O
More	O
prolonged	O
LDL-lowering	O
statin	O
treatment	O
produces	O
larger	O
absolute	O
reductions	O
in	O
vascular	O
events	O
.	O

Treatment	O
allocation	O
was	O
concealed	O
from	O
the	O
statistician	B-Blinding_Object_Others
and	O
blinded	O
assessors	B-Blinding_Object_Outcome_Assessors
of	O
the	O
digital	O
images	O
until	O
interventions	O
were	O
all	O
assigned	O
and	O
recruitment	O
,	O
data	O
collection	O
,	O
data	O
cleaning	O
,	O
and	O
blind	O
analysis	O
were	O
complete	O
.	O

Overall	O
,	O
adverse	O
events	O
led	O
to	O
the	O
discontinuation	O
of	O
study	O
treatment	O
in	O
15.6	O
%	O
of	O
patients	O
on	O
bosentan	O
and	O
12.2	O
%	O
on	O
placebo	O
.	O

The	O
pathogenesis	O
of	O
DUs	O
is	O
thought	O
to	O
include	O
many	O
of	O
the	O
hallmark	O
processes	O
of	O
critical	O
tissue	O
ischaemia	O
,	O
such	O
as	O
impaired	O
afferent	O
vasomotion	O
,	O
microvascular	O
disruption	O
,	O
reduced	O
venous	O
drainage	O
,	O
increased	O
local	O
platelet	O
activation	O
and	O
increased	O
leucocyte	O
adherence	O
.	O

Randomised	O
groups	O
were	O
compared	O
with	O
Kaplan-Meier	O
plots	O
,	O
log-rank	O
tests	O
,	O
and	O
proportional	O
hazards	O
models	O
,	O
stratified	O
by	O
randomisation	O
stratification	O
factors	O
(	O
including	O
the	O
other	O
factorial	O
)	O
for	O
time-to-event	O
disease	O
progression	O
,	O
ART	O
,	O
and	O
adverse	O
event	O
outcomes	O
,	O
censoring	O
at	O
the	O
earlier	O
of	O
trial	O
closure	O
or	O
last	O
follow-up	O
.	O

Excluding	O
the	O
five	O
patients	O
who	O
either	O
swapped	O
to	O
the	O
alternative	O
trial	O
drug	O
or	O
used	O
both	O
drugs	O
in	O
combination	O
before	O
the	O
six	O
week	O
visit	O
,	O
did	O
not	O
change	O
the	O
overall	O
treatment	O
effect	O
(	O
−0.036	O
,	O
−0.21	O
to	O
0.14	O
;	O
P=0.68	O
)	O
.	O

All	O
scans	O
were	O
sent	O
to	O
the	O
trial	O
centre	O
in	O
Edinburgh	O
for	O
masked	O
central	O
rating	O
of	O
any	O
signs	O
of	O
visible	O
early	O
ischaemia	O
(	O
presence	O
and	O
extent	O
of	O
hypo-attenuation	O
,	O
swelling	O
,	O
hyperattenuated	O
artery	O
)	O
,	O
haemorrhage	O
,	O
and	O
background	O
brain	O
changes	O
(	O
leukoaraiosis	O
,	O
atrophy	O
,	O
prior	O
stroke	O
lesions	O
,	O
non-stroke	O
lesions	O
)	O
with	O
validated	O
rating	O
methods	O
.	O

Patients	O
with	O
no	O
valid	O
assessment	O
post	O
baseline	O
(	O
three	O
patients	O
on	O
bosentan	O
,	O
one	O
on	O
placebo	O
)	O
were	O
excluded	O
from	O
the	O
main	O
analysis	O
.	O

Mean	O
CD4	O
percentage	O
change	O
did	O
not	O
differ	O
between	O
ART	O
groups	O
at	O
week	O
72	O
(	O
16·5	O
%	O
[	O
SD	O
8·6	O
]	O
vs	O
17·1	O
%	O
[	O
8·5	O
]	O
vs	O
17·3	O
%	O
[	O
8·0	O
]	O
,	O
p=0·33	O
)	O
or	O
week	O
144	O
(	O
p=0·69	O
)	O
,	O
but	O
four-drug	O
groups	O
(	O
B	O
,	O
C	O
)	O
were	O
superior	O
to	O
three-drug	O
group	O
A	O
at	O
week	O
36	O
(	O
12·4	O
%	O
[	O
7·2	O
]	O
vs	O
14·1	O
%	O
[	O
7·1	O
]	O
vs	O
14·6	O
%	O
[	O
7·3	O
]	O
,	O
p	O
<	O
0·0001	O
)	O
.	O

We	O
excluded	O
patients	O
with	O
pustular	O
or	O
granulomatous	O
variants	O
of	O
pyoderma	O
gangrenosum	O
(	O
as	O
they	O
may	O
respond	O
differently	O
to	O
treatment	O
,	O
and	O
measurement	O
of	O
a	O
single	O
ulcer	O
was	O
not	O
possible	O
)	O
;	O
patients	O
receiving	O
oral	O
prednisolone	O
,	O
ciclosporin	O
,	O
or	O
intravenous	O
immunoglobulin	O
in	O
the	O
previous	O
month	O
;	O
patients	O
participating	O
in	O
another	O
clinical	O
trial	O
;	O
women	O
who	O
were	O
pregnant	O
,	O
lactating	O
,	O
or	O
at	O
risk	O
of	O
pregnancy	O
;	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
either	O
of	O
the	O
study	O
treatments	O
;	O
patients	O
with	O
clinically	O
important	O
renal	O
impairment	O
or	O
other	O
pretreatment	O
findings	O
that	O
would	O
result	O
in	O
the	O
investigator	O
not	O
using	O
either	O
of	O
the	O
study	O
drugs	O
;	O
patients	O
with	O
malignant	O
or	O
premalignant	O
disease	O
;	O
patients	O
with	O
a	O
concurrent	O
medical	O
condition	O
for	O
which	O
treatments	O
might	O
interfere	O
with	O
ongoing	O
treatment	O
or	O
cause	O
harm	O
;	O
and	O
patients	O
taking	O
rosuvastatin	O
or	O
those	O
who	O
had	O
received	O
a	O
live	O
vaccine	O
in	O
the	O
two	O
weeks	O
before	O
randomisation	O
.	O

The	O
NNRTI	O
(	O
nevirapine	O
or	O
efavirenz	O
)	O
was	O
chosen	O
by	O
clinicians	O
according	O
to	O
local	O
availability	O
and	O
age	O
.	O

Each	O
treatment	O
was	O
administered	O
for	O
4	O
weeks	O
,	O
without	O
washout	O
between	O
treatment	O
periods	O
.	O

Results	O
Consistent	O
with	O
effective	O
conjugation	O
of	O
circulating	O
TNF-α	O
,	O
plasma	O
TNF-α	O
concentrations	O
increased	O
in	O
all	O
patients	O
following	O
etanercept	O
(	O
254±15	O
vs	O
0.12±0.02	O
pg/ml	O
;	O
p	O
<	O
0.0001	O
)	O
,	O
but	O
not	O
saline	O
infusion	O
.	O

No	O
important	O
differences	O
in	O
tolerability	O
were	O
found	O
.	O

A	O
minority	O
of	O
patients	O
,	O
76/326	O
(	O
23.3	O
%	O
)	O
had	O
been	O
prescribed	O
oseltamivir	O
or	O
zanamivir	O
before	O
enrolment	O
,	O
and	O
most	O
231/326	O
(	O
70.8	O
%	O
)	O
had	O
received	O
antibiotics	O
.	O

Results	O
Baseline	O
demographics	O
and	O
disease	O
characteristics	O
Between	O
December	O
2008	O
and	O
August	O
2009	O
,	O
432	B-Sample_Size_Actual_at_Enrollment
patients	O
from	O
75	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
16	B-Settings_Location
countries	I-Settings_Location
were	O
randomised	O
to	O
treatment	O
;	O
391	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
(	O
90.5	O
%	O
)	O
completed	O
the	O
study	O
(	O
figure	O
1	O
)	O
.	O

Despite	O
this	O
range	O
of	O
therapeutic	O
choices	O
,	O
at	O
least	O
40	O
%	O
of	O
patients	O
with	O
asthma	O
have	O
poorly	O
controlled	O
disease	O
.	O

In	O
these	O
studies	O
,	O
quilizumab	O
reduced	O
serum	O
total	O
IgE	O
by	O
approximately	O
25	O
%	O
.	O

Response	O
rates	O
to	O
mailed	O
questionnaires	O
and	O
from	O
family	O
doctors	O
during	O
the	O
post-trial	O
period	O
were	O
high	O
and	O
did	O
not	O
differ	O
by	O
previous	O
statin	O
allocation	O
(	O
table	O
1	O
)	O
.	O

One	O
patient	O
was	O
reported	O
with	O
alcohol	O
abuse	O
and	O
panic	O
attack	O
,	O
which	O
led	O
to	O
hospitalisation	O
.	O

All	O
patients	O
received	O
five	O
days	O
of	O
oseltamivir	O
.	O

The	O
rates	O
of	O
asthma	O
exacerbations	O
were	O
compared	O
between	O
study	O
groups	O
using	O
a	O
Poisson	O
regression	O
with	O
overdispersion	O
model	O
,	O
including	O
terms	O
for	O
periostin	O
status	O
(	O
<	O
50	O
,	O
≥50	O
ng/mL	O
)	O
,	O
number	O
of	O
prior	O
exacerbations	O
(	O
1	O
,	O
>	O
1	O
)	O
,	O
and	O
IgE	O
level	O
(	O
<	O
200	O
,	O
≥200	O
IU/mL	O
)	O
.	O

A	O
diagnosis	O
of	O
asthma	O
confirmed	O
at	O
Visit	O
1	O
was	O
required	O
,	O
with	O
bronchodilator	O
reversibility	O
(	O
15–30	O
minutes	O
after	O
400	O
μg	O
salbutamol	O
)	O
of	O
≥12	O
%	O
and	O
≥200	O
mL	O
.	O

Safety	O
criteria	O
There	O
were	O
no	O
significant	O
safety	O
differences	O
between	O
the	O
memantine	O
and	O
placebo	O
groups	O
.	O

Eligible	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
the	O
four	O
treatment	O
sequences	O
at	O
Visit	O
2	O
(	O
Figure	O
1	O
)	O
.	O

Participants	O
were	O
aged	O
18	O
years	O
or	O
more	O
,	O
with	O
a	O
diagnosis	O
of	O
pyoderma	O
gangrenosum	O
made	O
by	O
a	O
recruiting	O
dermatologist	O
.	O

Statistical	O
analysis	O
At	O
the	O
outset	O
of	O
the	O
trial	O
in	O
2000	O
,	O
we	O
estimated	O
that	O
,	O
among	O
the	O
type	O
of	O
patients	O
likely	O
to	O
be	O
recruited	O
at	O
the	O
time	O
,	O
to	O
detect	O
both	O
an	O
absolute	O
difference	O
of	O
10	O
%	O
in	O
the	O
proportion	O
of	O
patients	O
alive	O
and	O
independent	O
at	O
6	O
months	O
after	O
treatment	O
and	O
to	O
have	O
sufficient	O
power	O
to	O
permit	O
reliable	O
analyses	O
of	O
the	O
prespecified	O
subgroups	O
,	O
a	O
sample	O
of	O
6000	O
patients	O
would	O
be	O
needed	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
a	O
definitely	O
visible	O
ischaemic	O
lesion	O
(	O
vs	O
only	O
possible	O
or	O
no	O
early	O
ischaemic	O
change	O
)	O
on	O
baseline	O
imaging	O
rose	O
with	O
time	O
(	O
test	O
for	O
linear	O
trend	O
p=0·0045	O
)	O
.	O

Peripheral	O
oedema	O
and	O
elevated	O
aminotransferases	O
were	O
associated	O
with	O
bosentan	O
treatment	O
.	O

Overall	O
,	O
62	O
(	O
32	O
%	O
)	O
of	O
the	O
patients	O
had	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
six	O
months—29/95	O
(	O
31	O
%	O
)	O
of	O
patients	O
in	O
the	O
salicylic	O
acid	O
group	O
and	O
33/98	O
(	O
34	O
%	O
)	O
in	O
the	O
cryotherapy	O
group	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
(	O
difference	O
–3.15	O
%	O
(	O
–16.31	O
to	O
10.02	O
)	O
,	O
P=0.64	O
)	O
.	O

Endpoints	O
and	O
statistical	O
analysis	O
The	O
main	O
comparisons	O
entail	O
log-rank	O
analyses	O
of	O
the	O
first	O
post-randomisation	O
occurrence	O
of	O
particular	O
events	O
during	O
the	O
in-trial	O
period	O
(	O
defined	O
as	O
events	O
occurring	O
up	O
to	O
Nov	O
11	O
,	O
2001	O
)	O
and	O
during	O
the	O
post-trial	O
period	O
(	O
defined	O
as	O
events	O
occurring	O
from	O
Nov	O
11	O
,	O
2001	O
,	O
until	O
March	O
31	O
,	O
2007	O
)	O
among	O
all	O
those	O
originally	O
allocated	O
40	O
mg	O
simvastatin	O
daily	O
versus	O
all	O
those	O
allocated	O
matching	O
placebo	O
tablets	O
(	O
ie	O
,	O
intention-to-treat	O
analyses	O
)	O
.	O

Background	O
Currently	O
,	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
are	O
the	O
de	O
facto	O
first-line	O
therapy	O
for	O
the	O
management	O
of	O
poorly	O
controlled	O
,	O
persistent	O
asthma	O
.	O

The	O
trial	O
was	O
conducted	O
in	O
full	O
conformance	O
with	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
E6	O
guidelines	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
or	O
laws	O
and	O
regulations	O
of	O
the	O
country	O
where	O
the	O
research	O
was	O
conducted	O
,	O
whichever	O
afforded	O
greater	O
protection	O
to	O
the	O
individual	O
.	O

A	O
further	O
decrease	O
of	O
14	O
%	O
(	O
[	O
0–26	O
]	O
;	O
p=0·05	O
)	O
was	O
recorded	O
in	O
the	O
first	O
post-trial	O
year	O
in	O
patients	O
originally	O
allocated	O
simvastatin	O
,	O
but	O
little	O
difference	O
was	O
seen	O
between	O
treatment	O
groups	O
thereafter	O
.	O

SITAR	O
transforms	O
individual	O
growth	O
curves	O
so	O
that	O
they	O
become	O
essentially	O
the	O
same	O
as	O
each	O
other	O
and	O
,	O
when	O
superimposed	O
,	O
define	O
the	O
average	O
summary	O
curve	O
.	O

In	O
addition	O
,	O
when	O
the	O
Cochran–Mantel–Haenszel	O
analysis	O
was	O
re-run	O
with	O
study	O
(	O
REDUCE-1	O
or	O
-2	O
)	O
included	O
in	O
the	O
model	O
,	O
the	O
P	O
values	O
for	O
comparisons	O
of	O
all	O
three	O
end	O
points	O
remained	O
<	O
0.0001	O
.	O

In	O
clinical	O
practice	O
,	O
physicians	O
and	O
patients	O
are	O
concerned	O
about	O
preventing	O
ulcers	O
,	O
whether	O
they	O
are	O
gastric	O
or	O
duodenal	O
,	O
and	O
many	O
clinical	O
trials	O
use	O
this	O
primary	O
end	O
point	O
.	O

In	O
addition	O
,	O
post	O
hoc	O
subgroup	O
analysis	O
included	O
use	O
of	O
low-dose	O
aspirin	O
alone	O
,	O
and	O
presence	O
or	O
absence	O
of	O
erosions	O
at	O
screening	O
endoscopy	O
.	O

Nine	O
participants	O
(	O
8	O
%	O
)	O
increased	O
their	O
dose	O
of	O
randomised	O
drug	O
during	O
the	O
trial	O
:	O
four	O
in	O
the	O
prednisolone	O
group	O
,	O
with	O
increases	O
ranging	O
from	O
0.067	O
mg/kg	O
daily	O
to	O
0.6	O
mg/kg	O
daily	O
;	O
and	O
five	O
in	O
the	O
ciclosporin	O
group	O
,	O
with	O
increases	O
ranging	O
from	O
0.36	O
mg/kg	O
daily	O
to	O
0.98	O
mg/kg	O
daily	O
.	O

This	O
trial	O
is	O
registered	O
,	O
ISRCTN24791884	O
.	O

The	O
primary	O
end	O
point	O
for	O
REDUCE-2	O
was	O
upper	O
GI	O
(	O
gastric	O
or	O
duodenal	O
)	O
ulcers	O
identified	O
at	O
endoscopy	O
during	O
the	O
24-week	O
study	O
period	O
,	O
with	O
three	O
secondary	O
end	O
points	O
:	O
gastric	O
ulcers	O
,	O
duodenal	O
ulcers	O
,	O
and	O
GI	O
complications	O
.	O

Laboratory	O
tests	O
identified	O
increased	O
aminotransferases	O
to	O
>	O
3×ULN	O
in	O
10/95	O
(	O
10.5	O
%	O
)	O
patients	O
on	O
bosentan	O
(	O
which	O
included	O
one	O
patient	O
with	O
an	O
elevation	O
to	O
>	O
8×ULN	O
)	O
and	O
1/88	O
(	O
1.1	O
%	O
)	O
patients	O
on	O
placebo	O
.	O

Baseline	O
values	O
were	O
those	O
nearest	O
to	O
but	O
before	O
and	O
within	O
42	O
days	O
of	O
randomisation	O
.	O

Study	O
assessments	O
Spirometric	O
lung	O
function	O
tests	O
were	O
conducted	O
at	O
all	O
in-clinic	O
visits	O
(	O
Visits	O
1–6	O
)	O
.	O

For	O
platelet	O
expression	O
of	O
P-selectin	O
7500	O
events	O
were	O
collected	O
in	O
the	O
platelet	O
gate	O
.	O

The	O
densitometer	O
had	O
a	O
short-term	O
in	O
vivo	O
precision	O
of	O
6.4	O
%	O
for	O
areal	O
bone	O
density	O
at	O
the	O
distal	O
radius	O
and	O
ulna	O
,	O
and	O
7.2	O
%	O
at	O
the	O
proximal	O
1/3	O
radius	O
and	O
ulna	O
,	O
and	O
a	O
long-term	O
in	O
vitro	O
precision	O
of	O
1.1	O
%	O
.	O

We	O
identified	O
this	O
outcome	O
as	O
the	O
most	O
important	O
of	O
the	O
secondary	O
outcomes	O
.	O

Relative	O
changes	O
from	O
baseline	O
in	O
FEV1	O
compared	O
to	O
placebo	O
were	O
3.8	O
%	O
(	O
90	O
%	O
CI	O
:	O
−1.2	O
to	O
8.9	O
,	O
p	O
=	O
0.21	O
)	O
at	O
Week	O
12	O
and	O
5.6	O
%	O
(	O
90	O
%	O
CI	O
:	O
0.6	O
to	O
10.6	O
,	O
p	O
=	O
0.07	O
)	O
at	O
Week	O
36	O
in	O
the	O
150	O
mg	O
Q	O
treatment	O
arm	O
;	O
2.2	O
%	O
(	O
90	O
%	O
CI	O
:	O
−2.8	O
to	O
7.2	O
,	O
p	O
=	O
0.48	O
)	O
at	O
Week	O
12	O
and	O
0.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−5.0	O
to	O
5.1	O
,	O
p	O
=	O
0.98	O
)	O
at	O
Week	O
36	O
in	O
the	O
450	O
mg	O
Q	O
arm	O
;	O
and	O
1.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−3.9	O
to	O
6.1	O
,	O
p	O
=	O
0.72	O
)	O
at	O
Week	O
12	O
and	O
0.1	O
%	O
(	O
90	O
%	O
CI	O
:	O
−4.9	O
to	O
5.2	O
,	O
p	O
=	O
0.96	O
)	O
at	O
Week	O
36	O
in	O
the	O
300	O
mg	O
M	O
arm	O
(	O
Fig	O
.	O

Participants	O
Girls	O
with	O
Turner	O
’	O
s	O
syndrome	O
aged	O
7-13	O
years	O
at	O
recruitment	O
,	O
receiving	O
recombinant	O
growth	O
hormone	O
therapy	O
(	O
10	O
mg/m2/week	O
)	O
.	O

The	O
large	O
numbers	O
of	O
incident	O
cancers	O
recorded	O
during	O
the	O
combined	O
in-trial	O
and	O
post-trial	O
periods	O
allow	O
reliable	O
assessment	O
of	O
the	O
effects	O
of	O
a	O
substantial	O
5-year	O
reduction	O
in	O
cholesterol	O
on	O
11-year	O
risks	O
of	O
the	O
commoner	O
types	O
of	O
cancer	O
.	O

CD4	O
benefits	O
from	O
four-drug	O
induction	O
were	O
not	O
durable	O
,	O
but	O
three-NRTI	O
long-term	O
maintenance	O
was	O
immunologically	O
and	O
clinically	O
similar	O
to	O
NNRTI-based	O
ART	O
and	O
could	O
be	O
valuable	O
during	O
tuberculosis	O
co-treatment	O
.	O

Participants	O
were	O
advised	O
to	O
discuss	O
with	O
their	O
doctors	O
,	O
in	O
light	O
of	O
those	O
results	O
,	O
whether	O
non-trial	O
statin	O
treatment	O
should	O
be	O
prescribed	O
(	O
and	O
study	O
treatment	O
stopped	O
)	O
.	O

The	O
third	O
International	O
Stroke	O
Trial	O
(	O
IST-3	O
)	O
sought	O
to	O
determine	O
whether	O
a	O
wider	O
range	O
of	O
patients	O
might	O
benefit	O
up	O
to	O
6	O
h	O
from	O
stroke	O
onset	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
,	O
safety	O
,	O
and	O
pharmacokinetics	O
of	O
quilizumab	O
after	O
36	O
weeks	O
of	O
treatment	O
in	O
adults	O
with	O
allergic	O
asthma	O
inadequately	O
controlled	O
despite	O
high-dose	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
and	O
a	O
second	O
controller	O
.	O

These	O
previous	O
reports	O
included	O
limited	O
numbers	O
of	O
major	O
vascular	O
events	O
,	O
incident	O
cancers	O
,	O
and	O
non-vascular	O
deaths	O
during	O
prolonged	O
post-trial	O
follow-up	O
,	O
making	O
reliable	O
assessment	O
of	O
persistence	O
of	O
benefit	O
or	O
emergence	O
of	O
any	O
hazard	O
difficult	O
.	O

One	O
level	O
teaspoon	O
of	O
powdered	O
limestone	O
(	O
approximately	O
3.5	O
g=938	O
mg	O
of	O
elemental	O
calcium	O
)	O
was	O
mixed	O
with	O
the	O
child	O
's	O
food	O
or	O
porridge	O
twice	O
daily	O
.	O

After	O
a	O
30-day	O
dose	O
titration	O
phase	O
(	O
with	O
an	O
increase	O
of	O
5	O
mg	O
of	O
memantine	O
per	O
week	O
or	O
a	O
placebo	O
)	O
,	O
the	O
patients	O
received	O
a	B-Design_Parallel_Group
daily	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
(	I-Design_Parallel_Group
at	I-Design_Parallel_Group
7:00	I-Design_Parallel_Group
)	I-Design_Parallel_Group
of	I-Design_Parallel_Group
20	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
of	I-Design_Parallel_Group
memantine	I-Design_Parallel_Group
(	I-Design_Parallel_Group
ie	I-Design_Parallel_Group
,	I-Design_Parallel_Group
the	I-Design_Parallel_Group
usual	I-Design_Parallel_Group
recommended	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
for	O
a	O
further	O
60	O
days	O
.	O

Conclusions	O
Single	O
canakinumab	O
doses	O
≥50	O
mg	O
or	O
four	O
4-weekly	O
doses	O
provided	O
superior	O
prophylaxis	O
against	O
flares	O
compared	O
with	O
daily	O
colchicine	O
0.5	O
mg.	O

Sensitivity	O
analyses	O
adjusting	O
for	O
additional	O
baseline	O
covariates	O
was	O
consistent	O
with	O
the	O
main	O
result	O
(	O
hazard	O
ratio	O
1.01	O
,	O
95	O
%	O
confidence	O
interval	O
0.57	O
to	O
1.79	O
;	O
P=0.98	O
)	O
,	O
as	O
was	O
censoring	O
the	O
16	O
participants	O
who	O
changed	O
their	O
treatment	O
(	O
hazard	O
ratio	O
0.86	O
,	O
95	O
%	O
confidence	O
interval	O
0.49	O
to	O
1.52	O
;	O
P=0.60	O
)	O
.	O

Similarly	O
,	O
adjusted	O
mean	O
radiographic	O
scores	O
were	O
lower	O
in	O
the	O
Ca+D	O
group	O
at	O
12	O
weeks	O
(	O
p=0.01	O
)	O
but	O
not	O
at	O
24	O
weeks	O
(	O
p=0.12	O
)	O
.	O

Patient	O
self	O
treatment	O
with	O
50	O
%	O
salicylic	O
acid	O
(	O
Verrugon	O
)	O
daily	O
up	O
to	O
a	O
maximum	O
of	O
eight	O
weeks	O
.	O

We	O
monitored	O
all	O
baseline	O
and	O
postrandomisation	O
imaging	O
,	O
which	O
provided	O
additional	O
cross-checks	O
on	O
recruited	O
patients	O
and	O
centre	O
performance	O
.	O

The	O
combined	O
trial	O
data	O
of	O
the	O
primary	O
population	O
was	O
used	O
in	O
a	O
proportional	O
hazards	O
analysis	O
to	O
examine	O
multiple	O
risk	O
factors	O
in	O
relation	O
to	O
development	O
of	O
upper	O
GI	O
ulcers	O
.	O

However	O
,	O
targeting	O
the	O
IgE	O
pathway	O
via	O
depletion	O
of	O
IgE-switched	O
and	O
memory	O
B	O
cells	O
was	O
not	O
sufficient	O
for	O
a	O
clinically	O
meaningful	O
benefit	O
for	O
adults	O
with	O
allergic	O
asthma	O
uncontrolled	O
by	O
standard	O
therapy	O
.	O

Two	O
24-h	O
dietary	O
recalls	O
were	O
obtained	O
on	O
separate	O
days	O
to	O
determine	O
energy	O
,	O
phosphorus	O
and	O
calcium	O
intake	O
.	O

Outcomes	O
The	O
two	O
primary	O
end	O
points	O
were	O
(	O
1	O
)	O
the	O
mean	O
number	O
of	O
new	O
DUs	O
per	O
patient	O
assessed	O
by	O
the	O
investigator	O
up	O
to	O
week	O
24	O
and	O
(	O
2	O
)	O
the	O
time	O
to	O
healing	O
of	O
the	O
cardinal	O
ulcer	O
up	O
to	O
week	O
24	O
in	O
patients	O
with	O
cardinal	O
ulcer	O
healing	O
maintained	O
for	O
12	O
or	O
more	O
weeks	O
.	O

Primary	O
analysis	O
The	O
primary	O
analysis	O
compared	O
the	O
clearance	O
rate	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
between	O
the	O
two	O
randomised	O
groups	O
using	O
a	O
χ2	O
test	O
.	O

Data	O
are	O
presented	O
as	O
adjusted	O
mean	O
change	O
from	O
baseline	O
after	O
4	O
weeks	O
of	O
treatment	O
(	O
defined	O
as	O
response	O
)	O
,	O
unless	O
noted	O
otherwise	O
.	O

Patients	O
were	O
not	O
allowed	O
to	O
change	O
their	O
medication	O
regimen	O
or	O
STN	O
stimulation	O
settings	O
in	O
the	O
3	O
months	O
prior	O
to	O
the	O
study	O
or	O
during	O
the	O
study	O
itself	O
.	O

Exploratory	O
outcome	O
measures	O
included	O
the	O
change	O
in	O
asthma	O
control	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
as	O
measured	O
by	O
the	O
ACQ-5	O
.	O

Five	O
further	O
patients	O
discontinued	O
due	O
to	O
SAEs	O
(	O
canakinumab	O
,	O
n=4	O
(	O
1.2	O
%	O
)	O
;	O
colchicine	O
,	O
n=1	O
(	O
0.9	O
%	O
)	O
)	O
.	O

Ethics	O
,	O
consent	O
,	O
and	O
permissions	O
Quorum	O
Review	O
based	O
in	O
Seattle	O
,	O
WA	O
was	O
the	O
primary	O
central	O
IRB	O
used	O
by	O
sites	O
in	O
North	O
America	O
,	O
however	O
multiple	O
other	O
site-specific	O
institutional	O
review	O
boards	O
at	O
other	O
global	O
sites	O
approved	O
the	O
protocol	O
and	O
patients	O
gave	O
written	O
,	O
informed	O
consent	O
.	O

HLA	O
testing	O
was	O
not	O
done	O
.	O

Table	O
2	O
summarises	O
the	O
baseline	O
characteristics	O
of	O
their	O
plantar	O
warts	O
.	O

Children	O
were	O
eligible	O
for	O
enrolment	O
if	O
they	O
had	O
a	O
radiographic	O
score	O
of	O
at	O
least	O
2.5	O
on	O
a	O
validated	O
10-point	O
scoring	O
method	O
that	O
assessed	O
the	O
severity	O
of	O
rickets	O
in	O
the	O
growth	O
plates	O
of	O
the	O
distal	O
radius	O
and	O
ulna	O
and	O
around	O
the	O
knee	O
.	O

Non-vascular	O
mortality	O
during	O
the	O
in-trial	O
period	O
accounted	O
for	O
580	O
(	O
5·6	O
%	O
)	O
deaths	O
in	O
participants	O
allocated	O
simvastatin	O
versus	O
613	O
(	O
6·0	O
%	O
)	O
in	O
those	O
allocated	O
placebo	O
(	O
p=0·25	O
;	O
figure	O
4	O
)	O
.	O

The	O
following	O
parameters	O
were	O
analysed	O
under	O
standardised	O
conditions	O
before	O
and	O
after	O
acute	O
administration	O
of	O
L-dopa	O
:	O
gait	O
(	O
stride	O
length	O
as	O
primary	O
criterion	O
)	O
,	O
the	O
United-Parkinson's-Disease-Rating-Scale	O
(	O
UPDRS	O
)	O
motor	O
score	O
and	O
its	O
axial	O
subscore	O
,	O
the	O
hypertonia	O
and	O
strength	O
of	O
the	O
axial	O
extensors	O
and	O
flexors	O
(	O
isokinetic	O
dynamometer	O
)	O
,	O
the	O
Dyskinesia	O
Rating	O
Scale	O
score	O
(	O
DRS	O
)	O
and	O
its	O
axial	O
subscore	O
.	O

Main	O
outcome	O
measure	O
Final	O
height	O
.	O

The	O
primary	O
analysis	O
was	O
of	O
the	O
proportion	O
of	O
patients	O
alive	O
and	O
independent	O
,	O
as	O
defined	O
by	O
an	O
Oxford	O
Handicap	O
Score	O
(	O
OHS	O
)	O
of	O
0–2	O
at	O
6	O
months	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
Multi-centre	O
Research	O
Ethics	O
Committees	O
,	O
Scotland	O
(	O
reference	O
MREC/99/0/78	O
)	O
,	O
and	O
by	O
local	O
ethical	O
committees	O
.	O

For	O
patients	O
assigned	O
to	O
routine	O
laboratory	O
monitoring	O
,	O
results	O
were	O
returned	O
every	O
12	O
weeks	O
to	O
clinicians	O
;	O
for	O
clinically	O
driven	O
monitoring	O
,	O
toxicity	O
results	O
were	O
only	O
returned	O
for	O
requested	O
clinical	O
reasons	O
or	O
if	O
grade	O
4	O
.	O

Despite	O
previous	O
concerns	O
about	O
the	O
safety	O
of	O
lipid-lowering	O
treatment	O
in	O
elderly	O
people	O
and	O
those	O
with	O
below-average	O
cholesterol	O
concentrations	O
,	O
there	O
was	O
no	O
evidence	O
of	O
any	O
adverse	O
effect	O
on	O
non-vascular	O
mortality	O
in	O
statin-allocated	O
participants	O
aged	O
70	O
or	O
older	O
at	O
baseline	O
,	O
or	O
those	O
with	O
pretreatment	O
total	O
cholesterol	O
concentrations	O
less	O
than	O
5·0	O
mmol/L	O
(	O
webappendix	O
,	O
p	O
6	O
)	O
.	O

Results	O
Of	O
the	O
112	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
,	O
108	O
had	O
complete	O
primary	O
outcome	O
data	O
at	O
baseline	O
and	O
six	O
weeks	O
(	O
57	O
ciclosporin	O
;	O
51	O
prednisolone	O
)	O
.	O

Groups	O
were	O
balanced	O
at	O
baseline	O
.	O

However	O
,	O
at	O
week	O
36	O
(	O
when	O
all	O
children	O
moved	O
to	O
three	O
drugs	O
)	O
,	O
CD4	O
percentage	O
responses	O
were	O
significantly	O
greater	O
in	O
the	O
four-drug	O
induction	O
groups	O
(	O
p	O
<	O
0·0001	O
;	O
figure	O
4	O
;	O
appendix	O
)	O
.	O

In	O
addition	O
,	O
patients	O
may	O
not	O
take	O
their	O
protective	O
co-therapy	O
along	O
with	O
their	O
NSAID	O
,	O
especially	O
if	O
they	O
are	O
not	O
experiencing	O
any	O
symptoms	O
,	O
and	O
decreased	O
adherence	O
is	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
upper	O
GI	O
ulcers	O
or	O
bleeding	O
.	O

In	O
those	O
with	O
healed	O
ulcers	O
,	O
eight	O
(	O
30	O
%	O
)	O
receiving	O
ciclosporin	O
and	O
seven	O
(	O
28	O
%	O
)	O
receiving	O
prednisolone	O
had	O
a	O
recurrence	O
.	O

Higher	O
mean	O
pre-dose	O
PEFam	O
responses	O
(	O
measured	O
with	O
the	O
AM2+®	O
device	O
)	O
were	O
observed	O
with	O
all	O
three	O
tiotropium	O
Respimat®	O
treatments	O
compared	O
with	O
placebo	O
Respimat®	O
(	O
difference	O
from	O
placebo	O
:	O
5	O
μg	O
,	O
20.846	O
L/min	O
;	O
2.5	O
μg	O
,	O
17.895	O
L/min	O
;	O
1.25	O
μg	O
,	O
18.550	O
L/min	O
;	O
all	O
P	O
<	O
0.0001	O
)	O
.	O

Compared	O
with	O
the	O
non-infused	O
arm	O
,	O
substance	O
P	O
caused	O
dose-dependent	O
increases	O
in	O
plasma	O
t-PA	O
activity	O
(	O
ANOVA	O
:	O
p=0.001	O
)	O
.	O

Summary	O
Background	O
Thrombolysis	O
is	O
of	O
net	O
benefit	O
in	O
patients	O
with	O
acute	O
ischaemic	O
stroke	O
,	O
who	O
are	O
younger	O
than	O
80	O
years	O
of	O
age	O
and	O
are	O
treated	O
within	O
4·5	O
h	O
of	O
onset	O
.	O

Benefit	O
was	O
greatest	O
in	O
patients	O
treated	O
within	O
3	O
h	O
,	O
but	O
there	O
was	O
insufficient	O
power	O
to	O
examine	O
decay	O
of	O
benefit	O
with	O
time	O
.	O

The	O
initial	O
results	O
after	O
data	O
lock	O
and	O
unblinding	O
in	O
REDUCE-1	O
for	O
the	O
primary	O
end	O
point	O
of	O
proportion	O
of	O
patients	O
with	O
gastric	O
ulcers	O
at	O
24	O
weeks	O
was	O
12.9	O
%	O
for	O
HZT-501	O
and	O
25.3	O
%	O
for	O
ibuprofen	O
(	O
P=0.0009	O
;	O
NNT=11	O
)	O
.	O

Patients	O
Consecutive	O
patients	O
(	O
diagnosed	O
according	O
to	O
Gibb	O
's	O
criteria	O
and	O
monitored	O
at	O
Lille	B-Settings_Location
University	I-Settings_Single_Center
Hospital	I-Settings_Single_Center
's	I-Settings_Single_Center
PD	I-Settings_Single_Center
clinic	I-Settings_Single_Center
)	O
were	O
invited	O
to	O
participate	O
in	O
the	O
study	O
by	O
CM	O
,	O
AD	O
,	O
LD	O
and	O
DD	O
until	O
the	O
required	O
number	O
of	O
participants	O
was	O
obtained	O
.	O

Methods	O
20	B-Sample_Size_Actual_at_Enrollment
536	I-Sample_Size_Actual_at_Enrollment
patients	O
at	O
high	O
risk	O
of	O
vascular	O
and	O
non-vascular	O
outcomes	O
were	O
allocated	O
either	O
40	B-Design_Parallel_Group
mg	I-Design_Parallel_Group
simvastatin	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
using	O
minimised	B-Randomization_Type_Minimization
randomisation	I-Randomization_Type_Minimization
.	O

For	O
all	O
canakinumab	O
doses	O
≥50	O
mg	O
,	O
median	O
CRP	O
values	O
remained	O
consistently	O
lower	O
than	O
in	O
the	O
colchicine	O
group	O
throughout	O
the	O
study	O
and	O
were	O
below	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
(	O
ULN	O
,	O
3.0	O
mg/dl	O
)	O
up	O
to	O
week	O
24	O
.	O

Missing	O
data	O
on	O
new	O
DUs	O
were	O
imputed	O
using	O
extrapolation	O
,	O
with	O
the	O
incidence	O
rate	O
of	O
new	O
DUs	O
at	O
the	O
last	O
assessment	O
corrected	O
for	O
the	O
missing	O
time	O
period	O
.	O

The	O
most	O
common	O
modification	O
(	O
13	O
children	O
in	O
group	O
B	O
,	O
14	O
in	O
C	O
)	O
was	O
to	O
stop	O
(	O
on	O
four-drug	O
regimen	O
)	O
or	O
substitute	O
zidovudine	O
because	O
of	O
anaemia	O
,	O
even	O
though	O
grade	O
3	O
and	O
4	O
anaemias	O
occurred	O
similarly	O
across	O
all	O
three	O
groups	O
.	O

It	O
results	O
from	O
deposition	O
of	O
monosodium	O
urate	O
(	O
MSU	O
)	O
crystals	O
in	O
joints	O
,	O
which	O
leads	O
to	O
painful	O
inflammatory	O
acute	O
gouty	O
arthritis	O
flares	O
.	O

Conclusion	O
Prednisolone	O
and	O
ciclosporin	O
did	O
not	O
differ	O
across	O
a	O
range	O
of	O
objective	O
and	O
patient	O
reported	O
outcomes	O
.	O

For	O
patients	O
who	O
discontinued	O
the	O
study	O
prematurely	O
,	O
there	O
was	O
no	O
imputation	O
of	O
additional	O
exacerbations	O
.	O

Excess	O
grade	O
3	O
or	O
4	O
events	O
in	O
groups	O
B	O
(	O
one	O
or	O
more	O
events	O
reported	O
by	O
157	O
[	O
40	O
%	O
]	O
children	O
in	O
A	O
,	O
190	O
[	O
47	O
%	O
]	O
in	O
B	O
;	O
HR	O
[	O
B	O
:	O
A	O
]	O
1·32	O
,	O
1·07–1·63	O
)	O
and	O
C	O
(	O
218	O
[	O
54	O
%	O
]	O
children	O
in	O
C	O
;	O
HR	O
[	O
C	O
:	O
A	O
]	O
1·58	O
,	O
1·29–1·94	O
;	O
global	O
p=0·0001	O
)	O
were	O
driven	O
by	O
asymptomatic	O
neutropenia	O
in	O
zidovudine-containing	O
groups	O
(	O
B	O
,	O
C	O
;	O
86	O
group	O
A	O
,	O
133	O
group	O
B	O
,	O
184	O
group	O
C	O
)	O
,	O
but	O
resulted	O
in	O
drug	O
substitutions	O
in	O
only	O
zero	O
versus	O
two	O
versus	O
four	O
children	O
,	O
respectively	O
.	O

Children	O
were	O
reviewed	O
every	O
4–6	O
weeks	O
by	O
a	O
nurse	O
using	O
a	O
standard	O
symptom	O
checklist	O
.	O

The	O
burden	O
of	O
ischaemic	O
stroke	O
among	O
the	O
elderly	O
is	O
large	O
and	O
increasing	O
;	O
and	O
we	O
estimate	O
that	O
annually	O
ischaemic	O
stroke	O
affects	O
about	O
a	O
million	O
people	O
older	O
than	O
80	O
years	O
of	O
age	O
in	O
high-income	O
countries	O
and	O
about	O
3	O
million	O
in	O
low-income	O
and	O
middle-income	O
countries	O
.	O

Both	O
of	O
this	O
patient	O
’	O
s	O
adverse	O
events	O
accounted	O
for	O
discontinuation	O
of	O
the	O
study	O
drug	O
(	O
the	O
only	O
case	O
of	O
discontinuation	O
during	O
the	O
trial	O
)	O
.	O

Although	O
overall	O
progression	O
was	O
similar	O
,	O
a	O
prespecified	O
subgroup	O
analysis	O
showed	O
children	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
higher	O
event	O
rates	O
during	O
the	O
first	O
3	O
months	O
on	O
ART	O
and	O
lower	O
rates	O
from	O
the	O
second	O
year	O
on	O
ART	O
compared	O
with	O
those	O
on	O
clinically	O
driven	O
monitoring	O
(	O
heterogeneity	O
p=0·045	O
;	O
appendix	O
)	O
.	O

Introduction	O
In	O
late-stage	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
axial	O
signs	O
(	O
notably	O
with	O
gait	O
disorders	O
,	O
such	O
as	O
hypokinesia	O
)	O
,	O
abnormal	O
posture	O
,	O
falls	O
and	O
poor	O
balance	O
reduce	O
personal	O
independence	O
and	O
may	O
prompt	O
institutionalisation	O
.	O

A	O
Cox	O
proportional	O
hazards	O
model	O
was	O
used	O
to	O
compare	O
the	O
time	O
to	O
clearance	O
of	O
plantar	O
warts	O
between	O
the	O
two	O
groups	O
adjusting	O
for	O
the	O
same	O
covariates	O
as	O
for	O
the	O
primary	O
outcome	O
.	O

An	O
increasing	O
number	O
of	O
patients	O
have	O
comorbidities	O
which	O
make	O
standard	O
therapies	O
inappropriate	O
.	O

Differences	O
in	O
time	O
to	O
first	O
hospital	O
admission	O
were	O
smaller	O
(	O
HR	O
1·18	O
,	O
0·99–1·41	O
,	O
p=0·07	O
)	O
,	O
with	O
no	O
difference	O
in	O
duration	O
of	O
admission	O
(	O
median	O
5	O
[	O
IQR	O
3–6	O
]	O
days	O
in	O
clinically	O
driven	O
and	O
routine	O
laboratory	O
monitoring	O
;	O
rank-sum	O
p=0·54	O
)	O
.	O

Similarly	O
,	O
for	O
randomisation	O
2	O
,	O
final	O
height	O
was	O
significantly	O
greater	O
with	O
pubertal	O
induction	O
at	O
14	O
years	O
than	O
at	O
12	O
years	O
(	O
3.8	O
cm	O
,	O
0.0	O
to	O
7.5	O
;	O
P=0.05	O
)	O
.	O

Progression	O
to	O
new	O
WHO	O
stage	O
3	O
or	O
4	O
events	O
or	O
death	O
gave	O
similar	O
results	O
(	O
HR	O
[	O
clinically	O
driven	O
:	O
routine	O
laboratory	O
monitoring	O
]	O
1·00	O
,	O
0·73–1·38	O
;	O
p=0·98	O
;	O
appendix	O
)	O
.	O

Weight	O
for	O
age	O
and	O
height	O
for	O
age	O
did	O
not	O
differ	O
significantly	O
between	O
groups	O
(	O
p=0·71	O
,	O
p=0·07	O
;	O
appendix	O
)	O
.	O

The	O
age	O
of	O
attainment	O
of	O
final	O
height	O
was	O
similar	O
for	O
oxandrolone	O
and	O
placebo	O
(	O
16.2	O
v	O
16.7	O
years	O
;	O
P=0.1	O
)	O
and	O
later	O
,	O
by	O
design	O
,	O
for	O
late	O
versus	O
early	O
induction	O
(	O
16.9	O
v	O
16.1	O
years	O
;	O
P=0.009	O
)	O
.	O

We	O
also	O
extended	O
the	O
primary	O
outcome	O
model	O
to	O
explore	O
the	O
effect	O
of	O
patient	O
preferences	O
by	O
including	O
preference	O
and	O
an	O
interaction	O
term	O
between	O
preferred	O
treatment	O
and	O
randomised	O
treatment	O
.	O

Data	O
collection	O
ceased	O
if	O
participants	O
withdrew	O
consent	O
,	O
although	O
we	O
included	O
previously	O
collected	O
data	O
in	O
the	O
analysis	O
.	O

Tiotropium	O
,	O
a	O
once-daily	O
long-acting	O
anticholinergic	O
bronchodilator	O
,	O
is	O
the	O
established	O
first-line	O
maintenance	O
bronchodilator	O
for	O
the	O
management	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Assessments	O
Clinic	O
visits	O
took	O
place	O
at	O
baseline	O
,	O
week	O
2	O
,	O
and	O
week	O
6	O
(	O
primary	O
outcome	O
)	O
and	O
when	O
the	O
ulcer	O
had	O
healed	O
(	O
up	O
to	O
a	O
maximum	O
of	O
six	O
months	O
)	O
.	O

Introduction	O
The	O
Medical	O
Research	O
Council	O
and	O
British	O
Heart	O
Foundation	O
(	O
MRC/BHF	O
)	O
Heart	O
Protection	O
Study	O
(	O
HPS	O
)	O
,	O
among	O
20	O
000	O
patients	O
at	O
high	O
risk	O
of	O
vascular	O
and	O
non-vascular	O
outcomes	O
,	O
was	O
established	O
to	O
assess	O
the	O
long-term	O
efficacy	O
and	O
safety	O
of	O
lowering	O
LDL	O
cholesterol	O
concentrations	O
substantially	O
with	O
statin	O
treatment	O
.	O

(	O
see	O
Additional	O
file	O
1	O
:	O
Figure	O
S2	O
)	O
.	O

Data	O
analysis	O
was	O
performed	O
with	O
Excel	O
2003	O
(	O
Microsoft	O
Corp.	O
,	O
Redmond	O
,	O
Washington	O
,	O
USA	O
)	O
and	O
JMP	O
V.9.0.1	O
(	O
SAS	O
Institute	O
Inc.	O
,	O
Cary	O
,	O
North	O
Carolina	O
,	O
USA	O
)	O
.	O

Pulmonary	O
tuberculosis	O
was	O
the	O
commonest	O
WHO	O
stage	O
3	O
event	O
(	O
25	O
clinically	O
driven	O
monitoring	O
,	O
28	O
routine	O
laboratory	O
monitoring	O
)	O
.	O

All	O
188	B-Sample_Size_Actual_at_Enrollment
randomised	O
patients	O
received	O
study	O
treatment	O
,	O
with	O
mean	O
exposures	O
of	O
22.7±0.9	O
and	O
24.5±0.9	O
weeks	O
in	O
the	O
bosentan	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Clearance	O
of	O
plantar	O
wart	O
was	O
defined	O
as	O
the	O
restoration	O
of	O
normal	O
skin	O
on	O
close	O
inspection	O
.	O

The	O
system	O
used	O
a	O
minimisation	B-Randomization_Type_Minimization
algorithm	O
to	O
achieve	O
optimum	O
balance	O
for	O
key	B-Randomization_Minimization_Criteria
prognostic	I-Randomization_Minimization_Criteria
factors	I-Randomization_Minimization_Criteria
(	O
table	O
1	O
)	O
,	O
and	O
from	O
January	O
,	O
2006	O
,	O
minimisation	B-Randomization_Type_Minimization
was	O
additionally	O
stratified	B-Randomization_Type_Stratified
by	O
world	B-Randomization_Stratified_Criteria
region	I-Randomization_Stratified_Criteria
and	O
then	O
minimised	B-Randomization_Type_Minimization
on	O
all	B-Randomization_Minimization_Criteria
the	I-Randomization_Minimization_Criteria
other	I-Randomization_Minimization_Criteria
key	I-Randomization_Minimization_Criteria
factors	I-Randomization_Minimization_Criteria
within	I-Randomization_Minimization_Criteria
regions	I-Randomization_Minimization_Criteria
.	O

Median	O
(	O
range	O
)	O
times	O
to	O
death	O
were	O
2	O
days	O
(	O
1-12	O
)	O
in	O
those	O
with	O
avian	O
H5N1	O
and	O
5.5	O
days	O
(	O
1-13	O
)	O
days	O
in	O
those	O
with	O
other	O
influenza	O
viruses	O
(	O
table	O
5	O
)	O
.	O

The	O
N-methyl-D-aspartic-acid-related	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
MK-801	O
was	O
found	O
to	O
facilitate	O
locomotion	O
in	O
a	O
rat	O
model	O
of	O
PD	O
with	O
bilateral	O
PPN	O
lesions	O
.	O

The	O
estimated	O
canakinumab	O
dose	O
with	O
equivalent	O
efficacy	O
to	O
colchicine	O
was	O
below	O
the	O
range	O
of	O
doses	O
tested	O
.	O

Platelet-free	O
plasma	O
was	O
decanted	O
and	O
stored	O
at	O
-80°C	O
before	O
assay	O
.	O

Baseline	O
alkaline	O
phosphatase	O
and	O
radiographic	O
scores	O
were	O
unrelated	O
to	O
vitamin	O
D	O
status	O
.	O

Etanercept	O
treatment	O
reduced	O
neutrophil	O
(	O
7.4±0.6	O
vs	O
8.8±0.6×109	O
cells/l	O
;	O
p=0.03	O
)	O
and	O
plasma	O
interleukin-6	O
concentrations	O
(	O
5.8±2.0	O
vs	O
10.6±4.0	O
pg/ml	O
;	O
p=0.012	O
)	O
at	O
24	O
h	O
but	O
increased	O
platelet–monocyte	O
aggregation	O
(	O
30±5	O
vs	O
20±3	O
%	O
;	O
p=0.02	O
)	O
.	O

Testing	O
was	O
performed	O
with	O
α	O
=	O
0.025	B-Sample_Size_Calculation_Alpha_Value
(	I-Sample_Size_Calculation_Alpha_Value
one-sided	I-Sample_Size_Calculation_Alpha_Value
)	I-Sample_Size_Calculation_Alpha_Value
.	O

The	O
L-dopa	O
dose	O
used	O
in	O
the	O
assessment	O
was	O
150	O
%	O
of	O
the	O
usual	O
,	O
first	O
morning	O
dose	O
taken	O
by	O
patients	O
to	O
relieve	O
their	O
symptoms	O
(	O
table	O
1	O
)	O
.	O

In	O
the	O
48	O
children	O
who	O
were	O
randomised	O
twice	O
,	O
the	O
effects	O
on	O
final	O
height	O
(	O
compared	O
with	O
placebo	O
and	O
early	O
induction	O
of	O
puberty	O
)	O
of	O
oxandrolone	O
alone	O
,	O
late	O
induction	O
alone	O
,	O
and	O
oxandrolone	O
plus	O
late	O
induction	O
were	O
similar	O
,	O
averaging	O
7.1	O
(	O
3.4	O
to	O
10.8	O
)	O
cm	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Mean	O
in-trial	O
follow-up	O
was	O
5·3	O
years	O
(	O
SD	O
1·2	O
)	O
,	O
and	O
post-trial	O
follow-up	O
of	O
surviving	O
patients	O
yielded	O
a	O
mean	O
total	O
duration	O
of	O
11·0	O
years	O
(	O
SD	O
0·6	O
)	O
.	O

Study	O
population	O
Participants	O
were	O
eligible	O
for	O
the	O
study	O
if	O
they	O
were	O
aged	O
12	O
years	O
or	O
over	O
and	O
had	O
a	O
plantar	O
wart	O
(	O
verruca	O
)	O
that	O
,	O
in	O
the	O
opinion	O
of	O
a	O
healthcare	O
professional	O
,	O
was	O
suitable	O
for	O
treatment	O
with	O
both	O
salicylic	O
acid	O
and	O
cryotherapy	O
.	O

Two	O
dermatologists	O
independently	O
reviewed	O
all	O
images	O
to	O
ensure	O
that	O
the	O
lesions	O
were	O
consistent	O
with	O
a	O
diagnosis	O
of	O
pyoderma	O
gangrenosum	O
and	O
that	O
the	O
measurements	O
taken	O
by	O
the	O
trained	O
assessors	O
were	O
an	O
accurate	O
representation	O
of	O
the	O
ulcer	O
’	O
s	O
size	O
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
1:1:1:1	B-Randomization_Ratio
)	O
to	O
one	B-Design_Parallel_Group
of	I-Design_Parallel_Group
three	I-Design_Parallel_Group
dosing	I-Design_Parallel_Group
regimens	I-Design_Parallel_Group
of	I-Design_Parallel_Group
quilizumab	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
using	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
difference	O
in	O
the	O
time	O
to	O
clearance	O
between	O
cryotherapy	O
and	O
salicylic	O
acid	O
in	O
the	O
Cox	O
proportional	O
hazards	O
model	O
(	O
hazard	O
ratio	O
0.80	O
(	O
0.51	O
to	O
1.25	O
)	O
,	O
P=0.33	O
)	O
.	O

All	O
patients	O
with	O
H5N1	O
met	O
criteria	O
for	O
severe	O
influenza	O
and	O
were	O
therefore	O
analysed	O
as	O
such	O
.	O

Trial	O
registration	O
number	O
ClinicalTrials.gov	O
NCT00949832	O
.	O

Sample	O
size	O
This	O
was	O
a	O
superiority	B-Design_Comparative_Intent_Superiority
trial	O
,	O
with	O
prednisolone	O
as	O
the	O
control	O
intervention	O
.	O

At	O
the	O
end	O
of	O
24	O
weeks	O
,	O
25	O
(	O
OH	O
)	O
D	O
values	O
were	O
55.4±17.0	O
nmol/L	O
and	O
37.9±20.0	O
nmol/L	O
in	O
the	O
Ca+D	O
and	O
Ca	O
groups	O
,	O
respectively	O
,	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Adherence	O
by	O
self-reported	O
questionnaire	O
was	O
similar	O
in	O
both	O
monitoring	O
groups	O
:	O
mean	O
6·7	O
%	O
(	O
1813/26	O
917	O
)	O
of	O
children	O
on	O
clinically	O
driven	O
monitoring	O
reported	O
missing	O
doses	O
in	O
the	O
past	O
28	O
days	O
versus	O
6·5	O
%	O
(	O
1683/25	O
935	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
(	O
p=0·26	O
)	O
.	O

Injection-site	O
reactions	O
were	O
reported	O
in	O
20	O
(	O
6.2	O
%	O
)	O
patients	O
treated	O
with	O
canakinumab	O
and	O
4	O
(	O
3.7	O
%	O
)	O
patients	O
in	O
the	O
colchicine	O
group	O
.	O

Comparison	O
of	O
the	O
mean	O
values	O
of	O
the	O
parameters	O
by	O
trial	O
arm	O
showed	O
differences	O
in	O
size	O
(	O
oxandrolone	O
v	O
placebo	O
+2.6	O
cm	O
;	O
P=0.02	O
)	O
but	O
not	O
tempo	O
(	O
−0.3	O
years	O
;	O
P=0.1	O
)	O
,	O
and	O
the	O
mean	O
velocity	O
was	O
dramatically	O
greater	O
for	O
oxandrolone	O
(	O
difference	O
+23	O
%	O
,	O
SE	O
4	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Assessments	O
Flares	O
were	O
patient	O
reported	O
.	O

An	O
important	O
goal	O
in	O
the	O
long-term	O
management	O
of	O
gouty	O
arthritis	O
is	O
the	O
reduction	O
of	O
SU	O
levels	O
to	O
below	O
6	O
mg/dl	O
so	O
as	O
to	O
prevent	O
formation	O
of	O
new	O
crystals	O
,	O
dissolve	O
existing	O
crystals	O
and	O
ultimately	O
decrease	O
the	O
incidence	O
of	O
flares	O
.	O

For	O
the	O
150	O
mg	O
Q	O
,	O
450	O
mg	O
Q	O
,	O
and	O
300	O
mg	O
M	O
doses	O
,	O
the	O
mean	O
Cmax	O
,	O
obs	O
values	O
were	O
18	O
±	O
7.8	O
μg/mL	O
,	O
51.6	O
±	O
19.5	O
μg/mL	O
,	O
and	O
34	O
±	O
12.6	O
μg/mL	O
,	O
which	O
occurred	O
at	O
Tmax	O
,	O
obs	O
of	O
36.4	O
±	O
4.3	O
days	O
,	O
36.2	O
±	O
3.0	O
days	O
,	O
and	O
36.2	O
±	O
3.5	O
days	O
,	O
respectively	O
,	O
approximately	O
7	O
days	O
following	O
the	O
second	O
doses	O
.	O

Interventions	O
Participants	O
were	O
randomised	O
to	O
oxandrolone	B-Design_Parallel_Group
(	I-Design_Parallel_Group
0.05	I-Design_Parallel_Group
mg/kg/day	I-Design_Parallel_Group
,	I-Design_Parallel_Group
maximum	I-Design_Parallel_Group
2.5	I-Design_Parallel_Group
mg/day	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
from	O
9	O
years	O
of	O
age	O
.	O

The	O
threshold	O
for	O
statistical	O
significance	O
was	O
set	O
to	O
p=0.05	O
in	O
all	O
cases	O
.	O

The	O
sponsor	O
terminated	O
the	O
trial	O
early	O
because	O
of	O
the	O
lack	O
of	O
efficacy	O
for	O
the	O
primary	O
end-point	O
(	O
asthma	O
exacerbations	O
)	O
at	O
Week	O
36	O
,	O
with	O
the	O
median	O
time	O
in	O
the	O
study	O
at	O
72	O
weeks	O
.	O

This	O
similarity	O
in	O
statin	O
use	O
between	O
groups	O
was	O
supported	O
by	O
similar	O
LDL	O
cholesterol	O
concentrations	O
(	O
2·6	O
[	O
SE	O
0·03	O
]	O
vs	O
2·6	O
[	O
0·03	O
]	O
mmol/L	O
;	O
p=0·7	O
:	O
table	O
3	O
)	O
after	O
3·2	O
years	O
of	O
post-trial	O
follow-up	O
.	O

Comparison	O
between	O
treatment	O
arms	O
of	O
the	O
crude	O
proportions	O
of	O
patients	O
with	O
ulcers	O
at	O
24	O
weeks	O
with	O
a	O
Cochran–Mantel–Haenszel	O
test	O
stratified	O
by	O
the	O
two	O
randomization	O
risk	O
factor	O
strata	O
(	O
use	O
of	O
low-dose	O
aspirin	O
and	O
other	O
anticoagulants	O
,	O
prior	O
ulcer	O
history	O
)	O
was	O
specified	O
as	O
the	O
primary	O
statistical	O
analysis	O
at	O
the	O
time	O
of	O
sample	O
size	O
calculation	O
and	O
study	O
initiation	O
.	O

There	O
was	O
a	O
significant	O
association	O
between	O
patient	O
satisfaction	O
with	O
treatment	O
and	O
randomised	O
treatment	O
at	O
each	O
of	O
the	O
three	O
time	O
points	O
(	O
Fisher	O
’	O
s	O
exact	O
test	O
P=0.0336	O
for	O
week	O
1	O
,	O
P=0.0020	O
for	O
week	O
3	O
,	O
P=0.0065	O
for	O
week	O
12	O
)	O
.	O

Settings	O
and	O
participants	O
The	O
study	O
was	O
conducted	O
from	O
October	O
2003	O
to	O
May	O
2005	O
at	O
41	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
Europe	B-Settings_Location
and	I-Settings_Location
North	I-Settings_Location
America	I-Settings_Location
.	O

The	O
proportion	O
of	O
patients	O
with	O
one	O
or	O
more	O
new	O
DU	O
was	O
66.3	O
%	O
(	O
63/95	O
)	O
on	O
bosentan	O
compared	O
with	O
70.8	O
%	O
(	O
63/89	O
)	O
on	O
placebo	O
;	O
the	O
difference	O
in	O
observed	O
proportions	O
between	O
treatments	O
was	O
greater	O
in	O
patients	O
with	O
multiple	O
new	O
DUs	O
(	O
18.9	O
%	O
vs	O
29.2	O
%	O
with	O
≥4	O
,	O
10.5	O
%	O
vs	O
29.8	O
%	O
with	O
≥5	O
,	O
etc	O
;	O
figure	O
4	O
)	O
.	O

All	O
analyses	O
were	O
adjusted	O
for	O
the	O
stratification	O
variables	O
.	O

Few	O
studies	O
have	O
been	O
specifically	O
designed	O
to	O
examine	O
efficacy	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
DUs	O
.	O

Methods	O
Trial	O
design	O
ARROW	O
was	O
an	O
open-label	B-Blinding_Open_Label
randomised	O
parallel-group	B-Design_Parallel_Group
trial	O
in	O
untreated	O
(	O
except	O
for	O
ART	O
to	O
prevent	O
mother-to-child-transmission	O
)	O
children	O
or	O
adolescents	O
(	O
aged	O
3	O
months	O
to	O
17	O
years	O
)	O
with	O
HIV	O
who	O
met	O
WHO	O
2006	O
criteria	O
for	O
ART	O
initiation	O
from	O
three	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
Uganda	B-Settings_Location
(	O
Joint	O
Clinical	O
Research	O
Centre	O
,	O
Kampala	O
;	O
Baylor-Uganda	O
,	O
Mulago	O
;	O
MRC/UVRI	O
Uganda	O
Research	O
Unit	O
on	O
AIDS	O
,	O
Entebbe	O
)	O
,	O
and	O
one	O
in	O
Zimbabwe	B-Settings_Location
(	O
University	O
of	O
Zimbabwe	O
,	O
Harare	O
)	O
.	O

In	O
the	O
investigator-led	O
TALC	O
trial	O
(	O
Tiotropium	O
Bromide	O
as	O
an	O
Alternative	O
to	O
Increased	O
Inhaled	O
Glucocorticoid	O
in	O
Patients	O
Inadequately	O
Controlled	O
on	O
a	O
Lower	O
Dose	O
of	O
Inhaled	O
Corticosteroid	O
;	O
three-way	O
crossover	O
,	O
14	O
weeks	O
per	O
treatment	O
,	O
210	O
patients	O
)	O
,	O
improvements	O
in	O
lung	O
function	O
in	O
patients	O
with	O
asthma	O
treated	O
with	O
tiotropium	O
(	O
via	O
HandiHaler®	O
;	O
Boehringer	O
Ingelheim	O
Pharma	O
GmbH	O
&	O
Co.	O
KG	O
,	O
Ingelheim	O
am	O
Rhein	O
,	O
Germany	O
)	O
plus	O
beclomethasone	O
(	O
two	O
puffs	O
of	O
40	O
μg	O
,	O
twice	O
daily	O
)	O
were	O
shown	O
to	O
be	O
superior	O
to	O
a	O
doubling	O
of	O
the	O
ICS	O
dose	O
and	O
similar	O
to	O
the	O
addition	O
of	O
salmeterol	O
.	O

Main	O
outcome	O
measure	O
Achievement	O
of	O
a	O
10-point	O
radiographic	O
severity	O
score	O
≤1.5	O
and	O
serum	O
alkaline	O
phosphatase	O
≤350	O
U/L	O
.	O

Treatment	O
with	O
HZT-501	O
(	O
vs.	O
ibuprofen	O
)	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
risk	O
ratio	O
(	O
RR	O
)	O
for	O
upper	O
GI	O
ulcer	O
formation	O
in	O
the	O
initial	O
(	O
RR=0.44	O
,	O
0.33–0.58	O
)	O
and	O
post-adjudication	O
analyses	O
(	O
RR=0.46	O
,	O
0.34–0.61	O
)	O
.	O

All	O
analyses	O
were	O
done	O
with	O
Stata	O
12.1	O
.	O

A	O
marginally	O
significant	O
reduction	O
in	O
deaths	O
attributed	O
to	O
respiratory	O
disease	O
was	O
noted	O
in	O
simvastatin-allocated	O
participants	O
(	O
95	O
[	O
0·9	O
%	O
]	O
vs	O
124	O
[	O
1·2	O
%	O
]	O
;	O
p=0·04	O
)	O
,	O
but	O
deaths	O
from	O
cancer	O
,	O
or	O
other	O
prespecified	O
categories	O
of	O
non-vascular	O
death	O
,	O
did	O
not	O
differ	O
significantly	O
(	O
webappendix	O
,	O
p	O
4	O
)	O
.	O

Nine	O
serious	O
adverse	O
reactions	O
occurred	O
:	O
two	O
in	O
the	O
ciclosporin	O
group	O
(	O
ruptured	O
abdominal	O
aortic	O
aneurysm	O
and	O
acute	O
kidney	O
injury	O
with	O
increased	O
serum	O
creatinine	O
(	O
212	O
µmol/L	O
)	O
levels	O
)	O
and	O
seven	O
in	O
the	O
prednisolone	O
group	O
(	O
a	O
bowel	O
perforation	O
;	O
five	O
serious	O
infections	O
(	O
one	O
resulted	O
in	O
death	O
)	O
that	O
required	O
admission	O
to	O
hospital	O
or	O
parenteral	O
antibiotics	O
;	O
and	O
one	O
other	O
infection	O
)	O
.	O

Unless	O
otherwise	O
noted	O
,	O
means	O
and	O
SDs	O
are	O
reported	O
for	O
continuous	O
variables	O
with	O
normal	O
distributions	O
,	O
and	O
medians	O
are	O
reported	O
for	O
non-normally	O
distributed	O
variables	O
.	O

Results	O
Over	O
24	O
weeks	O
,	O
bosentan	O
treatment	O
was	O
associated	O
with	O
a	O
30	O
%	O
reduction	O
in	O
the	O
number	O
of	O
new	O
DUs	O
compared	O
with	O
placebo	O
(	O
mean±standard	O
error	O
:	O
1.9±0.2	O
vs	O
2.7±0.3	O
new	O
ulcers	O
;	O
p=0.04	O
)	O
.	O

The	O
Cox	O
proportional	O
hazard	O
assumption	O
was	O
tested	O
globally	O
by	O
the	O
correlation	O
of	O
Schoenfeld	O
residuals	O
and	O
survival	O
time	O
(	O
or	O
ranked	O
survival	O
time	O
)	O
and	O
separately	O
for	O
each	O
covariate	O
through	O
the	O
correlation	O
of	O
Schoenfeld	O
scaled	O
residuals	O
and	O
survival	O
time	O
(	O
or	O
ranked	O
survival	O
time	O
)	O
.	O

GI	O
complications	O
were	O
reported	O
by	O
investigators	O
for	O
three	O
patients	O
(	O
0.6	O
%	O
)	O
given	O
HZT-501	O
and	O
zero	O
given	O
ibuprofen	O
in	O
REDUCE-1	O
.	O

The	O
trial	O
was	O
approved	O
by	O
research	O
ethics	O
committees	O
in	O
Uganda	B-Settings_Location
,	I-Settings_Location
Zimbabwe	I-Settings_Location
,	O
and	O
the	O
UK	O
.	O

There	O
were	O
also	O
no	O
significant	O
differences	O
in	O
the	O
numbers	O
of	O
children	O
with	O
one	O
or	O
more	O
grade	O
4	O
adverse	O
events	O
(	O
63	O
[	O
16	O
%	O
]	O
vs	O
81	O
[	O
20	O
%	O
]	O
vs	O
76	O
[	O
19	O
%	O
]	O
;	O
HR	O
[	O
B	O
:	O
A	O
]	O
1·27	O
,	O
0·91–1·76	O
;	O
HR	O
[	O
C	O
:	O
A	O
]	O
1·20	O
,	O
0·86–1·68	O
;	O
global	O
p=0·34	O
)	O
or	O
serious	O
adverse	O
events	O
(	O
87	O
[	O
22	O
%	O
]	O
vs	O
82	O
[	O
20	O
%	O
]	O
vs	O
95	O
[	O
23	O
%	O
]	O
;	O
HR	O
[	O
B	O
:	O
A	O
]	O
0·92	O
,	O
0·68–1·25	O
;	O
HR	O
[	O
C	O
:	O
A	O
]	O
1·09	O
,	O
0·81–1·46	O
;	O
global	O
p=0·53	O
)	O
.	O

The	O
randomisation	O
list	O
was	O
sent	O
to	O
an	O
independent	O
contract	O
research	O
organisation	O
(	O
LC2	O
,	O
Lentilly	O
,	O
France	O
)	O
for	O
preparation	O
and	O
distribution	O
of	O
identical	O
capsules	O
of	O
memantine	B-Design_Parallel_Group
and	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	I-Design_Parallel_Group

The	O
adjusted	O
mean	O
difference	O
showed	O
no	O
between	O
group	O
difference	O
(	O
0.003	O
cm2/day	O
,	O
95	O
%	O
confidence	O
interval	O
−0.20	O
to	O
0.21	O
;	O
P=0.97	O
)	O
.	O

Study	O
swabs	O
were	O
collected	O
and	O
eluted	O
in	O
M4	O
media	O
(	O
Remel	O
,	O
Lenexa	O
,	O
KS	O
,	O
US	O
)	O
before	O
storage	O
at	O
−70	O
°C	O
.	O

Questionnaires	O
were	O
administered	O
by	O
post	O
or	O
were	O
completed	O
on	O
line	O
at	O
one	O
,	O
three	O
,	O
and	O
12	O
weeks	O
and	O
six	O
months	O
.	O

No	O
additional	O
medical	O
therapy	O
was	O
instituted	O
during	O
the	O
study	O
period	O
.	O

Secondary	O
outcomes	O
were	O
time	O
to	O
healing	O
,	O
global	O
treatment	O
response	O
,	O
resolution	O
of	O
inflammation	O
,	O
self	O
reported	O
pain	O
,	O
quality	O
of	O
life	O
,	O
number	O
of	O
treatment	O
failures	O
,	O
adverse	O
reactions	O
,	O
and	O
time	O
to	O
recurrence	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
arms	O
in	O
any	O
of	O
the	O
subgroups	O
on	O
day	O
five	O
(	O
tables	O
2	O
and	O
3	O
)	O
.	O

Measurement	O
of	O
PEFam	O
and	O
PEFpm	O
was	O
to	O
be	O
performed	O
prior	O
to	O
ICS	O
and	O
study	O
treatment	O
inhalation	O
,	O
at	O
approximately	O
the	O
same	O
time	O
each	O
day	O
,	O
from	O
06:00	O
to	O
08:00	O
for	O
PEFam	O
and	O
from	O
18:00	O
to	O
20:00	O
for	O
PEFpm	O
.	O

In	O
throat	O
samples	O
these	O
proportions	O
were	O
13/137	O
(	O
9.5	O
%	O
)	O
and	O
15/130	O
(	O
12	O
%	O
)	O
,	O
respectively	O
(	O
P=1.00	O
for	O
nose	O
and	O
P=0.59	O
for	O
throat	O
for	O
comparison	O
between	O
arms	O
)	O
;	O
corresponding	O
proportions	O
for	O
day	O
14	O
were	O
0/15	O
and	O
0/13	O
for	O
nose	O
and	O
1/15	O
and	O
1/13	O
for	O
throat	O
.	O

Following	O
etanercept	O
,	O
plasma	O
t-PA	O
activity	O
concentrations	O
were	O
reduced	O
at	O
24	O
h	O
(	O
0.8±0.1	O
vs	O
0.5±0.1	O
IU/ml	O
;	O
p=0.001	O
)	O
.	O

Among	O
the	O
14	O
patients	O
(	O
five	O
in	O
double	O
dose	O
arm	O
,	O
nine	O
in	O
standard	O
dose	O
arm	O
)	O
with	O
an	O
H1N1	O
virus	O
without	O
this	O
mutation	O
,	O
four	O
out	O
of	O
seven	O
(	O
two	O
double	O
dose	O
,	O
five	O
standard	O
dose	O
)	O
that	O
could	O
be	O
sequenced	O
after	O
day	O
0	O
developed	O
the	O
H275Y	O
mutation	O
during	O
treatment	O
(	O
four	O
standard	O
dose	O
)	O
.	O

The	O
treatment-emergent	O
ATA	O
rate	O
was	O
1.4	O
%	O
in	O
both	O
the	O
150	O
mg	O
Q	O
and	O
300	O
mg	O
M	O
groups	O
,	O
and	O
2.1	O
%	O
in	O
the	O
450	O
mg	O
Q	O
group	O
.	O

The	O
trials	O
continued	O
until	O
their	O
planned	O
completion	O
based	O
on	O
the	O
prespecified	O
sample	O
sizes	O
.	O

The	O
sample	O
size	O
,	O
re-estimated	O
in	O
2007	O
on	O
the	O
basis	O
of	O
event	O
rates	O
in	O
both	O
treatment	O
groups	O
combined	O
,	O
was	O
3100	B-Sample_Size_Target
.	O

47	O
(	O
8	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
39	O
(	O
7	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
a	O
new	O
WHO	O
stage	O
4	O
event	O
or	O
died	O
(	O
2·0	O
vs	O
1·7	O
per	O
100	O
child-years	O
,	O
respectively	O
)	O
.	O

A	O
further	O
3.9	O
%	O
(	O
13	O
)	O
were	O
false	O
positive	O
by	O
rapid	O
antigen	O
test	O
(	O
negative	O
by	O
RT-PCR	O
and	O
no	O
rise	O
in	O
convalescent	O
haemagglutination	O
inhibition	O
titers	O
)	O
.	O

Significant	O
trends	O
towards	O
larger	O
effects	O
of	O
treatment	O
in	O
more	O
severe	O
strokes	O
were	O
also	O
seen	O
(	O
as	O
assessed	O
by	O
the	O
NIHSS	O
and	O
by	O
the	O
predicted	O
probability	O
of	O
a	O
poor	O
outcome	O
)	O
.	O

Funding	O
UK	O
Medical	O
Research	O
Council	O
,	O
the	O
UK	O
Department	O
for	O
International	O
Development	O
;	O
drugs	O
donated	O
and	O
viral	O
load	O
assays	O
funded	O
by	O
ViiV	O
Healthcare	O
and	O
GlaxoSmithKline	O
.	O

SU	O
levels	O
At	O
baseline	O
,	O
85.2	O
%	O
to	O
92.6	O
%	O
of	O
patients	O
had	O
SU	O
levels	O
≥6	O
mg/dl	O
(	O
table	O
1	O
)	O
.	O

Allowances	O
for	O
multiple	O
comparisons	O
and	O
for	O
the	O
post-hoc	O
nature	O
of	O
such	O
analyses	O
were	O
made	O
in	O
their	O
interpretation	O
.	O

In	O
a	O
16-week	O
proof-of-concept	O
trial	O
in	O
B16-Arg/Arg	O
patients	O
with	O
symptomatic	O
moderate	O
asthma	O
already	O
receiving	O
ICS	O
,	O
tiotropium	O
5	O
μg	O
(	O
administered	O
via	O
the	O
Respimat®	O
SoftMist™	O
inhaler	O
[	O
hereinafter	O
referred	O
to	O
as	O
tiotropium	O
Respimat®	O
;	O
Boehringer	O
Ingelheim	O
Pharma	O
GmbH	O
&	O
Co.	O
KG	O
]	O
)	O
was	O
superior	O
to	O
placebo	O
Respimat®	O
and	O
non-inferior	O
to	O
salmeterol	O
.	O

The	O
committee	O
judged	O
these	O
data	O
never	O
met	O
the	O
protocol-specified	O
criteria	O
to	O
recommend	O
modification	O
of	O
the	O
protocol	O
or	O
halt	O
recruitment	O
to	O
the	O
study	O
.	O

After	O
day	O
five	O
,	O
the	O
proportions	O
of	O
patients	O
positive	O
for	O
RNA	O
in	O
the	O
double	O
and	O
standard	O
dose	O
arms	O
declined	O
but	O
were	O
similar	O
.	O

In	O
total	O
,	O
260	O
(	O
79.8	O
%	O
)	O
patients	O
were	O
infected	O
with	O
influenza	O
virus	O
A	O
(	O
133	O
(	O
40.8	O
%	O
)	O
with	O
A/H3N2	O
,	O
72	O
(	O
22.1	O
%	O
)	O
with	O
A/H1N1-pdm09	O
,	O
38	O
(	O
11.7	O
%	O
)	O
with	O
seasonal	O
A/H1N1	O
,	O
and	O
17	O
(	O
5.2	O
%	O
)	O
with	O
A/H5N1	O
)	O
and	O
53	O
(	O
16.2	O
%	O
)	O
with	O
influenza	O
virus	O
B	O
.	O

Additional	O
details	O
of	O
the	O
procedures	O
used	O
in	O
the	O
double-blinded	B-Blinding_Double_Blind
phase	O
of	O
the	O
study	O
are	O
reported	O
elsewhere	O
.	O

Reason	O
for	O
NSAID	O
use	O
across	O
both	O
trials	O
included	O
pain	O
(	O
37.9	O
%	O
)	O
,	O
osteoarthritis	O
(	O
50.6	O
%	O
)	O
,	O
rheumatoid	O
arthritis	O
(	O
3.5	O
%	O
)	O
,	O
and	O
other	O
(	O
7.8	O
%	O
)	O
.	O

The	O
changes	O
from	O
baseline	O
in	O
the	O
HAQ	O
disability	O
index	O
and	O
hand	O
disability	O
index	O
at	O
week	O
24	O
were	O
also	O
similar	O
in	O
both	O
treatment	O
groups	O
(	O
−0.04	O
(	O
95	O
%	O
CI	O
−0.15	O
to	O
0.08	O
)	O
,	O
p=0.51	O
and	O
−0.04	O
(	O
−0.20	O
to	O
0.12	O
)	O
,	O
p=0.62	O
,	O
respectively	O
)	O
.	O

Data	O
on	O
patient	O
satisfaction	O
with	O
the	O
treatment	O
and	O
adverse	O
events	O
were	O
summarised	O
by	O
treatment	O
group	O
but	O
no	O
statistical	O
analyses	O
were	O
performed	O
.	O

For	O
example	O
,	O
elevated	O
levels	O
of	O
serum	O
periostin	O
,	O
an	O
extracellular	O
matrix	O
protein	O
induced	O
by	O
IL-4	O
and	O
IL-13	O
in	O
airway	O
epithelium	O
,	O
identified	O
a	O
subset	O
of	O
asthma	O
patients	O
who	O
responded	O
better	O
to	O
lebrikizumab	O
,	O
an	O
anti-IL-13	O
monoclonal	O
antibody	O
.	O

The	O
results	O
did	O
not	O
change	O
when	O
the	O
analysis	O
was	O
repeated	O
but	O
with	O
adjustment	O
for	O
age	O
,	O
whether	O
the	O
wart	O
had	O
been	O
treated	O
previously	O
,	O
and	O
type	O
of	O
plantar	O
wart	O
or	O
for	O
patients	O
’	O
preferences	O
at	O
baseline	O
.	O

An	O
adjudication	O
committee	O
of	O
two	O
independent	O
gastroenterologists	O
then	O
reviewed	O
all	O
positive	O
endoscopy	O
reports	O
to	O
determine	O
how	O
many	O
ulcers	O
had	O
been	O
misclassified	O
.	O

The	O
median	O
adherence	O
to	O
calcium	O
supplementation	O
,	O
based	O
on	O
the	O
weight	O
of	O
unused	O
limestone	O
,	O
was	O
99	O
%	O
in	O
the	O
Ca	O
group	O
and	O
96	O
%	O
in	O
the	O
Ca+D	O
group	O
(	O
p=0.54	O
)	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
effects	O
of	O
lowering	O
LDL	O
cholesterol	O
on	O
cause-specific	O
mortality	O
and	O
major	O
morbidity	O
,	O
not	O
only	O
during	O
the	O
study	O
treatment	O
period	O
in	O
HPS	O
but	O
also	O
in	O
the	O
longer	O
term	O
,	O
post-trial	O
.	O

Biochemical	O
analyses	O
followed	O
local	O
protocols	O
,	O
and	O
the	O
results	O
were	O
reported	O
centrally	O
.	O

Methods	O
Study	O
design	O
and	O
patients	O
IST-3	O
was	O
a	O
pragmatic	O
international	B-Settings_Location
,	O
multicentre	B-Settings_Multicenter
,	O
randomised-controlled	O
,	O
open-treatment	B-Blinding_Open_Label
trial	O
.	O

Despite	O
substantial	O
numbers	O
of	O
grade	O
3	O
neutropenias	O
,	O
only	O
six	O
children	O
(	O
two	O
in	O
group	O
B	O
,	O
four	O
in	O
group	O
C	O
)	O
modified	O
ART	O
(	O
zidovudine	O
)	O
for	O
this	O
reason	O
.	O

The	O
main	O
inclusion	O
criterion	O
was	O
the	O
presence	O
of	O
a	O
severe	O
gait	O
disorder	O
(	O
defined	O
as	O
a	O
score	O
≥2	O
for	O
UPDRS	O
part	O
III	O
item	O
29	O
)	O
and	O
an	O
abnormal	O
,	O
forward-leaning	O
stance	O
(	O
a	O
score	O
≥2	O
for	O
item	O
28	O
)	O
despite	O
optimal	O
L-dopa	O
treatment	O
.	O

All	O
subsequent	O
results	O
for	O
participants	O
assigned	O
to	O
routine	O
laboratory	O
monitoring	O
were	O
returned	O
to	O
clinicians	O
,	O
whereas	O
results	O
at	O
and	O
after	O
randomisation	O
for	O
participants	O
allocated	O
clinically	O
driven	O
monitoring	O
were	O
only	O
returned	O
if	O
requested	O
for	O
clinical	O
management	O
(	O
authorised	O
by	O
centre	O
project	O
leaders	O
)	O
;	O
haemoglobin	O
results	O
at	O
week	O
8	O
were	O
automatically	O
returned	O
on	O
the	O
basis	O
of	O
early	O
anaemia	O
in	O
DART	O
,	O
as	O
were	O
grade	O
4	O
laboratory	O
toxicities	O
(	O
protocol	O
safety	O
criteria	O
;	O
grades	O
defined	O
apart	O
from	O
neutrophils	O
)	O
.	O

Membrane	O
IgE	O
is	O
expressed	O
on	O
IgE-switched	O
B	O
cells	O
,	O
IgE	O
memory	O
B	O
cells	O
,	O
and	O
IgE	O
plasmablasts	O
,	O
but	O
not	O
on	O
IgE	O
plasma	O
cells	O
.	O

An	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
model	O
with	O
factors	O
for	O
baseline	O
level	O
,	O
periostin	O
status	O
(	O
<	O
50	O
ng/mL	O
,	O
≥50	O
ng/mL	O
)	O
,	O
number	O
of	O
prior	O
exacerbations	O
(	O
1	O
,	O
>	O
1	O
)	O
,	O
and	O
IgE	O
level	O
(	O
<	O
200	O
IU/mL	O
,	O
≥200	O
IU/mL	O
)	O
was	O
fit	O
to	O
assess	O
the	O
treatment	O
effect	O
.	O

After	O
the	O
system	O
had	O
recorded	O
and	O
checked	O
the	O
data	O
,	O
patients	O
were	O
allocated	O
either	O
immediate	O
thrombolysis	O
with	O
0·9	B-Design_Parallel_Group
mg/kg	I-Design_Parallel_Group
of	I-Design_Parallel_Group
intravenous	I-Design_Parallel_Group
rt-PA	I-Design_Parallel_Group
to	I-Design_Parallel_Group
a	I-Design_Parallel_Group
maximum	I-Design_Parallel_Group
of	I-Design_Parallel_Group
90	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
(	I-Design_Parallel_Group
10	I-Design_Parallel_Group
%	I-Design_Parallel_Group
bolus	I-Design_Parallel_Group
with	I-Design_Parallel_Group
the	I-Design_Parallel_Group
remainder	I-Design_Parallel_Group
over	I-Design_Parallel_Group
1	I-Design_Parallel_Group
h	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
control	I-Design_Parallel_Group
treatment	I-Design_Parallel_Group
.	O

The	O
Breslow-Day	O
test	O
was	O
used	O
to	O
test	O
the	O
heterogeneity	O
of	O
the	O
results	O
between	O
study	O
sites	O
.	O

Post	O
hoc	O
analyses	O
of	O
new	O
DUs	O
In	O
unplanned	O
post	O
hoc	O
analyses	O
in	O
subgroups	O
defined	O
by	O
the	O
number	O
of	O
DUs	O
at	O
baseline	O
,	O
the	O
mean	O
treatment	O
effect	O
with	O
bosentan	O
was	O
−2.1	O
(	O
95	O
%	O
CI	O
−3.8	O
to	O
−0.4	O
)	O
new	O
DUs	O
(	O
p=0.02	O
)	O
in	O
patients	O
with	O
at	O
least	O
four	O
DUs	O
at	O
baseline	O
and	O
−0.3	O
(	O
−1.1	O
to	O
0.4	O
)	O
new	O
DUs	O
(	O
p=0.39	O
)	O
in	O
patients	O
with	O
less	O
than	O
four	O
DUs	O
at	O
baseline	O
(	O
table	O
2	O
)	O
.	O

We	O
chose	O
this	O
simple	O
form	O
of	O
imputation	O
because	O
it	O
effectively	O
classified	O
6-month	O
outcomes	O
in	O
patients	O
for	O
whom	O
both	O
7-day	O
and	O
6-month	O
data	O
were	O
known	O
(	O
data	O
not	O
shown	O
)	O
.	O

Subjects	O
The	O
study	O
was	O
performed	O
with	O
the	O
approval	O
of	O
the	O
local	O
research	O
ethics	O
committee	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
with	O
the	O
written	O
informed	O
consent	O
of	O
all	O
participants	O
.	O

For	O
the	O
ART-strategy	O
randomisation	O
,	O
1200	B-Sample_Size_Required
children	I-Sample_Size_Required
provided	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
differences	O
in	O
change	O
in	O
CD4	O
percentage	O
of	O
more	O
than	O
2·5	O
%	O
across	O
the	O
three	O
groups	O
(	O
F	O
test	O
,	O
two-sided	B-Sample_Size_Calculation_Alpha_Value
α=0·05	I-Sample_Size_Calculation_Alpha_Value
)	O
assuming	O
20	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
missing	I-Sample_Size_Calculation_Dropout_Rate_Value
data	I-Sample_Size_Calculation_Dropout_Rate_Value
(	O
loss	O
to	O
follow-up	O
,	O
missed	O
visit	O
or	O
test	O
)	O
and	O
standard	O
deviation	O
10	O
%	O
.	O

Enrolment	O
differed	O
by	O
country	O
:	O
235	O
(	O
72.1	O
%	O
)	O
were	O
from	O
Vietnam	O
,	O
71	O
(	O
21.8	O
%	O
)	O
from	O
Thailand	O
,	O
15	O
(	O
4.6	O
%	O
)	O
from	O
Indonesia	O
,	O
and	O
five	O
(	O
1.5	O
%	O
)	O
from	O
Singapore	O
.	O

To	O
assess	O
the	O
change	O
in	O
allergy-related	O
quality-of-life	O
measures	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
the	O
Standardized	O
Asthma	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
AQLQ	O
(	O
S	O
)	O
)	O
and	O
the	O
Standardized	O
Rhinoconjunctivitis	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
RQLQ	O
(	O
S	O
)	O
)	O
were	O
administered	O
at	O
patient	O
visits	O
throughout	O
the	O
treatment	O
and	O
follow-up	O
periods	O
.	O

Conclusions	O
In	O
children	O
with	O
calcium-deficiency	O
rickets	O
,	O
there	O
is	O
a	O
trend	O
for	O
vitamin	O
D	O
to	O
improve	O
the	O
response	O
to	O
treatment	O
with	O
calcium	O
carbonate	O
as	O
limestone	O
,	O
independent	O
of	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
.	O

Inclusion	O
and	O
exclusion	O
criteria	O
are	O
listed	O
in	O
detail	O
in	O
the	O
protocol	O
.	O

Role	O
of	O
the	O
funding	O
source	O
The	O
sponsors	O
of	O
the	O
study	O
had	O
no	O
role	O
in	O
design	O
,	O
data	O
collection	O
,	O
data	O
analysis	O
,	O
data	O
interpretation	O
,	O
or	O
writing	O
of	O
the	O
report	O
.	O

Participants	O
The	O
inclusion	O
criteria	O
were	O
age	O
≥1	O
year	O
,	O
respiratory	O
illness	O
with	O
duration	O
of	O
symptoms	O
≤10	O
days	O
,	O
laboratory	O
confirmed	O
influenza	O
,	O
and	O
either	O
evidence	O
of	O
severe	O
influenza	O
(	O
defined	O
below	O
)	O
or	O
positive	O
result	O
of	O
a	O
diagnostic	O
test	O
for	O
H5N1	O
.	O

Design	O
A	O
multicentre	B-Settings_Multicenter
,	O
open	B-Blinding_Open_Label
,	O
two	O
arm	O
randomised	B-Randomization_Type_Simple
controlled	O
trial	O
.	O

Unless	O
otherwise	O
indicated	O
by	O
subscript	O
notation	O
for	O
individual	O
metabolites	O
,	O
25	O
(	O
OH	O
)	O
D	O
refers	O
to	O
the	O
total	O
concentrations	O
of	O
25	O
(	O
OH	O
)	O
D2	O
and	O
25	O
(	O
OH	O
)	O
D3	O
.	O

Trough	O
FEV1	O
and	O
FEV1	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
(	O
0-3h	O
)	O
responses	O
were	O
greater	O
with	O
each	O
tiotropium	O
Respimat®	O
dose	O
than	O
with	O
placebo	O
(	O
all	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
both	O
were	O
greatest	O
with	O
5	O
μg	O
.	O

The	O
following	O
medications	O
were	O
proscribed	O
during	O
the	O
study	O
:	O
medications	O
that	O
may	O
reduce	O
ulcers	O
(	O
e.g.	O
,	O
misoprostol	O
,	O
proton-pump	O
inhibitors	O
,	O
and	O
non-study	O
H2RAs	O
)	O
,	O
non-study	O
NSAIDs	O
other	O
than	O
low-dose	O
aspirin	O
taken	O
for	O
cardiovascular	O
prophylaxis	O
.	O

The	O
forest	O
plot	O
of	O
these	O
is	O
shown	O
in	O
Figure	O
3	O
.	O

Overall	O
,	O
little	O
variation	O
occurred	O
in	O
the	O
adjusted	O
effects	O
of	O
treatment	O
in	O
different	O
subgroups	O
.	O

This	O
poor	O
quality	O
study	O
found	O
a	O
58	O
%	O
cure	O
rate	O
among	O
the	O
patients	O
allocated	O
to	O
cryotherapy	O
,	O
compared	O
with	O
41	O
%	O
among	O
those	O
treated	O
with	O
salicylic	O
acid	O
.	O

These	O
two	O
trials	O
were	O
designed	O
to	O
be	O
used	O
for	O
registration	O
,	O
and	O
,	O
in	O
pretrial	O
meetings	O
,	O
the	O
FDA	O
agreed	O
to	O
the	O
use	O
of	O
the	O
different	O
end	O
points	O
in	O
the	O
two	O
trials	O
.	O

2	O
)	O
.	O

Also	O
excluded	O
were	O
patients	O
with	O
body	O
weight	O
<	O
40	O
kg	O
,	O
severe	O
PAH	O
(	O
WHO	O
class	O
III/IV	O
)	O
,	O
moderate	O
to	O
severe	O
hepatic	O
impairment	O
or	O
serum	O
aminotransferase	O
levels	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
(	O
ULN	O
)	O
.	O

They	O
were	O
then	O
randomised	B-Randomization_Ratio
equally	I-Randomization_Ratio
to	O
receive	O
cryotherapy	B-Design_Parallel_Group
with	I-Design_Parallel_Group
liquid	I-Design_Parallel_Group
nitrogen	I-Design_Parallel_Group
or	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
self	I-Design_Parallel_Group
treatment	I-Design_Parallel_Group
with	I-Design_Parallel_Group
an	I-Design_Parallel_Group
over	I-Design_Parallel_Group
the	I-Design_Parallel_Group
counter	I-Design_Parallel_Group
50	I-Design_Parallel_Group
%	I-Design_Parallel_Group
salicylic	I-Design_Parallel_Group
acid	I-Design_Parallel_Group
treatment	I-Design_Parallel_Group
.	O

Virology	O
Testing	O
of	O
the	O
combined	O
nasal	O
and	O
throat	O
swab	O
specimens	O
on	O
day	O
five	O
,	O
which	O
was	O
the	O
primary	O
virological	O
study	O
endpoint	O
,	O
was	O
done	O
under	O
blinded	O
conditions	O
in	O
the	O
SEAICRN	O
reference	O
laboratories	O
in	O
Vietnam	O
and	O
Indonesia	O
.	O

All	O
statistical	O
analyses	O
were	O
conducted	O
using	O
SAS	O
software	O
,	O
version	O
9.2	O
and	O
R	O
version	O
2.10.1	O
.	O

At	O
the	O
end	O
of	O
24	O
weeks	O
,	O
29	O
(	O
67	O
%	O
;	O
95	O
%	O
CI	O
53	O
%	O
to	O
80	O
%	O
)	O
in	O
the	O
Ca+D	O
group	O
and	O
11	O
(	O
44	O
%	O
;	O
95	O
%	O
CI	O
27	O
%	O
to	O
63	O
%	O
)	O
in	O
the	O
Ca	O
group	O
achieved	O
the	O
primary	O
combined	O
outcome	O
of	O
radiographic	O
and	O
alkaline	O
phosphatase	O
endpoints	O
,	O
and	O
this	O
difference	O
was	O
marginally	O
significant	O
(	O
p=0.06	O
)	O
.	O

Vital	O
status	O
at	O
6	O
months	O
was	O
known	O
for	O
99	O
%	O
(	O
3011	O
of	O
3035	O
)	O
of	O
patients	O
.	O

Results	O
There	O
was	O
no	O
evidence	O
of	O
a	O
difference	O
between	O
the	O
salicylic	O
acid	O
and	O
cryotherapy	O
groups	O
in	O
the	O
proportions	O
of	O
participants	O
with	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
(	O
17/119	O
(	O
14	O
%	O
)	O
v	O
15/110	O
(	O
14	O
%	O
)	O
,	O
difference	O
0.65	O
%	O
(	O
95	O
%	O
CI	O
–8.33	O
to	O
9.63	O
)	O
,	O
P=0.89	O
)	O
.	O

Exclusion	O
criteria	O
were	O
pregnancy	O
or	O
positive	O
for	O
chorionic	O
gonadotrophin	O
(	O
hCG	O
)	O
in	O
urine	O
,	O
women	O
who	O
were	O
actively	O
breast	O
feeding	O
,	O
a	O
delay	O
of	O
more	O
than	O
72	O
hours	O
before	O
treatment	O
with	O
oseltamivir	O
,	O
and	O
severe	O
renal	O
impairment	O
defined	O
by	O
creatinine	O
clearance	O
<	O
10	O
mL/min	O
(	O
Cockcroft-Gault	O
equation	O
)	O
.	O

Adverse	O
events	O
occurring	O
in	O
more	O
patients	O
on	O
bosentan	O
than	O
placebo	O
included	O
peripheral	O
oedema	O
(	O
18.8	O
%	O
vs	O
4.4	O
%	O
)	O
and	O
events	O
denoting	O
elevated	O
aminotransferases	O
(	O
12.5	O
%	O
vs	O
2.2	O
%	O
)	O
.	O

In	O
the	O
conditional	O
multiple	O
logistic	O
regression	O
analysis	O
(	O
table	O
4	O
)	O
,	O
patients	O
who	O
had	O
no	O
viral	O
RNA	O
detected	O
on	O
day	O
five	O
were	O
more	O
likely	O
to	O
have	O
lower	O
nasal	O
viral	O
loads	O
at	O
baseline	O
,	O
human	O
(	O
non-avian	O
H5N1	O
)	O
influenza	O
virus	O
infection	O
,	O
and	O
a	O
higher	O
Karnofsky	O
score	O
(	O
≥50	O
)	O
.	O

Overall	O
,	O
32	O
of	O
the	O
229	O
(	O
14	O
%	O
)	O
had	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
,	O
corresponding	O
to	O
17/119	O
(	O
14	O
%	O
)	O
patients	O
in	O
the	O
salicylic	O
acid	O
group	O
and	O
15/110	O
(	O
14	O
%	O
)	O
patients	O
in	O
the	O
cryotherapy	O
group	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
difference	O
0.65	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
–8.33	O
to	O
9.63	O
)	O
,	O
P=0.89	O
)	O
.	O

Primary	O
outcome	O
:	O
determination	O
of	O
canakinumab	O
target	O
dose	O
No	O
evidence	O
of	O
a	O
dose-response	O
was	O
seen	O
in	O
any	O
of	O
the	O
four	O
predefined	O
dose	O
response	O
models	O
.	O

There	O
was	O
no	O
evidence	O
of	O
differences	O
between	O
ART-strategy	O
groups	O
in	O
progression	O
to	O
new	O
WHO	O
stage	O
4	O
event	O
or	O
death	O
(	O
HR	O
[	O
B	O
:	O
A	O
]	O
0·89	O
,	O
95	O
%	O
CI	O
0·53–1·48	O
;	O
HR	O
[	O
C	O
:	O
A	O
]	O
0·91	O
,	O
0·54–1·52	O
;	O
global	O
p=0·89	O
)	O
,	O
WHO	O
stage	O
3	O
or	O
4	O
event	O
or	O
death	O
(	O
HR	O
[	O
B	O
:	O
A	O
]	O
0·82	O
,	O
0·55–1·20	O
;	O
HR	O
[	O
C	O
:	O
A	O
]	O
0·80	O
,	O
0·54–1·17	O
;	O
global	O
p=0·44	O
)	O
,	O
or	O
mortality	O
overall	O
(	O
HR	O
[	O
B	O
:	O
A	O
]	O
0·66	O
,	O
0·33–1·31	O
;	O
HR	O
[	O
C	O
:	O
A	O
]	O
0·97	O
,	O
0·52–1·81	O
;	O
global	O
p=0·43	O
;	O
figure	O
4	O
;	O
appendix	O
)	O
.	O

The	O
baseline	O
mean	O
(	O
±SD	O
)	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
30.2±13.2	O
nmol/L	O
,	O
and	O
29	O
(	O
40	O
%	O
)	O
had	O
values	O
below	O
30	O
nmol/L	O
.	O

Setting	O
Jos	B-Settings_Single_Center
University	I-Settings_Single_Center
Teaching	I-Settings_Single_Center
Hospital	I-Settings_Single_Center
,	O
Jos	B-Settings_Location
,	I-Settings_Location
Nigeria	I-Settings_Location
.	O

Specifically	O
,	O
at	O
day	O
five	O
,	O
in	O
the	O
224	O
patients	O
infected	O
with	O
seasonal	O
influenza	O
(	O
excluding	O
H5N1	O
and	O
H1N1-pdm09	O
infections	O
)	O
the	O
proportions	O
of	O
patients	O
with	O
negative	O
results	O
for	O
viral	O
RNA	O
in	O
the	O
nasal	O
and	O
throat	O
swabs	O
were	O
similar	O
(	O
P=0.45	O
)	O
between	O
the	O
double	O
(	O
82/114	O
,	O
72	O
%	O
)	O
and	O
standard	O
dose	O
arms	O
(	O
74/110	O
,	O
67	O
%	O
)	O
.	O

Baseline	O
characteristics	O
were	O
similar	O
across	O
randomised	O
groups	O
(	O
table	O
1	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
determination	O
of	O
the	O
canakinumab	O
dose	O
producing	O
equivalent	O
efficacy	O
to	O
that	O
achieved	O
with	O
colchicine	O
0.5	O
mg	O
,	O
with	O
respect	O
to	O
the	O
mean	O
number	O
of	O
flares	O
per	O
patient	O
occurring	O
within	O
16	O
weeks	O
post	O
randomisation	O
(	O
ie	O
,	O
the	O
target	O
dose	O
)	O
.	O

The	O
primary	O
outcome	O
for	O
analyses	O
of	O
prolonged	O
follow-up	O
was	O
prespecified	O
to	O
be	O
the	O
first	O
post-randomisation	O
major	O
vascular	O
event	O
(	O
defined	O
as	O
non-fatal	O
myocardial	O
infarction	O
or	O
coronary	O
death	O
,	O
fatal	O
or	O
non-fatal	O
stroke	O
,	O
coronary	O
or	O
non-coronary	O
revascularisation	O
)	O
.	O

We	O
received	O
patient	O
self	O
reported	O
data	O
on	O
presence	O
or	O
absence	O
of	O
plantar	O
warts	O
at	O
six	O
months	O
from	O
193	O
participants	O
.	O

Baseline	O
rates	O
of	O
positivity	O
for	O
RNA	O
influenza	O
were	O
similar	O
for	O
the	O
nasal	O
(	O
239/317	O
,	O
75.4	O
%	O
)	O
and	O
throat	O
(	O
242/312	O
,	O
77.6	O
%	O
)	O
swabs	O
.	O

Results	O
Baseline	O
demographics	O
and	O
disposition	O
A	O
total	O
of	O
149	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
randomised	O
to	O
the	O
study	O
,	O
and	O
141	B-Sample_Size_Actual_at_Outcome_Analysis
patients	O
completed	O
the	O
study	O
.	O

About	O
1100	O
blood	O
samples	O
were	O
obtained	O
by	O
participants	O
'	O
family	O
doctors	O
and	O
were	O
mailed	O
to	O
a	O
central	O
laboratory	O
for	O
assay	O
using	O
previously	O
validated	O
methods	O
.	O

In	O
these	O
regression	O
models	O
,	O
the	O
quantifiable	O
viral	O
load	O
data	O
were	O
used	O
(	O
that	O
is	O
,	O
≥103	O
cDNA	O
copies/mL	O
)	O
and	O
data	O
from	O
samples	O
positive	O
by	O
qualitative	O
RT-PCR	O
but	O
not	O
quantifiable	O
were	O
given	O
a	O
value	O
of	O
103	O
cDNA	O
copies	O
(	O
c	O
)	O
/mL	O
,	O
the	O
lower	O
limit	O
of	O
detection	O
of	O
the	O
quantitative	O
RT-PCR	O
.	O

In	O
the	O
treated	O
set	O
,	O
slightly	O
more	O
patients	O
were	O
female	O
(	O
55.0	O
%	O
)	O
than	O
male	O
(	O
45.0	O
%	O
)	O
,	O
mean	O
age	O
was	O
49.3	O
years	O
and	O
mean	O
body	O
mass	O
index	O
was	O
26.9	O
kg/m2	O
(	O
Table	O
1	O
)	O
.	O

METHODS	O
:	O
Patients	O
(	O
40–80	O
years	O
)	O
requiring	O
daily	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
for	O
≥6	O
months	O
with	O
no	O
prior	O
ulcer	O
complications	O
,	O
negative	O
H.	O
pylori	O
stool	O
test	O
,	O
and	O
baseline	O
endoscopy	O
showing	O
no	O
ulcers	O
and	O
<	O
5	O
erosions	O
were	O
randomly	O
assigned	O
in	O
a	O
2:1	B-Randomization_Ratio
ratio	O
to	O
HZT-501	B-Design_Parallel_Group
or	I-Design_Parallel_Group
identical-appearing	I-Design_Parallel_Group
ibuprofen	I-Design_Parallel_Group
800	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
tablets	I-Design_Parallel_Group
thrice	O
daily	O
.	O

No	O
differences	O
were	O
found	O
between	O
double	O
and	O
standard	O
dose	O
arms	O
in	O
median	O
days	O
on	O
supplemental	O
oxygen	O
(	O
3	O
(	O
interquartile	O
range	O
2-5	O
)	O
v	O
3.5	O
(	O
2-7	O
)	O
)	O
,	O
in	O
intensive	O
care	O
(	O
4.5	O
(	O
3-6	O
)	O
v	O
5	O
(	O
2-11	O
)	O
,	O
and	O
on	O
mechanical	O
ventilation	O
(	O
2.5	O
(	O
1-16	O
)	O
v	O
8	O
(	O
1-16	O
)	O
)	O
,	O
respectively	O
.	O

Secondary	O
analysis	O
A	O
logistic	O
regression	O
model	O
was	O
used	O
to	O
adjust	O
the	O
primary	O
analysis	O
for	O
important	O
prognostic	O
variables	O
(	O
age	O
,	O
whether	O
the	O
plantar	O
wart	O
had	O
been	O
previously	O
treated	O
,	O
and	O
type	O
of	O
wart	O
)	O
.	O

In	O
Italy	O
and	O
Austria	O
,	O
all	O
follow-ups	O
were	O
done	O
as	O
telephone	O
interviews	O
by	O
a	O
clinician	B-Blinding_Object_Others
,	O
who	O
was	O
masked	O
to	O
treatment	O
allocation	O
and	O
was	O
highly	O
experienced	O
in	O
outcome	O
assessment	O
.	O

Patients	O
suitable	O
for	O
topical	O
treatment	O
were	O
entered	O
into	O
a	O
parallel	O
observational	O
study	O
,	O
the	O
results	O
of	O
which	O
will	O
be	O
reported	O
separately	O
.	O

More	O
deaths	O
occurred	O
within	O
7	O
days	O
in	O
the	O
rt-PA	O
group	O
(	O
163	O
[	O
11	O
%	O
]	O
)	O
than	O
in	O
the	O
control	O
group	O
(	O
107	O
[	O
7	O
%	O
]	O
,	O
adjusted	O
OR	O
1·60	O
,	O
95	O
%	O
CI	O
1·22–2·08	O
,	O
p=0·001	O
;	O
absolute	O
increase	O
37/1000	O
,	O
95	O
%	O
CI	O
17–57	O
)	O
,	O
but	O
between	O
7	O
days	O
and	O
6	O
months	O
there	O
were	O
fewer	O
deaths	O
in	O
the	O
rt-PA	O
group	O
than	O
in	O
the	O
control	O
group	O
,	O
so	O
that	O
by	O
6	O
months	O
,	O
similar	O
numbers	O
,	O
in	O
total	O
,	O
had	O
died	O
(	O
408	O
[	O
27	O
%	O
]	O
in	O
the	O
rt-PA	O
group	O
vs	O
407	O
[	O
27	O
%	O
]	O
in	O
the	O
control	O
group	O
)	O
.	O

These	O
data	O
suggest	O
that	O
IgE	O
may	O
drive	O
allergic	O
asthma	O
in	O
a	O
subset	O
of	O
patients	O
.	O

The	O
computer-generated	B-Randomization_Sequence_Generation_Method
sequentially	I-Randomization_Sequence_Generation_Method
numbered	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
(	O
with	O
variable	O
block	B-Randomization_Type_Block
sizes	O
)	O
containing	O
both	O
allocations	O
was	O
pre-prepared	O
by	O
the	O
trial	O
statistician	B-Randomization_Personnel
and	O
incorporated	O
within	O
the	O
secure	O
database	O
at	O
each	O
trial	O
centre	O
,	O
connected	O
to	O
but	O
not	O
located	O
within	O
each	O
clinical	O
centre	O
,	O
allowing	O
trial	O
managers	O
to	O
access	O
the	O
next	O
number	O
,	O
but	O
not	O
the	O
whole	O
list	O
.	O

Events	O
occurring	O
within	O
7	O
days	O
of	O
stroke	O
were	O
recorded	O
by	O
the	O
local	O
trial	O
clinician	O
on	O
the	O
7-day	O
form	O
:	O
deaths	O
subdivided	O
by	O
cause	O
(	O
swelling	O
of	O
the	O
initial	O
infarct	O
,	O
intracranial	O
haemorrhage	O
,	O
other	O
deaths	O
from	O
the	O
initial	O
stroke	O
,	O
recurrent	O
ischaemic	O
stroke	O
,	O
recurrent	O
stroke	O
of	O
unknown	O
type	O
,	O
any	O
other	O
cause	O
)	O
;	O
symptomatic	O
intracranial	O
haemorrhage	O
;	O
recurrent	O
ischaemic	O
stroke	O
;	O
recurrent	O
stroke	O
of	O
unknown	O
type	O
;	O
neurological	O
deterioration	O
attributed	O
to	O
swelling	O
of	O
the	O
initial	O
ischaemic	O
stroke	O
;	O
neurological	O
deterioration	O
not	O
attributable	O
to	O
swelling	O
of	O
the	O
initial	O
ischaemic	O
stroke	O
or	O
haemorrhage	O
;	O
and	O
major	O
extracranial	O
haemorrhage	O
(	O
operational	O
definitions	O
of	O
each	O
of	O
these	O
events	O
are	O
provided	O
in	O
the	O
published	O
protocol	O
and	O
statistical	O
analysis	O
plan	O
)	O
.	O

Interventions	O
Participants	O
received	O
oral	O
prednisolone	O
(	O
brand	O
chosen	O
according	O
to	O
local	O
practice	O
)	O
0.75	O
mg/kg/day	O
in	O
a	O
single	O
dose	O
or	O
ciclosporin	O
(	O
Neoral	O
;	O
Novartis	O
)	O
4	O
mg/kg/day	O
in	O
two	O
divided	O
doses	O
.	O

Weight	O
was	O
measured	O
with	O
a	O
hanging	O
weighing	O
scale	O
.	O

Eligible	O
participants	O
gave	O
written	O
informed	O
consent	O
.	O

Venous	O
17-gauge	O
cannulae	O
were	O
inserted	O
into	O
each	O
forearm	O
for	O
blood	O
sampling	O
and	O
a	O
27-standard	O
wire	O
gauge	O
steel	O
needle	O
placed	O
in	O
the	O
brachial	O
artery	O
of	O
the	O
non-dominant	O
forearm	O
for	O
vasodilator	O
infusions	O
.	O

The	O
incidence	O
of	O
a	O
first	O
diagnosis	O
of	O
any	O
type	O
of	O
cancer	O
(	O
excluding	O
,	O
as	O
prespecified	O
,	O
non-melanoma	O
skin	O
cancer	O
)	O
was	O
similar	O
throughout	O
the	O
in-trial	O
and	O
post-trial	O
periods	O
combined	O
(	O
1749	O
[	O
17·0	O
%	O
]	O
allocated	O
simvastatin	O
vs	O
1744	O
[	O
17·0	O
%	O
]	O
allocated	O
placebo	O
;	O
RR	O
0·98	O
[	O
0·92–1·05	O
]	O
;	O
p=0·60	O
;	O
figure	O
5	O
)	O
.	O

Median	O
baseline	O
quantitative	O
viral	O
loads	O
were	O
similar	O
between	O
the	O
two	O
arms	O
for	O
nose	O
(	O
9.6×10e4	O
copies	O
in	O
the	O
double	O
dose	O
(	O
n=99	O
)	O
and	O
1.5×10e5	O
copies	O
in	O
the	O
standard	O
dose	O
arm	O
(	O
n=96	O
)	O
)	O
and	O
throat	O
(	O
4.1×10e4	O
copies	O
in	O
the	O
double	O
dose	O
(	O
n=85	O
)	O
and	O
6.3×10e4	O
copies	O
in	O
the	O
standard	O
dose	O
arm	O
(	O
n=95	O
)	O
;	O
see	O
supplementary	O
figure	O
in	O
appendix	O
)	O
.	O

Heart	O
rate	O
and	O
blood	O
pressure	O
in	O
the	O
non-infused	O
arm	O
were	O
monitored	O
at	O
intervals	O
throughout	O
with	O
the	O
use	O
of	O
a	O
semiautomated	O
,	O
non-invasive	O
oscillometric	O
sphygmomanometer	O
.	O

The	O
weight	O
of	O
limestone	O
remaining	O
at	O
each	O
visit	O
was	O
recorded	O
to	O
assess	O
adherence	O
.	O

We	O
hypothesised	O
that	O
decreasing	O
excessive	O
,	O
NMDA-dependant	O
,	O
glutamatergic	O
transmission	O
might	O
partly	O
restore	O
gait	O
and	O
posture	O
control	O
.	O

Assessments	O
The	O
patient	O
daily	O
diary	O
included	O
two	O
sections	O
in	O
addition	O
to	O
peak	O
flow	O
measurements	O
:	O
1	O
)	O
a	O
morning	O
section	O
capturing	O
awakenings	O
and	O
rescue	O
medication	O
use	O
at	O
night	O
,	O
and	O
symptoms	O
on	O
awakening	O
;	O
and	O
2	O
)	O
an	O
evening	O
section	O
capturing	O
daytime	O
symptom	O
severity	O
,	O
rescue	O
medication	O
use	O
,	O
preventive	O
inhaler	O
use	O
,	O
activity	O
impairment	O
during	O
the	O
day	O
,	O
and	O
nasal	O
symptoms	O
.	O

Recently	O
,	O
a	O
number	O
of	O
clinical	O
trials	O
have	O
investigated	O
tiotropium	O
as	O
add-on	O
to	O
at	O
least	O
ICS	O
for	O
the	O
long-term	O
control	O
of	O
asthma	O
,	O
across	O
a	O
range	O
of	O
severities	O
.	O

Based	O
on	O
non-compartmental	O
analysis	O
,	O
the	O
mean	O
t1/2	O
values	O
of	O
quilizumab	O
across	O
the	O
dose	O
groups	O
ranged	O
from	O
16.4	O
to	O
18.7	O
days	O
,	O
which	O
suggests	O
that	O
steady-state	O
was	O
attained	O
by	O
the	O
time	O
the	O
final	O
doses	O
were	O
administered	O
for	O
both	O
monthly	O
and	O
quarterly	O
regimens	O
.	O

RESULTS	O
The	O
progress	O
of	O
the	O
studies	O
from	O
enrollment	O
through	O
analysis	O
is	O
shown	O
in	O
the	O
CONSORT	O
diagrams	O
in	O
Figure	O
1	O
.	O

Safety	O
and	O
tolerability	O
were	O
assessed	O
based	O
on	O
the	O
incidence	O
and	O
intensity	O
of	O
adverse	O
events	O
,	O
and	O
on	O
changes	O
in	O
vital	O
signs	O
.	O

Results	O
Between	O
May	O
,	O
2000	O
,	O
and	O
July	O
,	O
2011	O
,	O
3035	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
enrolled	O
in	O
156	B-Settings_Multicenter
centres	I-Settings_Multicenter
in	O
12	B-Settings_Multicenter
countries	I-Settings_Multicenter
.	O

Patients	O
Inclusion	O
criteria	O
were	O
:	O
age	O
18–80	O
years	O
,	O
diagnosis	O
of	O
gouty	O
arthritis	O
as	O
defined	O
by	O
the	O
American	O
College	O
of	O
Rheumatology	O
1977	O
preliminary	O
criteria	O
,	O
having	O
had	O
at	O
least	O
two	O
gouty	O
arthritis	O
flares	O
in	O
the	O
previous	O
year	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
of	O
≤40	O
kg/m2	O
and	O
willingness	O
to	O
initiate	O
allopurinol	O
treatment	O
or	O
having	O
initiated	O
allopurinol	O
treatment	O
within	O
1	O
month	O
of	O
screening	O
.	O

Logistic	O
regression	O
was	O
used	O
to	O
assess	O
the	O
effect	O
of	O
treatment	O
group	O
on	O
the	O
primary	O
outcome	O
while	O
controlling	O
for	O
baseline	O
group	O
differences	O
and	O
to	O
test	O
for	O
interactions	O
between	O
variables	O
.	O

Eligibility	O
criteria	O
included	O
≥60	O
%	O
and	O
≤90	O
%	O
of	O
predicted	O
normal	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
and	O
seven-question	O
Asthma	O
Control	O
Questionnaire	O
mean	O
score	O
of	O
≥1.5	O
.	O

The	O
trial	O
did	O
not	O
meet	O
its	O
original	O
target	O
of	O
6000	O
patients	O
,	O
and	O
so	O
was	O
no	O
longer	O
adequately	O
powered	O
to	O
detect	O
a	O
3	O
%	O
absolute	O
difference	O
in	O
the	O
primary	O
outcome	O
(	O
with	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
and	O
α=0·05	B-Sample_Size_Calculation_Alpha_Value
)	O
.	O

Size	O
,	O
tempo	O
,	O
and	O
velocity	O
are	O
thus	O
participant	O
specific	O
random	O
effects	O
summarising	O
how	O
each	O
girl	O
’	O
s	O
curve	O
differs	O
from	O
the	O
average	O
curve	O
.	O

Such	O
patients	O
may	O
develop	O
difficult-to-treat	O
disease	O
,	O
characterised	O
by	O
frequent	O
flares	O
and	O
persistent	O
inflammation	O
between	O
flares	O
which	O
contribute	O
to	O
joint	O
damage	O
and	O
have	O
a	O
major	O
impact	O
on	O
health-related	O
quality	O
of	O
life	O
and	O
an	O
individual	O
's	O
ability	O
to	O
work	O
.	O

Events	O
were	O
coded	O
according	O
to	O
prespecified	O
criteria	O
by	O
clinical	B-Blinding_Object_Others
staff	I-Blinding_Object_Others
in	O
the	O
coordinating	O
centre	O
,	O
who	O
were	O
unaware	O
of	O
the	O
study	O
treatment	O
allocation	O
.	O

Study	O
design	O
After	O
an	O
initial	O
screening	O
visit	O
and	O
a	O
4-week	O
run-in	O
period	O
,	O
patients	O
were	O
randomised	O
to	O
one	O
of	O
four	O
treatment	O
sequences	O
,	O
during	O
which	O
they	O
received	O
each	O
of	O
the	O
four	O
treatments	O
(	O
tiotropium	B-Design_Parallel_Group
5	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
2.5	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
1.25	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
all	O
delivered	O
via	O
the	O
Respimat®	O
SoftMist™	O
inhaler	O
)	O
(	O
Figure	O
1	O
)	O
.	O

Selected	O
baseline	O
characteristics	O
of	O
the	O
primary	O
population	O
analyzed	O
in	O
the	O
two	O
study	O
groups	O
for	O
each	O
trial	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Three	B-Sample_Size_Calculation_Dropout_Rate_Value
patients	I-Sample_Size_Calculation_Dropout_Rate_Value
dropped	I-Sample_Size_Calculation_Dropout_Rate_Value
out	I-Sample_Size_Calculation_Dropout_Rate_Value
due	O
to	O
lack	O
of	O
efficacy	O
(	O
placebo	O
:	O
n=2	O
;	O
memantine	O
:	O
n=1	O
)	O
but	O
two	O
of	O
the	O
latter	O
(	O
one	O
in	O
each	O
group	O
)	O
were	O
included	O
in	O
the	O
final	O
efficacy	O
analysis	O
because	O
they	O
had	O
dropped	O
out	O
shortly	O
before	O
the	O
end	O
of	O
the	O
study	O
(	O
see	O
the	O
see	O
online	O
supplementary	O
figure	O
(	O
flowchart	O
)	O
and	O
supplementary	O
data	O
on	O
the	O
criteria	O
for	O
ending	O
recruitment	O
)	O
.	O

For	O
major	O
coronary	O
events	O
,	O
a	O
27	O
%	O
(	O
SE	O
4	O
)	O
reduction	O
was	O
noted	O
during	O
the	O
in-trial	O
period	O
(	O
p	O
<	O
0·0001	O
)	O
.	O

A	O
change	O
to	O
the	O
protocol	O
was	O
made	O
in	O
August	O
2011	O
(	O
after	O
82	O
participants	O
had	O
been	O
enrolled	O
)	O
as	O
bowel	O
perforation	O
was	O
experienced	O
by	O
a	O
participant	O
receiving	O
prednisolone	O
110	O
mg/day	O
.	O

The	O
upper	O
95	O
%	O
confidence	O
limit	O
for	O
the	O
absolute	O
difference	O
was	O
below	O
the	O
non-inferiority	O
margin	O
of	O
1·6	O
.	O

However	O
,	O
there	O
was	O
also	O
no	O
suggestion	O
of	O
higher	O
event	O
rates	O
in	O
group	O
C	O
receiving	O
long-term	O
three-NRTI	O
maintenance	O
,	O
despite	O
lower	O
long-term	O
viral	O
load	O
suppression	O
;	O
if	O
anything	O
,	O
fewer	O
events	O
occurred	O
after	O
1	O
year	O
(	O
seven	O
deaths	O
in	O
group	O
A	O
vs	O
five	O
in	O
group	O
B	O
vs	O
two	O
in	O
group	O
C	O
;	O
18	O
vs	O
13	O
vs	O
eight	O
WHO	O
stage	O
4	O
events	O
or	O
deaths	O
;	O
37	O
vs	O
26	O
vs	O
17	O
WHO	O
stage	O
3	O
or	O
4	O
events	O
or	O
deaths	O
)	O
.	O

All	O
antibodies	O
were	O
diluted	O
1:20	O
with	O
flow	O
buffer	O
.	O

All	O
children	O
received	O
ART	O
as	O
syrups	O
or	O
tablets	O
dosed	O
according	O
to	O
WHO	O
weight-band	O
tables	O
.	O

The	O
number	O
of	O
plantar	O
warts	O
at	O
the	O
start	O
of	O
the	O
study	O
was	O
not	O
found	O
to	O
be	O
an	O
important	O
predictor	O
of	O
outcome	O
(	O
odds	O
ratio	O
0.81	O
(	O
0.65	O
to	O
1.01	O
)	O
)	O
.	O

To	O
allow	O
for	O
study	O
withdrawals	O
,	O
our	O
target	O
sample	O
size	O
was	O
300	B-Sample_Size_Target
patients	O
.	O

Results	O
The	O
two	O
treatment	O
groups	O
were	O
well	O
matched	O
with	O
respect	O
to	O
demographic	O
features	O
,	O
baseline	O
disease	O
characteristics	O
and	O
concomitant	O
treatment	O
for	O
DUs	O
at	O
baseline	O
(	O
table	O
1	O
)	O
.	O

Serum	O
anti-therapeutic	O
antibodies	O
(	O
ATAs	O
)	O
were	O
assessed	O
in	O
samples	O
at	O
Weeks	O
0	O
,	O
4	O
,	O
12	O
,	O
24	O
,	O
36	O
,	O
48	O
,	O
60	O
,	O
and	O
84	O
using	O
a	O
validated	O
bridging	O
ELISA	O
(	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

At	O
6	O
months	O
,	O
554	O
(	O
37	O
%	O
)	O
in	O
the	O
rt-PA	O
group	O
versus	O
534	O
(	O
35	O
%	O
)	O
in	O
the	O
control	O
group	O
were	O
alive	O
and	O
independent	O
in	O
activities	O
of	O
daily	O
living	O
(	O
OHS	O
0–2	O
;	O
table	O
2	O
)	O
.	O

Pharmacodynamic	O
biomarkers	O
Quilizumab	O
gradually	O
reduced	O
mean	O
serum	O
total	O
and	O
allergen-specific	O
IgE	O
,	O
reaching	O
a	O
30–40	O
%	O
reduction	O
at	O
Week	O
36	O
in	O
all	O
three	O
quilizumab	O
cohorts	O
(	O
p	O
<	O
0.01	O
compared	O
to	O
placebo	O
;	O
Fig	O
.	O

Subgroups	O
specified	O
in	O
the	O
analysis	O
plan	O
were	O
the	O
factorial	O
randomisations	O
,	O
time	O
on	O
ART	O
,	O
sex	O
,	O
age	O
,	O
centre	O
,	O
CD4	O
,	O
weight	O
for	O
age	O
,	O
randomisation	O
year	O
,	O
and	O
previous	O
ART	O
for	O
prevention	O
of	O
mother-to-child	O
transmission	O
.	O

The	O
only	O
infections	O
occurring	O
in	O
more	O
than	O
1	O
%	O
of	O
patients	O
receiving	O
canakinumab	O
were	O
upper	O
respiratory	O
tract	O
infections	O
(	O
3.7	O
%	O
)	O
,	O
nasopharyngitis	O
(	O
3.7	O
%	O
)	O
and	O
influenza	O
(	O
1.2	O
%	O
)	O
.	O

Background	O
Asthma	O
,	O
a	O
chronic	O
inflammatory	O
disorder	O
of	O
the	O
airways	O
,	O
affects	O
over	O
300	O
million	O
people	O
worldwide	O
.	O

This	O
effect	O
was	O
greater	O
in	O
patients	O
who	O
entered	O
the	O
trial	O
with	O
more	O
DUs	O
.	O

This	O
is	O
achieved	O
with	O
urate	O
lowering	O
therapies	O
(	O
ULT	O
)	O
.	O

These	O
symptoms	O
represent	O
a	O
public	O
health	O
issue	O
for	O
which	O
a	O
specific	O
treatment	O
is	O
currently	O
lacking	O
.	O

Statistical	O
methods	O
The	O
primary	O
outcome	O
was	O
final	O
height	O
,	O
defined	O
as	O
height	O
velocity	O
less	O
than	O
1	O
cm/year	O
and	O
bone	O
age	O
at	O
least	O
15.5	O
years	O
.	O

The	O
difference	O
was	O
almost	O
exclusively	O
driven	O
by	O
excess	O
asymptomatic	O
neutropenia	O
(	O
86	O
vs	O
133	O
vs	O
184	O
events	O
;	O
appendix	O
)	O
.	O

At	O
the	O
latest	O
test	O
,	O
median	O
3·7	O
(	O
IQR	O
3·0–4·1	O
)	O
years	O
after	O
ART	O
initiation	O
,	O
351	O
(	O
77	O
%	O
)	O
of	O
458	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
345	O
(	O
78	O
%	O
)	O
of	O
443	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
viral	O
load	O
less	O
than	O
400	O
copies	O
per	O
mL	O
(	O
p=0·66	O
)	O
,	O
similar	O
across	O
ages	O
(	O
heterogeneity	O
p=0·25	O
)	O
;	O
329	O
(	O
72	O
%	O
)	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
313	O
(	O
71	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
viral	O
load	O
less	O
than	O
80	O
copies	O
per	O
mL	O
(	O
p=0·70	O
)	O
.	O

Although	O
CT	O
scanning	O
was	O
preferred	O
,	O
MRI	O
was	O
allowed	O
.	O

For	O
secondary	O
and	O
exploratory	O
end	O
points	O
,	O
the	O
means	O
and	O
standard	O
deviations	O
of	O
all	O
values	O
for	O
relative	O
change	O
were	O
calculated	O
according	O
to	O
study	O
group	O
at	O
Weeks	O
12	O
and	O
36	O
.	O

Bosentan	O
was	O
well	O
tolerated	O
and	O
may	O
be	O
a	O
useful	O
adjunct	O
in	O
the	O
management	O
of	O
patients	O
with	O
SSc	O
with	O
recurrent	O
DUs	O
.	O

Participants	O
gave	O
written	O
informed	O
consent	O
.	O

Similarly	O
,	O
patients	O
with	O
high	O
levels	O
of	O
exhaled	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
blood	O
eosinophils	O
,	O
or	O
serum	O
periostin	O
,	O
had	O
fewer	O
asthma	O
exacerbations	O
following	O
treatment	O
with	O
omalizumab	O
,	O
a	O
neutralizing	O
anti-IgE	O
antibody	O
,	O
than	O
patients	O
with	O
low	O
biomarker	O
levels	O
.	O

Given	O
the	O
heterogeneity	O
of	O
the	O
enrolled	O
population	O
,	O
we	O
performed	O
post	O
hoc	O
exploratory	O
analyses	O
to	O
evaluate	O
detection	O
and	O
quantification	O
(	O
copy	O
numbers	O
)	O
of	O
virus	O
RNA	O
on	O
day	O
one	O
,	O
three	O
,	O
and	O
five	O
of	O
treatment	O
in	O
several	O
subgroups	O
of	O
interest	O
(	O
age	O
,	O
virus	O
,	O
days	O
of	O
illness	O
before	O
enrolment	O
)	O
.	O

Canakinumab	O
reduces	O
the	O
risk	O
of	O
acute	O
gouty	O
arthritis	O
flares	O
during	O
initiation	O
of	O
allopurinol	O
treatment	O
:	O
results	O
of	O
a	O
double-blind	B-Blinding_Double_Blind
,	O
randomised	B-Randomization_Type_Simple
study	O

Among	O
girls	O
previously	O
randomised	O
to	O
oxandrolone	O
,	O
the	O
effect	O
of	O
late	O
induction	O
compared	O
with	O
early	O
induction	O
was	O
clinically	O
insignificant	O
(	O
+0.7	O
cm	O
)	O
;	O
in	O
the	O
placebo	O
group	O
,	O
however	O
,	O
late	O
induction	O
added	O
6.2	O
cm	O
compared	O
with	O
early	O
induction	O
(	O
table	O
3	O
,	O
interaction	O
)	O
.	O

However	O
,	O
most	O
were	O
done	O
at	O
routine	O
visits	O
(	O
10	O
805	O
[	O
92	O
%	O
]	O
haematology	O
and	O
10	O
778	O
[	O
94	O
%	O
]	O
biochemistry	O
;	O
appendix	O
)	O
.	O

We	O
used	O
negative	O
binomial	O
regression	O
to	O
compare	O
the	O
number	O
of	O
plantar	O
warts	O
at	O
12	O
weeks	O
between	O
the	O
two	O
treatment	O
groups	O
with	O
adjustment	O
for	O
the	O
number	O
of	O
plantar	O
warts	O
at	O
baseline	O
.	O

Randomisation	O
and	O
blinding	O
Participants	O
were	O
randomised	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
treatment	O
allocation	O
using	O
a	B-Allocation_Concealment_Method
web	I-Allocation_Concealment_Method
based	I-Allocation_Concealment_Method
randomisation	I-Allocation_Concealment_Method
system	I-Allocation_Concealment_Method
hosted	O
by	O
Nottingham	B-Randomization_Sequence_Generation_Method
Clinical	I-Randomization_Sequence_Generation_Method
Trials	I-Randomization_Sequence_Generation_Method
Unit	I-Randomization_Sequence_Generation_Method
,	O
using	O
a	B-Randomization_Sequence_Generation_Method
computer	I-Randomization_Sequence_Generation_Method
generated	I-Randomization_Sequence_Generation_Method
pseudorandom	I-Randomization_Sequence_Generation_Method
list	I-Randomization_Sequence_Generation_Method
,	O
with	O
permuted	B-Randomization_Type_Block
blocks	I-Randomization_Type_Block
of	O
randomly	O
varying	B-Randomization_Block_Size
size	I-Randomization_Block_Size
between	I-Randomization_Block_Size
two	I-Randomization_Block_Size
and	I-Randomization_Block_Size
six	I-Randomization_Block_Size
(	O
RALLOC	O
add-on	O
for	O
Stata	O
,	O
TX	O
)	O
.	O

No	O
differences	O
in	O
viral	O
RNA	O
detection	O
rates	O
or	O
outcome	O
were	O
associated	O
with	O
presence	O
of	O
the	O
H275Y	O
mutation	O
at	O
day	O
0	O
or	O
day	O
five	O
among	O
patients	O
infected	O
with	O
seasonal	O
H1N1	O
viruses	O
,	O
but	O
numbers	O
were	O
small	O
.	O

Alkaline	O
phosphatase	O
values	O
and	O
radiographic	O
scores	O
improved	O
in	O
both	O
groups	O
(	O
figures	O
2	O
and	O
3	O
)	O
.	O

Switching	O
to	O
second-line	O
ART	O
(	O
including	O
a	O
ritonavir-boosted	O
protease	O
inhibitor	O
)	O
was	O
based	O
on	O
clinical	O
criteria	O
in	O
all	O
participants	O
(	O
new	O
or	O
recurrent	O
WHO	O
stage	O
4	O
event	O
;	O
or	O
WHO	O
stage	O
3	O
event	O
or	O
events	O
at	O
clinician	O
discretion	O
,	O
particularly	O
if	O
recurrent	O
or	O
persistent	O
)	O
,	O
or	O
on	O
laboratory	O
criteria	O
for	O
routine	O
laboratory	O
monitoring	O
(	O
confirmed	O
on-ART	O
CD4	O
of	O
<	O
15	O
%	O
at	O
age	O
1–2	O
years	O
,	O
<	O
10	O
%	O
at	O
3–4	O
years	O
,	O
<	O
100	O
cells/mL	O
at	O
≥5	O
years	O
)	O
.	O

Allopurinol	O
is	O
the	O
most	O
commonly	O
used	O
ULT	O
and	O
the	O
current	O
standard	O
of	O
care	O
.	O

Patients	O
were	O
required	O
to	O
have	O
a	O
seven-question	O
Asthma	O
Control	O
Questionnaire	O
(	O
ACQ-7	O
)	O
mean	O
score	O
of	O
≥1.5	O
at	O
Visits	O
1	O
and	O
2	O
,	O
to	O
have	O
a	O
pre-bronchodilator	O
FEV1	O
of	O
≥60	O
%	O
and	O
≤90	O
%	O
of	O
predicted	O
normal	O
FEV1	O
at	O
Visit	O
1	O
,	O
and	O
to	O
demonstrate	O
absolute	O
FEV1	O
variability	O
within	O
30	O
%	O
between	O
Visits	O
1	O
and	O
2	O
.	O

Secondary	O
outcomes	O
were	O
analysed	O
using	O
Cox	O
regression	O
models	O
(	O
for	O
time	O
to	O
event	O
outcomes	O
)	O
;	O
linear	O
regression	O
models	O
for	O
dermatology	O
life	O
quality	O
index	O
,	O
EQ-5D	O
,	O
and	O
EQ-VAS	O
(	O
adjusted	O
for	O
baseline	O
values	O
)	O
,	O
and	O
for	O
self	O
reported	O
pain	O
(	O
which	O
were	O
summarised	O
using	O
area	O
under	O
the	O
curve	O
)	O
;	O
proportional	O
odds	O
models	O
for	O
ordered	O
categorical	O
outcomes	O
;	O
and	O
logistic	O
regression	O
models	O
for	O
binary	O
outcomes	O
.	O

This	O
is	O
also	O
consistent	O
with	O
the	O
2010	O
position	O
paper	O
by	O
Ison	O
and	O
colleagues	O
on	O
the	O
choice	O
of	O
efficacy	O
endpoints	O
in	O
severe	O
influenza	O
studies	O
.	O

Corresponding	O
two-sided	O
p-values	O
and	O
90	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
reported	O
.	O

The	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
six	O
months	O
was	O
analysed	O
in	O
the	O
same	O
way	O
as	O
the	O
primary	O
outcome	O
with	O
adjustments	O
for	O
the	O
same	O
covariates	O
.	O

During	O
the	O
post-trial	O
period	O
,	O
the	O
incidence	O
rates	O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
(	O
0·98	O
[	O
0·86–1·12	O
]	O
;	O
p=0·77	O
)	O
,	O
with	O
no	O
adverse	O
effect	O
on	O
haemorrhagic	O
stroke	O
(	O
38	O
[	O
0·4	O
%	O
]	O
vs	O
51	O
[	O
0·6	O
%	O
]	O
;	O
p=0·13	O
)	O
.	O

Objective	O
To	O
investigate	O
the	O
validity	O
of	O
recommendations	O
in	O
treatment	O
guidelines	O
to	O
use	O
higher	O
than	O
approved	O
doses	O
of	O
oseltamivir	O
in	O
patients	O
with	O
severe	O
influenza	O
.	O

3	O
)	O
.	O

Exploratory	O
analyses	O
were	O
conducted	O
on	O
biomarker	O
subgroups	O
(	O
periostin	O
,	O
blood	O
eosinophils	O
,	O
serum	O
IgE	O
,	O
and	O
exhaled	O
nitric	O
oxide	O
)	O
.	O

At	O
week	O
12	O
,	O
more	O
patients	O
were	O
unhappy	O
with	O
salicylic	O
acid	O
than	O
with	O
cryotherapy	O
,	O
and	O
more	O
were	O
very	O
happy	O
with	O
cryotherapy	O
than	O
with	O
salicylic	O
acid	O
.	O

Vitamin	O
D	O
treatment	O
in	O
calcium-deficiency	O
rickets	O
:	O
a	O
randomised	B-Randomization_Type_Simple
controlled	O
trial	O

Cohen	O
’	O
s	O
κ	O
measure	O
,	O
used	O
to	O
assess	O
the	O
agreement	O
between	O
the	O
two	O
assessors	O
of	O
the	O
photographs	O
,	O
was	O
estimated	O
to	O
be	O
0.45	O
(	O
95	O
%	O
confidence	O
interval	O
0.35	O
to	O
0.55	O
)	O
,	O
which	O
indicates	O
a	O
moderate	O
level	O
of	O
agreement	O
.	O

Setting	O
Thirteen	B-Settings_Multicenter
hospitals	I-Settings_Multicenter
in	O
Indonesia	B-Settings_Location
,	I-Settings_Location
Singapore	I-Settings_Location
,	I-Settings_Location
Thailand	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
Vietnam	I-Settings_Location
.	O

Logistic	O
regression	O
analysis	O
showed	O
no	O
evidence	O
of	O
a	O
difference	O
between	O
the	O
salicylic	O
acid	O
and	O
cryotherapy	O
groups	O
(	O
odds	O
ratio	O
0.96	O
(	O
95	O
%	O
confidence	O
interval	O
0.44	O
to	O
2.11	O
)	O
,	O
P=0.92	O
which	O
favours	O
the	O
salicylic	O
group	O
)	O
.	O

METHODS	O
Patients	O
Male	O
and	O
female	O
patients	O
aged	O
40–80	O
years	O
expected	O
to	O
require	O
daily	O
NSAID	O
therapy	O
for	O
at	O
least	O
6	O
months	O
for	O
pain	O
and/or	O
inflammatory	O
conditions	O
were	O
eligible	O
.	O

Experimental	O
design	O
We	O
performed	O
a	O
90-day	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
pilot	O
study	O
.	O

Statistical	O
methods	O
All	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
(	O
intention-to-treat	O
,	O
ITT	O
population	O
)	O
and	O
were	O
included	O
in	O
all	O
safety	O
and	O
efficacy	O
analyses	O
.	O

Treatment	O
details	O
Table	O
3	O
summarises	O
the	O
cryotherapy	O
treatment	O
details	O
reported	O
by	O
the	O
treating	O
healthcare	O
professional	O
.	O

Patients	O
with	O
an	O
OHS	O
of	O
0	O
,	O
1	O
,	O
or	O
2	O
were	O
classed	O
as	O
independent	O
.	O

Results	O
We	O
prospectively	O
enrolled	O
25	B-Sample_Size_Actual_at_Enrollment
patients	O
with	O
a	O
severe	O
gait	O
disorder	O
and	O
an	O
abnormal	O
,	O
forward-leaning	O
stance	O
.	O

Interventions	O
Oral	B-Design_Parallel_Group
oseltamivir	I-Design_Parallel_Group
at	I-Design_Parallel_Group
double	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
(	I-Design_Parallel_Group
150	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
a	I-Design_Parallel_Group
day/paediatric	I-Design_Parallel_Group
equivalent	I-Design_Parallel_Group
)	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
standard	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
(	I-Design_Parallel_Group
75	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
twice	I-Design_Parallel_Group
a	I-Design_Parallel_Group
day/paediatric	I-Design_Parallel_Group
equivalent	I-Design_Parallel_Group
)	I-Design_Parallel_Group
.	O

However	O
,	O
four-drug	O
combinations	O
(	O
generally	O
three	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
[	O
NRTIs	O
]	O
plus	O
one	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
[	O
NNRTI	O
]	O
)	O
have	O
been	O
reported	O
to	O
show	O
superior	O
virological	O
and	O
immunological	O
responses	O
compared	O
with	O
three-drug	O
ART	O
(	O
two	O
NRTIs	O
plus	O
one	O
NNRTI	O
or	O
protease	O
inhibitor	O
)	O
in	O
an	O
observational	O
study	O
in	O
infants	O
.	O

This	O
study	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
quilizumab	O
in	O
adults	O
with	O
allergic	O
asthma	O
,	O
inadequately	O
controlled	O
despite	O
high-dose	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
and	O
a	O
second	O
controller	O
.	O

Study	O
design	O
Patients	O
were	O
randomly	O
assigned	O
,	O
using	O
a	B-Randomization_Sequence_Generation_Method
computer-generated	I-Randomization_Sequence_Generation_Method
randomization	I-Randomization_Sequence_Generation_Method
schedule	I-Randomization_Sequence_Generation_Method
,	O
from	O
a	O
central	O
location	O
utilizing	O
an	B-Randomization_Sequence_Generation_Method
interactive	I-Randomization_Sequence_Generation_Method
voice	I-Randomization_Sequence_Generation_Method
response	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
with	O
blinded	O
medication	O
kit	O
number	O
allocation	O
in	O
a	O
2:1	B-Randomization_Ratio
ratio	O
to	O
identical-appearing	B-Design_Parallel_Group
tablets	I-Design_Parallel_Group
of	I-Design_Parallel_Group
HZT-501	I-Design_Parallel_Group
(	I-Design_Parallel_Group
800	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
ibuprofen	I-Design_Parallel_Group
and	I-Design_Parallel_Group
26.6	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
famotidine	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
ibuprofen	I-Design_Parallel_Group
(	I-Design_Parallel_Group
800	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
)	I-Design_Parallel_Group
thrice	O
daily	O
for	O
24	O
weeks	O
.	O

Patients	O
were	O
well	O
matched	O
with	O
respect	O
to	O
all	O
relevant	O
baseline	O
characteristics	O
(	O
table	O
1	O
)	O
.	O

Effect	O
of	O
oxandrolone	O
and	O
timing	O
of	O
pubertal	O
induction	O
on	O
final	O
height	O
in	O
Turner	O
’	O
s	O
syndrome	O
:	O
randomised	O
,	O
double	B-Blinding_Double_Blind
blind	I-Blinding_Double_Blind
,	O
placebo	O
controlled	O
trial	O

Treatment	O
All	O
participants	O
received	O
the	O
growth	O
hormone	O
preparation	O
of	O
their	O
choice	O
at	O
10	O
mg/m2/week	O
in	O
daily	O
subcutaneous	O
injections	O
.	O

Once	O
the	O
trial	O
has	O
been	O
published	O
,	O
participants	O
will	O
be	O
informed	O
of	O
the	O
results	O
through	O
a	O
dedicated	O
website	O
(	O
www.stopgaptrial.co.uk	O
)	O
and	O
will	O
be	O
sent	O
details	O
of	O
the	O
results	O
in	O
a	O
study	O
newsletter	O
suitable	O
for	O
a	O
non-specialist	O
audience	O
.	O

Changes	O
to	O
first-line	O
therapy	O
occurred	O
at	O
rates	O
of	O
3·3	O
per	O
100	O
child-years	O
in	O
routine	O
laboratory	O
monitoring	O
versus	O
3·2	O
per	O
100	O
child-years	O
in	O
clinically	O
driven	O
monitoring	O
(	O
p=0·94	O
)	O
;	O
and	O
3·5	O
,	O
3·7	O
,	O
and	O
2·6	O
per	O
100	O
child-years	O
in	O
groups	O
A	O
,	O
B	O
,	O
and	O
C	O
,	O
respectively	O
(	O
p=0·25	O
)	O
.	O

During	O
the	O
in-trial	O
period	O
,	O
the	O
average	O
difference	O
in	O
statin	O
use	O
between	O
simvastatin-allocated	O
versus	O
placebo-allocated	O
patients	O
was	O
67	O
%	O
(	O
85	O
%	O
vs	O
17	O
%	O
)	O
,	O
resulting	O
in	O
an	O
average	O
LDL	O
cholesterol	O
difference	O
of	O
1·0	O
mmol/L	O
(	O
SE	O
0·02	O
)	O
.	O

Introduction	O
Intimal	O
hyperplasia	O
,	O
endothelial	O
dysfunction	O
and	O
occlusive	O
vasculopathy	O
are	O
ubiquitous	O
features	O
of	O
systemic	O
sclerosis	O
(	O
SSc	O
)	O
.	O

Only	O
observed	O
values	O
of	O
IgE	O
levels	O
were	O
analyzed	O
,	O
with	O
no	O
imputation	O
performed	O
for	O
missing	O
IgE	O
data	O
.	O

Virus	O
culture	O
and	O
genotypic	O
screening	O
for	O
oseltamivir	O
resistance	O
mutations	O
were	O
performed	O
as	O
described	O
previously	O
on	O
day	O
0	O
samples	O
for	O
all	O
enrolled	O
patients	O
and	O
on	O
day	O
five	O
samples	O
for	O
patients	O
with	O
positive	O
results	O
on	O
RT-PCR	O
.	O

Energy	O
and	O
mineral	O
intakes	O
were	O
calculated	O
using	O
food	O
composition	O
tables	O
for	O
African	O
foods	O
.	O

However	O
,	O
total	O
dietary	O
calcium	O
intake	O
was	O
positively	O
related	O
to	O
weight	O
for	O
height	O
(	O
r=0.29	O
;	O
p=0.01	O
)	O
,	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
r=0.24	O
;	O
p=0.04	O
)	O
and	O
total	O
energy	O
intake	O
(	O
r=0.59	O
;	O
p	O
<	O
0.001	O
)	O
.	O

These	O
doses	O
were	O
halved	O
for	O
patients	O
with	O
a	O
creatinine	O
clearance	O
≥10	O
and	O
<	O
30	O
mL/min	O
.	O

Statistical	O
comparison	O
between	O
the	O
study	O
groups	O
in	O
the	O
population	O
of	O
all	O
patients	O
randomized	O
was	O
also	O
prespecified	O
for	O
common	O
adverse	O
events	O
(	O
occurring	O
in	O
>	O
5	O
%	O
of	O
patients	O
)	O
with	O
a	O
Cochran–Mantel–Haenszel	O
test	O
.	O

Leukotriene	O
modifiers	O
or	O
sustained-release	O
theophylline	O
,	O
added	O
on	O
to	O
low-dose	O
ICS	O
,	O
are	O
alternative	O
options	O
for	O
these	O
patients	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
three	O
ART	O
strategy	O
randomisation	O
groups	O
in	O
mean	O
CD4	O
percentage	O
change	O
at	O
week	O
72	O
(	O
p=0·33	O
)	O
or	O
144	O
(	O
p=0·69	O
;	O
figure	O
4	O
)	O
.	O

Secondary	O
outcomes	O
were	O
(	O
a	O
)	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
controlling	O
for	O
age	O
,	O
whether	O
the	O
wart	O
had	O
been	O
treated	O
previously	O
,	O
and	O
type	O
of	O
wart	O
,	O
(	O
b	O
)	O
patient	O
self	O
reported	O
clearance	O
of	O
plantar	O
warts	O
at	O
six	O
months	O
,	O
(	O
c	O
)	O
time	O
to	O
clearance	O
of	O
plantar	O
wart	O
,	O
(	O
d	O
)	O
number	O
of	O
plantar	O
warts	O
at	O
12	O
weeks	O
,	O
and	O
(	O
e	O
)	O
patient	O
satisfaction	O
with	O
the	O
treatment	O
.	O

The	O
breakdown	O
of	O
karyotypes	O
was	O
45	O
,	O
X	O
(	O
39	O
)	O
,	O
45	O
,	O
X/46	O
,	O
XX	O
(	O
18	O
)	O
,	O
45	O
,	O
X/46	O
,	O
XrX	O
(	O
9	O
)	O
,	O
complex	O
mosaics	O
containing	O
three	O
or	O
more	O
cell	O
lines	O
(	O
8	O
)	O
,	O
45	O
,	O
X/46	O
,	O
XiX	O
(	O
7	O
)	O
,	O
45	O
,	O
X/45	O
,	O
XY	O
(	O
7	O
)	O
,	O
46	O
,	O
XX	O
including	O
a	O
structural	O
abnormality	O
of	O
second	O
X	O
(	O
7	O
)	O
,	O
45	O
,	O
X/46	O
,	O
XY	O
including	O
a	O
structural	O
abnormality	O
of	O
Y	O
(	O
3	O
)	O
,	O
45	O
,	O
X/46	O
,	O
XX	O
including	O
a	O
structural	O
abnormality	O
of	O
second	O
X	O
(	O
3	O
)	O
,	O
45	O
,	O
X/47	O
,	O
XXX	O
(	O
2	O
)	O
,	O
and	O
other	O
(	O
3	O
)	O
.	O

After	O
unblinding	O
and	O
performance	O
of	O
the	O
statistical	O
analyses	O
,	O
a	O
review	O
of	O
endoscopy	O
reports	O
revealed	O
that	O
some	O
patients	O
with	O
esophageal	O
ulcers	O
had	O
been	O
incorrectly	O
assigned	O
as	O
having	O
gastric	O
ulcers	O
.	O

Adverse	O
reactions	O
to	O
study	O
drugs—adverse	O
events	O
that	O
were	O
possibly	O
,	O
probably	O
,	O
or	O
definitely	O
related	O
to	O
the	O
study	O
drug	O
.	O

Methods	O
Patients	O
and	O
randomisation	O
Details	O
of	O
HPS	O
have	O
been	O
reported	O
previously	O
.	O

Main	O
outcome	O
measures	O
Complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
.	O

Quilizumab	O
(	O
Genentech	O
,	O
Inc.	O
,	O
South	O
San	O
Francisco	O
,	O
CA	O
)	O
was	O
delivered	O
subcutaneously	O
at	O
nine	O
monthly	O
intervals	O
at	O
300	O
mg	O
per	O
dose	O
(	O
300	O
mg	O
M	O
)	O
,	O
or	O
at	O
three	O
quarterly	O
intervals	O
and	O
at	O
Week	O
4	O
at	O
150	O
or	O
450	O
mg	O
per	O
dose	O
(	O
150	O
or	O
450	O
mg	O
Q	O
)	O
.	O

All	O
study	O
patients	O
provided	O
written	O
informed	O
consent	O
and	O
the	O
study	O
was	O
approved	O
by	O
institutional	O
review	O
boards	O
for	O
all	O
participating	O
centers	O
.	O

Based	O
on	O
the	O
primary	O
outcome	O
measures	O
of	O
radiographic	O
score	O
and	O
serum	O
alkaline	O
phosphatase	O
values	O
and	O
SDs	O
based	O
on	O
previous	O
studies	O
(	O
1.6	O
for	O
radiographic	O
score	O
and	O
150	O
U/L	O
in	O
alkaline	O
phosphatase	O
)	O
,	O
40	B-Sample_Size_Required
subjects	I-Sample_Size_Required
in	I-Sample_Size_Required
each	I-Sample_Size_Required
treatment	I-Sample_Size_Required
group	I-Sample_Size_Required
would	O
provide	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
and	O
95	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
CI	I-Sample_Size_Calculation_Alpha_Value
to	O
detect	O
a	O
difference	O
between	O
groups	O
of	O
1.0	O
in	O
final	O
radiographic	O
score	O
and	O
100	O
U/L	O
in	O
alkaline	O
phosphatase	O
.	O

Patient-reported	O
outcomes	O
During	O
the	O
36-week	O
treatment	O
period	O
,	O
no	O
meaningful	O
differences	O
were	O
observed	O
between	O
the	O
quilizumab	O
dose	O
groups	O
compared	O
with	O
the	O
placebo	O
group	O
for	O
the	O
total	O
mTASS	O
,	O
daytime	O
mTASS	O
,	O
ACQ-5	O
,	O
AQLQ	O
(	O
S	O
)	O
,	O
or	O
RQLQ	O
(	O
S	O
)	O
scores	O
(	O
Table	O
3	O
)	O
.	O

There	O
were	O
no	O
major	O
imbalances	O
between	O
treatment	O
groups	O
,	O
but	O
the	O
300	O
mg	O
monthly	O
quilizumab	O
group	O
had	O
a	O
lower	O
mean	O
age	O
(	O
45	O
versus	O
47–48	O
years	O
)	O
and	O
a	O
lower	O
median	O
IgE	O
level	O
(	O
190	O
versus	O
234–254	O
IU/mL	O
)	O
compared	O
to	O
the	O
other	O
treatment	O
arms	O
(	O
Table	O
1	O
)	O
.	O

Demographic	O
and	O
baseline	O
disease	O
characteristics	O
were	O
generally	O
well	O
balanced	O
across	O
treatment	O
groups	O
(	O
table	O
1	O
)	O
.	O

Assessment	O
of	O
the	O
secondary	O
ulcer	O
end	O
points	O
in	O
REDUCE-1	O
revealed	O
that	O
significantly	O
fewer	O
patients	O
receiving	O
HZT-501	O
developed	O
upper	O
GI	O
ulcers	O
in	O
both	O
the	O
initial	O
(	O
NNT=9	O
)	O
and	O
post-adjudication	O
analysis	O
(	O
NNT=10	O
)	O
,	O
and	O
significantly	O
fewer	O
patients	O
developed	O
duodenal	O
ulcers	O
(	O
NNT=25	O
)	O
.	O

Ten	O
were	O
classified	O
as	O
serious	O
adverse	O
events	O
,	O
as	O
they	O
involved	O
admission	O
to	O
hospital	O
for	O
procedures	O
including	O
appendicectomy	O
and	O
ear	O
,	O
nose	O
,	O
and	O
throat	O
surgery	O
(	O
for	O
example	O
,	O
grommet	O
(	O
ventilation	O
tube	O
)	O
insertion	O
)	O
.	O

At	O
the	O
end	O
of	O
the	O
pilot	O
phase	O
,	O
since	O
the	O
main	O
phase	O
compared	O
treatment	O
with	O
open	B-Blinding_Open_Label
control	I-Blinding_Open_Label
,	O
several	O
additional	O
measures	O
were	O
introduced	O
to	O
minimise	O
bias	O
in	O
the	O
assessment	O
of	O
early	O
and	O
late	O
outcomes	O
.	O

In	O
this	O
cohort	O
of	O
912	O
patients	O
,	O
tiotropium	O
Respimat®	O
5	O
μg	O
,	O
administered	O
as	O
add-on	O
to	O
ICS	O
+	O
LABA	O
,	O
significantly	O
reduced	O
the	O
risk	O
of	O
severe	O
exacerbations	O
and	O
improved	O
lung	O
function	O
,	O
compared	O
with	O
placebo	O
Respimat®	O
as	O
add-on	O
to	O
ICS	O
+	O
LABA	O
.	O

Z	O
scores	O
were	O
determined	O
with	O
the	O
British	O
reference	O
because	O
it	O
covers	O
the	O
full	O
age	O
range	O
of	O
ARROW	O
children	O
.	O

During	O
the	O
post-trial	O
period	O
,	O
participants	O
were	O
asked	O
each	O
year	O
about	O
their	O
current	O
statin	O
use	O
,	O
and	O
post-trial	O
lipid	O
profile	O
assays	O
were	O
sought	O
from	O
1500	O
randomly	O
selected	O
surviving	O
participants	O
between	O
May	O
,	O
2004	O
,	O
and	O
August	O
,	O
2004	O
(	O
ie	O
,	O
about	O
3	O
years	O
after	O
the	O
scheduled	O
treatment	O
period	O
)	O
.	O

Reassuringly	O
,	O
no	O
adverse	O
effects	O
on	O
particular	O
causes	O
of	O
non-vascular	O
mortality	O
or	O
major	O
morbidity	O
(	O
including	O
site-specific	O
cancers	O
)	O
were	O
seen	O
to	O
emerge	O
during	O
prolonged	O
follow-up	O
.	O

Time	O
to	O
recurrence—defined	O
as	O
the	O
interval	O
between	O
the	O
target	O
lesion	O
healing	O
and	O
a	O
further	O
episode	O
of	O
pyoderma	O
gangrenosum	O
(	O
at	O
any	O
site	O
)	O
.	O

These	O
post-adjudication	O
results	O
are	O
presented	O
in	O
Table	O
2	O
.	O

Secondary	O
efficacy	O
outcomes	O
included	O
assessments	O
of	O
lung	O
function	O
using	O
the	O
relative	O
change	O
in	O
pre-bronchodilator	O
FEV1	O
from	O
baseline	O
to	O
Weeks	O
12	O
and	O
36	O
and	O
the	O
change	O
in	O
asthma	O
symptoms	O
from	O
baseline	O
to	O
Week	O
36	O
,	O
using	O
total	O
and	O
daytime	O
symptom	O
severity	O
scores	O
derived	O
from	O
a	O
daily	O
patient	O
diary	O
.	O

Viral	O
load	O
suppression	O
was	O
similar	O
in	O
both	O
monitoring	O
groups	O
(	O
figure	O
3	O
;	O
global	O
p	O
>	O
0·7	O
)	O
.	O

One	O
death	O
occurred	O
in	O
the	O
two	O
studies	O
:	O
a	O
48-year-old	O
female	O
in	O
the	O
ibuprofen	O
group	O
died	O
of	O
cardiorespiratory	O
arrest	O
and	O
multiorgan	O
system	O
failure	O
attributed	O
to	O
acetaminophen	O
toxicity	O
.	O

The	O
code	O
for	O
randomisation	O
2	O
was	O
broken	O
at	O
15	O
years	O
to	O
allow	O
introduction	O
of	O
progesterone	O
therapy	O
:	O
oral	O
norethisterone	O
(	O
CP	O
Pharmaceuticals	O
,	O
Wrexham	O
,	O
UK	O
)	O
5	O
mg	O
daily	O
for	O
five	O
days	O
each	O
month	O
.	O

Older	O
people	O
have	O
been	O
under-represented	O
in	O
stroke	O
trials	O
in	O
general	O
,	O
and	O
in	O
stroke	O
thrombolysis	O
trials	O
in	O
particular	O
(	O
only	O
79	O
people	O
aged	O
older	O
than	O
80	O
years	O
had	O
been	O
included	O
in	O
trials	O
of	O
rt-PA	O
)	O
.	O

The	O
randomisation	O
list	O
was	O
generated	O
by	O
Boehringer	B-Randomization_Personnel
Ingelheim	I-Randomization_Personnel
Pharma	I-Randomization_Personnel
GmbH	I-Randomization_Personnel
&	I-Randomization_Personnel
Co.	O
KG	O
,	O
Biberach	O
an	O
der	O
Riss	O
,	O
Germany	O
,	O
using	O
a	B-Randomization_Sequence_Generation_Method
validated	I-Randomization_Sequence_Generation_Method
pseudo-random	I-Randomization_Sequence_Generation_Method
number	I-Randomization_Sequence_Generation_Method
generator	I-Randomization_Sequence_Generation_Method
and	I-Randomization_Sequence_Generation_Method
a	I-Randomization_Sequence_Generation_Method
supplied	I-Randomization_Sequence_Generation_Method
seed	I-Randomization_Sequence_Generation_Method
number	I-Randomization_Sequence_Generation_Method
.	O

More	O
additional	O
haematology	O
tests	O
were	O
requested	O
during	O
nurse	O
visits	O
or	O
extra	O
visits	O
in	O
routine	O
laboratory	O
than	O
in	O
clinically	O
driven	O
monitoring	O
(	O
p	O
<	O
0·0001	O
)	O
;	O
there	O
were	O
no	O
significant	O
differences	O
in	O
requests	O
for	O
additional	O
biochemistry	O
tests	O
(	O
p=0·17	O
)	O
or	O
other	O
non-routine	O
(	O
eg	O
,	O
electrolytes	O
)	O
tests	O
(	O
p=0·97	O
)	O
.	O

We	O
included	O
all	O
participants	O
with	O
available	O
data	O
at	O
both	O
the	O
baseline	O
and	O
the	O
six	O
week	O
visit	O
in	O
the	O
primary	O
analysis	O
.	O

On	O
the	O
basis	O
of	O
interviews	O
with	O
the	O
patients	O
and	O
caregivers	O
and	O
a	O
monthly	O
pill	O
count	O
,	O
the	O
treatment	O
compliance	O
was	O
above	O
90	B-Sample_Size_Actual_at_Outcome_Analysis
%	I-Sample_Size_Actual_at_Outcome_Analysis
for	I-Sample_Size_Actual_at_Outcome_Analysis
all	I-Sample_Size_Actual_at_Outcome_Analysis
patients	I-Sample_Size_Actual_at_Outcome_Analysis
.	O

Both	O
treatment	O
groups	O
had	O
blood	O
pressure	O
monitored	O
closely	O
over	O
the	O
first	O
24	O
h.	O
In	O
the	O
double-blinded	B-Blinding_Double_Blind
phase	O
,	O
both	O
groups	O
were	O
to	O
avoid	O
antiplatelet	O
or	O
anticoagulant	O
therapy	O
for	O
24	O
h.	O
In	O
the	O
open	B-Blinding_Open_Label
phase	O
,	O
patients	O
allocated	O
to	O
the	O
control	O
group	O
were	O
to	O
start	O
aspirin	O
immediately	O
.	O

All	O
patients	O
had	O
a	O
CT	O
or	O
MRI	O
brain	O
scan	O
before	O
randomisation	O
and	O
a	O
follow-up	O
scan	O
at	O
24–48	O
h.	O
A	O
repeat	O
brain	O
scan	O
was	O
required	O
if	O
the	O
patient	O
deteriorated	O
neurologically	O
or	O
intracranial	O
haemorrhage	O
was	O
suspected	O
for	O
any	O
reason	O
.	O

The	O
primary	O
trial	O
hypothesis	O
was	O
that	O
0·9	O
mg/kg	O
rt-PA	O
(	O
maximum	O
90	O
mg	O
)	O
given	O
to	O
adult	O
patients	O
of	O
all	O
ages	O
with	O
acute	O
ischaemic	O
stroke	O
,	O
within	O
6	O
h	O
of	O
symptom	O
onset	O
,	O
increased	O
the	O
proportion	O
of	O
people	O
who	O
were	O
alive	O
and	O
independent	O
at	O
6	O
months	O
.	O

The	O
21	O
deaths	O
occurred	O
at	O
similar	O
rates	O
in	O
the	O
double	O
(	O
n=12	O
;	O
7.3	O
%	O
,	O
4.2	O
%	O
to	O
12.3	O
%	O
)	O
and	O
standard	O
dose	O
(	O
n=9	O
;	O
5.6	O
%	O
,	O
3.0	O
%	O
to	O
10.3	O
%	O
)	O
arms	O
(	O
P=0.54	O
)	O
.	O

Setting	O
University	B-Settings_Multicenter
podiatry	I-Settings_Multicenter
school	I-Settings_Multicenter
clinics	I-Settings_Multicenter
,	I-Settings_Multicenter
NHS	I-Settings_Multicenter
podiatry	I-Settings_Multicenter
clinics	I-Settings_Multicenter
,	I-Settings_Multicenter
and	I-Settings_Multicenter
primary	I-Settings_Multicenter
care	I-Settings_Multicenter
in	O
England	B-Settings_Location
,	I-Settings_Location
Scotland	I-Settings_Location
,	I-Settings_Location
and	I-Settings_Location
Ireland	I-Settings_Location
.	O

Memantine	O
for	O
axial	O
signs	O
in	O
Parkinson	O
's	O
disease	O
:	O
a	O
randomised	B-Randomization_Type_Simple
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
pilot	O
study	O

The	O
primary	O
outcome	O
of	O
the	O
long-term	O
follow-up	O
of	O
HPS	O
was	O
first	O
post-randomisation	O
major	O
vascular	O
event	O
,	O
and	O
analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

RRs	O
of	O
upper	O
GI	O
ulcer	O
formation	O
for	O
low-dose	O
aspirin	O
use	O
were	O
1.40	O
(	O
0.97–2.02	O
)	O
for	O
initial	O
and	O
1.46	O
(	O
1.004–2.11	O
)	O
for	O
post-adjudication	O
analyses	O
and	O
for	O
prior	O
ulcer	O
history	O
they	O
were	O
1.55	O
(	O
0.95–2.53	O
)	O
for	O
initial	O
and	O
1.65	O
(	O
1.01–2.69	O
)	O
for	O
post-adjudication	O
analyses	O
.	O

The	O
system	O
would	O
not	O
accept	O
patients	O
with	O
blood	O
pressure	O
or	O
glucose	O
levels	O
outside	O
protocol-defined	O
criteria	O
(	O
appendix	O
pp	O
4–5	O
)	O
or	O
other	O
data	O
inconsistencies	O
.	O

Four	O
adverse	O
events	O
could	O
have	O
been	O
related	O
to	O
oxandrolone	O
or	O
ethinylestradiol	O
:	O
acne	O
in	O
a	O
15	O
year	O
old	O
(	O
all	O
study	O
drugs	O
were	O
continued	O
,	O
and	O
randomisation	O
was	O
later	O
revealed	O
as	O
oxandrolone	O
and	O
pubertal	O
induction	O
at	O
14	O
years	O
)	O
;	O
persistent	O
hypertension	O
in	O
a	O
13	O
year	O
old	O
(	O
oxandrolone/placebo	O
was	O
stopped	O
and	O
antihypertensive	O
treatment	O
started	O
,	O
blood	O
pressure	O
normalised	O
,	O
and	O
oxandrolone/placebo	O
treatment	O
was	O
restarted	O
;	O
the	O
randomisation	O
was	O
later	O
revealed	O
as	O
oxandrolone	O
and	O
pubertal	O
induction	O
at	O
12	O
years	O
)	O
;	O
abnormal	O
liver	O
function	O
in	O
a	O
16	O
year	O
old	O
(	O
the	O
participant	O
was	O
at	O
near	O
final	O
height	O
and	O
elected	O
to	O
stop	O
growth	O
promoting	O
treatment	O
;	O
randomisation	O
was	O
later	O
revealed	O
as	O
oxandrolone	O
and	O
pubertal	O
induction	O
at	O
14	O
years	O
)	O
;	O
and	O
episodic	O
“	O
hot	O
flushes	O
”	O
in	O
a	O
15	O
year	O
old	O
(	O
all	O
study	O
drugs	O
were	O
continued	O
;	O
randomisation	O
was	O
later	O
revealed	O
as	O
placebo	O
and	O
pubertal	O
induction	O
at	O
14	O
years	O
)	O
.	O

The	O
study	O
aimed	O
to	O
determine	O
the	O
canakinumab	O
dose	O
having	O
equivalent	O
efficacy	O
to	O
colchicine	O
0.5	O
mg	O
at	O
16	O
weeks	O
.	O

Pharmacokinetics	O
Quilizumab	O
displayed	O
linear	O
pharmacokinetics	O
with	O
a	O
dose-proportional	O
increase	O
in	O
exposure	O
as	O
shown	O
by	O
increases	O
in	O
Cmax	O
values	O
between	O
the	O
150	O
and	O
450	O
mg	O
Q	O
doses	O
at	O
Weeks	O
5	O
and	O
25	O
.	O

Primary	O
outcome	O
In	O
total	O
,	O
229	B-Sample_Size_Actual_at_Outcome_Analysis
participants	O
had	O
a	O
response	O
for	O
whether	O
there	O
was	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
after	O
randomisation	O
,	O
with	O
206	O
(	O
90	O
%	O
)	O
having	O
a	O
blinded	O
outcome	O
assessment	O
:	O
159	O
(	O
69	O
%	O
)	O
had	O
a	O
blinded	O
outcome	O
assessment	O
from	O
a	O
digital	O
photograph	O
(	O
cryotherapy=80	O
,	O
salicylic	O
acid=79	O
)	O
,	O
47	O
(	O
21	O
%	O
)	O
had	O
a	O
blinded	O
outcome	O
assessment	O
from	O
a	O
healthcare	O
professional	O
(	O
cryotherapy=22	O
,	O
salicylic	O
acid=25	O
)	O
,	O
four	O
(	O
2	O
%	O
)	O
had	O
an	O
unblinded	O
outcome	O
assessment	O
from	O
a	O
healthcare	O
professional	O
(	O
cryotherapy=1	O
,	O
salicylic	O
acid=3	O
)	O
,	O
and	O
19	O
(	O
8	O
%	O
)	O
had	O
patient	O
self	O
assessment	O
(	O
cryotherapy=7	O
,	O
salicylic	O
acid=12	O
)	O
.	O

Intervention	O
All	O
children	O
were	O
treated	O
with	O
calcium	O
carbonate	O
as	O
powdered	O
limestone	O
.	O

Intervention	O
Patients	B-Blinding_Object_Patients
,	O
study	B-Blinding_Object_Others
staff	I-Blinding_Object_Others
and	O
investigators	B-Blinding_Object_Investigators
were	O
blinded	O
to	O
the	O
assignment	O
.	O

Table	O
7	O
presents	O
the	O
specific	O
events	O
that	O
occurred	O
in	O
at	O
least	O
3	O
%	O
of	O
patients	O
in	O
either	O
treatment	O
group	O
.	O

The	O
writing	O
group	O
was	O
persuaded	O
by	O
the	O
recent	O
empirical	O
evidence	O
that	O
the	O
ordinal	O
method	O
was	O
both	O
statistically	O
more	O
efficient	O
(	O
effectively	O
reducing	O
the	O
sample	O
size	O
required	O
in	O
stroke	O
trials	O
)	O
and	O
robust	O
against	O
substantial	O
deviations	O
from	O
the	O
proportional	O
assumption	O
.	O

Of	O
these	O
,	O
one	O
event	O
(	O
a	O
ruptured	O
Achilles	O
tendon	O
requiring	O
hospitalisation	O
)	O
was	O
classed	O
as	O
serious	O
and	O
unrelated	O
to	O
the	O
trial	O
treatment	O
(	O
salicylic	O
acid	O
)	O
.	O

Results	O
Between	O
November	O
2006	O
and	O
January	O
2010	O
,	O
284	O
individuals	O
were	O
screened	O
as	O
potential	O
participants	O
,	O
and	O
242	B-Sample_Size_Actual_at_Enrollment
(	O
85	O
%	O
)	O
were	O
randomised—124	O
to	O
salicylic	O
acid	O
and	O
118	O
to	O
cryotherapy	O
.	O

During	O
the	O
post-trial	O
period	O
,	O
the	O
incidence	O
rates	O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
(	O
0·93	O
[	O
0·84–1·04	O
]	O
;	O
p=0·20	O
)	O
.	O

This	O
is	O
not	O
expected	O
if	O
satisfaction	O
with	O
treatment	O
was	O
independent	O
of	O
treatment	O
randomised	O
.	O

In	O
this	O
model	O
the	O
treatment	O
odds	O
ratios	O
between	O
one	O
level	O
and	O
the	O
next	O
were	O
assumed	O
to	O
be	O
constant	O
,	O
so	O
a	O
single	O
parameter	O
summarises	O
the	O
shift	O
in	O
outcome	O
distribution	O
between	O
treatment	O
and	O
control	O
groups	O
.	O

Post	O
hoc	O
analyses	O
included	O
:	O
(	O
1	O
)	O
the	O
number	O
of	O
new	O
DUs	O
up	O
to	O
week	O
12	O
in	O
the	O
overall	O
patient	O
population	O
and	O
in	O
subgroups	O
defined	O
by	O
randomisation	O
month	O
(	O
October–February	O
or	O
autumn–winter	O
and	O
March–September	O
or	O
spring–summer	O
)	O
and	O
(	O
2	O
)	O
number	O
of	O
new	O
DUs	O
,	O
time	O
to	O
each	O
successive	O
new	O
DU	O
and	O
total	O
number	O
of	O
DUs	O
through	O
week	O
24	O
in	O
subgroups	O
defined	O
by	O
the	O
number	O
of	O
DUs	O
at	O
baseline	O
(	O
<	O
4	O
and	O
≥4	O
)	O
.	O

Peripheral	O
blood	O
eosinophil	O
counts	O
were	O
obtained	O
from	O
standard	O
complete	O
blood	O
counts	O
.	O

Trial	O
registration	O
Current	O
Controlled	O
Trials	O
ISRCTN35898459	O
.	O

Given	O
the	O
detected	O
rates	O
of	O
viral	O
shedding	O
at	O
day	O
five	O
this	O
sample	O
of	O
224	O
patients	O
has	O
more	O
than	O
85	O
%	O
power	O
to	O
show	O
a	O
20	O
%	O
absolute	O
improvement	O
in	O
cessation	O
of	O
viral	O
shedding	O
at	O
two	O
sided	O
α	O
of	O
0.05	O
.	O

Results	O
The	O
median	O
(	O
range	O
)	O
age	O
of	O
enrolled	O
children	O
was	O
46	O
(	O
15–102	O
)	O
months	O
,	O
and	O
baseline	O
characteristics	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

The	O
SITAR	O
adjustment	O
process	O
estimated	O
the	O
size	O
,	O
tempo	O
,	O
and	O
velocity	O
parameters	O
for	O
each	O
participant	O
,	O
which	O
when	O
applied	O
to	O
their	O
curves	O
made	O
them	O
all	O
very	O
similar	O
,	O
with	O
a	O
residual	O
standard	O
deviation	O
of	O
0.6	O
mm	O
around	O
the	O
summary	O
curve	O
(	O
fig	O
2	O
,	O
bottom	O
panel	O
)	O
.	O

Venous	O
sampling	O
and	O
cytokine	O
analysis	O
Patients	O
abstained	O
from	O
food	O
and	O
caffeine	O
containing	O
drinks	O
for	O
4	O
h	O
,	O
and	O
24	O
h	O
from	O
ingestion	O
of	O
alcohol	O
prior	O
to	O
phlebotomy	O
.	O

Non-significant	O
correlation	O
indicates	O
that	O
there	O
is	O
not	O
enough	O
evidence	O
that	O
the	O
proportional	O
hazard	O
assumption	O
has	O
been	O
violated	O
.	O

To	O
verify	O
that	O
the	O
effect	O
of	O
treatment	O
would	O
not	O
vary	O
substantially	O
across	O
relevant	O
baseline	O
subgroups	O
,	O
the	O
number	O
of	O
new	O
DUs	O
up	O
to	O
week	O
24	O
was	O
additionally	O
analysed	O
in	O
subgroups	O
based	O
on	O
predefined	O
baseline	O
factors	O
associated	O
with	O
disease	O
severity	O
.	O

5	O
;	O
see	O
Additional	O
file	O
2	O
:	O
Table	O
S1	O
and	O
Additional	O
file	O
3	O
:	O
Table	O
S2	O
)	O
.	O

Treatment	O
effects	O
for	O
new	O
DUs	O
in	O
predefined	O
subgroups	O
were	O
presented	O
as	O
point	O
estimates	O
and	O
95	O
%	O
two-sided	O
CIs	O
.	O

Results	O
Of	O
326	B-Sample_Size_Actual_at_Enrollment
patients	O
(	O
including	O
246	O
(	O
75.5	O
%	O
)	O
children	O
aged	O
<	O
15	O
)	O
,	O
165	O
and	O
161	O
were	O
randomised	O
to	O
double	B-Design_Parallel_Group
or	I-Design_Parallel_Group
standard	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
oseltamivir	I-Design_Parallel_Group
,	O
respectively	O
.	O

Those	O
with	O
evidence	O
of	O
ovarian	O
failure	O
at	O
12	O
years	O
were	O
further	O
randomised	O
to	O
oral	B-Design_Parallel_Group
ethinylestradiol	I-Design_Parallel_Group
(	I-Design_Parallel_Group
year	I-Design_Parallel_Group
1	I-Design_Parallel_Group
,	I-Design_Parallel_Group
2	I-Design_Parallel_Group
µg	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
;	I-Design_Parallel_Group
year	I-Design_Parallel_Group
2	I-Design_Parallel_Group
,	I-Design_Parallel_Group
4	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
;	I-Design_Parallel_Group
year	I-Design_Parallel_Group
3	I-Design_Parallel_Group
,	I-Design_Parallel_Group
4	I-Design_Parallel_Group
months	I-Design_Parallel_Group
each	I-Design_Parallel_Group
of	I-Design_Parallel_Group
6	I-Design_Parallel_Group
,	I-Design_Parallel_Group
8	I-Design_Parallel_Group
,	I-Design_Parallel_Group
and	I-Design_Parallel_Group
10	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
;	O
participants	O
who	O
received	O
placebo	O
and	O
those	O
recruited	O
after	O
the	O
age	O
of	O
12.25	O
years	O
started	O
ethinylestradiol	O
at	O
age	O
14	O
.	O

Three	O
children	O
substituted	O
zidovudine	O
because	O
of	O
lipoatrophy	O
in	O
group	O
C	O
;	O
two	O
children	O
in	O
group	O
A	O
and	O
three	O
in	O
group	O
B	O
substituted	O
efavirenz	O
because	O
of	O
lipodystrophy	O
or	O
gynaecomastia	O
.	O

A	O
single	O
subcutaneous	O
25	O
mg	O
dose	O
of	O
etanercept	O
improves	O
endothelium-dependent	O
vasodilatation	O
within	O
6	O
h	O
of	O
administration	O
in	O
patients	O
with	O
heart	O
failure	O
.	O

Methods	O
In	O
this	O
double-blind	B-Blinding_Double_Blind
,	O
double-dummy	O
,	O
dose-ranging	O
study	O
,	O
432	B-Sample_Size_Actual_at_Enrollment
patients	O
with	O
gouty	O
arthritis	O
initiating	O
allopurinol	O
treatment	O
were	O
randomised	B-Randomization_Type_Simple
1:1:1:1:1:1:2	B-Randomization_Ratio
to	O
receive	O
:	O
a	B-Design_Parallel_Group
single	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
of	I-Design_Parallel_Group
canakinumab	I-Design_Parallel_Group
,	I-Design_Parallel_Group
25	I-Design_Parallel_Group
,	I-Design_Parallel_Group
50	I-Design_Parallel_Group
,	I-Design_Parallel_Group
100	I-Design_Parallel_Group
,	I-Design_Parallel_Group
200	I-Design_Parallel_Group
,	I-Design_Parallel_Group
or	I-Design_Parallel_Group
300	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
subcutaneously	I-Design_Parallel_Group
;	I-Design_Parallel_Group
4×4-weekly	I-Design_Parallel_Group
doses	I-Design_Parallel_Group
of	I-Design_Parallel_Group
canakinumab	I-Design_Parallel_Group
(	I-Design_Parallel_Group
50+50+25+25	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
subcutaneously	I-Design_Parallel_Group
)	I-Design_Parallel_Group
;	I-Design_Parallel_Group
or	I-Design_Parallel_Group
daily	I-Design_Parallel_Group
colchicine	I-Design_Parallel_Group
0.5	I-Design_Parallel_Group
mg	I-Design_Parallel_Group
orally	I-Design_Parallel_Group
for	I-Design_Parallel_Group
16	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
.	O

A	O
randomized	O
trial	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
quilizumab	O
in	O
adults	O
with	O
inadequately	O
controlled	O
allergic	O
asthma	O

Thrombolytic	O
therapy	O
with	O
intravenous	O
recombinant	O
tissue	O
plasminogen	O
activator	O
(	O
rt-PA	O
)	O
,	O
when	O
approved	O
in	O
Europe	O
,	O
was	O
restricted	O
to	O
the	O
treatment	O
of	O
patients	O
younger	O
than	O
80	O
years	O
of	O
age	O
with	O
acute	O
ischaemic	O
stroke	O
who	O
could	O
be	O
treated	O
within	O
3	O
h.	O
A	O
Cochrane	O
systematic	O
review	O
of	O
the	O
11	O
completed	O
trials	O
of	O
thrombolysis	O
(	O
including	O
3977	O
patients	O
)	O
with	O
intravenous	O
rt-PA	O
for	O
acute	O
ischaemic	O
stroke	O
showed	O
that	O
treatment	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
survival	O
free	O
of	O
disability	O
,	O
despite	O
an	O
early	O
3	O
%	O
excess	O
of	O
fatal	O
intracranial	O
haemorrhage	O
.	O

If	O
multiple	O
lesions	O
were	O
present	O
,	O
we	O
designated	O
the	O
largest	O
lesion	O
that	O
could	O
be	O
photographed	O
on	O
a	O
single	O
plane	O
as	O
the	O
target	O
lesion	O
.	O

Once	O
randomised	O
,	O
allocation	B-Blinding_Open_Label
was	I-Blinding_Open_Label
open—ie	O
,	O
physicians	B-Blinding_Open_Label
and	I-Blinding_Open_Label
carers	I-Blinding_Open_Label
were	I-Blinding_Open_Label
aware	I-Blinding_Open_Label
of	I-Blinding_Open_Label
group	I-Blinding_Open_Label
assignment	I-Blinding_Open_Label
.	O

Background	O
Quilizumab	O
,	O
a	O
humanized	O
IgG1	O
monoclonal	O
antibody	O
,	O
targets	O
the	O
M1-prime	O
segment	O
of	O
membrane-expressed	O
IgE	O
,	O
leading	O
to	O
depletion	O
of	O
IgE-switched	O
and	O
memory	O
B	O
cells	O
.	O

Placebo	O
capsules	O
were	O
manufactured	O
by	O
the	O
pharmaceutical	O
development	O
section	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
Clinical	O
Center	O
(	O
Bethesda	O
,	O
MD	O
,	O
US	O
)	O
.	O

The	O
differences	O
here	O
were	O
smaller	O
,	O
the	O
curves	O
diverging	O
only	O
after	O
14	O
years	O
;	O
the	O
late	O
versus	O
early	O
comparisons	O
for	O
size	O
(	O
+2.2	O
cm	O
)	O
and	O
velocity	O
(	O
−9	O
%	O
)	O
were	O
statistically	O
insignificant	O
(	O
P	O
>	O
0.1	O
)	O
,	O
whereas	O
tempo	O
was	O
slightly	O
delayed	O
in	O
the	O
late	O
induction	O
arm	O
(	O
+0.4	O
years	O
;	O
P=0.06	O
)	O
.	O

For	O
revascularisation	O
procedures	O
,	O
a	O
significant	O
24	O
%	O
(	O
SE	O
4	O
)	O
reduction	O
was	O
seen	O
during	O
the	O
in-trial	O
period	O
(	O
p	O
<	O
0·0001	O
)	O
.	O

A	O
baseline	O
30	O
min	O
intra-arterial	O
infusion	O
of	O
saline	O
was	O
followed	O
by	O
intra-arterial	O
infusion	O
of	O
substance	O
P	O
at	O
2	O
,	O
4	O
and	O
8	O
pmol/min	O
;	O
then	O
acetylcholine	O
at	O
5	O
,	O
10	O
and	O
20	O
µg/min	O
;	O
and	O
finally	O
sodium	O
nitroprusside	O
at	O
2	O
,	O
4	O
and	O
8	O
μg/min	O
,	O
infused	O
for	O
10	O
min	O
at	O
each	O
dose	O
with	O
each	O
agonist	O
separated	O
by	O
a	O
20	O
min	O
saline	O
infusion	O
.	O

At	O
treatment	O
Weeks	O
4	O
,	O
12	O
,	O
and	O
24	O
,	O
the	O
mean	O
trough	O
serum	O
concentrations	O
of	O
quilizumab	O
were	O
:	O
(	O
150	O
mg	O
Q	O
)	O
5.7	O
±	O
2.3	O
μg/mL	O
,	O
2.6	O
±	O
2.0	O
μg/mL	O
,	O
and	O
1.3	O
±	O
4.6	O
μg/mL	O
,	O
respectively	O
;	O
(	O
450	O
mg	O
Q	O
)	O
17.1	O
±	O
7.0	O
μg/mL	O
,	O
7.2	O
±	O
3.8	O
μg/mL	O
,	O
and	O
2.3	O
±	O
2.2	O
μg/mL	O
,	O
respectively	O
;	O
and	O
(	O
300	O
mg	O
M	O
)	O
11.6	O
±	O
4.5	O
μg/mL	O
,	O
16.7	O
±	O
6.7	O
μg/mL	O
,	O
and	O
16.8	O
±	O
7.7	O
μg/mL	O
,	O
respectively	O
.	O

Plasma	O
PAI-1	O
antigen	O
concentrations	O
were	O
similar	O
between	O
the	O
groups	O
at	O
baseline	O
and	O
did	O
not	O
differ	O
following	O
either	O
treatment	O
(	O
p	O
>	O
0.1	O
)	O
.	O

These	O
decreases	O
were	O
sustained	O
for	O
at	O
least	O
6	O
months	O
after	O
the	O
last	O
dose	O
,	O
in	O
contrast	O
to	O
omalizumab	O
,	O
which	O
must	O
be	O
administered	O
every	O
2–4	O
weeks	O
to	O
maintain	O
reduced	O
IgE	O
levels	O
.	O

Only	O
two	O
adverse	O
event	O
terms	O
were	O
reported	O
in	O
either	O
study	O
at	O
a	O
rate	O
of	O
≥5	O
%	O
:	O
dyspepsia	O
and	O
nausea	O
.	O

Citrate	O
and	O
acidified	O
buffered	O
citrate	O
samples	O
were	O
centrifuged	O
at	O
2000	O
g	O
for	O
30	O
min	O
at	O
4°C	O
and	O
EDTA	O
samples	O
at	O
1000	O
g	O
for	O
10	O
min	O
at	O
20°C	O
.	O

Adverse	O
events	O
Between	O
1999	O
and	O
2009	O
,	O
197	O
adverse	O
events	O
were	O
reported	O
;	O
none	O
of	O
them	O
were	O
suspected	O
to	O
be	O
unexpected	O
serious	O
adverse	O
reactions	O
.	O

As	O
a	O
result	O
,	O
clinicians	O
and	O
participants	O
were	O
informed	O
of	O
their	O
treatment	O
allocation	O
once	O
data	O
had	O
been	O
irrevocably	O
entered	O
into	O
the	O
randomisation	O
database	O
.	O

A	O
further	O
13	O
(	O
3.9	O
%	O
)	O
were	O
positive	O
by	O
rapid	O
antigen	O
test	O
but	O
negative	O
by	O
RT-PCR	O
.	O

A	O
paired	O
t-test	O
was	O
used	O
to	O
compare	O
values	O
of	O
continuous	O
normally	O
distributed	O
variables	O
with	O
baseline	O
values	O
,	O
and	O
an	O
unpaired	O
t-test	O
was	O
used	O
to	O
compare	O
values	O
of	O
continuous	O
variables	O
between	O
groups	O
.	O

The	O
PPN	O
is	O
particularly	O
involved	O
in	O
posture	O
and	O
gait	O
control	O
.	O

Mechanisms	O
that	O
ensure	O
adherence	O
to	O
protective	O
therapy	O
,	O
such	O
as	O
the	O
combination	O
of	O
an	O
NSAID	O
and	O
a	O
protective	O
agent	O
in	O
one	O
pill	O
,	O
theoretically	O
should	O
decrease	O
the	O
GI	O
risk	O
associated	O
with	O
the	O
NSAID	O
therapy	O
.	O

This	O
sample	O
size	O
gave	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
an	O
absolute	O
difference	O
of	O
4·7	O
%	O
in	O
the	O
primary	O
outcome	O
.	O

Interpretation	O
For	O
the	O
types	O
of	O
patient	O
recruited	O
in	O
IST-3	O
,	O
despite	O
the	O
early	O
hazards	O
,	O
thrombolysis	O
within	O
6	O
h	O
improved	O
functional	O
outcome	O
.	O

Of	O
those	O
enrolled	O
,	O
68	O
(	O
94	O
%	O
)	O
completed	O
24	O
weeks	O
of	O
treatment	O
.	O

At	O
the	O
final	O
follow-up	O
(	O
May–October	O
,	O
2001	O
)	O
,	O
participants	O
were	O
encouraged	O
to	O
continue	O
their	O
allocated	O
study	O
treatment	O
(	O
unless	O
it	O
was	O
contraindicated	O
)	O
until	O
the	O
study	O
results	O
were	O
sent	O
to	O
them	O
and	O
their	O
family	O
doctors	O
on	O
Nov	O
11	O
,	O
2001	O
.	O

These	O
benefits	O
must	O
be	O
confirmed	O
in	O
a	O
broader	O
population	O
of	O
patients	O
.	O

To	O
further	O
explore	O
the	O
dose–response	O
curve	O
in	O
asthma	O
,	O
we	O
investigated	O
the	O
efficacy	O
and	O
safety	O
of	O
three	O
different	O
doses	O
of	O
tiotropium	O
Respimat®	O
as	O
add-on	O
to	O
ICS	O
in	O
symptomatic	O
patients	O
with	O
moderate	O
persistent	O
asthma	O
.	O

The	O
main	O
secondary	O
outcome	O
was	O
the	O
mean	O
number	O
of	O
flares	O
per	O
patient	O
at	O
16	O
weeks	O
.	O

Swabs	O
were	O
obtained	O
for	O
virus	O
detection	O
in	O
the	O
nose	O
and	O
throat	O
on	O
days	O
0	O
to	O
10	O
and	O
day	O
14	O
.	O

The	O
largest	O
adjusted	O
mean	O
difference	O
from	O
placebo	O
Respimat®	O
was	O
observed	O
with	O
tiotropium	O
Respimat®	O
5	O
μg	O
(	O
188	O
mL	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
140	O
,	O
236	O
)	O
.	O

Serum	O
calcium	O
,	O
phosphorus	O
,	O
alkaline	O
phosphatase	O
and	O
albumin	O
were	O
measured	O
with	O
standard	O
methods	O
.	O

The	O
Third	O
International	O
Stroke	O
Trial	O
(	O
IST-3	O
)	O
,	O
therefore	O
,	O
had	O
the	O
following	O
objectives	O
:	O
to	O
establish	O
the	O
balance	O
of	O
benefits	O
and	O
harms	O
of	O
thrombolytic	O
therapy	O
with	O
rt-PA	O
in	O
patients	O
who	O
did	O
not	O
exactly	O
meet	O
the	O
licence	O
criteria	O
(	O
especially	O
elderly	O
patients	O
)	O
;	O
determine	O
whether	O
a	O
wider	O
range	O
of	O
patients	O
might	O
benefit	O
from	O
this	O
treatment	O
;	O
assess	O
which	O
categories	O
of	O
patients	O
were	O
most	O
likely	O
to	O
benefit	O
by	O
investigating	O
possible	O
interactions	O
between	O
treatment	O
effect	O
and	O
various	O
factors	O
(	O
including	O
age	O
,	O
stroke	O
severity	O
,	O
and	O
early	O
brain	O
imaging	O
results	O
)	O
;	O
refine	O
current	O
estimates	O
of	O
the	O
duration	O
of	O
the	O
therapeutic	O
time	O
window	O
;	O
and	O
to	O
improve	O
the	O
external	O
validity	O
and	O
precision	O
of	O
the	O
existing	O
estimates	O
of	O
the	O
overall	O
treat-ment	O
effects	O
(	O
benefits	O
and	O
harms	O
)	O
.	O

Only	O
33	O
(	O
3	O
%	O
)	O
children	O
(	O
median	O
follow-up	O
150	O
[	O
IQR	O
46–169	O
]	O
weeks	O
)	O
not	O
known	O
to	O
have	O
died	O
were	O
not	O
seen	O
after	O
trial	O
closure	O
(	O
figure	O
1	O
)	O
.	O

Additional	O
baseline	O
characteristics	O
are	O
shown	O
in	O
appendix	O
pp	O
2–3	O
.	O

Six	O
serious	O
infections	O
(	O
erysipelas	O
,	O
gangrene	O
,	O
sepsis	O
,	O
tonsillitis	O
,	O
ear	O
infection	O
and	O
pneumonia	O
)	O
were	O
reported	O
in	O
four	O
patients	O
receiving	O
canakinumab	O
(	O
table	O
3	O
)	O
.	O

All	O
patients	O
provided	O
written	O
,	O
informed	O
consent	O
.	O

Secondary	O
outcomes	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
treatment	O
groups	O
,	O
including	O
global	O
assessments	O
of	O
efficacy	O
(	O
fig	O
3	O
)	O
,	O
resolution	O
of	O
inflammation	O
(	O
tables	O
4	O
and	O
5	O
)	O
,	O
self	O
reported	O
pain	O
in	O
the	O
first	O
six	O
weeks	O
,	O
quality	O
of	O
life	O
over	O
the	O
duration	O
of	O
the	O
study	O
(	O
table	O
6	O
)	O
,	O
health	O
related	O
quality	O
of	O
life	O
(	O
table	O
6	O
)	O
,	O
and	O
time	O
to	O
recurrence	O
(	O
table	O
3	O
)	O
.	O

Baseline	O
characteristics	O
were	O
well	O
balanced	O
between	O
treatment	O
groups	O
(	O
figure	O
1	O
,	O
table	O
1	O
)	O
.	O

Analyses	O
are	O
presented	O
of	O
other	O
outcomes	O
,	O
some	O
of	O
which	O
(	O
eg	O
,	O
site-specific	O
cancer	O
,	O
cerebral	O
haemorrhage	O
)	O
were	O
prespecified	O
for	O
the	O
in-trial	O
period	O
whereas	O
some	O
were	O
not	O
(	O
eg	O
,	O
cancer	O
incidence	O
each	O
year	O
)	O
.	O

However	O
,	O
as	O
the	O
distribution	O
of	O
flares	O
per	O
patient	O
was	O
observed	O
to	O
be	O
skewed	O
,	O
the	O
preplanned	O
ANCOVA	O
was	O
considered	O
inappropriate	O
for	O
these	O
data	O
.	O

Serum	O
chemistries	O
,	O
complete	O
blood	O
count	O
,	O
and	O
prothrombin	O
time	O
were	O
performed	O
at	O
screening	O
,	O
week	O
8	O
,	O
week	O
16	O
,	O
and	O
the	O
final	O
study	O
visit	O
(	O
week	O
24	O
or	O
earlier	O
if	O
early	O
termination	O
)	O
.	O

Study	O
patients	O
Male	O
or	O
female	O
patients	O
aged	O
18–75	O
years	O
,	O
with	O
at	O
least	O
a	O
3-month	O
history	O
of	O
asthma	O
at	O
the	O
time	O
of	O
enrolment	O
and	O
an	O
initial	O
diagnosis	O
of	O
asthma	O
made	O
before	O
the	O
age	O
of	O
40	O
years	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Interim	O
data	O
were	O
reviewed	O
annually	O
by	O
an	O
independent	O
data	O
monitoring	O
committee	O
(	O
four	O
meetings	O
)	O
using	O
the	O
Haybittle-Peto	O
criterion	O
(	O
p	O
<	O
0·001	O
)	O
.	O

The	O
mean	O
number	O
of	O
visits	O
to	O
the	O
clinic	O
or	O
general	O
practice	O
for	O
cryotherapy	O
was	O
3.6	O
,	O
with	O
a	O
mean	O
duration	O
between	O
visits	O
of	O
18.3	O
days	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
peak	O
FEV1	O
measured	O
within	O
3	O
hours	O
after	O
dosing	O
(	O
peak	O
FEV1	O
(	O
0-3h	O
)	O
)	O
at	O
the	O
end	O
of	O
each	O
4-week	O
period	O
,	O
analysed	O
as	O
a	O
response	O
(	O
change	O
from	O
study	O
baseline	O
)	O
.	O

Maintenance	O
of	O
cardinal	O
ulcer	O
healing	O
required	O
no	O
recurrence	O
at	O
or	O
contiguous	O
to	O
the	O
original	O
location	O
at	O
week	O
24	O
(	O
if	O
healing	O
occurred	O
before	O
or	O
at	O
week	O
12	O
)	O
or	O
during	O
12	O
weeks	O
of	O
observation	O
with	O
permissible	O
extension	O
of	O
the	O
treatment	O
period	O
(	O
if	O
healing	O
occurred	O
after	O
week	O
12	O
)	O
.	O

Biomarker	O
subgroups	O
did	O
not	O
reveal	O
meaningful	O
efficacy	O
benefits	O
following	O
quilizumab	O
treatment	O
.	O

For	O
determination	O
of	O
the	O
primary	O
outcome	O
,	O
the	O
number	O
of	O
flares	O
per	O
patient	O
during	O
16	O
weeks	O
was	O
modelled	O
using	O
a	O
negative	O
binomial	O
distribution	O
and	O
a	O
common	O
overdispersion	O
(	O
variance	O
divided	O
by	O
expectation	O
minus	O
1	O
)	O
for	O
all	O
treatment	O
arms	O
(	O
see	O
supplementary	O
material	O
for	O
more	O
details	O
)	O
.	O

Additional	O
secondary	O
outcomes	O
were	O
to	O
be	O
reported	O
separately	O
.	O

We	O
performed	O
the	O
REDUCE	O
trials	O
(	O
Registration	O
Endoscopic	O
Studies	O
to	O
Determine	O
Ulcer	O
Formation	O
of	O
HZT-501	O
Compared	O
with	O
Ibuprofen	O
:	O
Efficacy	O
and	O
Safety	O
Studies	O
)	O
to	O
assess	O
whether	O
double-dose	O
famotidine	O
given	O
in	O
a	O
single-tablet	O
combination	O
with	O
ibuprofen	O
(	O
HZT-501	O
(	O
ibuprofen	O
800	O
mg	O
plus	O
famotidine	O
26.6	O
mg	O
)	O
;	O
Horizon	O
Pharma	O
,	O
Northbrook	O
,	O
IL	O
)	O
significantly	O
reduces	O
the	O
proportion	O
of	O
patients	O
who	O
develop	O
gastric	O
ulcers	O
(	O
REDUCE-1	O
)	O
or	O
upper	O
GI	O
(	O
gastric	O
or	O
duodenal	O
)	O
ulcers	O
(	O
REDUCE-2	O
)	O
during	O
24	O
weeks	O
of	O
treatment	O
as	O
compared	O
with	O
ibuprofen	O
in	O
adult	O
NSAID	O
users	O
.	O

Fibrinolytic	O
response	O
Plasma	O
t-PA	O
activity	O
concentrations	O
were	O
similar	O
between	O
groups	O
at	O
baseline	O
and	O
were	O
unaffected	O
by	O
saline	O
placebo	O
(	O
p=1.0	O
)	O
.	O

The	O
effects	O
of	O
treatment	O
allocation	O
on	O
cholesterol	O
concentrations	O
were	O
assessed	O
by	O
assaying	O
blood	O
obtained	O
at	O
study	O
clinics	O
from	O
a	O
sample	O
of	O
about	O
5	O
%	O
of	O
participants	O
scheduled	O
for	O
follow-up	O
at	O
about	O
the	O
same	O
time	O
each	O
year	O
,	O
and	O
from	O
all	O
participants	O
attending	O
follow-up	O
between	O
August	O
,	O
2000	O
,	O
and	O
February	O
,	O
2001	O
.	O

Design	O
Double	B-Blinding_Double_Blind
blind	I-Blinding_Double_Blind
randomised	O
trial	O
.	O

Immunolabelling	O
was	O
performed	O
on	O
whole	O
blood	O
to	O
avoid	O
artefactual	O
platelet	O
activation	O
caused	O
by	O
purification	O
procedures	O
.	O

Assessing	O
the	O
primary	O
outcome	O
at	O
six	O
weeks	O
also	O
minimised	O
loss	O
to	O
follow-up	O
and	O
the	O
impact	O
of	O
participants	O
switching	O
to	O
alternative	O
treatments	O
before	O
primary	O
outcome	O
assessment	O
.	O

In	O
the	O
Ca+D	O
and	O
Ca	O
groups	O
,	O
the	O
final	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
greater	O
in	O
those	O
who	O
achieved	O
the	O
primary	O
outcome	O
(	O
56.4±17.2	O
nmol/L	O
)	O
than	O
in	O
those	O
who	O
did	O
not	O
(	O
37.7±18.5	O
nmol/L	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Results	O
One	B-Sample_Size_Actual_at_Enrollment
hundred	I-Sample_Size_Actual_at_Enrollment
and	I-Sample_Size_Actual_at_Enrollment
six	I-Sample_Size_Actual_at_Enrollment
girls	I-Sample_Size_Actual_at_Enrollment
with	O
Turner	O
’	O
s	O
syndrome	O
were	O
recruited	O
from	O
36	B-Settings_Multicenter
UK	B-Settings_Location
hospitals	I-Settings_Multicenter
between	O
1999	O
and	O
2003	O
,	O
of	O
whom	O
14	O
withdrew	O
(	O
four	O
of	O
them	O
because	O
of	O
early	O
organisational	O
errors	O
)	O
,	O
leaving	O
92	B-Sample_Size_Actual_at_Outcome_Analysis
to	O
complete	O
the	O
study	O
(	O
fig	O
1	O
)	O
.	O

During	O
the	O
in-trial	O
period	O
,	O
2153	O
(	O
21·0	O
%	O
)	O
first	O
major	O
vascular	O
events	O
arose	O
in	O
10	O
269	O
participants	O
allocated	O
simvastatin	O
versus	O
2712	O
(	O
26·4	O
%	O
)	O
in	O
10	O
267	O
allocated	O
placebo	O
,	O
corresponding	O
to	O
a	O
significant	O
23	O
%	O
(	O
SE	O
3	O
)	O
proportional	O
reduction	O
(	O
p	O
<	O
0·0001	O
:	O
figure	O
1	O
)	O
.	O

Statistical	O
analyses	O
Efficacy	O
data	O
are	O
reported	O
for	O
the	O
full	O
analysis	O
set	O
,	O
which	O
was	O
defined	O
as	O
all	O
randomised	O
patients	O
who	O
were	O
treated	O
with	O
at	O
least	O
one	O
dose	O
of	O
study	O
medication	O
,	O
had	O
baseline	O
data	O
and	O
had	O
at	O
least	O
one	O
on-treatment	O
efficacy	O
measurement	O
after	O
4	O
weeks	O
of	O
treatment	O
within	O
a	O
period	O
.	O

Topical	O
treatment	O
was	O
prohibited	O
during	O
the	O
trial	O
.	O

Panel	O
tests	O
could	O
also	O
be	O
requested	O
in	O
both	O
groups	O
at	O
extra	O
patient-initiated	O
visits	O
.	O

Conclusions	O
Memantine	O
treatment	O
was	O
associated	O
with	O
lower	O
axial	O
motor	O
symptom	O
and	O
dyskinesia	O
scores	O
but	O
did	O
not	O
improve	O
gait	O
.	O

Data	O
were	O
analysed	O
according	O
to	O
an	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
with	O
treatment	O
group	O
,	O
allopurinol	O
dose	O
at	O
baseline	O
and	O
BMI	O
at	O
baseline	O
as	O
covariates	O
.	O

Stride	O
length	O
was	O
assessed	O
in	O
an	O
optoelectronic	O
analysis	O
with	O
a	O
6-camera	O
VICON	O
Video	O
System	O
from	O
Oxford	O
Metrics	O
(	O
Oxford	O
,	O
UK	O
)	O
(	O
sampling	O
rate	O
:	O
50	O
Hz	O
)	O
.	O

Baseline	O
characteristics	O
were	O
balanced	O
between	O
the	O
groups	O
(	O
table	O
1	O
)	O
.	O

A	O
sample	O
size	O
for	O
REDUCE-2	O
of	O
600	B-Sample_Size_Required
was	O
calculated	O
based	O
on	O
a	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
difference	O
of	O
6	O
%	O
vs.	O
16	O
%	O
in	O
the	O
incidence	O
of	O
upper	O
GI	O
ulcers	O
with	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
α	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.05	I-Sample_Size_Calculation_Alpha_Value
and	O
assuming	O
a	O
15	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
drop-out	O
rate	O
.	O

Additional	O
post	O
hoc	O
analysis	O
of	O
data	O
at	O
week	O
2	O
showed	O
no	O
differences	O
between	O
the	O
groups	O
in	O
onset	O
of	O
treatment	O
response	O
(	O
P=0.21	O
)	O
.	O

Data	O
were	O
collected	O
regarding	O
symptoms	O
of	O
rickets	O
,	O
the	O
frequency	O
and	O
quantity	O
of	O
dairy	O
product	O
intake	O
,	O
and	O
usual	O
sunlight	O
exposure	O
.	O

All	O
children	O
on	O
routine	O
laboratory	O
monitoring	O
meeting	O
CD4	O
switch	O
criteria	O
actually	O
switched	O
.	O

Despite	O
our	O
use	O
of	O
a	O
more	O
sensitive	O
optoelectronic	O
analysis	O
in	O
the	O
present	O
study	O
,	O
we	O
adopted	O
the	O
same	O
anticipated	O
stride	O
length	O
difference	O
,	O
that	O
is	O
,	O
0.4	O
m	O
(	O
SD	O
:	O
0.4	O
)	O
.	O

For	O
example	O
,	O
in	O
older	O
patients	O
the	O
time	O
to	O
randomisation	O
was	O
shorter	O
.	O

Patients	O
were	O
required	O
to	O
continue	O
maintenance	O
treatment	O
with	O
stable	O
medium-dose	O
ICS	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
and	O
during	O
the	O
treatment	O
period	O
.	O

Interpretation	O
Prolonged	O
follow-up	O
in	O
the	O
Heart	O
Protection	O
Study	O
now	O
shows	O
that	O
reduction	O
of	O
about	O
a	O
quarter	O
in	O
vascular	O
mortality	O
and	O
morbidity—produced	O
by	O
an	O
average	O
1	O
mmol/L	O
reduction	O
in	O
LDL	O
cholesterol	O
with	O
5	O
years	O
of	O
statin	O
therapy—persisted	O
largely	O
unchanged	O
during	O
the	O
subsequent	O
6	O
years	O
,	O
despite	O
similar	O
LDL	O
cholesterol	O
concentrations	O
and	O
statin	O
use	O
in	O
both	O
treatment	O
groups	O
.	O

Participants	O
Members	O
of	O
the	O
British	O
Society	O
for	O
Paediatric	O
Endocrinology	O
and	O
Diabetes	O
recruited	O
patients	O
from	O
participating	O
paediatric	B-Settings_Multicenter
endocrinology	I-Settings_Multicenter
departments	I-Settings_Multicenter
in	O
UK	B-Settings_Location
hospitals	O
.	O

During	O
the	O
post-trial	O
period	O
,	O
vascular	O
mortality	O
rates	O
were	O
similar	O
in	O
both	O
treatment	O
groups	O
(	O
1019	O
[	O
11·5	O
%	O
]	O
vs	O
1007	O
[	O
11·6	O
%	O
]	O
;	O
RR	O
0·98	O
[	O
95	O
%	O
CI	O
0·90–1·07	O
]	O
;	O
p=0·71	O
)	O
,	O
so	O
in-trial	O
survival	O
gains	O
persisted	O
.	O

This	O
approach	O
also	O
requires	O
no	O
α	O
adjustment	O
for	O
multiple	O
comparisons	O
.	O

Patients	O
were	O
evaluated	O
at	O
randomisation/baseline	O
and	O
every	O
4	O
weeks	O
during	O
treatment	O
(	O
or	O
premature	O
withdrawal	O
,	O
week	O
24	O
and	O
,	O
if	O
applicable	O
,	O
12	O
weeks	O
after	O
healing	O
of	O
the	O
cardinal	O
ulcer	O
)	O
,	O
with	O
DUs	O
assessed	O
at	O
each	O
study	O
visit	O
.	O

Patients	O
were	O
followed	O
for	O
24	O
weeks	O
.	O

Efficacy	O
criteria	O
The	O
‘	O
off-L-dopa	O
’	O
condition	O
could	O
not	O
be	O
studied	O
,	O
since	O
18	O
patients	O
with	O
very	O
advanced	O
PD	O
were	O
unable	O
to	O
walk	O
unaided	O
when	O
L-dopa	O
had	O
been	O
withdrawn	O
.	O

Efficacy	O
Primary	O
analysis	O
The	O
addition	O
of	O
tiotropium	O
Respimat®	O
5	O
μg	O
,	O
2.5	O
μg	O
or	O
1.25	O
μg	O
to	O
stable	O
medium-dose	O
ICS	O
therapy	O
was	O
associated	O
with	O
improved	O
lung	O
function	O
:	O
at	O
the	O
end	O
of	O
the	O
4-week	O
treatment	O
period	O
,	O
statistically	O
significant	O
differences	O
from	O
placebo	O
Respimat®	O
in	O
adjusted	O
mean	O
peak	O
FEV1	O
(	O
0-3h	O
)	O
responses	O
were	O
observed	O
for	O
all	O
doses	O
of	O
tiotropium	O
Respimat®	O
(	O
P	O
<	O
0.0001	O
at	O
all	O
doses	O
)	O
(	O
Figure	O
3	O
)	O
.	O

Cohen	O
’	O
s	O
κ	O
measure	O
of	O
inter-rater	O
agreement	O
was	O
used	O
to	O
assess	O
agreement	O
between	O
the	O
two	O
assessors	O
of	O
the	O
photographs	O
for	O
clearance	O
.	O

Quilizumab	O
also	O
abrogated	O
the	O
increase	O
in	O
challenge-specific	O
IgE	O
in	O
patients	O
with	O
mild	O
asthma	O
following	O
a	O
whole-lung	O
allergen	O
challenge	O
,	O
and	O
reduced	O
the	O
early	O
and	O
late	O
asthmatic	O
reactions	O
.	O

For	O
the	O
analyses	O
of	O
symptom	O
scores	O
,	O
rescue	O
medication	O
use	O
,	O
and	O
nighttime	O
awakenings	O
,	O
daily	O
scores	O
were	O
averaged	O
over	O
the	O
previous	O
7	O
days	O
prior	O
to	O
the	O
time	O
point	O
of	O
interest	O
.	O

To	O
achieve	O
this	O
,	O
each	O
individual	O
curve	O
is	O
suitably	O
altered	O
in	O
three	O
distinct	O
ways	O
:	O
the	O
curve	O
is	O
shifted	O
up/down	O
(	O
a	O
measure	O
of	O
the	O
child	O
’	O
s	O
size	O
in	O
cm	O
)	O
and	O
left/right	O
(	O
a	O
measure	O
of	O
growth	O
tempo	O
in	O
years	O
)	O
,	O
and	O
the	O
age	O
axis	O
is	O
stretched/squashed	O
(	O
a	O
measure	O
of	O
percentage	O
velocity	O
)	O
.	O

Prespecified	O
pooled	O
analyses	O
showed	O
significantly	O
fewer	O
gastric	O
(	O
12.5	O
%	O
vs.	O
20.7	O
%	O
)	O
and	O
duodenal	O
ulcers	O
(	O
1.1	O
%	O
vs.	O
5.1	O
%	O
)	O
with	O
HZT-501	O
vs.	O
ibuprofen	O
.	O

An	O
unadjusted	O
analysis	O
is	O
also	O
presented	O
.	O

Mortality	O
The	O
overall	O
case	O
fatality	O
rate	O
was	O
21/326	O
(	O
6.4	O
%	O
,	O
4.3	O
%	O
to	O
9.6	O
%	O
)	O
.	O

Study	O
medication	O
was	O
to	O
be	O
taken	O
immediately	O
after	O
ICS	O
inhalation	O
if	O
normal	O
ICS	O
dosing	O
was	O
in	O
the	O
evening	O
.	O

The	B-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
informed	I-Randomization_Sequence_Generation_Method
local	I-Randomization_Sequence_Generation_Method
clinicians	I-Randomization_Sequence_Generation_Method
of	I-Randomization_Sequence_Generation_Method
the	I-Randomization_Sequence_Generation_Method
patients	I-Randomization_Sequence_Generation_Method
'	I-Randomization_Sequence_Generation_Method
unique	I-Randomization_Sequence_Generation_Method
trial	I-Randomization_Sequence_Generation_Method
identification	I-Randomization_Sequence_Generation_Method
number	I-Randomization_Sequence_Generation_Method
,	O
and	O
the	O
weight-adjusted	O
dose	O
of	O
drug	O
or	O
placebo	O
in	O
the	O
double-blinded	B-Blinding_Double_Blind
phase	O
,	O
or	O
of	O
the	O
weight-adjusted	O
drug	O
dose	O
among	O
those	O
allocated	O
thrombolysis	O
in	O
the	O
open	B-Blinding_Open_Label
phase	I-Blinding_Open_Label
,	O
to	O
be	O
given	O
as	O
a	O
10	O
%	O
bolus	O
with	O
the	O
remainder	O
by	O
an	O
infusion	O
over	O
1	O
h.	O
With	O
the	O
exception	O
of	O
the	O
276	O
patients	O
treated	O
in	O
the	O
double-blinded	O
phase	O
of	O
the	O
trial	O
,	O
treatment	O
was	O
given	O
openly	O
and	O
neither	O
the	O
patient	O
nor	O
the	O
treating	O
clinicians	O
were	O
masked	O
.	O

Background	O
Tiotropium	O
,	O
a	O
once-daily	O
long-acting	O
anticholinergic	O
bronchodilator	O
,	O
when	O
administered	O
via	O
Respimat®	O
SoftMist™	O
inhaler	O
(	O
tiotropium	O
Respimat®	O
)	O
significantly	O
reduces	O
the	O
risk	O
of	O
severe	O
exacerbations	O
and	O
improves	O
lung	O
function	O
in	O
patients	O
with	O
severe	O
persistent	O
asthma	O
that	O
is	O
not	O
fully	O
controlled	O
despite	O
using	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
and	O
long-acting	O
β2-agonists	O
.	O

Inclusion	O
criteria	O
were	O
a	O
typical	O
history	O
of	O
myocardial	O
ischaemia	O
lasting	O
more	O
than	O
20	O
min	O
within	O
24	O
h	O
of	O
hospitalisation	O
with	O
ischaemic	O
electrocardiographic	O
changes	O
and	O
an	O
elevated	O
troponin-I	O
concentration	O
(	O
>	O
0.2	O
µg/l	O
)	O
.	O

The	O
Cox	O
regression	O
model	O
for	O
time	O
to	O
healing	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
interventions	O
(	O
hazard	O
ratio	O
0.94	O
,	O
95	O
%	O
confidence	O
interval	O
0.55	O
to	O
1.63	O
;	O
P=0.84	O
)	O
(	O
table	O
3	O
and	O
fig	O
2	O
)	O
.	O

The	O
initial	O
results	O
for	O
the	O
primary	O
end	O
point	O
in	O
REDUCE-2	O
showed	O
the	O
proportions	O
of	O
patients	O
with	O
upper	O
GI	O
ulcers	O
of	O
13.8	O
%	O
for	O
HZT-501	O
and	O
22.6	O
%	O
for	O
ibuprofen	O
(	O
P=0.0304	O
;	O
NNT=11	O
)	O
.	O

Study	O
design	O
We	O
devised	O
a	O
double	B-Blinding_Double_Blind
blind	I-Blinding_Double_Blind
,	O
placebo	O
controlled	O
,	O
randomised	O
controlled	O
trial	O
,	O
including	O
two	O
randomisations	O
in	O
a	O
two	B-Design_Factorial_Factor_Treatment
by	I-Design_Factorial_Factor_Treatment
two	I-Design_Factorial_Factor_Treatment
factorial	B-Design_Factorial
design	O
.	O

Higher	O
mean	O
pre-dose	O
PEFpm	O
responses	O
were	O
also	O
observed	O
with	O
all	O
three	O
tiotropium	O
Respimat®	O
treatments	O
compared	O
with	O
placebo	O
Respimat®	O
(	O
difference	O
from	O
placebo	O
:	O
5	O
μg	O
,	O
21.581	O
L/min	O
;	O
2.5	O
μg	O
,	O
14.577	O
L/min	O
;	O
1.25	O
μg	O
,	O
21.251	O
L/min	O
;	O
all	O
P	O
<	O
0.0001	O
)	O
.	O

Patients	O
also	O
recorded	O
rescue	O
medication	O
use	O
and	O
pain	O
for	O
at	O
least	O
7	O
days	O
after	O
the	O
onset	O
of	O
the	O
flare	O
or	O
longer	O
if	O
the	O
flares	O
persisted	O
for	O
more	O
than	O
7	O
days	O
.	O

After	O
unblinding	O
and	O
initial	O
analyses	O
,	O
12	O
patients	O
were	O
found	O
to	O
be	O
misclassified	O
as	O
having	O
gastric	O
ulcers	O
based	O
on	O
the	O
adjudication	O
of	O
endoscopy	O
reports	O
,	O
and	O
analyses	O
were	O
re-run	O
.	O

Interestingly	O
,	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
not	O
predictive	O
of	O
a	O
response	O
to	O
vitamin	O
D	O
,	O
as	O
there	O
was	O
no	O
interaction	O
of	O
treatment	O
group	O
with	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
(	O
p=0.42	O
for	O
interaction	O
)	O
.	O

Patients	O
using	O
ICS	O
plus	O
short-acting	O
β2-agonist	O
or	O
ICS	O
+	O
LABA	O
fixed-dose	O
combinations	O
were	O
switched	O
to	O
the	O
same	O
dose	O
of	O
ICS	O
mono-product	O
at	O
least	O
8	O
or	O
24	O
hours	O
,	O
respectively	O
,	O
prior	O
to	O
Visit	O
1	O
.	O

No	O
difference	O
between	O
treatments	O
was	O
observed	O
in	O
the	O
mean	O
total	O
number	O
of	O
DUs	O
(	O
baseline	O
plus	O
new	O
)	O
per	O
patient	O
among	O
patients	O
with	O
at	O
least	O
four	O
DUs	O
at	O
baseline	O
(	O
−3.4	O
(	O
95	O
%	O
CI	O
−4.8	O
to	O
−1.9	O
)	O
on	O
bosentan	O
and	O
−3.6	O
(	O
−5.4	O
to	O
−1.7	O
)	O
DUs	O
on	O
placebo	O
)	O
and	O
those	O
with	O
fewer	O
than	O
four	O
DUs	O
at	O
baseline	O
(	O
−0.6	O
(	O
−1.0	O
to	O
−0.2	O
)	O
and	O
−0.5	O
(	O
−1.1	O
to	O
0.1	O
)	O
DUs	O
,	O
respectively	O
)	O
.	O

In	O
2008	O
,	O
the	O
decision	O
was	O
taken	O
to	O
terminate	O
the	O
treatment	O
arm	O
forthwith	O
,	O
resulting	O
in	O
eight	O
participants	O
stopping	O
oxandrolone	O
treatment	O
prematurely	O
.	O

(	O
The	O
LS	O
mean	O
number	O
of	O
flares	O
per	O
patient	O
is	O
the	O
best-fitting	O
unbiased	O
estimate	O
calculated	O
from	O
the	O
ANCOVA	O
model	O
.	O

Nifedipine	O
and	O
intravenous	O
iloprost	O
resulted	O
in	O
the	O
reduction	O
from	O
baseline	O
in	O
the	O
mean	O
number	O
of	O
DUs	O
in	O
a	O
small	O
study	O
.	O

Methods	O
In	O
this	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
four-way	B-Design_Crossover_Period_Treatment
crossover	B-Design_Crossover
study	O
,	O
patients	O
were	O
randomised	O
to	O
tiotropium	B-Design_Parallel_Group
Respimat®	I-Design_Parallel_Group
5	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
,	I-Design_Parallel_Group
2.5	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
1.25	I-Design_Parallel_Group
μg	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
Respimat®	O
,	O
once	O
daily	O
in	O
the	O
evening	O
.	O

Serum	O
total	O
and	O
allergen-specific	O
IgE	O
in	O
quilizumab-treated	O
patients	O
gradually	O
increased	O
throughout	O
the	O
safety	O
follow-up	O
period	O
,	O
but	O
did	O
not	O
return	O
to	O
pre-dose	O
levels	O
by	O
the	O
end	O
of	O
the	O
study	O
period	O
(	O
Week	O
84	O
)	O
.	O

The	O
incidence	O
of	O
AEs	O
over	O
the	O
24-week	O
period	O
was	O
similar	O
across	O
the	O
six	O
canakinumab	O
groups	O
(	O
51.9	O
%	O
to	O
58.5	O
%	O
)	O
and	O
for	O
the	O
colchicine	O
group	O
(	O
53.7	O
%	O
)	O
(	O
table	O
3	O
)	O
.	O

Three	O
recent	O
trials	O
used	O
colchicine	O
for	O
prophylaxis	O
in	O
patients	O
initiating	O
ULT	O
(	O
with	O
febuxostat	O
)	O
,	O
but	O
provide	O
limited	O
data	O
on	O
the	O
efficacy	O
of	O
colchicine	O
.	O

During	O
prolonged	O
follow-up	O
in	O
observational	O
epidemiological	O
studies	O
,	O
lower	O
blood	O
cholesterol	O
concentrations	O
have	O
been	O
associated	O
with	O
higher	O
rates	O
of	O
particular	O
types	O
of	O
cancer	O
,	O
and	O
with	O
other	O
non-vascular	O
morbidity	O
and	O
mortality	O
.	O

Participants	O
were	O
randomly	O
assigned	O
(	O
1:1	B-Randomization_Ratio
)	O
to	O
clinically	O
driven	O
monitoring	O
versus	O
routine	O
laboratory	O
plus	O
clinical	O
monitoring	O
for	O
toxicity	O
(	O
haematology	O
and	O
biochemistry	O
)	O
and	O
efficacy	O
(	O
CD4	O
)	O
.	O

Randomisation	O
was	O
performed	O
by	O
a	B-Randomization_Sequence_Generation_Method
computer	I-Randomization_Sequence_Generation_Method
generated	I-Randomization_Sequence_Generation_Method
sequence	I-Randomization_Sequence_Generation_Method
to	O
ensure	O
concealment	O
of	O
treatment	O
allocation	O
and	O
following	O
minimisation	B-Randomization_Type_Minimization
for	O
age	B-Randomization_Minimization_Criteria
,	O
sex	B-Randomization_Minimization_Criteria
,	O
time	B-Randomization_Minimization_Criteria
to	I-Randomization_Minimization_Criteria
randomisation	I-Randomization_Minimization_Criteria
,	O
peak	B-Randomization_Minimization_Criteria
troponin	I-Randomization_Minimization_Criteria
,	O
serum	B-Randomization_Minimization_Criteria
cholesterol	I-Randomization_Minimization_Criteria
and	I-Randomization_Minimization_Criteria
cardiovascular	I-Randomization_Minimization_Criteria
risk	I-Randomization_Minimization_Criteria
factors	I-Randomization_Minimization_Criteria
including	I-Randomization_Minimization_Criteria
diabetes	I-Randomization_Minimization_Criteria
mellitus	I-Randomization_Minimization_Criteria
,	I-Randomization_Minimization_Criteria
hypertension	I-Randomization_Minimization_Criteria
and	I-Randomization_Minimization_Criteria
smoking	I-Randomization_Minimization_Criteria
.	O

For	O
64	O
participants	O
(	O
32	O
in	O
each	O
group	O
)	O
the	O
pyoderma	O
gangrenosum	O
improved	O
(	O
decreased	O
in	O
size	O
)	O
,	O
with	O
a	O
median	O
decrease	O
of	O
those	O
that	O
decreased	O
of	O
1.96	O
cm2	O
in	O
the	O
ciclosporin	O
group	O
and	O
3.04	O
cm2	O
in	O
the	O
prednisolone	O
group	O
.	O

The	O
results	O
for	O
the	O
analyses	O
were	O
then	O
re-run	O
with	O
these	O
patients	O
no	O
longer	O
listed	O
as	O
having	O
gastric	O
ulcers	O
.	O

Most	O
of	O
the	O
362	O
serious	O
adverse	O
events	O
(	O
217	O
clinically	O
driven	O
,	O
145	O
routine	O
laboratory	O
monitoring	O
)	O
were	O
malaria	O
(	O
113	O
clinically	O
driven	O
,	O
65	O
routine	O
laboratory	O
monitoring	O
)	O
,	O
and	O
most	O
(	O
179	O
clinically	O
driven	O
,	O
117	O
routine	O
laboratory	O
monitoring	O
)	O
were	O
admissions	O
to	O
hospital	O
.	O

No	O
significant	O
treatment-by-subgroup	O
interactions	O
were	O
identified	O
for	O
the	O
subgroups	O
assessed	O
(	O
all	O
P	O
values	O
>	O
0.10	O
)	O
.	O

The	O
pre-specified	O
hypotheses	O
were	O
tested	O
using	O
a	O
mixed	O
effects	O
model	O
with	O
repeated	O
measures	O
.	O

Patients	O
were	O
enrolled	O
between	O
May	O
2010	O
and	O
November	O
2010	O
,	O
following	O
their	O
provision	O
of	O
written	O
,	O
informed	O
consent	O
to	O
participation	O
.	O

At	O
week	O
24	O
,	O
suppression	O
was	O
significantly	O
greater	O
in	O
induction	O
groups	O
receiving	O
four	O
drugs	O
(	O
285	O
[	O
88	O
%	O
]	O
of	O
324	O
children	O
in	O
groups	O
B	O
and	O
C	O
vs	O
114	O
[	O
77	O
%	O
]	O
of	O
148	O
in	O
group	O
A	O
)	O
.	O

Study	O
procedures	O
were	O
all	O
completed	O
prior	O
to	O
invasive	O
angiography	O
or	O
percutaneous	O
coronary	O
intervention	O
.	O

Pain	O
and	O
disability	O
Patient-rated	O
measures	O
of	O
overall	O
hand	O
pain	O
and	O
pain	O
of	O
the	O
cardinal	O
ulcer	O
,	O
as	O
assessed	O
by	O
visual	O
analogue	O
scales	O
,	O
showed	O
no	O
differential	O
treatment	O
effect	O
in	O
pain	O
at	O
week	O
24	O
(	O
mean	O
treatment	O
effects	O
of	O
−1.7	O
(	O
95	O
%	O
CI	O
−11.4	O
to	O
7.9	O
)	O
,	O
p=0.73	O
and	O
−1.6	O
(	O
−11.5	O
to	O
8.3	O
)	O
,	O
p=0.75	O
,	O
respectively	O
)	O
.	O

For	O
randomisation	O
1	O
,	O
final	O
height	O
was	O
significantly	O
greater	O
with	O
oxandrolone	O
than	O
placebo	O
(	O
4.6	O
cm	O
,	O
95	O
%	O
confidence	O
interval	O
1.9	O
to	O
7.2	O
;	O
P=0.001	O
)	O
.	O

Baseline	O
25	O
(	O
OH	O
)	O
D	O
did	O
not	O
alter	O
treatment	O
group	O
effects	O
(	O
p=0.99	O
for	O
interaction	O
)	O
.	O

In	O
all	O
cases	O
on	O
bosentan	O
,	O
elevated	O
aminotransferases	O
resolved	O
during	O
continued	O
treatment	O
,	O
after	O
a	O
decrease	O
in	O
dose	O
,	O
or	O
following	O
temporary	O
or	O
permanent	O
treatment	O
discontinuation	O
.	O

Randomisation	O
1	O
,	O
to	O
oxandrolone	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
took	O
place	O
at	O
age	O
9	O
years	O
(	O
or	O
at	O
enrolment	O
,	O
if	O
older	O
)	O
and	O
was	O
balanced	B-Randomization_Type_Stratified
for	O
enrolling	B-Randomization_Stratified_Criteria
centre	I-Randomization_Stratified_Criteria
,	O
quarter	B-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
mid-parental	I-Randomization_Stratified_Criteria
height	I-Randomization_Stratified_Criteria
,	O
and	O
previous	B-Randomization_Stratified_Criteria
exposure	I-Randomization_Stratified_Criteria
to	I-Randomization_Stratified_Criteria
growth	I-Randomization_Stratified_Criteria
hormone	I-Randomization_Stratified_Criteria
treatment	I-Randomization_Stratified_Criteria
.	O

Patient	O
reported	O
outcomes	O
were	O
collected	O
from	O
daily	O
diaries	O
or	O
postal	O
questionnaires	O
.	O

There	O
was	O
no	O
clear	O
pattern	O
with	O
respect	O
to	O
the	O
incidence	O
of	O
infections	O
with	O
either	O
treatment	O
.	O

Design	O
Randomised	O
,	O
double	B-Blinding_Double_Blind
blind	I-Blinding_Double_Blind
,	O
placebo	O
controlled	O
trial	O
.	O

The	O
percentage	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
flare	O
in	O
the	O
16-week	O
period	O
was	O
lower	O
for	O
all	O
canakinumab	O
groups	O
versus	O
colchicine	O
0.5	O
mg	O
(	O
canakinumab	O
,	O
15	O
%	O
to	O
27	O
%	O
;	O
colchicine	O
,	O
44	O
%	O
,	O
p≤0.05	O
)	O
,	O
and	O
all	O
patients	O
receiving	O
canakinumab	O
were	O
significantly	O
less	O
likely	O
to	O
experience	O
at	O
least	O
one	O
flare	O
compared	O
with	O
patients	O
treated	O
with	O
colchicine	O
(	O
estimated	O
odds	O
ratio	O
(	O
OR	O
)	O
vs	O
colchicine	O
:	O
0.22–0.47	O
,	O
p≤0.05	O
)	O
(	O
table	O
2	O
)	O
.	O

For	O
each	O
flare	O
,	O
patients	O
recorded	O
in	O
a	O
diary	O
the	O
start	O
date	O
,	O
the	O
most	O
affected	O
joint	O
on	O
that	O
day	O
and	O
the	O
severity	O
of	O
pain	O
(	O
see	O
supplementary	O
material	O
for	O
further	O
details	O
)	O
.	O

Routine	O
versus	O
clinically	O
driven	O
laboratory	O
monitoring	O
and	O
first-line	O
antiretroviral	O
therapy	O
strategies	O
in	O
African	O
children	O
with	O
HIV	O
(	O
ARROW	O
)	O
:	O
a	O
5-year	O
open-label	B-Blinding_Open_Label
randomised	O
factorial	B-Design_Factorial
trial	O

The	O
median	O
durations	O
of	O
these	O
interventions	O
were	O
similar	O
between	O
the	O
two	O
treatment	O
arms	O
(	O
table	O
6	O
)	O
.	O

Information	O
was	O
sought	O
about	O
any	O
suspected	O
heart	O
attacks	O
,	O
strokes	O
,	O
vascular	O
procedures	O
,	O
cancers	O
,	O
or	O
other	O
serious	O
adverse	O
events	O
.	O

Exploratory	O
analysis	O
of	O
the	O
difference	O
in	O
response	O
between	O
tiotropium	O
Respimat®	O
doses	O
found	O
that	O
peak	O
FEV1	O
(	O
0-3h	O
)	O
,	O
FEV1	O
AUC	O
(	O
0-3h	O
)	O
,	O
peak	O
FVC	O
(	O
0-3h	O
)	O
and	O
FVC	O
AUC	O
(	O
0-3h	O
)	O
responses	O
were	O
all	O
statistically	O
significantly	O
greater	O
with	O
tiotropium	O
Respimat®	O
5	O
μg	O
than	O
with	O
either	O
of	O
the	O
two	O
lower	O
doses	O
(	O
Table	O
2	O
)	O
.	O

For	O
the	O
other	O
22	O
(	O
20	O
%	O
)	O
participants	O
whose	O
digital	O
images	O
were	O
either	O
unavailable	O
or	O
of	O
insufficient	O
quality	O
to	O
allow	O
assessment	O
,	O
healing	O
speed	O
was	O
assessed	O
using	O
unblinded	O
physical	O
measurements	O
taken	O
during	O
clinic	O
visits	O
.	O

Participants	O
240	B-Sample_Size_Actual_at_Enrollment
patients	O
aged	O
12	O
years	O
and	O
over	O
,	O
with	O
a	O
plantar	O
wart	O
that	O
in	O
the	O
opinion	O
of	O
the	O
healthcare	O
professional	O
was	O
suitable	O
for	O
treatment	O
with	O
both	O
cryotherapy	O
and	O
salicylic	O
acid	O
.	O

Statistical	O
comparisons	O
were	O
predefined	O
to	O
be	O
done	O
with	O
a	O
fixed	O
testing	O
sequence	O
(	O
hierarchical	O
)	O
in	O
the	O
following	O
order	O
of	O
primary	O
followed	O
by	O
secondary	O
end	O
points	O
:	O
REDUCE-1	O
:	O
gastric	O
ulcers	O
,	O
upper	O
GI	O
ulcers	O
,	O
duodenal	O
ulcers	O
,	O
GI	O
complications	O
;	O
REDUCE-2	O
:	O
upper	O
GI	O
ulcers	O
,	O
gastric	O
ulcers	O
,	O
duodenal	O
ulcers	O
,	O
GI	O
complications	O
.	O

Secondary	O
outcomes	O
Clinical	O
outcomes	O
The	O
least-squares	O
(	O
LS	O
)	O
mean	O
number	O
of	O
flares	O
per	O
patient	O
for	O
the	O
16	O
weeks	O
(	O
according	O
to	O
the	O
preplanned	O
ANCOVA	O
)	O
was	O
lower	O
for	O
all	O
canakinumab	O
doses	O
compared	O
with	O
colchicine	O
0.5	O
mg	O
;	O
differences	O
were	O
statistically	O
significant	O
for	O
the	O
canakinumab	O
100	O
mg	O
and	O
300	O
mg	O
doses	O
(	O
p≤0.05	O
,	O
table	O
2	O
)	O
.	O

Although	O
many	O
national	O
and	O
international	O
groups	O
recommend	O
protective	O
therapy	O
in	O
NSAID	O
users	O
at	O
increased	O
risk	O
of	O
GI	O
events	O
,	O
most	O
such	O
patients	O
are	O
not	O
prescribed	O
protective	O
therapy	O
.	O

Conclusion	O
Oxandrolone	O
had	O
a	O
positive	O
effect	O
on	O
final	O
height	O
in	O
girls	O
with	O
Turner	O
’	O
s	O
syndrome	O
treated	O
with	O
growth	O
hormone	O
,	O
as	O
did	O
late	O
pubertal	O
induction	O
with	O
ethinylestradiol	O
at	O
age	O
14	O
years	O
.	O

Design	O
and	O
setting	O
and	O
patients	O
A	O
double-blind	B-Blinding_Double_Blind
,	O
parallel	B-Design_Parallel_Group
group	I-Design_Parallel_Group
,	O
randomised	O
controlled	O
trial	O
performed	O
in	O
a	B-Settings_Single_Center
tertiary	I-Settings_Single_Center
referral	I-Settings_Single_Center
cardiac	I-Settings_Single_Center
centre	I-Settings_Single_Center
.	O

Time-to-event	O
analyses	O
up	O
to	O
week	O
24	O
indicated	O
an	O
increasing	O
reduction	O
in	O
risk	O
with	O
bosentan	O
compared	O
with	O
placebo	O
for	O
the	O
appearance	O
of	O
each	O
successive	O
new	O
DU	O
,	O
with	O
a	O
HR	O
of	O
0.45	O
(	O
95	O
%	O
CI	O
0.21	O
to	O
0.95	O
,	O
p=0.03	O
)	O
for	O
the	O
fifth	O
new	O
DU	O
.	O

In	O
the	O
tiotropium	O
Respimat®	O
5	O
μg	O
group	O
,	O
one	O
patient	O
reported	O
dry	O
mouth	O
.	O

All	O
patients	O
in	O
the	O
trial	O
were	O
to	O
be	O
treated	O
within	O
that	O
organised	O
system	O
of	O
stroke	O
care	O
,	O
irrespective	O
of	O
treatment	O
allocation	O
.	O

There	O
was	O
no	O
between	O
group	O
difference	O
in	O
speed	O
of	O
healing	O
over	O
six	O
weeks	O
(	O
adjusted	O
mean	O
difference	O
0.003	O
cm2/day	O
,	O
95	O
%	O
confidence	O
interval	O
−0.20	O
to	O
0.21	O
;	O
P=0.97	O
)	O
(	O
table	O
2	O
)	O
.	O

Asthma	O
exacerbations	O
were	O
defined	O
as	O
new	O
or	O
increased	O
asthma	O
symptoms	O
(	O
wheezing	O
,	O
cough	O
,	O
chest	O
tightness	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
nighttime	O
awakening	O
due	O
to	O
symptoms	O
)	O
that	O
led	O
to	O
treatment	O
with	O
systemic	O
corticosteroids	O
for	O
at	O
least	O
3	O
days	O
or	O
to	O
hospitalization	O
.	O

Statistically	O
significant	O
improvements	O
in	O
peak	O
FEV1	O
(	O
0-3h	O
)	O
response	O
were	O
observed	O
with	O
each	O
tiotropium	B-Design_Parallel_Group
Respimat®	I-Design_Parallel_Group
dose	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	O
all	O
P	O
<	O
0.0001	O
)	O
.	O

Vital	O
signs	O
were	O
measured	O
and	O
recorded	O
in	O
conjunction	O
with	O
lung	O
function	O
tests	O
at	O
Visits	O
2–6	O
.	O

If	O
appropriate	O
,	O
the	O
IST-3	O
trial	O
office	O
masked	O
staff	O
then	O
mailed	O
a	O
postal	O
questionnaire	O
to	O
patients	O
to	O
assess	O
outcome	O
.	O

If	O
cholesterol	O
lowering	O
with	O
statin	O
treatment	O
had	O
effects	O
on	O
cancer	O
then	O
these	O
might	O
be	O
expected	O
to	O
be	O
restricted	O
to	O
particular	O
types	O
.	O

There	O
was	O
a	O
dose-dependent	O
increase	O
in	O
forearm	O
blood	O
flow	O
with	O
all	O
intra-arterial	O
vasodilators	O
:	O
substance	O
P	O
,	O
acetylcholine	O
and	O
sodium	O
nitroprusside	O
(	O
p	O
<	O
0.001	O
)	O
.	O

As	O
this	O
was	O
a	O
pragmatic	O
trial	O
,	O
the	O
dose	O
could	O
be	O
adjusted	O
according	O
to	O
normal	O
practice	O
,	O
to	O
a	O
maximum	O
of	O
1	O
mg/kg/day	O
for	O
prednisolone	O
and	O
5	O
mg/kg/day	O
for	O
ciclosporin	O
.	O

HIV	O
viral	O
loads	O
were	O
done	O
retrospectively	O
on	O
stored	O
samples	O
.	O

Conclusions	O
Bosentan	O
treatment	O
reduced	O
the	O
occurrence	O
of	O
new	O
DUs	O
in	O
patients	O
with	O
SSc	O
but	O
had	O
no	O
effect	O
on	O
DU	O
healing	O
.	O

The	O
six	O
deaths	O
not	O
related	O
to	O
H5N1	O
(	O
two	O
with	O
H3N2	O
,	O
one	O
with	O
influenza	O
B	O
,	O
one	O
with	O
H1N1pdm09	O
,	O
and	O
two	O
negative	O
)	O
were	O
not	O
significantly	O
different	O
between	O
arms	O
.	O

Randomisation	O
Each	O
patient	O
received	O
all	O
treatments	O
.	O

The	O
two	O
primary	O
end	O
points	O
were	O
the	O
number	O
of	O
new	O
DUs	O
and	O
the	O
time	O
to	O
healing	O
of	O
the	O
cardinal	O
ulcer	O
.	O

Non-normally	O
distributed	O
data	O
were	O
log-transformed	O
.	O

Patients	O
were	O
stratified	B-Randomization_Type_Stratified
for	O
two	O
risk	O
factors	O
for	O
ulcer	O
development	O
:	O
concomitant	B-Randomization_Stratified_Criteria
use	I-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
low-dose	I-Randomization_Stratified_Criteria
aspirin	I-Randomization_Stratified_Criteria
(	I-Randomization_Stratified_Criteria
≤325	I-Randomization_Stratified_Criteria
mg	I-Randomization_Stratified_Criteria
daily	I-Randomization_Stratified_Criteria
)	I-Randomization_Stratified_Criteria
and/or	I-Randomization_Stratified_Criteria
anticoagulant	I-Randomization_Stratified_Criteria
medication	I-Randomization_Stratified_Criteria
and	O
history	B-Randomization_Stratified_Criteria
of	I-Randomization_Stratified_Criteria
gastric	I-Randomization_Stratified_Criteria
or	I-Randomization_Stratified_Criteria
duodenal	I-Randomization_Stratified_Criteria
ulcer	I-Randomization_Stratified_Criteria
.	O

Treatment-by-subgroup	O
interaction	O
was	O
also	O
assessed	O
among	O
these	O
subgroups	O
in	O
the	O
model	O
.	O

Study	O
baseline	O
,	O
defined	O
as	O
pre-treatment	O
values	O
measured	O
at	O
Visit	O
2	O
in	O
the	O
evening	O
,	O
was	O
included	O
as	O
covariate	O
.	O

A	O
previous	O
double-blind	O
,	O
randomised	O
,	O
placebo-controlled	O
trial	O
investigated	O
the	O
role	O
of	O
bosentan	O
in	O
the	O
reduction	O
of	O
new	O
DUs	O
in	O
122	O
patients	O
with	O
SSc	O
and	O
a	O
history	O
of	O
DUs	O
within	O
the	O
previous	O
year	O
.	O

The	O
pharmacokinetic	O
outcomes	O
included	O
:	O
serum	O
concentrations	O
prior	O
to	O
dosing	O
at	O
Weeks	O
0	O
,	O
4	O
,	O
12	O
,	O
24	O
,	O
and	O
32	O
;	O
serum	O
concentrations	O
at	O
Week	O
5	O
and	O
Week	O
25	O
;	O
maximum	O
observed	O
serum	O
concentrations	O
(	O
Cmax	O
,	O
obs	O
)	O
;	O
time	O
of	O
maximum	O
observed	O
serum	O
concentration	O
(	O
Tmax	O
,	O
obs	O
)	O
;	O
and	O
terminal	O
elimination	O
half-life	O
(	O
t1/2	O
)	O
.	O

No	O
differences	O
were	O
found	O
in	O
clearance	O
of	O
virus	O
in	O
subgroup	O
analyses	O
by	O
virus	O
type/subtype	O
,	O
age	O
,	O
and	O
duration	O
of	O
illness	O
before	O
randomisation	O
.	O

Next	O
,	O
on	O
the	O
basis	O
of	O
(	O
i	O
)	O
a	O
coefficient	O
of	O
0.4	O
for	O
the	O
correlation	O
between	O
the	O
baseline	O
measurement	O
and	O
the	O
end-of-study	O
measurement	O
in	O
a	O
covariance	O
analysis	O
,	O
(	O
ii	O
)	O
a	O
very	O
low	O
dropout	O
rate	O
and	O
(	O
iii	O
)	O
the	O
replacement	O
of	O
dropouts	O
,	O
we	O
calculated	O
the	O
required	O
sample	O
size	O
to	O
be	O
14	B-Sample_Size_Target
patients	I-Sample_Size_Target
per	I-Sample_Size_Target
group	I-Sample_Size_Target
.	O

Indirect	O
evidence	O
implicates	O
endothelin	O
(	O
ET	O
)	O
as	O
a	O
potential	O
mediator	O
of	O
the	O
vascular	O
dysfunction	O
in	O
SSc	O
.	O

Analysis	O
was	O
conducted	O
using	O
intention	O
to	O
treat	O
principles	O
;	O
defined	O
as	O
all	O
randomised	O
participants	O
,	O
excluding	O
those	O
with	O
a	O
later	O
diagnosis	O
determined	O
to	O
be	O
something	O
other	O
than	O
pyoderma	O
gangrenosum	O
.	O

Therefore	O
,	O
the	O
primary	O
analysis	O
of	O
the	O
effect	O
of	O
treatment	O
on	O
the	O
primary	O
outcome	O
was	O
adjusted	O
by	O
logistic	O
regression	O
for	O
linear	O
effects	O
for	O
the	O
following	O
covariates	O
:	O
age	O
;	O
National	O
Institutes	O
of	O
Health	O
stroke	O
scale	O
(	O
NIHSS	O
)	O
score	O
;	O
time	O
from	O
onset	O
of	O
stroke	O
symptoms	O
to	O
randomisation	O
;	O
and	O
presence	O
(	O
vs	O
absence	O
)	O
of	O
ischaemic	O
change	O
on	O
the	O
prerandomisation	O
brain	O
scan	O
according	O
to	O
expert	O
assessment	O
.	O

Most	O
patients	O
were	O
cared	O
for	O
in	O
a	O
stroke	O
unit	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
a	O
major	O
imbalance	O
in	O
the	O
use	O
of	O
background	O
treatments	O
or	O
place	O
of	O
care	O
(	O
admissions	O
ward	O
,	O
or	O
stroke	O
unit	O
)	O
over	O
the	O
first	O
7	O
days	O
;	O
an	O
analysis	O
of	O
blood	O
pressure	O
in	O
patients	O
measured	O
after	O
randomisation	O
showed	O
no	O
significant	O
difference	O
at	O
each	O
timepoint	O
over	O
the	O
first	O
24	O
h	O
in	O
either	O
systolic	O
or	O
diastolic	O
blood	O
pressures	O
between	O
the	O
two	O
treatment	O
groups	O
.	O

If	O
we	O
assume	O
that	O
30	O
%	O
of	O
children	O
and	O
55	O
%	O
of	O
adults	O
treated	O
with	O
standard	O
dose	O
oseltamivir	O
would	O
test	O
negative	O
for	O
virus	O
on	O
day	O
five	O
,	O
a	O
sample	O
size	O
of	O
242	B-Sample_Size_Required
patients	O
would	O
be	O
required	O
to	O
show	O
a	O
20	O
%	O
absolute	O
improvement	O
in	O
cessation	O
of	O
viral	O
shedding	O
with	O
85	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
and	O
a	B-Sample_Size_Calculation_Alpha_Value
two	I-Sample_Size_Calculation_Alpha_Value
sided	I-Sample_Size_Calculation_Alpha_Value
α	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.05	I-Sample_Size_Calculation_Alpha_Value
.	O

Digital	O
photographs	O
of	O
the	O
plantar	O
wart	O
(	O
s	O
)	O
were	O
taken	O
at	O
baseline	O
and	O
at	O
the	O
outcome	O
assessment	O
.	O

Results	O
were	O
similar	O
when	O
restricted	O
to	O
children	O
younger	O
than	O
5	O
years	O
(	O
not	O
shown	O
)	O
or	O
3	O
years	O
(	O
appendix	O
)	O
.	O

The	O
mean	O
number	O
of	O
flares	O
in	O
the	O
past	O
year	O
ranged	O
from	O
3.6	O
to	O
4.7	O
for	O
the	O
different	O
treatment	O
groups	O
.	O

Confidence	O
intervals	O
for	O
proportions	O
and	O
their	O
differences	O
were	O
calculated	O
with	O
Wilson	O
’	O
s	O
method	O
.	O

In	O
children	O
,	O
the	O
corresponding	O
rates	O
were	O
77/99	O
(	O
71	O
%	O
)	O
in	O
the	O
double	O
dose	O
versus	O
62/94	O
(	O
66	O
%	O
)	O
in	O
the	O
standard	O
dose	O
arm	O
(	O
P=0.48	O
)	O
,	O
and	O
in	O
adults	O
12/15	O
(	O
80	O
%	O
)	O
versus	O
12/16	O
(	O
75	O
%	O
)	O
,	O
respectively	O
(	O
P=0.74	O
)	O
.	O

This	O
included	O
subgroups	O
of	O
limited	O
and	O
diffuse	O
SSc	O
,	O
with	O
no	O
difference	O
between	O
the	O
two	O
subgroups	O
in	O
the	O
treatment	O
effect	O
(	O
overlapping	O
95	O
%	O
CIs	O
)	O
.	O

Viral	O
load	O
suppression	O
less	O
than	O
400	O
copies	O
per	O
mL	O
was	O
similar	O
in	O
the	O
three	O
ART	O
strategy	O
groups	O
at	O
weeks	O
4	O
,	O
36	O
,	O
and	O
48	O
(	O
p	O
>	O
0·4	O
)	O
,	O
but	O
differed	O
significantly	O
at	O
weeks	O
24	O
(	O
p=0·009	O
)	O
and	O
144	O
(	O
p=0·009	O
;	O
figure	O
4	O
)	O
.	O

Notable	O
differences	O
included	O
new	O
onset	O
diabetes	O
and	O
hyperglycaemia	O
in	O
the	O
prednisolone	O
group	O
,	O
and	O
headaches	O
,	O
gastrointestinal	O
disturbance	O
,	O
and	O
renal	O
dysfunction	O
commonly	O
in	O
the	O
ciclosporin	O
group	O
.	O

Most	O
AEs	O
were	O
mild	O
or	O
moderate	O
in	O
severity	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
a	O
dose-response	O
for	O
any	O
AE	O
.	O

To	O
allow	O
unbiased	O
assessment	O
of	O
subsequent	O
long-term	O
effects	O
,	O
participants	O
and	O
their	O
doctors	O
were	O
not	O
made	O
aware	O
of	O
their	O
previously	O
allocated	O
study	O
treatment	O
unless	O
there	O
was	O
a	O
particular	O
request	O
to	O
do	O
so	O
,	O
and	O
only	O
15	O
%	O
of	O
participants	O
were	O
unblinded	O
(	O
18	O
%	O
simvastatin-allocated	O
vs	O
13	O
%	O
placebo-allocated	O
)	O
.	O

Serum	O
samples	O
were	O
stored	O
at	O
−20°C	O
until	O
transported	O
frozen	O
to	O
the	O
Mayo	O
Clinic	O
for	O
analysis	O
.	O

Patients	O
who	O
died	O
before	O
day	O
five	O
were	O
assumed	O
to	O
be	O
virus	O
positive	O
on	O
day	O
five	O
unless	O
the	O
virus	O
was	O
cleared	O
before	O
death	O
.	O

Exclusion	O
criteria	O
included	O
history	O
of	O
erosive	O
esophagitis	O
;	O
history	O
of	O
GI	O
complications	O
(	O
bleeding	O
,	O
perforated	O
ulcer	O
,	O
gastric	O
outlet	O
obstruction	O
due	O
to	O
an	O
ulcer	O
)	O
;	O
history	O
of	O
NSAID-associated	O
asthma	O
exacerbations	O
,	O
acute	O
renal	O
failure	O
,	O
interstitial	O
nephritis	O
,	O
or	O
hepatitis	O
;	O
history	O
of	O
GI	O
malignancy	O
;	O
history	O
of	O
myocardial	O
infarction	O
,	O
unstable	O
cardiac	O
arrhythmias	O
,	O
or	O
stroke	O
within	O
6	O
months	O
of	O
study	O
entry	O
;	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
within	O
14	O
days	O
of	O
study	O
entry	O
;	O
uncontrolled	O
congestive	O
heart	O
failure	O
or	O
hypertension	O
at	O
entry	O
;	O
acid-suppressive	O
therapy	O
or	O
misoprostol	O
within	O
14	O
days	O
before	O
study	O
entry	O
or	O
investigational	O
drug	O
or	O
NSAIDs	O
(	O
including	O
aspirin	O
>	O
325	O
mg	O
daily	O
)	O
within	O
30	O
days	O
before	O
study	O
entry	O
;	O
ulcer	O
or	O
>	O
5	O
erosions	O
on	O
screening	O
upper	O
GI	O
tract	O
endoscopy	O
;	O
or	O
one	O
of	O
the	O
following	O
abnormalities	O
on	O
baseline	O
laboratory	O
testing	O
:	O
creatinine	O
clearance	O
<	O
45	O
ml/min	O
;	O
aminotransferase	O
>	O
2.5	O
times	O
upper	O
limit	O
of	O
normal	O
;	O
fasting	O
blood	O
sugar	O
>	O
200	O
mg/dl	O
;	O
serum	O
pregnancy	O
test	O
positive	O
;	O
serologic	O
tests	O
positive	O
for	O
human	O
immunodeficiency	O
virus	O
,	O
hepatitis	O
B	O
,	O
or	O
hepatitis	O
C	O
;	O
or	O
stool	O
antigen	O
for	O
H.	O
pylori	O
positive	O
.	O

Overall	O
14	O
(	O
19	O
%	O
)	O
adverse	O
events	O
were	O
judged	O
as	O
possibly	O
,	O
probably	O
,	O
or	O
definitely	O
related	O
to	O
oseltamivir	O
.	O

Procedures	O
Clinicians	O
entered	O
baseline	O
data	O
via	O
a	B-Randomization_Sequence_Generation_Method
telephone	I-Randomization_Sequence_Generation_Method
voice-activated	I-Randomization_Sequence_Generation_Method
or	I-Randomization_Sequence_Generation_Method
a	I-Randomization_Sequence_Generation_Method
secure	I-Randomization_Sequence_Generation_Method
web-based	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
system	I-Randomization_Sequence_Generation_Method
.	O

Methods	O
We	O
performed	O
a	O
90-day	O
,	O
randomised	B-Randomization_Type_Simple
,	O
double-blind	B-Blinding_Double_Blind
,	O
study	O
with	O
two	O
parallel	B-Design_Parallel_Group
arms	O
:	O
20	B-Design_Parallel_Group
mg/day	I-Design_Parallel_Group
memantine	I-Design_Parallel_Group
versus	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
(	O
ClinicalTrials.gov	O
:	O
NCT01108029	O
)	O
.	O

Only	O
if	O
both	O
the	O
clinician	O
and	O
the	O
patient	O
(	O
or	O
a	O
relevant	O
proxy	O
for	O
the	O
patient	O
)	O
felt	O
that	O
the	O
treatment	O
was	O
promising	O
but	O
unproven	O
,	O
could	O
the	O
patient	O
be	O
included	O
in	O
the	O
trial	O
after	O
appropriate	O
informed	O
consent	O
from	O
the	O
patient	O
or	O
a	O
valid	O
proxy	O
.	O

Members	O
of	O
the	O
UK	O
Dermatology	O
Clinical	O
Trials	O
Network	O
also	O
identified	O
this	O
research	O
as	O
being	O
a	O
priority	O
area	O
for	O
clinicians	O
treating	O
patients	O
with	O
pyoderma	O
gangrenosum	O
.	O

SAEs	O
were	O
reported	O
in	O
14	O
(	O
4.3	O
%	O
)	O
patients	O
treated	O
with	O
canakinumab	O
and	O
6	O
(	O
5.6	O
%	O
)	O
patients	O
treated	O
with	O
colchicine	O
;	O
2	O
were	O
considered	O
by	O
the	O
investigator	O
to	O
be	O
possibly	O
related	O
to	O
study	O
medication	O
:	O
erysipelas	O
of	O
the	O
left	O
leg	O
in	O
the	O
canakinumab	O
25	O
mg	O
group	O
and	O
cancer	O
of	O
the	O
right	O
kidney	O
in	O
the	O
colchicine	O
group	O
.	O

Histopathology	O
is	O
rarely	O
pathognomonic	O
for	O
pyoderma	O
gangrenosum	O
,	O
and	O
many	O
clinicians	O
avoid	O
biopsy	O
because	O
of	O
the	O
risk	O
of	O
an	O
immunological	O
reaction	O
that	O
results	O
in	O
ulcer	O
extension	O
at	O
the	O
biopsy	O
site	O
.	O

Oestrogen/progesterone	O
therapy	O
continued	O
at	O
an	O
adult	O
replacement	O
dose	O
once	O
pubertal	O
induction	O
was	O
completed	O
.	O

These	O
vascular	O
lesions	O
are	O
the	O
underlying	O
basis	O
of	O
important	O
clinical	O
syndromes	O
in	O
SSc	O
,	O
including	O
scleroderma	O
renal	O
crisis	O
,	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
)	O
and	O
Raynaud	O
's	O
phenomenon	O
.	O

However	O
,	O
the	O
mean	O
total	O
number	O
of	O
DUs	O
(	O
baseline	O
and	O
new	O
)	O
per	O
patient	O
decreased	O
to	O
a	O
similar	O
extent	O
in	O
the	O
bosentan	O
and	O
placebo	O
groups	O
(	O
−1.7	O
.	O

Indeed	O
,	O
even	O
during	O
the	O
later	O
years	O
of	O
this	O
prolonged	O
follow-up	O
,	O
no	O
suggestion	O
was	O
noted	O
of	O
any	O
emerging	O
difference	O
in	O
the	O
overall	O
incidence	O
of	O
cancer	O
.	O

One	O
or	O
more	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
occurred	O
in	O
283	O
(	O
47	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
versus	O
282	O
(	O
47	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
(	O
HR	O
0·98	O
,	O
0·83–1·16	O
,	O
p=0·83	O
)	O
.	O

The	O
RRs	O
for	O
proton-pump	O
inhibitor	O
vs.	O
placebo	O
co-therapy	O
in	O
the	O
meta-analysis	O
were	O
0.40	O
(	O
0.32–0.51	O
)	O
for	O
gastric	O
ulcers	O
and	O
0.19	O
(	O
0.09–0.37	O
)	O
for	O
duodenal	O
ulcers	O
.	O

76	O
(	O
49	O
%	O
)	O
centres	O
were	O
classed	O
as	O
experienced	O
in	O
treating	O
stroke	O
with	O
thrombolysis	O
,	O
and	O
1143	O
patients	O
were	O
recruited	O
by	O
these	O
centres	O
.	O

Patients	O
recorded	O
details	O
of	O
flares	O
in	O
diaries	O
.	O

Assessors	B-Blinding_Object_Outcome_Assessors
blind	O
to	O
the	O
allocated	O
treatment	O
assessed	O
the	O
ulcer	O
size	O
and	O
global	O
treatment	O
response	O
from	O
digital	O
images	O
of	O
the	O
target	O
lesion	O
.	O

Analysis	O
of	O
adverse	O
events	O
and	O
vital	O
signs	O
was	O
descriptive	O
in	O
nature	O
.	O

Patients	O
were	O
enrolled	O
a	O
median	O
of	O
5	O
(	O
range	O
1-10	O
)	O
days	O
after	O
the	O
onset	O
of	O
illness	O
:	O
7	O
(	O
3-11	O
)	O
days	O
for	O
patients	O
with	O
H5N1	O
infected	O
and	O
5	O
(	O
1-10	O
)	O
days	O
in	O
other	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Treatment	O
appeared	O
at	O
least	O
as	O
effective	O
in	O
this	O
age	O
group	O
as	O
in	O
younger	O
patients	O
.	O

Randomisation	O
and	O
masking	O
Subjects	O
were	O
randomly	B-Randomization_Type_Simple
assigned	I-Randomization_Type_Simple
to	O
memantine	B-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
.	O

Equally	O
,	O
if	O
the	O
patient	O
had	O
a	O
clear	O
contraindication	O
to	O
treatment	O
they	O
were	O
not	O
to	O
be	O
entered	O
in	O
the	O
trial	O
.	O

Thirteen	O
of	O
the	O
participants	O
had	O
previously	O
been	O
enrolled	O
in	O
the	O
observational	O
study	O
of	O
topical	O
treatments	O
but	O
had	O
failed	O
to	O
respond	O
to	O
treatment	O
and	O
so	O
were	O
subsequently	O
re-consented	O
for	O
the	O
randomised	O
controlled	O
trial	O
.	O

Figure	O
3	O
(	O
bottom	O
panel	O
)	O
shows	O
the	O
corresponding	O
comparison	O
of	O
summary	O
height	O
curves	O
for	O
randomisation	O
2	O
,	O
late	O
versus	O
early	O
induction	O
.	O

Double-Blind	B-Blinding_Double_Blind
Randomized	O
Trials	O
of	O
Single-Tablet	O
Ibuprofen/High-Dose	O
Famotidine	O
vs.	O
Ibuprofen	O
Alone	O
for	O
Reduction	O
of	O
Gastric	O
and	O
Duodenal	O
Ulcers	O

Findings	O
3035	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
enrolled	O
by	O
156	B-Settings_Multicenter
hospitals	I-Settings_Multicenter
in	O
12	B-Settings_Multicenter
countries	I-Settings_Multicenter
.	O

111	O
(	O
18	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
109	O
(	O
18	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
one	O
or	O
more	O
grade	O
4	O
adverse	O
events	O
(	O
HR	O
0·99	O
,	O
0·76–1·29	O
,	O
p=0·94	O
)	O
.	O

After	O
enrolment	O
,	O
an	O
additional	O
five	O
patients	O
needed	O
supplemental	O
oxygen	O
,	O
four	O
required	O
admission	O
to	O
intensive	O
care	O
,	O
and	O
six	O
were	O
mechanically	O
ventilated	O
.	O

In	O
order	O
to	O
achieve	O
a	O
rapid	O
onset	O
of	O
action	O
,	O
we	O
elected	O
to	O
use	O
the	O
intravenous	O
route	O
,	O
and	O
single	O
intravenous	O
doses	O
of	O
up	O
to	O
10	O
mg/m2	O
have	O
been	O
used	O
safely	O
in	O
patients	O
with	O
heart	O
failure	O
.	O

Demographic	O
and	O
baseline	O
characteristics	O
were	O
summarized	O
using	O
descriptive	O
statistics	O
.	O

Efficacy	O
and	O
safety	O
analyses	O
were	O
then	O
performed	O
when	O
all	O
patients	O
had	O
completed	O
the	O
study	O
(	O
24	O
weeks	O
)	O
.	O

All	O
patients	O
were	O
required	O
to	O
continue	O
maintenance	O
treatment	O
with	O
stable	O
medium-dose	O
ICS	O
(	O
400–800	O
μg	O
budesonide	O
or	O
equivalent	O
)	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
Visit	O
1	O
and	O
until	O
Visit	O
7	O
.	O

The	O
final	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
greater	O
in	O
those	O
who	O
achieved	O
the	O
primary	O
outcome	O
than	O
in	O
those	O
who	O
did	O
not	O
(	O
56.4±17.2	O
nmol/L	O
vs	O
37.7±18.5	O
nmol/L	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Sample	O
size	O
calculation	O
In	O
a	O
previous	O
study	O
of	O
17	O
patients	O
on	O
methylphenidate	O
,	O
we	O
had	O
observed	O
a	O
stride	O
length	O
increase	O
(	O
relative	O
to	O
baseline	O
)	O
of	O
0.4	O
m	O
(	O
SD	O
:	O
0.4	O
)	O
in	O
the	O
stand-walk-sit	O
test	O
after	O
3	O
months	O
of	O
treatment	O
.	O

Objective	O
To	O
examine	O
the	O
effect	O
of	O
oxandrolone	O
and	O
the	O
timing	O
of	O
pubertal	O
induction	O
on	O
final	O
height	O
in	O
girls	O
with	O
Turner	O
’	O
s	O
syndrome	O
receiving	O
a	O
standard	O
dose	O
of	O
growth	O
hormone	O
.	O

The	O
increase	O
in	O
distal	O
and	O
proximal	O
1/3	O
bone	O
mineral	O
content	O
was	O
unrelated	O
to	O
treatment	O
response	O
,	O
as	O
assessed	O
by	O
the	O
combined	O
outcome	O
of	O
radiographic	O
and	O
alkaline	O
phosphatase	O
endpoints	O
.	O

47	O
(	O
8	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
39	O
(	O
7	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
had	O
a	O
new	O
WHO	O
stage	O
4	O
event	O
or	O
died	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
1·13	O
,	O
95	O
%	O
CI	O
0·73–1·73	O
,	O
p=0·59	O
;	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
criterion	O
met	O
)	O
.	O

Conclusions	O
Quilizumab	O
had	O
an	O
acceptable	O
safety	O
profile	O
and	O
reduced	O
serum	O
IgE	O
.	O

Blood	O
samples	O
were	O
obtained	O
through	O
a	O
17-gauge	O
cannula	O
with	O
careful	O
attention	O
to	O
ensure	O
smooth	O
extraction	O
of	O
blood	O
to	O
avoid	O
artefactual	O
platelet	O
activation	O
ex	O
vivo	O
,	O
and	O
anticoagulated	O
with	O
D-phenylalanyl-L-propyl-L-arginine	O
chloromethyl-ketone	O
(	O
PPACK	O
)	O
.	O

The	O
corresponding	O
author	O
had	O
full	O
access	O
to	O
all	O
data	O
and	O
responsibility	O
for	O
submission	O
for	O
publication	O
.	O

However	O
,	O
the	O
proportion	O
of	O
those	O
who	O
had	O
spent	O
at	O
least	O
1	O
day	O
in	O
a	O
high-dependency	O
area	O
was	O
somewhat	O
higher	O
among	O
patients	O
assigned	O
to	O
the	O
rt-PA	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
328	O
[	O
24	O
%	O
]	O
vs	O
237	O
[	O
17	O
%	O
]	O
)	O
,	O
though	O
in	O
both	O
groups	O
,	O
the	O
median	O
stay	O
in	O
such	O
an	O
area	O
was	O
just	O
1	O
day	O
.	O

Infectious	O
AEs	O
were	O
reported	O
in	O
58	O
(	O
18.0	O
%	O
)	O
patients	O
receiving	O
canakinumab	O
and	O
13	O
(	O
12.0	O
%	O
)	O
patients	O
receiving	O
colchicine	O
0.5	O
mg	O
(	O
table	O
3	O
)	O
.	O

In	O
one	O
series	O
,	O
the	O
incidence	O
of	O
finger	O
amputation	O
as	O
a	O
consequence	O
of	O
DUs	O
was	O
1.2	O
%	O
per	O
patient-year	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
grade	O
3	O
or	O
4	O
anaemia	O
or	O
grade	O
4	O
only	O
anaemia	O
(	O
with	O
or	O
without	O
clinical	O
symptoms	O
;	O
grade	O
3	O
or	O
4	O
:	O
38	O
vs	O
44	O
vs	O
44	O
,	O
respectively	O
;	O
grade	O
4	O
:	O
21	O
vs	O
24	O
vs	O
25	O
,	O
respectively	O
)	O
.	O

The	O
trial	O
protocol	O
has	O
been	O
published	O
previously	O
.	O

These	O
findings	O
support	O
prompt	O
initiation	O
and	O
long-term	O
continuation	O
of	O
statin	O
treatment	O
in	O
people	O
at	O
increased	O
risk	O
of	O
vascular	O
events	O
.	O

During	O
both	O
the	O
in-trial	O
and	O
post-trial	O
periods	O
,	O
information	O
about	O
the	O
sites	O
of	O
registered	O
cancers	O
and	O
certified	O
causes	O
of	O
deaths	O
was	O
requested	O
from	O
UK	O
national	O
registries	O
for	O
all	O
randomised	O
patients	O
.	O

Laboratory	O
measurements	O
and	O
adherence	O
were	O
compared	O
across	O
randomised	O
groups	O
over	O
time	O
with	O
generalised	O
estimating	O
equations	O
(	O
independent	O
correlation	O
;	O
closest	O
measurement	O
to	O
each	O
scheduled	O
visit	O
within	O
equally	O
spaced	O
windows	O
)	O
.	O

Analysis	O
of	O
variance	O
with	O
repeated	O
measures	O
and	O
a	O
two-tailed	O
Student	O
t	O
test	O
were	O
performed	O
as	O
appropriate	O
with	O
the	O
use	O
of	O
GraphPad	O
Prism	O
software	O
.	O

Role	O
of	O
the	O
funding	O
sources	O
The	O
sponsor	O
(	O
UK	O
Medical	O
Research	O
Council	O
)	O
,	O
other	O
funders	O
(	O
UK	O
Department	O
for	O
International	O
Development	O
)	O
,	O
and	O
ViiV	O
Healthcare/GlaxoSmithKline	O
(	O
donated	O
drugs	O
;	O
funded	O
viral	O
load	O
assays	O
)	O
had	O
no	O
direct	O
role	O
in	O
study	O
design	O
,	O
data	O
collection	O
,	O
analysis	O
,	O
interpretation	O
,	O
report	O
writing	O
,	O
or	O
the	O
decision	O
to	O
submit	O
for	O
publication	O
.	O

One	O
patient	O
(	O
in	O
the	O
50	O
mg	O
group	O
)	O
developed	O
low	O
levels	O
of	O
anti-canakinumab	O
antibodies	O
at	O
week	O
24	O
.	O

Briefly	O
,	O
patients	O
were	O
eligible	O
according	O
to	O
the	O
following	O
criteria	O
:	O
they	O
had	O
symp-toms	O
and	O
signs	O
of	O
clinically	O
definite	O
acute	O
stroke	O
;	O
the	O
time	O
of	O
stroke	O
onset	O
was	O
known	O
;	O
treatment	O
could	O
be	O
started	O
within	O
6	O
h	O
of	O
onset	O
;	O
and	O
CT	O
or	O
MRI	O
had	O
reliably	O
excluded	O
both	O
intracranial	O
haemorrhage	O
and	O
structural	O
brain	O
lesions	O
,	O
which	O
could	O
mimic	O
stroke	O
(	O
eg	O
,	O
cerebral	O
tumour	O
)	O
.	O

Main	O
outcome	O
measures	O
Leucocyte	O
count	O
,	O
plasma	O
cytokine	O
concentrations	O
,	O
flow	O
cytometric	O
measures	O
of	O
platelet	O
activation	O
and	O
peripheral	O
vasomotor	O
and	O
fibrinolytic	O
function	O
were	O
determined	O
before	O
and	O
24	O
h	O
after	O
study	O
intervention	O
.	O

Secondary	O
outcomes	O
Secondary	O
outcomes	O
included	O
(	O
a	O
)	O
complete	O
clearance	O
of	O
all	O
plantar	O
warts	O
at	O
12	O
weeks	O
after	O
controlling	O
for	O
age	O
,	O
whether	O
the	O
plantar	O
wart	O
had	O
been	O
treated	O
previously	O
,	O
and	O
type	O
of	O
wart	O
and	O
(	O
b	O
)	O
a	O
second	O
model	O
to	O
explore	O
the	O
effect	O
of	O
patient	O
preferences	O
,	O
(	O
c	O
)	O
with	O
clearance	O
of	O
plantar	O
wart	O
at	O
six	O
months	O
,	O
(	O
d	O
)	O
number	O
of	O
warts	O
at	O
12	O
weeks	O
,	O
(	O
e	O
)	O
time	O
to	O
clearance	O
of	O
wart	O
,	O
(	O
f	O
)	O
patient	O
satisfaction	O
with	O
the	O
treatment	O
,	O
and	O
(	O
g	O
)	O
adverse	O
events	O
.	O

Secondary	O
objectives	O
were	O
to	O
evaluate	O
the	O
effect	O
of	O
bosentan	O
on	O
pain	O
and	O
disability	O
,	O
as	O
well	O
as	O
its	O
tolerability	O
and	O
safety	O
in	O
these	O
patients	O
.	O

The	O
standard	O
deviation	O
for	O
the	O
combined	O
group	O
was	O
5.1	O
cm	O
,	O
rather	O
less	O
than	O
the	O
7.4	O
cm	O
for	O
the	O
placebo/early	O
induction	O
group	O
(	O
P=0.1	O
)	O
,	O
suggesting	O
that	O
treatment	O
preferentially	O
benefited	O
the	O
shortest	O
girls	O
.	O

Registration	O
Clinical	O
Trials	O
NCT00298233	O

In	O
order	O
to	O
assess	O
the	O
feasibility	O
of	O
a	O
multicentre	O
clinical	O
trial	O
,	O
we	O
used	O
sensitive	O
measures	O
and	O
a	O
standardised	O
,	O
acute	O
L-dopa	O
challenge	O
to	O
examine	O
the	O
impact	O
of	O
memantine	O
on	O
gait	O
,	O
axial	O
motor	O
symptoms	O
and	O
L-dopa-induced	O
dyskinesia	O
(	O
LID	O
)	O
in	O
advanced	O
PD	O
patients	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
pilot	O
study	O
.	O

The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
across	O
treatment	O
groups	O
.	O

No	O
significant	O
difference	O
was	O
noted	O
during	O
the	O
first	O
year	O
,	O
but	O
significant	O
reductions	O
of	O
about	O
a	O
quarter	O
were	O
seen	O
during	O
each	O
subsequent	O
in-trial	O
year	O
(	O
figure	O
2	O
)	O
.	O

Secondary	O
outcomes	O
Time	O
to	O
healing—defined	O
as	O
the	O
time	O
at	O
which	O
sterile	O
dressings	O
were	O
no	O
longer	O
required	O
(	O
reported	O
by	O
patients	O
and	O
confirmed	O
by	O
clinicians	O
at	O
subsequent	O
clinic	O
visits	O
)	O
.	O

Objective	O
The	O
inflammatory	O
cytokine	O
,	O
tumour	O
necrosis	O
factor	O
α	O
(	O
TNF-α	O
)	O
,	O
exerts	O
deleterious	O
cardiovascular	O
effects	O
.	O

Patients	O
were	O
excluded	O
if	O
they	O
had	O
received	O
intravenous	O
prostanoids	O
within	O
the	O
previous	O
3	O
months	O
,	O
had	O
used	O
phosphodiesterase	O
inhibitors	O
other	O
than	O
for	O
intermittent	O
treatment	O
of	O
male	O
erectile	O
dysfunction	O
,	O
or	O
had	O
received	O
inhaled	O
or	O
oral	O
prostanoids	O
or	O
injected	O
botulinum	O
toxin	O
in	O
an	O
affected	O
finger	O
within	O
1	O
month	O
.	O

Analyses	O
were	O
done	O
with	O
SAS	O
(	O
version	O
9.2	O
)	O
.	O

This	O
trial	O
is	O
registered	O
,	O
ISRCTN24791884	O
.	O

To	O
provide	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
(	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
level	O
of	O
significance	O
)	O
to	O
detect	O
a	O
difference	O
in	O
means	O
of	O
0.5	O
standard	O
deviations	O
in	O
the	O
primary	O
outcome	O
of	O
speed	O
of	O
healing	O
over	O
six	O
weeks	O
,	O
the	O
target	O
sample	O
size	O
was	O
140	B-Sample_Size_Required
participants	O
,	O
assuming	O
a	O
loss	O
to	O
follow-up	O
of	O
10	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
.	O

Because	O
of	O
the	O
nature	O
of	O
coin	O
toss	O
randomisation	O
,	O
the	O
number	O
of	O
subjects	O
in	O
the	O
Ca+D	O
group	O
(	O
n=44	O
)	O
was	O
greater	O
than	O
the	O
number	O
in	O
the	O
Ca	O
group	O
(	O
n=28	O
)	O
.	O

If	O
no	O
photographs	O
were	O
available	O
for	O
a	O
participant	O
,	O
however	O
,	O
then	O
the	O
blinded	O
outcome	O
assessment	O
undertaken	O
at	O
the	O
site	O
was	O
used	O
.	O

Methods	O
This	O
was	O
a	O
Phase	B-Design_Phase_2
II	I-Design_Phase_2
,	O
randomised	O
,	O
double-blind	B-Blinding_Double_Blind
,	O
placebo-controlled	O
,	O
crossover	B-Design_Crossover
study	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
three	O
doses	O
of	O
once-daily	O
tiotropium	O
Respimat®	O
.	O

Enrolled	O
children	O
were	O
randomised	B-Randomization_Type_Simple
by	O
coin	B-Randomization_Sequence_Generation_Method
toss	I-Randomization_Sequence_Generation_Method
(	O
performed	O
by	O
TDT	O
)	O
to	O
receive	O
under	O
direct	O
observation	O
either	O
oral	B-Design_Parallel_Group
vitamin	I-Design_Parallel_Group
D2	I-Design_Parallel_Group
as	I-Design_Parallel_Group
50	I-Design_Parallel_Group
000	I-Design_Parallel_Group
IU	I-Design_Parallel_Group
(	I-Design_Parallel_Group
ergocalciferol	I-Design_Parallel_Group
;	I-Design_Parallel_Group
Pliva	I-Design_Parallel_Group
,	I-Design_Parallel_Group
Inc.	I-Design_Parallel_Group
,	I-Design_Parallel_Group
East	I-Design_Parallel_Group
Hanover	I-Design_Parallel_Group
,	I-Design_Parallel_Group
New	I-Design_Parallel_Group
Jersey	I-Design_Parallel_Group
)	I-Design_Parallel_Group
once	I-Design_Parallel_Group
every	I-Design_Parallel_Group
4	I-Design_Parallel_Group
weeks	I-Design_Parallel_Group
(	I-Design_Parallel_Group
Ca+D	I-Design_Parallel_Group
group	I-Design_Parallel_Group
)	I-Design_Parallel_Group
or	I-Design_Parallel_Group
placebo	I-Design_Parallel_Group
,	O
which	O
was	O
a	O
single	O
vitamin	O
B	O
complex	O
tablet	O
,	O
once	O
every	O
4	O
weeks	O
(	O
Ca	O
group	O
)	O
for	O
24	O
weeks	O
.	O

Procedures	O
All	O
participants	O
were	O
examined	O
by	O
a	O
doctor	O
and	O
had	O
routine	O
full	O
blood	O
count	O
with	O
white	O
cell	O
differential	O
,	O
lymphocyte	O
subsets	O
(	O
CD4	O
,	O
CD8	O
)	O
,	O
biochemistry	O
tests	O
(	O
bilirubin	O
,	O
urea	O
,	O
creatinine	O
,	O
aspartate	O
aminotransferase	O
,	O
alanine	O
aminotransferase	O
)	O
at	O
screening	O
,	O
randomisation	O
(	O
lymphocytes	O
only	O
)	O
,	O
weeks	O
4	O
,	O
8	O
,	O
and	O
12	O
,	O
then	O
every	O
12	O
weeks	O
.	O

Plasma	O
interleukin-6	O
concentrations	O
were	O
similarly	O
reduced	O
(	O
10.6±4.0	O
vs	O
5.8±2.0	O
pg/ml	O
;	O
p=0.01	O
)	O
.	O

Hospital	O
course	O
During	O
the	O
study	O
,	O
98/326	O
(	O
30.1	O
%	O
)	O
of	O
all	O
patients	O
required	O
supplemental	O
oxygen	O
,	O
61/326	O
(	O
18.7	O
%	O
)	O
were	O
admitted	O
to	O
intensive	O
care	O
,	O
and	O
40/326	O
(	O
12.3	O
%	O
)	O
required	O
mechanical	O
ventilation	O
.	O

Dopaminergic	O
depletion	O
induces	O
glutamatergic	O
hyperactivity	O
in	O
the	O
brain	O
in	O
general	O
and	O
in	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
and	O
its	O
efferent	O
pathways	O
projecting	O
to	O
the	O
pedunculopontine	O
nucleus	O
(	O
PPN	O
)	O
in	O
particular	O
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
drowsiness	O
over	O
the	O
course	O
of	O
the	O
memantine	O
treatment	O
.	O

Persistent	O
detection	O
of	O
viral	O
RNA	O
on	O
day	O
five	O
was	O
found	O
in	O
17/34	O
(	O
50	O
%	O
,	O
34.1	O
%	O
to	O
65.9	O
%	O
)	O
of	O
patients	O
meeting	O
criteria	O
for	O
clinical	O
failure	O
on	O
day	O
five	O
compared	O
with	O
75/275	O
(	O
27	O
%	O
,	O
22.3	O
%	O
to	O
32.8	O
%	O
)	O
of	O
patients	O
not	O
meeting	O
criteria	O
for	O
clinical	O
failure	O
(	O
P=0.006	O
)	O
.	O

Upper	O
respiratory	O
tract	O
infections	O
(	O
3.7	O
%	O
)	O
and	O
cystitis	O
(	O
1.9	O
%	O
)	O
were	O
the	O
only	O
infections	O
occurring	O
in	O
more	O
than	O
1	O
%	O
of	O
patients	O
receiving	O
colchicine	O
.	O

Interpretation	O
NNRTI	O
plus	O
NRTI-based	O
three-drug	O
or	O
four-drug	O
ART	O
can	O
be	O
given	O
across	O
childhood	O
without	O
routine	O
toxicity	O
monitoring	O
;	O
CD4	O
monitoring	O
provided	O
clinical	O
benefit	O
after	O
the	O
first	O
year	O
on	O
ART	O
,	O
but	O
event	O
rates	O
were	O
very	O
low	O
and	O
long-term	O
survival	O
high	O
,	O
suggesting	O
ART	O
rollout	O
should	O
take	O
priority	O
.	O

Anthropometric	O
z-scores	O
were	O
calculated	O
with	O
Epi	O
Info	O
3.2.2	O
(	O
CDC	O
,	O
Atlanta	O
,	O
Georgia	O
,	O
USA	O
)	O
.	O

Randomisation	O
was	O
performed	O
by	O
a	B-Randomization_Personnel
member	I-Randomization_Personnel
of	I-Randomization_Personnel
the	I-Randomization_Personnel
research	I-Randomization_Personnel
team	I-Randomization_Personnel
either	O
telephoning	B-Randomization_Sequence_Generation_Method
an	I-Randomization_Sequence_Generation_Method
independent	I-Randomization_Sequence_Generation_Method
,	I-Randomization_Sequence_Generation_Method
secure	I-Randomization_Sequence_Generation_Method
,	I-Randomization_Sequence_Generation_Method
remote	I-Randomization_Sequence_Generation_Method
,	I-Randomization_Sequence_Generation_Method
telephone	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
service	I-Randomization_Sequence_Generation_Method
(	I-Randomization_Sequence_Generation_Method
York	I-Randomization_Sequence_Generation_Method
Trials	I-Randomization_Sequence_Generation_Method
Unit	I-Randomization_Sequence_Generation_Method
)	I-Randomization_Sequence_Generation_Method
or	O
accessing	B-Randomization_Sequence_Generation_Method
a	I-Randomization_Sequence_Generation_Method
secure	I-Randomization_Sequence_Generation_Method
online	I-Randomization_Sequence_Generation_Method
web	I-Randomization_Sequence_Generation_Method
randomisation	I-Randomization_Sequence_Generation_Method
programme	I-Randomization_Sequence_Generation_Method
,	O
thereby	O
concealing	O
treatment	O
allocation	O
until	O
the	O
moment	O
of	O
randomisation	O
.	O

Of	O
the	O
small	O
proportion	O
of	O
patients	O
who	O
had	O
previously	O
smoked	O
(	O
19.5	O
%	O
;	O
n	O
=	O
29	O
)	O
,	O
the	O
mean	O
number	O
of	O
pack-years	O
was	O
5.6	O
.	O

At	O
enrolment	O
,	O
57	O
(	O
17.5	O
%	O
)	O
patients	O
needed	O
immediate	O
admission	O
to	O
intensive	O
care	O
,	O
of	O
whom	O
34	O
(	O
10.4	O
%	O
)	O
required	O
mechanical	O
ventilation	O
,	O
and	O
25	O
(	O
7.7	O
%	O
)	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
table	O
1	O
)	O
.	O

The	O
two	O
different	O
primary	O
end	O
points	O
in	O
the	O
individual	O
studies	O
were	O
chosen	O
to	O
address	O
both	O
the	O
more	O
clinically	O
relevant	O
end	O
point	O
of	O
upper	O
GI	O
ulcers	O
(	O
gastric	O
and/or	O
duodenal	O
)	O
and	O
the	O
traditional	O
US	O
FDA	O
(	O
Food	O
and	O
Drug	O
Administration	O
)	O
end	O
point	O
of	O
gastric	O
ulcers	O
.	O

A	O
sample	O
size	O
for	O
REDUCE-1	O
of	O
875	B-Sample_Size_Required
was	O
calculated	O
based	O
on	O
a	O
90	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
to	O
detect	O
a	O
difference	O
of	O
6	O
%	O
vs.	O
14	O
%	O
in	O
the	O
incidence	O
of	O
gastric	O
ulcers	O
with	O
a	B-Sample_Size_Calculation_Alpha_Value
two-sided	I-Sample_Size_Calculation_Alpha_Value
α	I-Sample_Size_Calculation_Alpha_Value
of	I-Sample_Size_Calculation_Alpha_Value
0.05	I-Sample_Size_Calculation_Alpha_Value
and	O
assuming	O
a	O
15	B-Sample_Size_Calculation_Dropout_Rate_Value
%	I-Sample_Size_Calculation_Dropout_Rate_Value
drop-out	O
rate	O
.	O

Differences	O
in	O
average	O
duration	O
between	O
all	O
canakinumab	O
groups	O
versus	O
colchicine	O
0.5	O
mg	O
,	O
however	O
,	O
were	O
not	O
statistically	O
significant	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
peak	O
FEV1	O
measured	O
within	O
the	O
first	O
3	O
hours	O
after	O
dosing	O
(	O
peak	O
FEV1	O
(	O
0-3h	O
)	O
)	O
.	O

The	O
photographs	O
were	O
assessed	O
by	O
two	O
assessors	B-Blinding_Object_Outcome_Assessors
who	O
were	O
blind	O
to	O
treatment	O
allocation	O
.	O

To	O
assess	O
the	O
durability	O
of	O
any	O
treatment	O
benefit	O
beyond	O
6	O
months	O
,	O
patients	O
recruited	O
in	O
the	O
UK	O
(	O
and	O
in	O
other	O
countries	O
where	O
appropriate	O
funding	O
had	O
been	O
obtained	O
)	O
were	O
also	O
followed	O
up	O
at	O
18	O
months	O
.	O

A	O
fixed	O
block	B-Randomization_Type_Block
randomisation	O
,	O
with	O
a	B-Randomization_Block_Size
block	I-Randomization_Block_Size
size	I-Randomization_Block_Size
of	I-Randomization_Block_Size
4	I-Randomization_Block_Size
,	O
was	O
used	O
to	O
ensure	O
balanced	O
and	O
equal	O
assignment	O
.	O

Patient	O
involvement	O
Patients	O
were	O
involved	O
in	O
the	O
design	O
and	O
conduct	O
of	O
this	O
research	O
.	O

However	O
,	O
a	O
significant	O
difference	O
did	O
occur	O
in	O
the	O
adjusted	O
effect	O
of	O
treatment	O
between	O
patients	O
older	O
than	O
80	O
years	O
and	O
in	O
patients	O
80	O
years	O
or	O
younger	O
(	O
p=0·027	O
)	O
,	O
suggesting	O
greater	O
benefit	O
in	O
those	O
older	O
than	O
80	O
years	O
of	O
age	O
;	O
contrary	O
to	O
expectations	O
.	O

Results	O
Twenty-five	B-Sample_Size_Actual_at_Enrollment
patients	O
were	O
included	O
.	O

Those	O
with	O
persistent	O
tachypnoea	O
,	O
dyspnoea	O
,	O
or	O
hypoxia	O
on	O
day	O
five	O
of	O
the	O
study	O
were	O
defined	O
as	O
meeting	O
the	O
criteria	O
for	O
clinical	O
failure	O
and	O
continued	O
to	O
take	O
the	O
randomised	O
dose	O
for	O
an	O
additional	O
five	O
days	O
.	O

We	O
therefore	O
undertook	O
the	O
first	O
paediatric	O
trial	O
(	O
AntiRetroviral	O
Research	O
fOr	O
Watoto	O
[	O
ARROW	O
]	O
)	O
to	O
evaluate	O
the	O
long-term	O
effect	O
of	O
routine	O
efficacy	O
and	O
toxicity	O
monitoring	O
and	O
different	O
first-line	O
ART	O
strategies	O
in	O
a	O
factorial	O
design	O
in	O
African	O
children	O
.	O

Intervention	O
Oral	O
prednisolone	O
0.75	O
mg/kg/day	O
compared	O
with	O
ciclosporin	O
4	O
mg/kg/day	O
,	O
to	O
a	O
maximum	O
dose	O
of	O
75	O
and	O
400	O
mg/day	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
we	O
prespecified	O
comparison	O
of	O
the	O
proportion	O
of	O
patients	O
who	O
reported	O
any	O
symptom	O
consistent	O
with	O
dyspepsia	O
(	O
e.g.	O
,	O
dyspepsia	O
,	O
upper	O
abdominal	O
pain	O
or	O
discomfort	O
,	O
epigastric	O
pain	O
or	O
discomfort	O
,	O
stomach	O
pain	O
or	O
discomfort	O
;	O
with	O
and	O
without	O
nausea	O
)	O
.	O

To	O
be	O
eligible	O
to	O
join	O
the	O
trial	O
,	O
participating	O
hospitals	O
had	O
to	O
have	O
an	O
organised	O
system	O
of	O
stroke	O
care	O
.	O

When	O
the	O
11	O
years	O
of	O
in-trial	O
and	O
post-trial	O
follow-up	O
are	O
considered	O
together	O
,	O
allocation	O
to	O
about	O
5	O
years	O
of	O
statin	O
treatment	O
was	O
not	O
associated	O
with	O
any	O
increase	O
in	O
non-vascular	O
mortality	O
,	O
either	O
overall	O
(	O
1523	O
[	O
14·8	O
%	O
]	O
vs	O
1555	O
[	O
15·1	O
%	O
]	O
;	O
RR	O
0·96	O
[	O
95	O
%	O
CI	O
0·89–1·03	O
]	O
;	O
p=0·24	O
)	O
or	O
for	O
any	O
prespecified	O
category	O
of	O
death	O
.	O

Follow-up	O
of	O
participants	O
who	O
did	O
not	O
complete	O
questionnaires	O
was	O
sought	O
from	O
their	O
family	O
doctors	O
.	O

In	O
order	O
to	O
give	O
80	B-Sample_Size_Calculation_Power_Value
%	I-Sample_Size_Calculation_Power_Value
power	O
(	O
5	B-Sample_Size_Calculation_Alpha_Value
%	I-Sample_Size_Calculation_Alpha_Value
two	I-Sample_Size_Calculation_Alpha_Value
sided	I-Sample_Size_Calculation_Alpha_Value
significance	I-Sample_Size_Calculation_Alpha_Value
)	O
to	O
show	O
a	O
difference	O
in	O
cure	O
rates	O
of	O
70	O
%	O
for	O
salicylic	O
acid	O
versus	O
85	O
%	O
for	O
cryotherapy	O
at	O
12	O
weeks	O
,	O
a	O
sample	O
size	O
of	O
120	B-Sample_Size_Required
patients	I-Sample_Size_Required
in	I-Sample_Size_Required
each	I-Sample_Size_Required
treatment	I-Sample_Size_Required
group	I-Sample_Size_Required
was	O
required	O
,	O
or	O
133	O
patients	O
in	O
each	O
group	O
after	O
allowing	O
for	O
10	O
%	O
attrition	O
(	O
266	O
patients	O
in	O
total	O
)	O
.	O

Exclusion	O
criteria	O
were	O
major	O
systemic	O
illness	O
that	O
might	O
affect	O
growth	O
and	O
social	O
or	O
psychological	O
difficulties	O
likely	O
to	O
seriously	O
impair	O
concordance	O
.	O

Nifedipine	O
and	O
intravenous	O
iloprost	O
reduced	O
the	O
frequency	O
and	O
severity	O
of	O
SSc-related	O
Raynaud	O
's	O
phenomenon	O
attacks	O
,	O
and	O
iloprost	O
was	O
shown	O
to	O
improve	O
DU	O
healing	O
in	O
another	O
trial	O
that	O
included	O
patients	O
with	O
active	O
DUs	O
.	O

During	O
the	O
first	O
weeks	O
and	O
months	O
after	O
initiating	O
ULT	O
,	O
rapid	O
reductions	O
in	O
SU	O
levels	O
can	O
induce	O
acute	O
gouty	O
arthritis	O
flares	O
.	O

Patients	O
were	O
required	O
to	O
have	O
been	O
on	O
maintenance	O
treatment	O
with	O
stable	O
medium-dose	O
ICS	O
(	O
400–800	O
μg	O
budesonide	O
or	O
equivalent	O
)	O
,	O
alone	O
or	O
in	O
a	O
fixed-dose	O
combination	O
with	O
a	O
LABA	O
or	O
short-acting	O
β2-agonist	O
,	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
Visit	O
1	O
.	O

rt-PA	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
extracranial	O
haemorrhages	O
(	O
table	O
3	O
)	O
.	O

Trial	O
registration	O
ClinicalTrials.gov	O
NCT01582503	O
Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi:10.1186/s12931-016-0347-2	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

One	O
or	O
more	O
grade	O
3	O
or	O
4	O
adverse	O
events	O
(	O
co-primary	O
endpoint	O
)	O
occurred	O
in	O
283	O
(	O
47	O
%	O
)	O
children	O
on	O
clinically	O
driven	O
monitoring	O
versus	O
282	O
(	O
47	O
%	O
)	O
on	O
routine	O
laboratory	O
monitoring	O
(	O
HR	O
0·98	O
,	O
95	O
%	O
CI	O
0·83–1·16	O
,	O
p=0·83	O
;	O
figure	O
3	O
)	O
.	O

Safety	O
variables	O
included	O
the	O
incidence	O
of	O
AEs	O
,	O
serious	O
AEs	O
(	O
SAEs	O
)	O
and	O
infectious	O
AEs	O
,	O
the	O
incidence	O
and	O
severity	O
of	O
injection-site	O
reactions	O
,	O
and	O
immunogenicity	O
.	O

Additionally	O
,	O
if	O
the	O
patient	O
had	O
a	O
clear	O
indication	O
for	O
intravenous	O
thrombolysis	O
with	O
rt-PA	O
,	O
they	O
were	O
to	O
be	O
treated	O
in	O
accordance	O
with	O
local	O
guidelines	O
.	O

Conclusions	O
Once-daily	O
tiotropium	O
Respimat®	O
add-on	O
to	O
medium-dose	O
ICS	O
improves	O
lung	O
function	O
in	O
symptomatic	O
patients	O
with	O
moderate	O
asthma	O
.	O

Adverse	O
reactions	O
were	O
similar	O
for	O
the	O
two	O
groups	O
(	O
68	O
%	O
ciclosporin	O
and	O
66	O
%	O
prednisolone	O
)	O
,	O
but	O
serious	O
adverse	O
reactions	O
,	O
especially	O
infections	O
,	O
were	O
more	O
common	O
in	O
the	O
prednisolone	O
group	O
.	O

However	O
,	O
a	O
Cochrane	O
systematic	O
review	O
of	O
placebo-controlled	O
randomized	O
trials	O
≥3	O
months	O
identified	O
one	O
study	O
showing	O
a	O
significant	O
benefit	O
of	O
double-dose	O
H2RAs	O
in	O
reducing	O
both	O
gastric	O
ulcers	O
(	O
relative	O
risk	O
(	O
RR	O
)	O
=0.42	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
0.18–0.97	O
)	O
and	O
duodenal	O
ulcers	O
(	O
RR=0.19	O
,	O
0.04–0.85	O
)	O
.	O

A	O
total	O
of	O
28	O
adverse	O
events	O
were	O
reported	O
in	O
19	O
participants	O
.	O

Radiographs	O
of	O
the	O
left	O
wrist	O
were	O
obtained	O
annually	O
,	O
and	O
a	O
single	O
observer	O
(	O
WFP	O
)	O
analysed	O
them	O
for	O
bone	O
age	O
estimation	O
according	O
to	O
the	O
Tanner	O
Whitehouse	O
II	O
method	O
.	O

Methods	O
In	O
this	O
open-label	B-Blinding_Open_Label
parallel-group	B-Design_Parallel_Group
trial	O
,	O
Ugandan	B-Settings_Location
and	I-Settings_Location
Zimbabwean	I-Settings_Location
children	O
or	O
adolescents	O
with	O
HIV	O
,	O
aged	O
3	O
months	O
to	O
17	O
years	O
and	O
eligible	O
for	O
ART	O
,	O
were	O
randomly	O
assigned	O
in	O
a	O
factorial	B-Design_Factorial
design	O
.	O

Web	O
Extra	O
Material	O
Research	O
in	O
context	O
Systematic	O
review	O
Electronic	O
searches	O
of	O
Medline	O
,	O
PubMed	O
,	O
and	O
Scopus	O
,	O
supplemented	O
by	O
hand	O
searches	O
of	O
reference	O
lists	O
of	O
meta-analyses	O
and	O
other	O
review	O
articles	O
,	O
identified	O
reports	O
from	O
five	O
large	O
randomised	O
trials	O
of	O
statin	O
therapy	O
with	O
post-trial	O
follow-up	O
of	O
clinical	O
outcomes	O
.	O

Treatment	O
decisions	O
for	O
individual	O
patients	O
may	O
be	O
guided	O
by	O
the	O
different	O
side	O
effect	O
profiles	O
of	O
the	O
two	O
drugs	O
and	O
patient	O
preference	O
.	O

Change	O
in	O
treatment	O
occurred	O
before	O
the	O
six	O
week	O
primary	O
outcome	O
assessment	O
in	O
five	O
participants	O
(	O
prednisolone	O
n=1	O
,	O
ciclosporin	O
n=4	O
)	O
.	O

Objective	O
To	O
determine	O
whether	O
children	O
with	O
calcium-deficiency	O
rickets	O
have	O
a	O
better	O
response	O
to	O
treatment	O
with	O
vitamin	O
D	O
and	O
calcium	O
than	O
with	O
calcium	O
alone	O
.	O

Memantine	O
(	O
1-amino-3,5-dimethyladamantane	O
)	O
is	O
an	O
uncompetitive	O
,	O
partial	O
antagonist	O
of	O
the	O
open	O
NMDA	O
receptor	O
.	O

We	O
previously	O
evaluated	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
activity	O
of	O
quilizumab	O
in	O
Phase	O
Ia	O
(	O
31	O
healthy	O
volunteers	O
)	O
,	O
Phase	O
Ib	O
(	O
24	O
allergic	O
rhinitis	O
patients	O
)	O
and	O
Phase	O
IIa	O
(	O
15	O
mild	O
asthma	O
patients	O
)	O
studies	O
.	O

The	O
subgroup	O
analyses	O
are	O
of	O
the	O
adjusted	O
effects	O
and	O
take	O
account	O
of	O
the	O
fact	O
that	O
,	O
for	O
a	O
specific	O
prognostic	O
factor	O
,	O
the	O
distribution	O
of	O
other	O
factors	O
might	O
differ	O
between	O
subcategories	O
.	O

Self	O
reported	O
pain—participants	O
self	O
reported	O
the	O
severity	O
of	O
pain	O
daily	O
using	O
a	O
score	O
from	O
0	O
to	O
4	O
(	O
none	O
,	O
mild	O
,	O
moderate	O
,	O
severe	O
,	O
or	O
extreme	O
)	O
.	O

When	O
allergen	O
cross-links	O
IgE	O
bound	O
to	O
IgE	O
receptors	O
on	O
mast	O
cells	O
and	O
basophils	O
,	O
cell	O
activation	O
and	O
allergic	O
mediator	O
release	O
occur	O
,	O
which	O
may	O
lead	O
to	O
mucus	O
production	O
and	O
airway	O
hyperreactivity	O
.	O

To	O
control	O
the	O
probability	O
of	O
a	O
type	O
I	O
error	O
in	O
the	O
primary	O
efficacy	O
analysis	O
,	O
stepwise	O
testing	O
of	O
the	O
null	O
hypothesis	O
was	O
used	O
to	O
test	O
the	O
efficacy	O
of	O
tiotropium	O
Respimat®	O
5	O
μg	O
,	O
then	O
2.5	O
μg	O
and	O
then	O
1.25	O
μg	O
,	O
each	O
over	O
placebo	O
Respimat®	O
.	O

We	O
also	O
examined	O
numerous	O
secondary	O
clinical	O
endpoints	O
(	O
such	O
as	O
mortality	O
,	O
mechanical	O
ventilation	O
,	O
admission	O
to	O
intensive	O
care	O
,	O
symptoms	O
,	O
resumption	O
of	O
activity	O
)	O
and	O
virological	O
endpoints	O
.	O

All	O
assessments	O
were	O
performed	O
once	O
before	O
the	O
90-day	O
course	O
of	O
study	O
medication	O
and	O
once	O
afterwards	O
.	O

The	O
time	O
to	O
clearance	O
of	O
plantar	O
warts	O
was	O
derived	O
as	O
the	O
number	O
of	O
days	O
from	O
randomisation	O
until	O
the	O
date	O
of	O
clearance	O
,	O
as	O
detailed	O
from	O
the	O
participant	O
’	O
s	O
self	O
reported	O
questionnaire	O
.	O

The	O
primary	O
criterion	O
was	O
tested	O
in	O
a	O
covariance	O
analysis	O
(	O
with	O
adjustment	O
for	O
baseline	O
)	O
for	O
all	O
patients	O
with	O
data	O
recorded	O
in	O
the	O
final	O
assessment	O
.	O

Mortality	O
was	O
similar	O
:	O
12/165	O
(	O
7.3	O
%	O
,	O
4.2	O
%	O
to	O
12.3	O
%	O
)	O
in	O
double	O
dose	O
recipients	O
versus	O
9/161	O
(	O
5.6	O
%	O
,	O
3.0	O
%	O
to	O
10.3	O
%	O
)	O
in	O
standard	O
dose	O
recipients	O
.	O

Most	O
patients	O
were	O
men	O
(	O
89	O
%	O
to	O
100	O
%	O
)	O
and	O
28	O
%	O
to	O
44	O
%	O
had	O
had	O
gouty	O
arthritis	O
for	O
at	O
least	O
10	O
years	O
.	O

In	O
light	O
of	O
the	O
findings	O
with	O
the	O
10	O
μg	O
and	O
5	O
μg	O
doses	O
of	O
tiotropium	O
Respimat®	O
(	O
outlined	O
above	O
)	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
further	O
explore	O
the	O
dose–response	O
curve	O
by	O
comparing	O
the	O
efficacy	O
and	O
tolerability	O
of	O
once-daily	O
evening	O
dosing	O
of	O
tiotropium	O
Respimat®	O
5	O
μg	O
,	O
2.5	O
μg	O
or	O
1.25	O
μg	O
,	O
versus	O
placebo	O
Respimat®	O
,	O
each	O
added	O
on	O
to	O
medium-dose	O
ICS	O
,	O
in	O
adult	O
patients	O
with	O
symptomatic	O
moderate	O
asthma	O
.	O

With	O
this	O
approach	O
,	O
the	O
first	O
null	O
hypothesis	O
that	O
is	O
accepted	O
(	O
i.e.	O
,	O
P≥0.05	O
)	O
will	O
cause	O
immediate	O
acceptance	O
of	O
all	O
subsequent	O
null	O
hypotheses	O
in	O
the	O
sequence	O
(	O
subsequent	O
comparisons	O
will	O
be	O
considered	O
not	O
significantly	O
different	O
and	O
no	O
statistical	O
comparison	O
will	O
be	O
performed	O
)	O
.	O

The	O
doses	O
were	O
75	O
mg	O
or	O
150	O
mg	O
twice	O
daily	O
in	O
those	O
aged	O
≥15	O
or	O
weighing	O
>	O
40	O
kg	O
;	O
60	O
mg	O
or	O
120	O
mg	O
twice	O
daily	O
in	O
those	O
weighing	O
>	O
23-40	O
kg	O
;	O
45	O
mg	O
or	O
90	O
mg	O
twice	O
daily	O
in	O
those	O
weighing	O
>	O
15-23	O
kg	O
;	O
and	O
30	O
mg	O
or	O
60	O
mg	O
twice	O
daily	O
in	O
those	O
weighing	O
≤15	O
kg	O
.	O

Subgroup	O
analysis	O
by	O
baseline	O
serum	O
periostin	O
(	O
≥50	O
ng/ml	O
,	O
<	O
50	O
ng/ml	O
)	O
,	O
blood	O
eosinophils	O
(	O
≥300	O
cells/μl	O
,	O
<	O
300	O
cells/μl	O
)	O
,	O
FeNO	O
(	O
≥20	O
ppb	O
,	O
<	O
20	O
ppb	O
)	O
and	O
serum	O
total	O
IgE	O
(	O
≥200	O
IU/mL	O
,	O
<	O
200	O
IU/mL	O
)	O
demonstrated	O
no	O
consistent	O
effect	O
of	O
quilizumab	O
on	O
the	O
exacerbation	O
rate	O
across	O
all	O
doses	O
when	O
compared	O
to	O
the	O
ITT	O
population	O
(	O
Fig	O
.	O

If	O
digital	O
images	O
were	O
not	O
available	O
,	O
the	O
assessors	O
used	O
physical	O
measurements	O
of	O
the	O
lesion	O
taken	O
during	O
clinic	O
visits	O
and	O
global	O
response	O
by	O
the	O
treating	O
clinician	O
.	O

Baseline	O
dairy	O
product	O
intake	O
was	O
not	O
significantly	O
associated	O
with	O
height	O
for	O
age	O
(	O
r=0.19	O
)	O
,	O
weight	O
for	O
height	O
(	O
r=0.02	O
)	O
,	O
serum	O
calcium	O
(	O
r=0.07	O
)	O
or	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(	O
r=−0.05	O
)	O
.	O

Tiotropium	O
Respimat®	O
in	O
asthma	O
:	O
a	O
double-blind	B-Blinding_Double_Blind
,	O
randomised	O
,	O
dose-ranging	O
study	O
in	O
adult	O
patients	O
with	O
moderate	O
asthma	O

All	O
events	O
were	O
mild	O
except	O
for	O
one	O
moderate	O
event	O
in	O
the	O
canakinumab	O
50	O
mg	O
group	O
.	O

Quilizumab	O
was	O
evaluated	O
for	O
effects	O
on	O
the	O
rate	O
of	O
asthma	O
exacerbations	O
,	O
lung	O
function	O
,	O
patient	O
symptoms	O
,	O
serum	O
IgE	O
,	O
and	O
pharmacokinetics	O
.	O

Baseline	O
forearm	O
blood	O
flow	O
in	O
the	O
non-infused	O
arm	O
was	O
similar	O
and	O
was	O
unaffected	O
by	O
either	O
treatment	O
.	O

SITAR	O
analysis	O
of	O
height	O
curves	O
We	O
applied	O
the	O
SITAR	O
analysis	O
to	O
the	O
105	O
participants	O
with	O
at	O
least	O
one	O
height	O
measurement	O
(	O
one	O
girl	O
in	O
the	O
control	O
group	O
withdrew	O
immediately	O
after	O
randomisation	O
1	O
)	O
.	O

Allergic	O
asthma	O
is	O
a	O
hypersensitivity	O
driven	O
by	O
the	O
complex	O
interaction	O
of	O
epithelial	O
,	O
dendritic	O
,	O
and	O
type	O
2	O
innate	O
lymphoid	O
cells	O
,	O
leading	O
to	O
activation	O
of	O
CD4+	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
in	O
response	O
to	O
allergen	O
exposure	O
.	O

Inclusion	O
criteria	O
for	O
participation	O
of	O
patients	O
were	O
karyotype	O
confirmed	O
Turner	O
’	O
s	O
syndrome	O
(	O
all	O
karyotypes	O
were	O
eligible	O
,	O
including	O
mosaic	O
)	O
,	O
age	O
7-13	O
years	O
,	O
no	O
previous	O
growth	O
hormone	O
treatment	O
or	O
previous	O
treatment	O
in	O
the	O
range	O
8.3-11.7	O
mg/m2/week	O
in	O
five	O
to	O
seven	O
injections	O
a	O
week	O
,	O
no	O
previous	O
oxandrolone	O
and	O
oestrogen	O
therapy	O
,	O
and	O
open	O
epiphyses	O
.	O

However	O
,	O
in	O
years	O
2–5	O
,	O
rates	O
were	O
higher	O
in	O
children	O
on	O
clinically	O
driven	O
monitoring	O
(	O
1·3	O
vs	O
0·4	O
per	O
100	O
child-years	O
,	O
difference	O
0·99	O
,	O
0·37–1·60	O
,	O
p=0·002	O
)	O
.	O

These	O
patients	O
are	O
at	O
the	O
highest	O
risk	O
for	O
future	O
exacerbations	O
and	O
unscheduled	O
use	O
of	O
healthcare	O
resources	O
.	O

)	O
However	O
,	O
as	O
the	O
distribution	O
of	O
flares	O
per	O
patient	O
was	O
observed	O
to	O
be	O
skewed	O
(	O
most	O
patients	O
had	O
no	O
or	O
few	O
flares	O
and	O
few	O
had	O
many	O
flares	O
)	O
,	O
the	O
preplanned	O
ANCOVA	O
was	O
considered	O
inappropriate	O
for	O
these	O
data	O
.	O

If	O
the	O
clinical	O
diagnosis	O
was	O
uncertain	O
,	O
a	O
biopsy	O
was	O
performed	O
to	O
exclude	O
other	O
diagnoses	O
such	O
as	O
malignancy	O
,	O
granulomatous	O
pyoderma	O
gangrenosum	O
,	O
and	O
arteritis	O
,	O
and	O
advice	O
was	O
sought	O
from	O
an	O
expert	O
panel	O
as	O
necessary	O
.	O

Standing	O
height	O
was	O
measured	O
with	O
a	O
wall-mounted	O
stadiometer	O
.	O

Safety	O
and	O
tolerability	O
Overall	O
incidence	O
of	O
adverse	O
events	O
was	O
comparable	O
between	O
placebo	O
Respimat®	O
and	O
the	O
three	O
tiotropium	O
Respimat®	O
treatment	O
doses	O
(	O
Table	O
3	O
)	O
.	O

These	O
models	O
are	O
used	O
to	O
estimate	O
the	O
number	O
of	O
occurrences	O
of	O
an	O
event	O
when	O
the	O
event	O
has	O
Poisson	O
variation	O
with	O
over-dispersion	O
.	O

The	O
modified	O
total	O
asthma	O
symptom	O
score	O
(	O
mTASS	O
)	O
was	O
generated	O
from	O
a	O
subset	O
of	O
diary	O
questions	O
adapted	O
from	O
a	O
previous	O
questionnaire	O
,	O
scoring	O
nighttime	O
awakenings	O
(	O
0–3	O
)	O
,	O
symptoms	O
on	O
awakening	O
(	O
0–1	O
)	O
,	O
and	O
daytime	O
symptom	O
severity	O
(	O
0–4	O
)	O
,	O
for	O
a	O
total	O
score	O
range	O
of	O
0–8	O
.	O

The	O
most	O
commonly	O
reported	O
adverse	O
events	O
by	O
preferred	O
term	O
were	O
asthma	O
exacerbation	O
and	O
nasopharyngitis	O
.	O

26	O
[	O
7	O
%	O
]	O
children	O
in	O
group	O
A	O
switched	O
to	O
second-line	O
treatment	O
versus	O
17	O
[	O
4	O
%	O
]	O
in	O
group	O
B	O
and	O
20	O
(	O
5	O
%	O
)	O
in	O
group	O
C	O
;	O
these	O
differences	O
were	O
not	O
significant	O
(	O
p=0·25	O
;	O
figure	O
2	O
)	O
.	O

In	O
clinically	O
driven	O
monitoring	O
,	O
apart	O
from	O
week	O
8	O
haemoglobin	O
(	O
returned	O
per	O
protocol	O
)	O
,	O
very	O
few	O
results	O
were	O
released	O
(	O
from	O
486	O
[	O
4	O
%	O
]	O
panels	O
)	O
;	O
most	O
commonly	O
requested	O
results	O
were	O
haemoglobin	O
(	O
2	O
%	O
,	O
n=265	O
)	O
and	O
neutrophils	O
(	O
3	O
%	O
,	O
n=323	O
;	O
appendix	O
)	O
.	O

All	O
WHO	O
stage	O
3	O
or	O
4	O
events	O
,	O
deaths	O
,	O
and	O
serious	O
adverse	O
events	O
were	O
reviewed	O
against	O
prespecified	O
criteria	O
by	O
an	O
endpoint	O
review	O
committee	O
with	O
an	O
independent	O
chair	O
and	O
members	O
,	O
masked	O
to	O
randomised	O
allocations	O
.	O

Samples	O
of	O
limestone	O
had	O
no	O
toxic	O
concentrations	O
of	O
heavy	O
metals	O
.	O

Patients	O
were	O
required	O
never	O
to	O
have	O
smoked	O
,	O
or	O
to	O
be	O
ex-smokers	O
who	O
had	O
stopped	O
smoking	O
at	O
least	O
1	O
year	O
prior	O
to	O
enrolment	O
and	O
had	O
a	O
smoking	O
history	O
of	O
less	O
than	O
10	O
pack-years	O
.	O

Children	O
were	O
also	O
randomly	O
assigned	O
(	O
1:1:1	B-Randomization_Ratio
)	O
in	O
a	O
factorial	B-Design_Factorial
design	O
to	O
three	O
approaches	O
for	O
first-line	O
ART	O
:	O
open-label	B-Blinding_Open_Label
lamivudine	O
,	O
abacavir	O
,	O
plus	O
NNRTI	O
continuously	O
(	O
group	O
A	O
,	O
control	O
)	O
;	O
induction-maintenance	O
with	O
four-drug	O
lamivudine	O
,	O
abacavir	O
,	O
NNRTI	O
,	O
plus	O
zidovudine	O
for	O
36	O
weeks	O
,	O
then	O
lamivudine	O
,	O
abacavir	O
,	O
plus	O
NNRTI	O
(	O
group	O
B	O
)	O
;	O
or	O
induction-maintenance	O
with	O
lamivudine	O
,	O
abacavir	O
,	O
NNRTI	O
,	O
plus	O
zidovudine	O
for	O
36	O
weeks	O
,	O
then	O
lamivudine	O
,	O
abacavir	O
,	O
plus	O
zidovudine	O
(	O
group	O
C	O
)	O
.	O

For	O
multiple	O
regression	O
we	O
forced	O
important	O
variables	O
such	O
as	O
age	O
group	O
,	O
(	O
sub	O
)	O
type	O
of	O
virus	O
,	O
and	O
treatment	O
arm	O
in	O
the	O
model	O
,	O
while	O
for	O
other	O
factors	O
we	O
used	O
forward	O
stepwise	O
variable	O
selection	O
procedure	O
with	O
5	O
%	O
significance	O
.	O

At	O
16	O
weeks	O
,	O
there	O
was	O
a	O
62	O
%	O
to	O
72	O
%	O
reduction	O
in	O
the	O
mean	O
number	O
of	O
flares	O
per	O
patient	O
for	O
canakinumab	O
doses	O
≥50	O
mg	O
versus	O
colchicine	O
based	O
on	O
a	O
negative	O
binomial	O
model	O
(	O
rate	O
ratio	O
:	O
0.28–0.38	O
,	O
p≤0.0083	O
)	O
,	O
and	O
the	O
percentage	O
of	O
patients	O
experiencing	O
≥1	O
flare	O
was	O
significantly	O
lower	O
for	O
all	O
canakinumab	O
doses	O
(	O
15	O
%	O
to	O
27	O
%	O
)	O
versus	O
colchicine	O
(	O
44	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Among	O
64	O
samples	O
from	O
83	O
patients	O
positive	O
for	O
RT-PCR	O
on	O
day	O
five	O
,	O
samples	O
from	O
6/28	O
(	O
21	O
%	O
,	O
10.2	O
%	O
to	O
39.5	O
%	O
)	O
double	O
dose	O
patients	O
and	O
5/36	O
(	O
14	O
%	O
,	O
6.1	O
%	O
to	O
28.7	O
%	O
)	O
standard	O
dose	O
patients	O
had	O
infectious	O
virus	O
detected	O
in	O
cell	O
culture	O
(	O
P=0.43	O
)	O
.	O

The	O
hypothesis	O
was	O
that	O
clinically	O
driven	O
monitoring	O
would	O
result	O
in	O
similar	O
outcomes	O
to	O
routine	O
laboratory	O
monitoring	O
(	O
non-inferiority	B-Design_Comparative_Intent_NonInferiority
)	O
and	O
that	O
four-drug	O
induction-maintenance	O
would	O
have	O
greater	O
efficacy	O
than	O
would	O
standard	O
three-drug	O
ART	O
.	O

The	O
remaining	O
12	O
adverse	O
events	O
in	O
the	O
cryotherapy	O
group	O
were	O
either	O
unrelated	O
to	O
the	O
trial	O
treatment	O
(	O
7	O
)	O
or	O
unlikely	O
to	O
be	O
related	O
(	O
5	O
)	O
.	O

A	O
pooled	O
analysis	O
of	O
the	O
patients	O
in	O
REDUCE-1	O
and	O
-2	O
was	O
prespecified	O
,	O
with	O
the	O
primary	O
end	O
point	O
being	O
upper	O
GI	O
ulcers	O
,	O
and	O
the	O
secondary	O
end	O
points	O
being	O
gastric	O
ulcers	O
and	O
duodenal	O
ulcers	O
.	O

Standardised	O
pharmacovigilance	O
procedures	O
were	O
followed	O
,	O
with	O
recording	O
of	O
adverse	O
events	O
or	O
reactions	O
at	O
each	O
visit	O
and	O
subsequent	O
review	O
by	O
the	O
Data	O
and	O
Safety	O
Monitoring	O
Group	O
.	O

Nine	O
participants	O
(	O
four	O
in	O
the	O
prednisolone	O
group	O
;	O
five	O
in	O
the	O
ciclosporin	O
group	O
)	O
showed	O
no	O
change	O
in	O
lesion	O
area	O
two	O
weeks	O
after	O
baseline	O
,	O
and	O
two	O
had	O
missing	O
data	O
at	O
week	O
2	O
.	O

A	O
preplanned	O
interim	O
analysis	O
was	O
performed	O
when	O
200	O
patients	O
had	O
completed	O
16	O
weeks	O
.	O

The	O
two	O
curves	O
cross	O
at	O
10	O
years	O
,	O
and	O
height	O
velocity	O
is	O
consistently	O
greater	O
in	O
the	O
oxandrolone	O
arm	O
.	O

Patients	O
with	O
SSc	O
are	O
at	O
high	O
risk	O
for	O
the	O
development	O
of	O
ischaemic	O
digital	O
ulcers	O
(	O
DUs	O
)	O
,	O
which	O
occur	O
in	O
35	O
%	O
to	O
60	O
%	O
of	O
patients	O
with	O
SSc	O
and	O
are	O
an	O
important	O
source	O
of	O
morbidity	O
.	O

Before	O
study	O
termination	O
and	O
unblinding	O
,	O
the	O
primary	O
analysis	O
was	O
changed	O
to	O
a	O
comparison	O
between	O
treatment	O
arms	O
of	O
the	O
life	O
table	O
estimates	O
of	O
the	O
proportion	O
of	O
patients	O
with	O
ulcers	O
at	O
24	O
weeks	O
employing	O
a	O
modified	O
χ2	O
using	O
the	O
sum	O
of	O
squares	O
from	O
the	O
life	O
table	O
in	O
the	O
error	O
term	O
,	O
with	O
the	O
comparison	O
of	O
crude	O
proportions	O
using	O
the	O
Cochran–Mantel–Haenszel	O
test	O
maintained	O
as	O
a	O
secondary	O
analysis	O
.	O

For	O
determination	O
of	O
PMA	O
a	O
total	O
of	O
3000	O
events	O
were	O
collected	O
in	O
the	O
CD14	O
monocyte	O
gate	O
.	O

After	O
16	O
weeks	O
of	O
treatment	O
,	O
patients	O
receiving	O
bosentan	O
had	O
a	O
48	O
%	O
reduction	O
in	O
the	O
mean	O
number	O
of	O
new	O
DUs	O
compared	O
with	O
placebo	O
(	O
1.4	O
vs	O
2.7	O
new	O
ulcers	O
;	O
p=0.01	O
)	O
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
treatments	O
in	O
end	O
points	O
assessing	O
DU	O
healing	O
in	O
the	O
63	O
%	O
of	O
patients	O
with	O
active	O
DUs	O
at	O
baseline	O
.	O

In	O
REDUCE-1	O
,	O
the	O
primary	O
end	O
point	O
of	O
proportion	O
of	O
patients	O
with	O
gastric	O
ulcers	O
at	O
24	O
weeks	O
was	O
12.7	O
%	O
for	O
HZT-501	O
and	O
22.9	O
%	O
for	O
ibuprofen	O
(	O
P=0.0044	O
;	O
NNT=12	O
)	O
.	O

Healing	O
was	O
defined	O
as	O
complete	O
epithelialisation	O
,	O
regardless	O
of	O
residual	O
pain	O
.	O

See	O
appendix	O
for	O
further	O
details	O
.	O

Compliance	O
was	O
determined	O
by	O
pill	O
count	O
of	O
returned	O
bottles	O
of	O
study	O
medication	O
.	O

Each	O
treatment	O
was	O
administered	O
for	O
4	O
weeks	O
,	O
and	O
there	O
was	O
no	O
washout	O
between	O
treatment	O
periods	O
as	O
pharmacodynamic	O
steady	O
state	O
with	O
tiotropium	O
is	O
known	O
to	O
be	O
achieved	O
after	O
3	O
weeks	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Quantitative	O
RT-PCR	O
for	O
influenza	O
virus	O
A	O
and	O
B	O
,	O
with	O
a	O
lower	O
limit	O
of	O
quantification	O
of	O
103	O
copies	O
of	O
cDNA	O
per	O
mL	O
,	O
was	O
performed	O
as	O
described	O
previously	O
.	O

Statistical	O
analysis	O
All	O
analyses	O
were	O
conducted	O
on	O
an	O
intention	O
to	O
treat	O
basis	O
,	O
including	O
all	O
patients	O
in	O
the	O
groups	O
to	O
which	O
they	O
were	O
randomised	O
.	O

The	O
increases	O
varied	O
between	O
patients	O
,	O
with	O
a	O
median	O
increase	O
in	O
those	O
that	O
increased	O
of	O
2.16	O
cm2	O
in	O
the	O
ciclosporin	O
group	O
and	O
2.55	O
cm2	O
in	O
the	O
prednisolone	O
group	O
.	O

Most	O
deaths	O
(	O
19	O
clinically	O
driven	O
and	O
20	O
routine	O
laboratory	O
monitoring	O
)	O
were	O
primarily	O
HIV-related	O
;	O
only	O
one	O
was	O
drug-related	O
(	O
chemotherapy	O
plus	O
zidovudine	O
)	O
.	O

The	O
main	O
inclusion	O
criterion	O
was	O
the	O
presence	O
of	O
a	O
severe	O
gait	O
disorder	O
and	O
an	O
abnormal	O
,	O
forward-leaning	O
stance	O
.	O

Incidence	O
of	O
adverse	O
